DE10015836A1 - New epothilone derivatives used for treating e.g. malignant melanoma, breast carcinoma, psoriasis, multiple sclerosis and arthritis - Google Patents

New epothilone derivatives used for treating e.g. malignant melanoma, breast carcinoma, psoriasis, multiple sclerosis and arthritis

Info

Publication number
DE10015836A1
DE10015836A1 DE10015836A DE10015836A DE10015836A1 DE 10015836 A1 DE10015836 A1 DE 10015836A1 DE 10015836 A DE10015836 A DE 10015836A DE 10015836 A DE10015836 A DE 10015836A DE 10015836 A1 DE10015836 A1 DE 10015836A1
Authority
DE
Germany
Prior art keywords
dione
dihydroxy
tetramethyl
ethenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10015836A
Other languages
German (de)
Inventor
Ulrich Klar
Wolfgang Schwede
Werner Skuballa
Bernd Buchmann
Jens Hoffmann
Rosemarie Lichtner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to DE10015836A priority Critical patent/DE10015836A1/en
Priority to ARP000102024A priority patent/AR023792A1/en
Priority to PE2000000403A priority patent/PE20010116A1/en
Priority to BR0010190-7A priority patent/BR0010190A/en
Priority to CA2371226A priority patent/CA2371226C/en
Priority to EEP200100568A priority patent/EE05292B1/en
Priority to EA200101025A priority patent/EA011502B1/en
Priority to HU0201010A priority patent/HUP0201010A3/en
Priority to AT00922826T priority patent/ATE440847T1/en
Priority to PT00922826T priority patent/PT1173441E/en
Priority to AU43103/00A priority patent/AU772750C/en
Priority to CA2651653A priority patent/CA2651653C/en
Priority to SI200031044T priority patent/SI1173441T1/en
Priority to PCT/IB2000/000657 priority patent/WO2000066589A1/en
Priority to NZ514989A priority patent/NZ514989A/en
Priority to DK00922826T priority patent/DK1173441T3/en
Priority to CZ20013885A priority patent/CZ299653B6/en
Priority to IL14593800A priority patent/IL145938A0/en
Priority to ES00922826T priority patent/ES2331506T3/en
Priority to JP2000615619A priority patent/JP4024003B2/en
Priority to MEP-139/08A priority patent/MEP13908A/en
Priority to PL351491A priority patent/PL210762B1/en
Priority to DE60042821T priority patent/DE60042821D1/en
Priority to SK1551-2001A priority patent/SK286858B6/en
Priority to EP00922826A priority patent/EP1173441B1/en
Priority to MXPA01011039A priority patent/MXPA01011039A/en
Priority to YUP-776/01A priority patent/RS51023B/en
Priority to KR1020017013840A priority patent/KR100721488B1/en
Priority to CNB008069786A priority patent/CN100368415C/en
Priority to US09/979,939 priority patent/US7125893B1/en
Priority to TW095145399A priority patent/TWI294292B/en
Priority to TW89108133A priority patent/TWI280962B/en
Publication of DE10015836A1 publication Critical patent/DE10015836A1/en
Priority to IL145938A priority patent/IL145938A/en
Priority to BG106053A priority patent/BG65601B1/en
Priority to NO20015278A priority patent/NO328149B1/en
Priority to ZA200109859A priority patent/ZA200109859B/en
Priority to HR20010892A priority patent/HRP20010892A2/en
Priority to HK02108204.3A priority patent/HK1046681B/en
Priority to US10/965,802 priority patent/US7645891B2/en
Priority to US11/214,988 priority patent/US7700621B2/en
Priority to JP2007104224A priority patent/JP4886578B2/en
Priority to CY20091101237T priority patent/CY1109768T1/en
Priority to US12/721,614 priority patent/US20100168179A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Epothilone derivatives (I) are new. Epothilone derivatives of formula (I) are new. R1a, R1b = H, 1-10C alkyl, 6-12C aryl or 7-20C aralkyl (all optionally substituted) or R1a + R1b = (CH2)m or (CH2)-O-(CH2); m = 1-5; R2a = H, 1-10C alkyl, 6-12C aryl or 7-20C aralkyl (all optionally substituted), (CH2)raC equivalent to C-(CH2)pa-R26a, (CH2)raCH=CH-(CH2)pa-R26a or a group of formula (i) or (ii); R2b = (CH2)rbC equivalent to C-(CH2)pb-R26a, (CH2)rbCH=CH-(CH2)pb-R26a or a group of formula (iii) or (iv); n = 0-5; ra, rb = 0-4; pa, pb = 0-3; R3a = H or 1-10C alkyl, 6-12C aryl or 7-20C aralkyl (all optionally substituted); R3b = OH or OPG<14>; PG<14> = a protective group; R<14> = H, OR14a or hal; R14a = H, SO2-alkyl, SO2-aryl or SO<2>-aralkyl; R<4> = H, 1-10C alkyl, 6-12C aryl or 7-20C aralkyl (all optionally substituted), hal, OR<25> or CN; R<25> = H or a protective group PG<5>; R26a, R26b = H or 1-10C alkyl, 6-12C aryl or 7-20C aralkyl (all optionally substituted), 1-10C acyl or, if pa or pb is greater then 0, additionally OR<27>; R<27> = H or a protective group PG<6>; R<5> = H or 1-10C alkyl, 6-12C aryl, 7-20C aralkyl (all optionally substituted) or (CH2)s-T; s = 1-4; T = OR<22> or hal; R<22> = H or a protective group PG<4>; R<6>, R<7> = H or R<6> + R<7> = an additional bond or O; G = X=CR<8> or bi- or tri-cyclic aryl; R<8> = H, hal, CN or 1-20C alkyl, 6-12C aryl, 7-20C aralkyl (all optionally substituted); X = O, 2 OR<23> groups, 2-10C alkylene- alpha ,omega-dioxy, H/OR<9> or CR<10>R<11>; R<23> = 1-20C alkyl; R<9> = H or protective group PGx; R<10>, R<11> = H or 1-20C alkyl, 6-12C aryl or 7-20C aralkyl (all optionally substituted) or CR<10>R<11> = 5-7 membered carbocyclyl; D-E = CH2-CH2 or O-CH2; A-Y = OCO, O-CH2, CH2CO, NR<29>CO or NR<29>-SO2; R<29> = H or 1-10C alkyl; Z = O or H/OR<12>; R<12> = H or protective group PGz and hal = halogen. An Independent claim is included for the preparation of (I).

Description

Von Höfle et al. wird die cytotoxische Wirkung der Naturstoffe Epothilon A (R = Wasserstoff) und Epothilon B (R = Methyl)
From Höfle et al. the cytotoxic effect of the natural substances epothilone A (R = hydrogen) and epothilone B (R = methyl)

z. B. in Angew. Chem. 1996, 108, 1671-1673, beschrieben. Wegen der in-vitro- Selektivität gegenüber Brust- und Darmzelllinien und ihrer im Vergleich zu Taxol deutlich höheren Aktivität gegen P-Glycoprotein-bildende, multiresistente Tumorlinien sowie ihre gegenüber Taxol verbesserten physikalischen Eigenschaften, z. B eine um den Faktor 30 höhere Wasserlöslichkeit, ist diese neuartige Strukturklasse für die Entwicklung eines Arzneimittels zur Therapie maligner Tumoren besonders interessant.z. B. in Angew. Chem. 1996, 108, 1671-1673. Because of the in vitro Selectivity towards breast and intestinal cell lines and their compared to taxol significantly higher activity against P-glycoprotein-forming, multi-resistant tumor lines as well as their improved physical properties over taxol, e.g. B one around water solubility by a factor of 30, is this new type of structural class for the Development of a drug for the therapy of malignant tumors is particularly interesting.

Die Naturstoffe sind sowohl chemisch als auch metabolisch für eine Arzneimittelentwicklung nicht ausreichend stabil. Zur Beseitigung dieser Nachteile sind Modifikationen an dem Naturstoff nötig. Derartige Modifikationen sind nur auf totalsynthetischem Wege möglich und setzen Synthesestrategien voraus, die eine breite Modifikation des Naturstoffes ermöglichen. Ziel der Strukturveränderungen ist es auch, die therapeutische Breite zu erhöhen. Dies kann durch eine Verbesserung der Selektivität der Wirkung und/oder eine Erhöhung der Wirkstärke und/oder eine Reduktion unerwünschter toxischer Nebenwirkungen, wie sie in Proc. Natl. Acad. Sci. USA 1998, 95, 9642-9647 beschrieben sind, erfolgen.The natural substances are both chemically and metabolically for one Drug development not sufficiently stable. To eliminate these disadvantages are Modifications to the natural substance are necessary. Such modifications are only available totally synthetic route possible and require synthesis strategies that a enable broad modification of the natural substance. It is the aim of the structural changes also to increase the therapeutic range. This can be done by improving the Selectivity of the effect and / or an increase in the potency and / or a Reduction of unwanted toxic side effects as described in Proc. Natl. Acad. Sci. USA 1998, 95, 9642-9647.

Die Totalsynthese von Epothilon A ist von Schinzer et al. in Chem. Eur. J. 1996, 2, No. 11, 1477-1482 und in Angew. Chem. 1997, 109, Nr. 5, S. 543-544 beschrieben.The total synthesis of epothilone A is from Schinzer et al. in Chem. Eur. J. 1996, 2, no. 11, 1477-1482 and in Angew. Chem. 1997, 109, No. 5, pp. 543-544.

Epothilon-Derivate wurden bereits von Höfle et al. in der WO 97/19086 beschrieben. Diese Derivate wurden ausgehend vom natürlichen Epothilon A oder B hergestellt. Auch Epothilon C und D (Doppelbindung zwischen den Kohlenstoffatomen 12 und 13: Epothilon C = Desoxyepothilon A; Epothilon D = Desoxyepothilon B) sind als mögliche Ausgangsprodukte hierfür beschrieben.Epothilone derivatives have already been used by Höfle et al. described in WO 97/19086. These derivatives were made from the natural epothilone A or B. Also epothilone C and D (double bond between carbon atoms 12 and 13: Epothilone C = deoxyepothilone A; Epothilone D = Desoxyepothilone B) are possible Starting products for this are described.

Eine weitere Synthese von Epothilon und Epothilonderivaten wurde von Nicolaou et al. in Angew. Chem. 1997, 109, Nr. 1/2, S. 170-172 beschrieben. Die Synthese von Epothilon A und B und einiger Epothilon-Analoga wurde in Nature, Vol. 387, 1997, S. 268-272, die Synthese von Epothilon A und seinen Derivaten in J. Am. Chem. Soc., Vol. 119, No. 34, 1997, S. 7960-7973 sowie die Synthese von Epothilon A und B und einiger Epothilon-Analoga in J. Am. Chem. Soc., Vol. 119, No. 34, 1997, S. 7974-7991 ebenfalls von Nicolaou et al. beschrieben.Another synthesis of epothilone and epothilone derivatives was carried out by Nicolaou et al. in Angew. Chem. 1997, 109, No. 1/2, pp. 170-172. The synthesis of Epothilone A and B and some epothilone analogs have been described in Nature, Vol. 387, 1997, pp. 268-272, the synthesis of epothilone A and its derivatives in J. Am. Chem. Soc., Vol. 119, no. 34, 1997, pp. 7960-7973 and the synthesis of Epothilone A and B and some epothilone analogs in J. Am. Chem. Soc., Vol. 119, no. 34, 1997, pp. 7974-7991 also by Nicolaou et al. described.

Ebenfalls Nicolaou et al. beschreiben in Angew. Chem. 1997, 109, Nr. 19, S. 2181-2187 die Herstellung von Epothilon A-Analoga mittels kombinatorischer Festphasensynthese. Auch einige Epothilon B-Analoga sind dort beschrieben.Also Nicolaou et al. describe in Angew. Chem. 1997, 109, No. 19, pp. 2181-2187 the production of epothilone A analogs by means of combinatorial solid phase synthesis. Some epothilone B analogs are also described there.

Epothilon-Derivate, z. T. auch Epothilon C und D, sind des weiteren in den Patentanmeldungen WO 99/07692, WO 99/02514, WO 99/01124, WO 99/67252, WO 98/25929, WO 97/19086, WO 98/38192, WO 98/22461 und WO 99/58534 beschrieben.Epothilone derivatives, e.g. T. also Epothilon C and D are also in the Patent applications WO 99/07692, WO 99/02514, WO 99/01124, WO 99/67252, WO 98/25929, WO 97/19086, WO 98/38192, WO 98/22461 and WO 99/58534.

In den bisher bekannt gewordenen Epothilon-Derivaten kann am Kohlenstoffatom 6 des Epothilongerüstes kein Alkenyl-, Alkinyl- oder Epoxyrest stehen.In the previously known epothilone derivatives, carbon atom 6 des Epothilongerüstes do not have an alkenyl, alkynyl or epoxy radical.

Die Aufgabe der vorliegenden Erfindung besteht darin, neue Epothilon-Derivate zur Verfügung zu stellen, die sowohl chemisch als auch metabolisch für eine Arzneimittelentwicklung ausreichend stabil sind und die hinsichtlich ihrer therapeutischen Breite, ihrer Selektivität der Wirkung und/oder unerwünschter toxischer Nebenwirkungen und/oder ihrer Wirkstärke den natürlichen Derivaten überlegen sind.The object of the present invention is to provide new epothilone derivatives for To provide that both chemically and metabolically for a Drug development are sufficiently stable and with regard to their therapeutic breadth, their selectivity of action and / or undesirable toxic Side effects and / or their potency are superior to the natural derivatives.

Die vorliegende Erfindung beschreibt die neuen Epothilon-Derivate der allgemeinen Formel I,
The present invention describes the new epothilone derivatives of the general formula I,

worin
R1a, R1b gleich oder verschieden sind und Wasserstoff, C1-C10-Alkyl, Aryl, C7- C20-Aralkyl, oder gemeinsam eine -(CH2)m-Gruppe mit m = 1, 2, 3, 4 oder 5, eine -(CH2)-O-(CH2)-Gruppe,
R2a Wasserstoff, C1-C10-Alkyl, Aryl, C7-C20-Aralkyl, -(CH2)ra-C∼C-(CH2)pa-R26a, -(CH2)ra-C=C-(CH2)pa-R26a,
wherein
R 1a , R 1b are identical or different and are hydrogen, C 1 -C 10 -alkyl, aryl, C 7 -C 20 -aralkyl, or together a - (CH 2 ) m group with m = 1, 2, 3, 4 or 5, a - (CH 2 ) -O- (CH 2 ) group,
R 2a is hydrogen, C 1 -C 10 alkyl, aryl, C 7 -C 20 aralkyl, - (CH 2 ) ra -C∼C- (CH 2 ) pa -R 26a , - (CH 2 ) ra -C = C- (CH 2 ) pa -R 26a ,

R2b -(CH2)rb-C∼C-(CH2)pb-R26b, -(CH2)rb-C=C-(CH2)pb-R26b,
R 2b - (CH 2 ) rb -C∼C- (CH 2 ) pb -R 26b , - (CH 2 ) rb -C = C- (CH 2 ) pb -R 26b ,

n 0 bis 5,
ra, rb gleich oder verschieden sind und 0 bis 4,
pa, pb gleich oder verschieden sind und 0 bis 3,
R3a Wasserstoff, C1-C10-Alkyl, Aryl, C7-C20-Aralkyl,
R14 Wasserstoff, OR14a, Hal,
R3b OPG14,
R4 Wasserstoff, C1-C10-Alkyl, Aryl, C7-C20-Aralkyl, Hal, OR25, CN,
R25 Wasserstoff, eine Schutzgruppe PG5,
R26a, R26b gleich oder verschieden sind und Wasserstoff, C1-C10-Alkyl, Aryl, C7- C20-Aralkyl, C1-C10-Acyl, oder, falls pa bzw. pb < 0 sind, eine Gruppe OR27,
R27 Wasserstoff, eine Schutzgruppe PG6,
R5 Wasserstoff, C1-C10-Alkyl, Aryl, C7-C20-Aralkyl, (CH2)s-T, wobei s für 1, 2, 3 oder 4,
T für OR22 oder Hal,
R22 für Wasserstoff oder PG4 stehen,
R6, R7 je ein Wasserstoffatom, gemeinsam eine zusätzliche Bindung oder ein Sauerstoffatom,
G eine Gruppe X=CR8-, ein bi- oder tricyclischer Arylrest,
R8 Wasserstoff, Halogen, CN, C1-C20-Alkyl, Aryl, C7-C20-Aralkyl, die alle substituiert sein können,
X ein Sauerstoffatom, zwei Alkoxygruppen OR23, eine C2-C10-Alkylen-α,ω- dioxygruppe, die geradkettig oder verzweigt sein kann, H/OR9 oder eine Gruppierung CR10R11,
wobei
R23 für einen C1-C20-Alkylrest,
R9 für Wasserstoff oder eine Schutzgruppe PGx,
R10, R11 gleich oder verschieden sind und für Wasserstoff, einen C1-C20- Alkyl-, Aryl-, C7-C20-Aralkylrest oder R10 und R11 zusammen mit dem Methylenkohlenstoffatom gemeinsam für einen 5- bis 7-gliedrigen carbocyclischen Ring
stehen,
D-E eine Gruppe -CH2-CH2-, -O-CH2-,
A-Y eine Gruppe O-C(=O), O-CH2, CH2C(=O), NR29-C(=O), NR29-SO2,
R29 Wasserstoff, C1-C10-Alkyl,
Z ein Sauerstoffatom oder H/OR12,
wobei
R12 Wasserstoff oder eine Schutzgruppe PGz
ist,
Hal Halogen, vorzugsweise Fluor, Chlor, Brom oder Iod,
bedeuten.n 0 to 5,
ra, rb are the same or different and 0 to 4,
pa, pb are the same or different and 0 to 3,
R 3a is hydrogen, C 1 -C 10 -alkyl, aryl, C 7 -C 20 -aralkyl,
R 14 hydrogen, OR 14a , Hal,
R 3b OPG 14 ,
R 4 hydrogen, C 1 -C 10 -alkyl, aryl, C 7 -C 20 -aralkyl, Hal, OR 25 , CN,
R 25 hydrogen, a protective group PG 5 ,
R 26a , R 26b are identical or different and are hydrogen, C 1 -C 10 -alkyl, aryl, C 7 -C 20 -aralkyl, C 1 -C 10 -acyl, or, if pa and pb are <0, a Group OR 27 ,
R 27 is hydrogen, a protective group PG 6 ,
R 5 is hydrogen, C 1 -C 10 -alkyl, aryl, C 7 -C 20 -aralkyl, (CH 2 ) s -T, where s is 1, 2, 3 or 4,
T for OR 22 or Hal,
R 22 represents hydrogen or PG 4 ,
R 6 , R 7 each represent a hydrogen atom, together an additional bond or an oxygen atom,
G is a group X = CR 8 -, a bi- or tricyclic aryl radical,
R 8 is hydrogen, halogen, CN, C 1 -C 20 -alkyl, aryl, C 7 -C 20 -aralkyl, all of which can be substituted,
X is an oxygen atom, two alkoxy groups OR 23 , a C 2 -C 10 -alkylene-α, ω-dioxy group, which can be straight-chain or branched, H / OR 9 or a grouping CR 10 R 11 ,
in which
R 23 is a C 1 -C 20 -alkyl radical,
R 9 for hydrogen or a protective group PG x ,
R 10, R 11 are identical or different and represent hydrogen, a C 1 -C 20 - alkyl, aryl, C 7 -C 20 aralkyl, or R 10 and R 11 together with the methylene carbon atom jointly represent a 5- to 7 -linked carbocyclic ring
stand,
DE is a group -CH 2 -CH 2 -, -O-CH 2 -,
AY is a group OC (= O), O-CH 2 , CH 2 C (= O), NR 29 -C (= O), NR 29 -SO 2 ,
R 29 hydrogen, C 1 -C 10 -alkyl,
Z is an oxygen atom or H / OR 12 ,
in which
R 12 is hydrogen or a protective group PG e.g.
is
Hal halogen, preferably fluorine, chlorine, bromine or iodine,
mean.

Die Darstellung der neuen Epothilon-Derivate basiert auf der Verknüpfung dreier Teilfragmente A, B und C. Die Schnittstellen liegen wie in der allgemeinen Formel I' angedeutet. The presentation of the new epothilone derivatives is based on the combination of three Part fragments A, B and C. The interfaces are as in the general formula I ' indicated.

A bedeutet ein C1-C6-Fragment (Epothilon-Zählweise) der allgemeinen Formel A-1 oder A-2
A denotes a C 1 -C 6 fragment (epothilone counting method) of the general formula A-1 or A-2

worin
R1a', R1b', R2a' und R2b' die bereits für R1a, R1b, R2a und R2b genannten Bedeutungen haben und
R13 CH2OR13a, CH2-Hal, CHO, CO2R13b, COHal,
R14 Wasserstoff, OR14a, Hal, OSO2R14b,
R13a, R14a Wasserstoff, SO2-Alkyl, SO2-Aryl, SO2-Aralkyl oder gemeinsam eine -(CH2)o-Gruppe oder gemeinsam eine CR15aR15b-Gruppe,
R13b, R14b Wasserstoff, C1-C20-Alkyl, Aryl, C1-C20-Aralkyl,
R15a, R15b gleich oder verschieden sind und Wasserstoff, C1-C10-Alkyl, Aryl, C7-C20-Aralkyl, oder gemeinsam eine -(CH2)q-Gruppe,
o 2 bis 4,
q 3 bis 6,
R30 Wasserstoff,
R31 Hydroxyl, oder
R30, R31 gemeinsam ein Sauerstoffatom, oder eine C2-C10-Alkylen-α,ω- dioxygruppe, die geradkettig oder verzweigt sein kann,
R30, R31 jeweils eine C1-C10-Alkoxygruppe,
einschließlich aller Stereoisomeren sowie deren Gemische bedeuten sowie
freie Hydroxylgruppen in R13, R14 und R31 verethert oder verestert, freie Carbonylgruppen in A-1 bzw A-2 und R13 ketalisiert, in einen Enolether überführt oder reduziert sowie freie Säuregruppen in A-1 bzw A-2 in deren Salze mit Basen überführt sein können.wherein
R 1a ' , R 1b' , R 2a ' and R 2b' have the meanings already mentioned for R 1a , R 1b , R 2a and R 2b and
R 13 CH 2 OR 13a , CH 2 -Hal, CHO, CO 2 R 13b , COHal,
R 14 hydrogen, OR 14a , Hal, OSO 2 R 14b ,
R 13a , R 14a hydrogen, SO 2 alkyl, SO 2 aryl, SO 2 aralkyl or together a - (CH 2 ) o group or together a CR 15a R 15b group,
R 13b , R 14b hydrogen, C 1 -C 20 -alkyl, aryl, C 1 -C 20 -aralkyl,
R 15a , R 15b are identical or different and are hydrogen, C 1 -C 10 -alkyl, aryl, C 7 -C 20 -aralkyl, or together a - (CH 2 ) q group,
o 2 to 4,
q 3 to 6,
R 30 hydrogen,
R 31 hydroxyl, or
R 30 , R 31 together represent an oxygen atom, or a C 2 -C 10 -alkylene-α, ω-dioxy group, which can be straight-chain or branched,
R 30 , R 31 are each a C 1 -C 10 alkoxy group,
including all stereoisomers and their mixtures mean as well as
free hydroxyl groups in R 13 , R 14 and R 31 etherified or esterified, free carbonyl groups in A-1 or A-2 and R 13 ketalized, converted into an enol ether or reduced, and free acid groups in A-1 or A-2 in their salts can be transferred with bases.

B steht für ein C7-C12-Fragment (Epothilon-Zählweise) der allgemeinen Formel
B stands for a C 7 -C 12 fragment (epothilone counting method) of the general formula

worin
D, E, R3a', R4' und R5' die bereits für D, E, R3a, R4 und R5 genannten Bedeutungen haben, und
V ein Sauerstoffatom, zwei Alkoxygruppen OR17, eine C2-C10-Alkylen-α,ω- dioxygruppe, die geradkettig oder verzweigt sein kann oder H/OR16,
W ein Sauerstoffatom, zwei Alkoxygruppen OR19, eine C2-C10-Alkylen-α,ω- dioxygruppe, die geradkettig oder verzweigt sein kann oder H/OR18,
R16, R18 unabhängig voneinander Wasserstoff oder eine Schutzgruppe PG1,
R17, R19 unabhängig voneinander C1-C20-Alkyl,
bedeuten.wherein
D, E, R 3a ' , R 4' and R 5 'have the meanings already mentioned for D, E, R 3a , R 4 and R 5 , and
V is an oxygen atom, two alkoxy groups OR 17 , a C 2 -C 10 -alkylene-α, ω-dioxy group, which can be straight-chain or branched or H / OR 16 ,
W is an oxygen atom, two alkoxy groups OR 19 , a C 2 -C 10 -alkylene-α, ω-dioxy group, which can be straight-chain or branched, or H / OR 18 ,
R 16 , R 18 independently of one another are hydrogen or a protective group PG 1 ,
R 17 , R 19 independently of one another are C 1 -C 20 -alkyl,
mean.

C steht für ein C13-C16-Fragment (Epothilon-Zählweise) der allgemeinen Formel
C stands for a C13-C16 fragment (epothilone counting method) of the general formula

worin
G' eine Gruppe X=CR8'-, ein bicyclischer oder tricyclischer Arylrest,
R8' die bereits in der allgemeinen Formel I für R8 genannte Bedeutung hat und
R7' ein Wasserstoffatom,
R20 Halogen, N3, NHR29, eine Hydroxygruppe, eine geschützte Hydroxygruppe OPG2, eine geschützte Aminogruppe NR29PG2, eine C1-C10- Alkylsulfonyloxygruppe, die gegebenenfalls perfluoriert sein kann, eine gegebenenfalls durch C1-C4-Alkyl, Nitro, Chlor oder Brom substituierte Benzoyloxy-Gruppe, eine NR29SO2CH3-Gruppe, eine NR29C(=O)CH3-Gruppe, eine CH2-C(=O)-CH3-Gruppe,
R21 eine Hydroxygruppe, Halogen, eine geschützte Hydroxygruppe OPG3, ein Phosphoniumhalogenidrest PPh3 +Hal- (Ph = Phenyl; Hal = F, Cl, Br, I), ein Phosphonatrest P(O)(OQ)2 (Q = C1-C10-Alkyl oder Phenyl) oder ein Phosphinoxidrest P(O)Ph2 (Ph = Phenyl),
X ein Sauerstoffatom, zwei Alkoxygruppen OR23, eine C2-C10-Alkylen-α,ω- dioxygruppe, die geradkettig oder verzweigt sein kann, H/OR9 oder eine Gruppierung CR10R11,
wobei
R23 für einen C1-C20-Alkylrest,
R9 für Wasserstoff oder eine Schutzgruppe PG3,
R10, R11 gleich oder verschieden sind und für Wasserstoff, einen C1-C20-Alkyl-, Aryl-, C7-C20-Aralkylrest oder R10 und R11 zusammen mit dem Methylenkohlenstoffatom gemeinsam für einen 5- bis 7-gliedrigen carbocyclischen Ring stehen,
bedeuten.wherein
G 'is a group X = CR 8' -, a bicyclic or tricyclic aryl radical,
R 8 'has the meaning already mentioned in general formula I for R 8 and
R 7 'is a hydrogen atom,
R 20 halogen, N 3 , NHR 29 , a hydroxyl group, a protected hydroxyl group OPG 2 , a protected amino group NR 29 PG 2 , a C 1 -C 10 -alkylsulfonyloxy group, which can optionally be perfluorinated, an optionally by C 1 -C 4 -Alkyl, nitro, chlorine or bromine substituted benzoyloxy group, an NR 29 SO 2 CH 3 group, an NR 29 C (= O) CH 3 group, a CH 2 -C (= O) -CH 3 group ,
R 21 is a hydroxyl group, halogen, a protected hydroxyl group OPG 3 , a phosphonium halide residue PPh 3 + Hal - (Ph = phenyl; Hal = F, Cl, Br, I), a phosphonate residue P (O) (OQ) 2 (Q = C 1 -C 10 -alkyl or phenyl) or a phosphine oxide residue P (O) Ph 2 (Ph = phenyl),
X is an oxygen atom, two alkoxy groups OR 23 , a C 2 -C 10 -alkylene-α, ω-dioxy group, which can be straight-chain or branched, H / OR 9 or a grouping CR 10 R 11 ,
in which
R 23 is a C 1 -C 20 -alkyl radical,
R 9 for hydrogen or a protective group PG 3 ,
R 10 , R 11 are identical or different and represent hydrogen, a C 1 -C 20 -alkyl, aryl, C 7 -C 20 -aralkyl radical, or R 10 and R 11 together with the methylene carbon atom together for a 5- to 7 -linked carbocyclic ring,
mean.

Als Alkylgruppen R1a, R1b, R2a, R2b, R3a, R4, R5, R8, R10, R11, R13a, R13b, R14a, R14b, R15a, R15b, R17, R19, R23, R26a, R26b, R28a, R28b und R29 sind gerad- oder verzweigtkettige Alkylgruppen mit 1-20 Kohlenstoffatomen zu betrachten, wie beispielsweise Methyl, Ethyl, Propyl, Isopropyl, Butyl, Isobutyl, tert.-Butyl, Pentyl, Isopentyl, Neopentyl, Heptyl, Hexyl, Decyl.As alkyl groups R 1a , R 1b , R 2a , R 2b , R 3a , R 4 , R 5 , R 8 , R 10 , R 11 , R 13a , R 13b , R 14a , R 14b , R 15a , R 15b , R 17 , R 19 , R 23 , R 26a , R 26b , R 28a , R 28b and R 29 are straight or branched chain alkyl groups with 1-20 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl , tert-butyl, pentyl, isopentyl, neopentyl, heptyl, hexyl, decyl.

Die Alkylgruppen R1a, R1b, R2a, R2b, R3a, R4, R5, R8, R10, R11, R13a, R13b, R14a, R14b, R15a, R15b, R17, R19, R23, R26a, R26b, R28a, R28b können perfluoriert oder substituiert sein durch 1-5 Halogenatome, Hydroxygruppen, C1-C4- Alkoxygruppen, C6-C12-Arylgruppen (die durch 1-3 Halogenatome substituiert sein können). The alkyl groups R 1a , R 1b , R 2a , R 2b , R 3a , R 4 , R 5 , R 8 , R 10 , R 11 , R 13a , R 13b , R 14a , R 14b , R 15a , R 15b , R 17 , R 19 , R 23 , R 26a , R 26b , R 28a , R 28b can be perfluorinated or substituted by 1-5 halogen atoms, hydroxyl groups, C 1 -C 4 alkoxy groups, C 6 -C 12 aryl groups (the can be substituted by 1-3 halogen atoms).

Als Arylrest R1a, R1b, R2a, R2b, R3a, R4, R5, R8, R10, R11, R13a, R13b, R14a, R14b, R15a, R15b, R26a, R26b, R28a und R28b kommen substituierte und unsubstituierte carbocyclische oder heterocyclische Reste mit einem oder mehreren Heteroatomen wie z. B. Phenyl, Naphthyl, Furyl, Thienyl, Pyridyl, Pyrazolyl, Pyrimidinyl, Oxazolyl, Pyridazinyl, Pyrazinyl, Chinolyl, Thiazolyl, Benzothiazolyl, Benzoxazolyl, die einfach oder mehrfach substituiert sein können durch Halogen, OH, O-Alkyl, CO2H, CO2-Alkyl, -NH2, -NO2, -N3, -CN, C1-C20-Alkyl, C1-C20-Acyl, C1-C20-Acyloxy- Gruppen, in Frage.As aryl radicals R 1a , R 1b , R 2a , R 2b , R 3a , R 4 , R 5 , R 8 , R 10 , R 11 , R 13a , R 13b , R 14a , R 14b , R 15a , R 15b , R 26a , R 26b , R 28a and R 28b come substituted and unsubstituted carbocyclic or heterocyclic radicals with one or more heteroatoms such as. B. phenyl, naphthyl, furyl, thienyl, pyridyl, pyrazolyl, pyrimidinyl, oxazolyl, pyridazinyl, pyrazinyl, quinolyl, thiazolyl, benzothiazolyl, benzoxazolyl, which can be substituted one or more times by halogen, OH, O-alkyl, CO 2 H, CO 2 -alkyl, -NH 2 , -NO 2 , -N 3 , -CN, C 1 -C 20 -alkyl, C 1 -C 20 -acyl, C 1 -C 20 -acyloxy groups.

Als bi- und tricyclische Arylreste G kommen substituierte und unsubstituierte carbocyclische oder heterocyclische Reste mit einem oder mehreren Heteroatomen wie z. B. Naphthyl, Anthryl, Benzothiazolyl, Benzoxazolyl, Benzim 99999 00070 552 001000280000000200012000285919988800040 0002010015836 00004 99880idazolyl, Chinolyl, Isochinolyl, Benzoxazinyl, Benzofuranyl, Indolyl, Indazolyl, Chinoxalinyl, Tetrahydroisochinolinyl, Tetrahydrochinolinyl, Thienopyridinyl, Pyridopyridinyl, Benzopyrazolyl, Benzotriazolyl, Dihydroindolyl, die einfach oder mehrfach substituiert sein können durch Halogen, OH, O-Alkyl, CO2H, CO2-Alkyl, -NH2, -NO2, -N3, -CN, C1- C20-Alkyl, C1-C20-Acyl, C1-C20-Acyloxy-Gruppen, in Frage.As bi- and tricyclic aryl radicals G are substituted and unsubstituted carbocyclic or heterocyclic radicals with one or more heteroatoms such as. , Naphthyl, anthryl, benzothiazolyl, benzoxazolyl, Benzim 99999 00070 552 00004 001000280000000200012000285919988800040 0002010015836 99880idazolyl, quinolyl, isoquinolyl, benzoxazinyl, benzofuranyl, indolyl, indazolyl, quinoxalinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, thienopyridinyl, pyridopyridinyl, benzopyrazolyl, benzotriazolyl, dihydroindolyl, which simply or C C 20 alkyl, C 1 -C 20 - -NH 2, -NO 2, -N 3, -CN, C 1 may be substituted more times by halogen, OH, O-alkyl, CO 2 H, CO 2 alkyl, Acyl, C 1 -C 20 acyloxy groups.

Die Aralkylgruppen in R1a, R1b, R2a, R2b, R3a, R4, R5, R8, R10, R11, R13a, R13b, R14a, R14b, R15a, R15b, R26a, R26b, R28a und R28b können im Ring bis 14 C- Atome, bevorzugt 6 bis 10 und in der Alkylkette 1 bis 8, bevorzugt 1 bis 4 Atome enthalten. Als Aralkylreste kommen beispielweise in Betracht Benzyl, Phenylethyl, Naphthylmethyl, Naphthylethyl, Furylmethyl, Thienylethyl, Pyridylpropyl. Die Ringe können einfach oder mehrfach substituiert sein durch Halogen, OH, O-Alkyl, CO2H, CO2-Alkyl, -NO2, -N3, -CN, C1-C20-Alkyl, C1-C20-Acyl, C1-C20-Acyloxy-Gruppen.The aralkyl groups in R 1a , R 1b , R 2a , R 2b , R 3a , R 4 , R 5 , R 8 , R 10 , R 11 , R 13a , R 13b , R 14a , R 14b , R 15a , R 15b , R 26a , R 26b , R 28a and R 28b can contain up to 14 carbon atoms, preferably 6 to 10, and in the alkyl chain 1 to 8, preferably 1 to 4 atoms. Examples of suitable aralkyl radicals are benzyl, phenylethyl, naphthylmethyl, naphthylethyl, furylmethyl, thienylethyl, pyridylpropyl. The rings can be substituted one or more times by halogen, OH, O-alkyl, CO 2 H, CO 2 -alkyl, -NO 2 , -N 3 , -CN, C 1 -C 20 -alkyl, C 1 -C 20 Acyl, C 1 -C 20 acyloxy groups.

Die in R30, R31 und X in der allgemeinen Formel I enthaltenen Alkoxygruppen sollen jeweils 1 bis 20 Kohlenstoffatome enthalten, wobei Methoxy-, Ethoxy-, Propoxy-, Isopropoxy- und t-Butyloxygruppen bevorzugt sind.The alkoxy groups contained in R 30 , R 31 and X in general formula I should each contain 1 to 20 carbon atoms, methoxy, ethoxy, propoxy, isopropoxy and t-butyloxy groups being preferred.

Als Vertreter für die Schutzgruppen PG sind Alkyl- und/oder Aryl-substituiertes Silyl, C1- C20-Alkyl, C4-C7-Cycloalkyl, das im Ring zusätzlich ein Sauerstoffatom enthalten kann, Aryl, C7-C20-Aralkyl, C1-C20-Acyl, Aroyl sowie C1-C20-Alkoxycarbonyl zu nennen.Representatives of the protective groups PG are alkyl- and / or aryl-substituted silyl, C 1 -C 20 -alkyl, C 4 -C 7 -cycloalkyl, which can also contain an oxygen atom in the ring, aryl, C 7 -C 20 - Mention should be made of aralkyl, C 1 -C 20 acyl, aroyl and C 1 -C 20 alkoxycarbonyl.

Als Alkyl-, Silyl- und Acylreste für die Schutzgruppen PG kommen die dem Fachmann bekannten Reste in Betracht. Bevorzugt sind aus den entsprechenden Alkyl- und Silylethern leicht abspaltbare Alkyl- bzw. Silylreste, wie beispielsweise der Methoxymethyl-, Methoxyethyl-, Ethoxyethyl-, Tetrahydropyranyl-, Tetrahydrofuranyl-, Trimethylsilyl-, Triethylsilyl-, tert.-Butyldimethylsilyl-, tert.-Butyldiphenylsilyl-, Tribenzylsilyl-, Triisopropylsilyl-, Benzyl-, para-Nitrobenzyl-, para-Methoxybenzyl-Rest sowie Alkylsulfonyl- und Arylsulfonylreste. Als Acylreste kommen z. B. Formyl, Acetyl, Propionyl, Isopropionyl, Pivalyl, Butyryl oder Benzoyl, die mit Amino- und/oder Hydroxygruppen substituiert sein können, in Frage.The person skilled in the art will find alkyl, silyl and acyl radicals for the protective groups PG known remains into consideration. Are preferred from the corresponding alkyl and Alkyl or silyl radicals that can be easily split off from silyl ethers, such as, for example Methoxymethyl, methoxyethyl, ethoxyethyl, tetrahydropyranyl, tetrahydrofuranyl, Trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, Tribenzylsilyl, triisopropylsilyl, benzyl, para-nitrobenzyl, para-methoxybenzyl radical as well as alkylsulfonyl and arylsulfonyl radicals. As acyl radicals, for. B. formyl, acetyl, Propionyl, isopropionyl, pivalyl, butyryl or benzoyl, with amino and / or Hydroxy groups can be substituted in question.

Als Aminoschutzgruppen kommen die dem Fachmann bekannten Reste in Betracht. Beispielsweise genannt seien die Alloc-, Boc-, Z-, Benzyl-, f-Moc-, Troc-, Stabase- oder Benzostabase-Gruppe.The residues known to the person skilled in the art can be used as amino protective groups. Examples include the Alloc, Boc, Z, Benzyl, f-Moc, Troc, Stabase or Benzostabase group.

Die Acylgruppen PG können 1 bis 20 Kohlenstoffatome enthalten, wobei Formyl-, Acetyl-, Propionyl-, Isopropionyl- und Pivalylgruppen bevorzugt sind.The acyl groups PG can contain 1 to 20 carbon atoms, whereby formyl, Acetyl, propionyl, isopropionyl and pivalyl groups are preferred.

Der Index m in der aus R1a und R1b gebildeten Alkylengruppe steht vorzugsweise für 1, 2, 3 oder 4.The index m in the alkylene group formed from R 1a and R 1b is preferably 1, 2, 3 or 4.

Die für R30, R31, U, V, W und X mögliche C2-C10-Alkylen-α,ω-dioxygruppe ist vorzugsweise eine Ethylenketal- oder Neopentylketalgruppe. The C 2 -C 10 -alkylene-α, ω-dioxy group possible for R 30 , R 31 , U, V, W and X is preferably an ethylene ketal or neopentyl ketal group.

Die nachstehend genannten Verbindungen sind erfindungsgemäß bevorzugt:
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13- tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-fluor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-chlor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13- tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-fluor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-chlor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1- oxa-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-fluor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-chlor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13- tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-chlor-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl- 2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13- tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-chlor-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1- oxa-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-chlor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-methyl-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-fluor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-chlor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-methyl-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-fluor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-chlor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methiazol-4-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-methyl-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1- oxa-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-chlor-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl- 2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-chlor-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-methyl-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1- oxa-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-chlor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-methyl-2- (2-methyloxazol-4-yl-ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-fluor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-chlor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-methyl-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-fluor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-chlor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-methyl-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1- oxa-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-chlor-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl- 2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,93,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-chlor-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-methyl-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1- oxa-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-chlor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5-trimethylen-9,13-dimethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa-5,5- trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- pyridyl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa-5,5- trimethylen-9,13-dimethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-pyridyl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5-trimethylen-9,13-dimethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-pyridyl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5-trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2- (2-methylthiazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5-trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- methylthiazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-oxa- 5,5-trimethylen-9,13-dimethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5-trimethylen-9,13-dimethyl-7-(oxacyclopropylmethyl)-cyclohexadec- 13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-oxa- 5,5-trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5-trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5-trimethylen-9,13-dimethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl- 2-(2-methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5-trimethylen-9,13-dimethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1- oxa-5,5-trimethylen-9,13-dimethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6- dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (2-(2-methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5-trimethylen-9,13-dimethyl-7-(oxacyclopropylmethyl)-cyclohexadec- 13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-chlor-2-(2-methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1- methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1- methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1- methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1- methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1- yl)-3-(1-methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1- methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1- methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-en-1-yl)-3-(1- methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1- methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1- yl)-3-(1-methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-oxa-5,5,9,13- tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1- methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-oxa-5,5,9,13- tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1- methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-oxa-5,5,9,13- tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1- methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-oxa-5,5,9,13- tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1- methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-oxa-5,5,9,13- tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1- yl)-3-(1-methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1- methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1- methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1- methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1- methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1- yl)-3-(1-methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1- methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1- methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1- methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1- methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1- yl)-3-(1-methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-aza-5,5,9,13- tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1- methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-aza-5,5,9,13- tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1- methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-aza-5,5,9,13- tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1- methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-aza-5,5,9,13- tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1- methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-aza-5,5,9,13- tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1- yl)-3-(1-methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-aza-5,5,9,13- tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-fluor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-chlor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-aza-5,5,9,13- tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-fluor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-chlor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1- aza-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-fluor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-chlor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-aza-5,5,9,13- tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-chlor-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl- 2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-aza-5,5,9,13- tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-chlor-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1- aza-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-chlor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-methyl-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-fluor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-chlor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-methyl-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-fluor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-chlor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-methyl-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1- aza-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-chlor-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl- 2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-chlor-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-methyl-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1- aza-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-chlor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-methyl-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-fluor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-chlor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-methyl-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-fluor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-chlor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-methyl-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1- aza-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-chlor-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl- 2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-chlor-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-methyl-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1- aza-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-chlor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-aza- 5,5-trimethylen-9,13-dimethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza-5,5- trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- pyridyl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza-5,5- trimethylen-9,13-dimethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-pyridyl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza- 5,5-trimethylen-9,13-dimethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-pyridyl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5-trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2- (2-methylthiazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5-trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- methylthiazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-aza- 5,5-trimethylen-9,13-dimethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5-trimethylen-9,13-dimethyl-7-(oxacyclopropylmethyl)-cyclohexadec- 13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-aza- 5,5-trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5-trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5-trimethylen-9,13-dimethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl- 2-(2-methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5-trimethylen-9,13-dimethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1- aza-5,5-trimethylen-9,13-dimethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6- dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (2-(2-methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5-trimethylen-9,13-dimethyl-7-(oxacyclopropylmethyl)-cyclohexadec- 13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-chlor-2-(2-methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13- tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)- 1-oxa- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- fluor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- chlor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- methyl-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- fluor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- chlor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- methyl-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- fluor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- chlor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-aza-5,5,9,13- tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- fluor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- chlor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- methyl-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- fluor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R, 3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- chlor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- methyl-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- fluor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- chlor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion The compounds mentioned below are preferred according to the invention:
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-oxa-5,5,9,13- tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- [2- (2 - pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-chloro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-oxa-5,5,9,13- tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- [2- (2 - pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-chloro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa-5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-methyl -2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9 , 13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (2- ( 2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa- 5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-fluoro -2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-oxa- 5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-chloro -2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-oxa-5,5,9,13- tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (2- (2 - pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-chloro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-oxa-5,5,9,13- tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- [2- (2 - pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-chloro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa-5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-methyl-2- (2- pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9 , 13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa- 5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-oxa- 5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-chloro-2- (2- pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4- yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- [2- (2 - methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-chloro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4- yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- [2- (2 - methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-chloro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-methyl-2- (2-methiazol-4-4-yl) ethenyl) -1-oxa-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-methyl -2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-oxa-5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (2- ( 2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-fluoro -2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-chloro -2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4- yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (2- (2 - methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-chloro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4- yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- [2- (2 - methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-chloro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-methyl-2- (2- methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-oxa-5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (2- (2-methylthiazole-4- yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-chloro-2- (2- methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl-ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- [2- (2 - methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-chloro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- [2- (2 - methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-chloro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-methyl -2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-oxa-5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (2- ( 2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-fluoro -2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-chloro -2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (2- (2 - methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-chloro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- [2- (2 - methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 93,13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-chloro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-methyl-2- (2- methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-oxa-5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (2- (2-methyloxazole-4- yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-chloro-2- (2- methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5- trimethylene-9,13-dimethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa-5,5- trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa-5,5- trimethylene-9,13-dimethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa- 5 , 5-trimethylene-9,13-dimethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- pyridyl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4- yl) ethenyl) -1-oxa- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-oxa- 5,5- trimethylene-9,13-dimethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- [2- (2 - methylthiazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -1 -oxa-5,5-trimethylene-9,13-dimethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- methylthiazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5- trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (2- (2 - methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-oxa-5 , 5-trimethylene-9,13-dimethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (2- (2-methyloxazole-4- yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) -1 -oxa-5,5-trimethylene-9,13-dimethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-chloro-2- (2- methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1- methyl- 2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1- methyl- 2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1- methyl- 2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1- methyl- 2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1- methyl- 2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1- methyl- 2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-en-1-yl) -3- (1-methyl-2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1- methyl- 2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-oxa-5,5,9,13-tetramethyl-7 - (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1- methyl- 2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (quinolin-2-yl) -1-oxa-5,5,9,13-tetramethyl-7- ( prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1- methyl- 2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-oxa-5,5,9,13-tetramethyl-7 - (But-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1- methyl- 2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-oxa-5,5,9,13-tetramethyl-7 - (But-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1- methyl- 2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-oxa-5,5,9,13-tetramethyl-7 - (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1- methyl- 2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1- methyl- 2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1- methyl- 2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1- methyl- 2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1- methyl- 2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1- methyl- 2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1- methyl- 2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1- methyl- 2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-aza-5,5,9,13-tetramethyl-7 - (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1- methyl- 2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-aza-5,5,9,13-tetramethyl-7 - (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1- methyl- 2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-aza-5,5,9,13-tetramethyl-7 - (But-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1- methyl- 2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-aza-5,5,9,13-tetramethyl-7 - (But-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1- methyl- 2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-aza-5,5,9,13-tetramethyl-7 - (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-aza-5,5,9,13- tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- [2- (2 - pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-chloro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-aza-5,5,9,13- tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- [2- (2 - pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-chloro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-methyl -2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-aza-5,5,9 , 13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (2- ( 2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-fluoro -2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-chloro -2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-aza-5,5,9,13- tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (2- (2 - pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-chloro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-aza-5,5,9,13- tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- [2- (2 - pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-chloro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-methyl-2- (2- pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-aza-5,5,9 , 13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-chloro-2- (2- pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- [2- (2 - methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-chloro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- [2- (2 - methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-chloro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-methyl -2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (2- ( 2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-fluoro -2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-chloro -2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (2- (2 - methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-chloro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- [2- (2 - methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-chloro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-methyl-2- (2- methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (2- (2-methylthiazole-4- yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-chloro-2- (2- methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- [2- (2 - methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-chloro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- [2- (2 - methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-chloro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-methyl -2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (2- ( 2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-fluoro -2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-chloro -2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (2- (2 - methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-chloro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- [2- (2 - methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-chloro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-methyl-2- (2- methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (2- (2-methyloxazole-4- yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-chloro-2- (2- methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-aza- 5,5- trimethylene-9,13-dimethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5,5- trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5,5- trimethylene-9,13-dimethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5 , 5-trimethylene-9,13-dimethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- pyridyl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1-aza- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-aza- 5,5- trimethylene-9,13-dimethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- [2- (2 - methylthiazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -1 -aza-5,5-trimethylene-9,13-dimethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- methylthiazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-aza- 5,5- trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (2- (2 - methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-aza- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-aza-5 , 5-trimethylene-9,13-dimethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (2- (2-methyloxazole-4- yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) -1 -aza-5,5-trimethylene-9,13-dimethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-chloro-2- (2- methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-oxa-5,5,9,13- tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) - 1-oxa- 5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-fluoro-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-chloro-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4- yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-chloro-2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-chloro-2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-aza-5,5,9,13- tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-fluoro-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-chloro-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-chloro-2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-chloro-2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione

Darstellung der Teilfragmente ARepresentation of the partial fragments A

Die Teilfragmente (Synthesebausteine) der allgemeinen Formel A-1 lassen sich ausgehend von den in WO 99/07692 beschriebenen Vorstufen wie beispielsweise A-I herstellen. Dies wird beispielhaft in Schema 1 weiter ausgeführtThe partial fragments (synthesis building blocks) of the general formula A-1 can be starting from the precursors described in WO 99/07692, such as, for example, A-I produce. This is exemplified further in scheme 1

Schema 1 Scheme 1

Schritt a (A-I ⇒ A-II)Step a (A-I ⇒ A-II)

Die durch PG7 in A-I geschützte Hydroxylgruppe wird freigesetzt. Als Schutzgruppe PG7 kommen die, dem Fachmann bekannten Schutzgruppen wie z. B. der Methoxymethyl-, Methoxyethyl-, Ethoxyethyl-, Tetrahydropyranyl-, Tetrahydrofuranyl-, Trimethylsilyl-, Triethylsilyl-, tert.-Butyldimethylsilyl-, tert.-Butyldiphenylsilyl-, Tribenzylsilyl-, Triisopropylsilyl-, Benzyl-, para-Nitrobenzyl-, para-Methoxybenzyl-, Formyl-, Acetyl-, Propionyl-, Isopropionyl-, Pivalyl-, Butyryl- oder Benzoylrest in Frage. Eine Übersicht befindet sich z. B. in "Protective Groups in Organic Synthesis" Theodora W. Green, John Wiley and Sons).The hydroxyl group protected by PG 7 in AI is released. As protective group PG 7, the come, known to those skilled protecting groups such. B. the methoxymethyl, methoxyethyl, ethoxyethyl, tetrahydropyranyl, tetrahydrofuranyl, trimethylsilyl, triethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, tribenzylsilyl, triisopropylsilyl, benzyl, benzyl, para-methoxybenzyl, formyl, acetyl, propionyl, isopropionyl, pivalyl, butyryl or benzoyl radical in question. An overview is z. B. "Protective Groups in Organic Synthesis" Theodora W. Green, John Wiley and Sons).

Bevorzugt sind solche Schutzgruppen, die unter Einwirkung von Fluorid gespalten werden können, wie z. B. der Trimethylsilyl-, tert.-Butyldimethylsilyl-, tert.- Butyldiphenylsilyl-, Tribenzylsilyl-, Triisopropylsilyl-Rest.Preference is given to protecting groups which are cleaved under the action of fluoride can be, such as B. the trimethylsilyl, tert.-butyldimethylsilyl, tert.- Butyldiphenylsilyl, tribenzylsilyl, triisopropylsilyl radical.

Besonders bevorzugt ist der tert.-Butyldimethylsilyl-, der Triisopropylsilyl- und der tert.- Butyldiphenylsilyl-Rest. Particularly preferred is the tert-butyldimethylsilyl, the triisopropylsilyl and the tert.- Butyldiphenylsilyl radical.

Als Schutzgruppen PG8a und PG8b kommen die bereits für PG7 genannten Gruppen sowie gemeinsam eine -CR28aR28b- -Gruppe, worin R28a und R28b gleich oder verschieden sein können und Wasserstoff, C1-C10-Alkyl, Aryl, C7-C20-Aralkyl bedeuten, in Frage.Protective groups PG 8a and PG 8b are the groups already mentioned for PG 7 and, together, a -CR 28a R 28b - group, in which R 28a and R 28b can be identical or different and are hydrogen, C 1 -C 10 -alkyl, aryl , C 7 -C 20 aralkyl are in question.

Bevorzugt sind solche -CR28aR28b- -Schutzgruppen, worin R28a und R28b C1-C8- Alkyl oder R28a Wasserstoff und R28b Aryl bedeuten.Preference is given to those —CR 28a R 28b - protective groups in which R 28a and R 28b are C 1 -C 8 -alkyl or R 28a are hydrogen and R 28b are aryl.

Besonders bevorzugt ist eine -C(CH3)2- -Gruppe.A -C (CH 3 ) 2 - group is particularly preferred.

Die Schutzgruppe PG7 wird nach den dem Fachmann bekannten Verfahren gespalten. Handelt es sich um einen Silylether, so eignet sich für die Spaltung die Umsetzung mit Fluoriden wie beispielsweise Tetrabutylammoniumfluorid, dem Fluorwasserstoff-Pyridin- Komplex, Kaliumfluorid oder die Anwendung verdünnter Mineralsäuren, die Verwendung von katalytischen Mengen Säuren wie z. B. para-Toluolsulfonsäure, para- Toluolsulfonsäure-pyridiniumsalz, Camphersulfonsäure in alkoholischen Lösungen, vorzugsweise in Ethanol oder Isopropanol.The protective group PG 7 is cleaved according to the method known to the person skilled in the art. If it is a silyl ether, the reaction with fluorides such as tetrabutylammonium fluoride, the hydrogen fluoride-pyridine complex, potassium fluoride or the use of dilute mineral acids is suitable for the cleavage. B. para-toluenesulfonic acid, para-toluenesulfonic acid pyridinium salt, camphorsulfonic acid in alcoholic solutions, preferably in ethanol or isopropanol.

Schritt b (A-II ⇒ A-III)Step b (A-II ⇒ A-III)

Die Oxidation des primären Alkohols in A-II zum Aldehyd A-III erfolgt nach den, dem Fachmann bekannten Methoden. Beispielsweise genannt sei die Oxidation mit Pyridiniumchlorochromat, Pyridiniumdichromat, Chromtrioxid-Pyridin-Komplex, die Oxidation nach Swern oder verwandter Methoden z. B. unter Verwendung von Oxalylchlorid in Dimethylsulfoxid, die Verwendung des Dess-Martin-Periodinans, die Verwendung von Stickstoffoxiden wie z. B. N-Methyl-morpholino-N-oxid in Gegenwart geeigneter Katalysatoren wie z. B. Tetrapropylammoniumperruthenat in inerten Lösungsmitteln. Bevorzugt ist die Oxidation nach Swern sowie mit N-Methyl- morpholino-N-oxid unter Verwendung von Tetrapropylammoniumperruthenat.The oxidation of the primary alcohol in A-II to the aldehyde A-III takes place after, the Methods known to those skilled in the art. Oxidation with may be mentioned as an example Pyridinium chlorochromate, pyridinium dichromate, chromium trioxide pyridine complex, the Oxidation according to Swern or related methods e.g. B. using Oxalyl chloride in dimethyl sulfoxide, the use of the Dess-Martin periodinane, the Use of nitrogen oxides such. B. N-methyl-morpholino-N-oxide in the presence suitable catalysts such. B. Tetrapropylammonium perruthenate in inert Solvents. Oxidation according to Swern and with N-methyl- morpholino-N-oxide using tetrapropylammonium perruthenate.

Schritt c (A-III ⇒ A-IV)Step c (A-III ⇒ A-IV)

Die Umsetzung der Aldehyde A-III zu Alkoholen der Formel A-IV erfolgt mit metallorganischen Verbindungen der theoretischen Formel M-CH2R2a', worin M für Indium, ein Alkalimetall, vorzugsweise Lithium oder ein zweiwertiges Metall MX, worin X ein Halogen repräsentiert und der Rest R2a' die oben genannten Bedeutungen aufweist. Als zweiwertiges Metall ist bevorzugt Magnesium und Zink, als Halogen X ist bevorzugt Chlor, Brom und Iod.The conversion of the aldehydes A-III to alcohols of the formula A-IV takes place with organometallic compounds of the theoretical formula M-CH 2 R 2a ' , where M is indium, an alkali metal, preferably lithium or a divalent metal MX, where X represents a halogen and the radical R 2a 'has the meanings given above. Magnesium and zinc are preferred as divalent metal, chlorine, bromine and iodine are preferred as halogen X.

Schritt d (A-IV ⇒ A-V)Step d (A-IV ⇒ A-V)

Die Oxidation des sekundären Alkohols in A-IV zum Keton A-V erfolgt nach den, unter Schritt b) genannten Bedingungen. Bevorzugt ist die Oxidation mit N-Methyl- morpholino-N-oxid unter Verwendung von Tetrapropylammoniumperruthenat.The oxidation of the secondary alcohol in A-IV to the ketone A-V takes place according to the, below Step b) mentioned conditions. Oxidation with N-methyl- morpholino-N-oxide using tetrapropylammonium perruthenate.

Schritt e (A-V ⇒ A-VI)Step e (A-V ⇒ A-VI)

Zur optionalen Einführung eines Restes R2b', der außer Wasserstoff die bereits genannten Bedeutungen besitzen kann, wird das Keton der allgemeinen Formel A-V unter Verwendung starker Basen wie vorzugsweise Lithiumdiisopropylamid in das Enolat mit M in der Bedeutung des Gegenkations überführt.For the optional introduction of a radical R 2b ' , which can have the meanings already mentioned in addition to hydrogen, the ketone of the general formula AV is converted into the enolate with M as the counter cation using strong bases such as, preferably, lithium diisopropylamide.

Schritt f (A-VI ⇒ A-VII)Step f (A-VI ⇒ A-VII)

Das Enolat der Formel A-VI wird mit einer Verbindung der allgemeinen Formel X-R2b', worin X ein Halogen oder eine sonstige Abgangsguppe wie beispielsweise ein Alkyl- oder Arylsulfonat repräsentiert, umgesetzt. Als Halogen X ist bevorzugt Chlor, Brom und Iod.The enolate of the formula A-VI is reacted with a compound of the general formula XR 2b ' , in which X represents a halogen or another leaving group such as, for example, an alkyl or aryl sulfonate. The preferred halogen X is chlorine, bromine and iodine.

Die Teilfragmente (Synthesebausteine) der allgemeinen Formel A-2 lassen sich wie in Angew. Chemie 1996, 108, 2976-2978 beschrieben herstellen. Ein weiteres Verfahren zeigt Schema 2:The partial fragments (synthesis building blocks) of the general formula A-2 can be broken down as in Angew. Chemie 1996, 108, 2976-2978 described. Another procedure shows scheme 2:

Schema 2 Scheme 2

Schritt a (A-VIII ⇒ A-IX)Step a (A-VIII ⇒ A-IX)

Die Oxidation des primären Alkohols in A-VIII zum Aldehyd A-IX erfolgt nach den für Schema 1, Schritt b beschriebenen Methoden. Bevorzugt ist die Oxidation nach Swern sowie mit N-Methyl-morpholino-N-oxid unter Verwendung von Tetrapropylammoniumperruthenat. The oxidation of the primary alcohol in A-VIII to the aldehyde A-IX takes place according to the for Scheme 1, step b described methods. The Swern oxidation is preferred as well as with N-methyl-morpholino-N-oxide using Tetrapropylammonium perruthenate.

Schritt b (A-IX ⇒ A-X)Step b (A-IX ⇒ A-X)

Die Carbonylgruppe in A-IX kann gegebenfalls nach den, dem Fachmann bekannten Methoden in ein Ketal überführt werden.The carbonyl group in A-IX can, if appropriate, according to those known to the person skilled in the art Methods can be converted into a ketal.

Schritt c (A-X ⇒ A-XI)Step c (A-X ⇒ A-XI)

Die durch PG9 in A-X geschützte Hydroxylgruppe wird freigesetzt. Als Schutzgruppe PG9 kommen die unter Schema 1, Schritt a beschriebenen Schutzgruppen in Betracht. Bevorzugt sind solche Schutzgruppen, die unter Einwirkung von Fluorid gespalten werden können, wie z. B. der Trimethylsilyl-, tert.-Butyldimethylsilyl-, tert.- Butyldiphenylsilyl-, Tribenzylsilyl-, Triisopropylsilyl-Rest.The hydroxyl group protected by PG 9 in AX is released. As protective group PG 9 , the protective groups described under scheme 1, step a come into consideration. Preference is given to those protecting groups which can be cleaved under the action of fluoride, such as. B. the trimethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, tribenzylsilyl, triisopropylsilyl radical.

Besonders bevorzugt ist der tert.-Butyldimethylsilyl-, der Triisopropylsilyl- und der tert.- Butyldiphenylsilyl-Rest.Particularly preferred is the tert-butyldimethylsilyl, the triisopropylsilyl and the tert.- Butyldiphenylsilyl radical.

Schritt d (A-XI ⇒ A-XII)Step d (A-XI ⇒ A-XII)

Die Oxidation des primären Alkohols in A-IX zum Aldehyd A-XII erfolgt nach den für Schema 1, Schritt b beschriebenen Methoden. Bevorzugt ist die Oxidation nach Swern sowie mit N-Methyl-morpholino-N-oxid unter Verwendung von Tetrapropylammoniumperruthenat.The oxidation of the primary alcohol in A-IX to the aldehyde A-XII takes place according to the for Scheme 1, step b described methods. The Swern oxidation is preferred as well as with N-methyl-morpholino-N-oxide using Tetrapropylammonium perruthenate.

Schritt e (A-XII ⇒ A-XIII)Step e (A-XII ⇒ A-XIII)

Die Einführung der Reste R2a' und/oder R2b' und Darstellung des Ketons A-XIII erfolgt wie unter Schema 1 in den Schritten c bis f beschrieben.The introduction of the radicals R 2a ' and / or R 2b' and the preparation of the ketone A-XIII are carried out as described under scheme 1 in steps c to f.

Darstellung der Teilfragmente BRepresentation of the partial fragments B

Die Teilfragmente (Synthesebausteine) der allgemeinen Formel B lassen sich wie in WO 99/07692 beschrieben herstellen.The partial fragments (synthesis building blocks) of the general formula B can be broken down as in WO 99/07692 described produce.

Darstellung der Teilfragmente CRepresentation of the partial fragments C

Die Teilfragmente (Synthesebausteine) der allgemeinen Formel C lassen sich wie in DE 197 51 200.3, DE 199 07 480.1 und WO 99/07692 sowie in der PCT/EP00/01333 und Beispiel 21 beschrieben, herstellen.The partial fragments (synthesis building blocks) of the general formula C can be as in DE 197 51 200.3, DE 199 07 480.1 and WO 99/07692 as well as in PCT / EP00 / 01333 and Example 21 described, produce.

Darstellung der Teilfragmente ABC und deren Zyklisierung zu I erfolgt ebenfalls analog wie in WO 99/07692 für zahlreiche Epothilon-Derivate beschrieben ist, mit der Abweichung, daß in den bekannten Derivaten in 6-Position kein ungesättigter Rest steht. WO 99/07692 belegt schon die allgemeine Anwendbarkeit des nachfolgend für die erfindungsgemäßen Verbindungen beschriebenen Syntheseprinzips. Außerdem gehen aus WO 99/07692 zahlreiche Synthesebausteine der allgemeinen Formeln A, B und C hervor, mit denen, gegebenenfalls in modifizierter Form im Falle der erfindungsgemäßen Substitution am Kohlenstoffatom 6, sich weitere der hier beanspruchten Verbindungen der allgemeinen Formel I erhalten fassen. Synthesebausteine der allgemeinen Formel C, in denen als R8 ein Halogenatom, insbesondere ein Fluor-, Chlor- oder Bromatom, vorhanden ist, sind Gegenstand der DE 199 07 480.1 sowie der PCT/EP00/01333.Representation of the partial fragments ABC and their cyclization to I also takes place analogously to that described in WO 99/07692 for numerous epothilone derivatives, with the difference that there is no unsaturated radical in the 6-position in the known derivatives. WO 99/07692 already proves the general applicability of the synthesis principle described below for the compounds according to the invention. In addition, WO 99/07692 reveals numerous synthetic building blocks of the general formulas A, B and C with which, optionally in modified form in the case of the substitution according to the invention at carbon atom 6, further compounds of the general formula I claimed here can be obtained. Synthesis building blocks of the general formula C in which a halogen atom, in particular a fluorine, chlorine or bromine atom, is present as R 8 , are the subject matter of DE 199 07 480.1 and PCT / EP00 / 01333.

Teilfragmente der allgemeinen Formel AB
Partial fragments of the general formula AB

worin R1a', R1b', R2a', R2b', R3a, R4, R5, R13, R14, R30, R31, V und Z die bereits genannten Bedeutungen haben und PG14 ein Wasserstoffatom oder eine Schutzgruppe PG darstellt, werden aus den zuvor genannten Fragmenten A und B nach dem in Schema 3 gezeigten Verfahren erhalten.wherein R 1a ' , R 1b' , R 2a ' , R 2b' , R 3a , R 4 , R 5 , R 13 , R 14 , R 30 , R 31 , V and Z have the meanings already mentioned and PG 14 is a Represents hydrogen atom or a protecting group PG are obtained from the aforementioned fragments A and B according to the procedure shown in Scheme 3.

Schema 3 Scheme 3

Schritt aa (A + B ⇒ AB)Step aa (A + B ⇒ AB)

Die Verbindung B, worin W die Bedeutung eines Sauerstoffatomes hat und eventuell vorhandene zusätzliche Carbonylgruppen geschützt sind, wird mit dem Enolat einer Carbonylverbindung der allgemeinen Formel A alkyliert. Das Enolat wird durch Einwirkung starker Basen wie z. B. Lithiumdiisopropylamid, Lithiumhexamethyldisilazan bei niedrigen Temperaturen hergestellt.The compound B, in which W has the meaning of an oxygen atom and possibly Any additional carbonyl groups present are protected, becomes one with the enolate Carbonyl compound of the general formula A is alkylated. The enolate is through Exposure to strong bases such as B. lithium diisopropylamide, lithium hexamethyldisilazane manufactured at low temperatures.

Teilfragmente der allgemeinen Formel BC
Partial fragments of the general formula BC

worin R3a, R4, R5, R6, R7, R20, D, E, G und W die bereits genannten Bedeutungen haben, werden aus den zuvor beschriebenen Fragmenten B und C nach dem in Schema 4 gezeigten Verfahren erhalten.wherein R 3a , R 4 , R 5 , R 6 , R 7 , R 20 , D, E, G and W have the meanings already mentioned, are obtained from the previously described fragments B and C by the method shown in Scheme 4.

Schema 4 Scheme 4

Schritt ab (B + C ⇒ BC)Step down (B + C ⇒ BC)

Die Verbindung C, in der R21 die Bedeutung eines Wittigsalzes hat und eventuell vorhandene zusätzliche Carbonylgruppen geschützt sind, wird durch eine geeignete Base wie z. B. n-Butyllithium, Lithiumdiisopropylamid, Kalium-tert.butanolat, Natrium- oder Lithium-hexamethyldisilazid deprotoniert und mit einer Verbindung B, worin V die Bedeutung von Sauerstoff und W die Bedeutung zweier Alkoxygruppen OR19, einer C2-C10-Alkylen-α,ω-dioxygruppe, die geradkettig oder verzweigt sein kann oder H/OR18 hat, umsetzt.The compound C, in which R 21 has the meaning of a Wittig salt and any additional carbonyl groups present are protected, is replaced by a suitable base such as. B. n-butyllithium, lithium diisopropylamide, potassium tert-butoxide, sodium or lithium hexamethyldisilazide and deprotonated with a compound B, where V is the meaning of oxygen and W is two alkoxy groups OR 19 , a C 2 -C 10 alkylene -α, ω-dioxy group, which can be straight-chain or branched or has H / OR 18 , converts.

Teilfragmente der allgemeinen Formel ABC (AB + C)
Partial fragments of the general formula ABC (AB + C)

worin R1a', R1b', R2a', R2b', R3a, R4, R5, R6, R7, R13, R14, R30, R31, D, E, G und Z die bereits genannten Bedeutungen haben und PG14 ein Wasserstoffatom oder eine Schutzgruppe PG darstellt, werden aus den zuvor beschriebenen Fragmenten AB und C nach dem in Schema 5 und Schema 6 gezeigten Verfahren erhalten.wherein R 1a ' , R 1b' , R 2a ' , R 2b' , R 3a , R 4 , R 5 , R 6 , R 7 , R 13 , R 14 , R 30 , R 31 , D, E, G and Z have the meanings already mentioned and PG 14 represents a hydrogen atom or a protective group PG are obtained from the fragments AB and C described above by the process shown in Scheme 5 and Scheme 6.

Schema 5 Scheme 5

Schritt ac (AB + C ⇒ ABC)Step ac (AB + C ⇒ ABC)

Die Verbindung C, in der R21 die Bedeutung eines Wittigsalzes hat und eventuell vorhandene zusätzliche Carbonylgruppen gegebenenfalls geschützt sind, wird durch eine geeignete Base wie z. B. n-Butyllithium, Lithiumdiisopropylamid, Kalium- tert.butanolat, Natrium- oder Lithium-hexamethyldisilazid deprotoniert und mit einer Verbindung AB, worin V die Bedeutung eines Sauerstoffatomes hat, umgesetzt.The compound C, in which R 21 has the meaning of a Wittig salt and any additional carbonyl groups present may be protected, is replaced by a suitable base such as. B. n-butyllithium, lithium diisopropylamide, potassium tert-butanolate, sodium or lithium hexamethyldisilazide deprotonated and reacted with a compound AB, where V is an oxygen atom.

Schema 6 Scheme 6

Schritt ad (A + BC ⇒ ABC)Step ad (A + BC ⇒ ABC)

Die Verbindung BC, worin W die Bedeutung eines Sauerstoffatomes hat und eventuell vorhandene zusätzliche Carbonylgruppen geschützt sind, wird mit dem Enolat einer Carbonylverbindung der allgemeinen Formel A alkyliert. Das Enolat wird durch Einwirkung starker Basen wie z. B. Lithiumdiisopropylamid, Lithiumhexamethyldisilazan bei niedrigen Temperaturen hergestellt. The compound BC, in which W has the meaning of an oxygen atom and possibly Any additional carbonyl groups present are protected, becomes one with the enolate Carbonyl compound of the general formula A is alkylated. The enolate is through Exposure to strong bases such as B. lithium diisopropylamide, lithium hexamethyldisilazane manufactured at low temperatures.

Schritt ae (ABC-1 ⇒ I)Step ae (ABC-1 ⇒ I)

Die Verbindungen ABC-1, in denen R13 eine Carbonsäure CO2H und R20 eine Hydroxylgruppe oder eine Aminogruppe darstellt, setzt man nach den, dem Fachmann bekannten Methoden für die Bildung großer Macrolide bzw. Macrolactame zu Verbindungen der Formel I, in denen A-Y die Bedeutung einer O-(C=O)-Gruppe oder NR29-C(=O)-Gruppe besitzt, um. Beispielsweise bevorzugt für die Lactonbildung wird die in "Reagents for Organic Synthesis, Vol. 16, p 353" beschriebene Methode unter Verwendung von 2,4,6-Trichlorbenzoesäurechlorid und geeigneten Basen wie z. B. Triethylamin, 4-Dimethylaminopyridin, Natriumhydrid. Beispielsweise bevorzugt für die Lactambildung wird die Umsetzung der Aminosäure (R13 eine Carbonsäure CO2H und R20 eine NHR29-Gruppe) mit Diphenylphosphorylazid in Gegenwart einer Base.The compounds ABC-1, in which R 13 is a carboxylic acid CO 2 H and R 20 is a hydroxyl group or an amino group, are converted to compounds of the formula I according to the methods known to the person skilled in the art for the formation of large macrolides or macrolactams AY has the meaning of an O- (C = O) group or NR 29 -C (= O) group to. For example, preferred for lactone formation is the method described in "Reagents for Organic Synthesis, Vol. 16, p 353" using 2,4,6-trichlorobenzoic acid chloride and suitable bases such as. B. triethylamine, 4-dimethylaminopyridine, sodium hydride. For example, preferred for lactam formation is the reaction of the amino acid (R 13 a carboxylic acid CO 2 H and R 20 an NHR 29 group) with diphenylphosphoryl azide in the presence of a base.

Schritt af (ABC-1 ⇒ I)Step af (ABC-1 ⇒ I)

Die Verbindungen ABC-1, in denen R13 eine Gruppe CH2OH und R20 eine Hydroxylgruppe darstellt, lassen sich vorzugsweise unter Verwendung von Triphenylphosphin und Azodiestern wie beispielsweise Azodicarbonsäurediethylester zu Verbindungen der Formel I, in denen A-Y die Bedeutung einer O-CH2-Gruppe hat, umsetzen.The compounds ABC-1, in which R 13 is a group CH 2 OH and R 20 is a hydroxyl group, can preferably be converted to compounds of the formula I in which AY has the meaning of O-CH 2 using triphenylphosphine and azodiesters such as, for example, azodicarboxylic acid diethyl ester -Group has to implement.

Die Verbindungen ABC, in denen R13 eine Gruppe CH2-Hal oder CH2OSO2Alkyl oder CH2OSO2Aryl oder CH2OSO2Aralkyl und R20 eine Hydroxylgruppe darstellt, lassen sich nach Deprotonierung mit geeigneten Basen wie beispielsweise Natriumhydrid, n- Butyllithium, 4-Dimethylaminopyridin, Hünig-Base, Alkalihexamethyldisilazanen zu Verbindungen der Formel I, in denen A-Y die Bedeutung einer O-CH2-Gruppe hat, zyklisieren.The compounds ABC, in which R 13 is a group CH 2 -Hal or CH 2 OSO 2 alkyl or CH 2 OSO 2 aryl or CH 2 OSO 2 aralkyl and R 20 is a hydroxyl group, can be after deprotonation with suitable bases such as sodium hydride, n-Butyllithium, 4-dimethylaminopyridine, Hünig base, alkali metal hexamethyldisilazanes to form compounds of the formula I in which AY has the meaning of an O-CH 2 group.

Schritt ag (ABC-2 ⇒ I)Step ag (ABC-2 ⇒ I)

Die Verbindungen ABC-2, in denen R30 und R31 gemeinsam ein Sauerstoffatom und R20 eine NR29SO2CH3-Gruppe darstellt, lassen sich durch Einwirkung starker Basen wie z. B. Lithiumdiisopropylamid, Lithiumhexamethyldisilazan bei niedrigen Temperaturen zum Sulfonamid I, in dem A-Y die Bedeutung einer NR29SO2-Gruppe hat, zyklisieren.The compounds ABC-2, in which R 30 and R 31 together represent an oxygen atom and R 20 represents an NR 29 SO 2 CH 3 group, can be removed by the action of strong bases such as. B. lithium diisopropylamide, lithium hexamethyldisilazane at low temperatures to the sulfonamide I, in which AY has the meaning of an NR 29 SO 2 group, cyclize.

Schritt ah (ABC-2 ⇒ I)Step ah (ABC-2 ⇒ I)

Die Verbindungen ABC-2, in denen R30 und R31 gemeinsam ein Sauerstoffatom und R20 eine O-C(=O)CH3-Gruppe darstellt, lassen sich durch Einwirkung starker Basen wie z. B. Lithiumdiisopropylamid, Alkalihexamethyldisilazan bei niedrigen Temperaturen zum Lacton I, in dem A-Y die Bedeutung einer O-C(=O)-Gruppe hat, zyklisieren.The compounds ABC-2, in which R 30 and R 31 together represent an oxygen atom and R 20 represents an OC (= O) CH 3 group, can be removed by the action of strong bases such as. B. lithium diisopropylamide, alkali hexamethyldisilazane at low temperatures to the lactone I, in which AY has the meaning of an OC (= O) group, cyclize.

Schritt ah (ABC-2 ⇒ I)Step ah (ABC-2 ⇒ I)

Die Verbindungen ABC-2, in denen R30 und R31 gemeinsam ein Sauerstoffatom und R20 eine CH2C(=O)CH3-Gruppe darstellt, lassen sich durch Einwirkung starker Basen wie z. B. Lithiumdiisopropylamid, Alkalihexamethyldisilazan bei niedrigen Temperaturen zum Lacton I, in dem A-Y die Bedeutung einer CH2C(=O)-Gruppe hat, zyklisieren.The compounds ABC-2, in which R 30 and R 31 together represent an oxygen atom and R 20 represents a CH 2 C (= O) CH 3 group, can be converted by the action of strong bases such as. B. lithium diisopropylamide, alkali hexamethyldisilazane at low temperatures to the lactone I, in which AY has the meaning of a CH 2 C (= O) group, cyclize.

Einführung der Stickstoffunktion für R20 Introduction of the nitrogen function for R 20

Die Aminogruppe NHR29 kann auf der Stufe des C-Fragmentes, des BC-Fragmentes oder des ABC-Fragmentes nach den, dem Fachmann bekannten Methoden eingeführt werden. Bevorzugt ist die Herstellung aus dem Azid (R20 = N3), das nach den, dem Fachmann bekannten Methoden vorzugsweise unter Verwendung eines Phosphins wie beispielsweise Triphenylphosphin zunächst in das Phosphaimin überführt wird, das dann in Gegenwart von Wasser in das gegebenenfalls für den weiteren Reaktionsverlauf zu schützende Amin (R20 = NHR29) überführt wird. Die Einführung des Azides kann unter Anwendung der Mitsunobu-Reaktion in Gegenwart von Metallaziden vorzugsweise Natrium- oder Zinkazid oder durch Substitution einer geeigneten Abgangsgruppe wie beispielsweise eines Chlor-, Brom- oder Iodatomes, einer Alkylsulfonyloxy-, einer perfluorierten Alkylsulfonyloxy-, einer Arylsulfonyloxy- oder einer Aralkylsulfonyloxy-Gruppe durch Azide erfolgen. The amino group NHR 29 can be introduced at the level of the C fragment, the BC fragment or the ABC fragment by methods known to the person skilled in the art. The preparation from the azide (R 20 = N 3 ) is preferred, which is first converted into the phosphaimine by the methods known to the person skilled in the art, preferably using a phosphine such as triphenylphosphine, which is then converted in the presence of water into the phosphaimine, if necessary for the further Amine to be protected (R 20 = NHR 29 ) is transferred over the course of the reaction. The introduction of the azide can using the Mitsunobu reaction in the presence of metal azides, preferably sodium or zinc azide or by substitution of a suitable leaving group such as a chlorine, bromine or iodine atom, an alkylsulfonyloxy, a perfluorinated alkylsulfonyloxy, an arylsulfonyloxy or an aralkylsulfonyloxy group by azides.

Die flexible Funktionalisierung der beschriebenen Bausteine A, B und C gewährleistet auch eine von dem oben beschriebenen Verfahren abweichende Verknüpfungsreihenfolge, die zu den Bausteinen ABC führt. Diese Verfahren sind in der folgenden Tabelle zusammengestellt:
The flexible functionalization of the described building blocks A, B and C also ensures a linking sequence that deviates from the method described above and leads to the building blocks ABC. These procedures are summarized in the following table:

Nach diesen Verfahren la 99999 00070 552 001000280000000200012000285919988800040 0002010015836 00004 99880ssen sich die Bausteine A, B und C, wie in Schema 7 angegeben, verknüpfen:According to this procedure la 99999 00070 552 001000280000000200012000285919988800040 0002010015836 00004 99880 the building blocks A, B and C, as in scheme 7 specified, link:

Schema 7 Scheme 7

Freie Hydroxylgruppen in I, A, B, C, AB, BC, ABC können durch Veretherung oder Veresterung, freie Carbonylgruppen durch Ketalisierung, Enoletherbildung oder Reduktion weiter funktionell abgewandelt sein.Free hydroxyl groups in I, A, B, C, AB, BC, ABC can be etherified or Esterification, free carbonyl groups by ketalization, enol ether formation or Reduction to be further modified functionally.

Die Erfindung betrifft alle Stereoisomeren dieser Verbindungen und auch deren Gemische.The invention relates to all stereoisomers of these compounds and also to their Mixtures.

Die Erfindung betrifft weiterhin alle Prodrugformulierungen dieser Verbindungen, d. h. alle Verbindungen, die in vivo eine bioaktive Wirkstoffkomponente der allgemeinen Formel I freisetzen. The invention further relates to all prodrug formulations of these compounds, i. H. all compounds that are a bioactive component of the general in vivo Release Formula I.

Biologische Wirkungen und Anwendungsbereiche der neuen DerivateBiological effects and areas of application of the new derivatives

Die neuen Verbindungen der Formel I sind wertvolle Pharmaka. Sie interagieren mit Tubulin, indem sie gebildete Mikrotubuli stabilisieren und sind somit in der Lage, die Zellteilung phasenspezifisch zu beeinflussen. Dies betrifft vor allem schnell wachsende, neoplastische Zellen, deren Wachstum durch interzelluläre Regelmechnismen weitgehend unbeeinflußt ist. Wirkstoffe dieser Art sind prinzipiell geeignet zur Behandlung maligner Tumoren. Als Anwendungsbereich seien beispielweise genannt die Therapie von Ovarial-, Magen-, Colon-, Adeno-, Brust-, Lungen-, Kopf- und Nacken- Karzinomen, dem malignen Melanom, der akuten lymphozytären und myelocytären Leukämie. Die erfindungsgemäßen Verbindungen eignen sich aufgrund ihrer Eigenschaften prinzipiell zur Anti-Angiogenese-Therapie sowie zur Behandlung chronischer entzündlicher Erkrankungen wie beispielsweise der Psoriasis, der multiplen Sklerose oder der Arthritis. Zur Vermeidung unkontrollierter Zellwucherungen an sowie der besseren Verträglichkeit von medizinischen Implantaten lassen sie sich prinzipiell in die hierfür verwendeten polymeren Materialien auf- bzw. einbringen. Die erfindungsgemäßen Verbindungen können alleine oder zur Erzielung additiver oder synergistischer Wirkungen in Kombination mit weiteren in der Tumortherapie anwendbaren Prinzipien und Substanzklassen verwendet werden.The new compounds of the formula I are valuable pharmaceuticals. You interact with Tubulin by stabilizing formed microtubules and are thus able to produce the To influence cell division phase-specifically. This particularly applies to fast-growing, neoplastic cells whose growth is controlled by intercellular regulatory mechanisms is largely unaffected. Active ingredients of this type are in principle suitable for Treatment of malignant tumors. Examples of application areas are mentioned the therapy of ovarian, stomach, colon, adeno, chest, lung, head and neck Carcinoma, malignant melanoma, acute lymphocytic and myelocytic Leukemia. The compounds according to the invention are suitable because of their Properties principally for anti-angiogenesis therapy and treatment chronic inflammatory diseases such as psoriasis, multiple Sclerosis or arthritis. To avoid uncontrolled cell growth on as well the better compatibility of medical implants, they can in principle be included in apply or bring in the polymeric materials used for this purpose. The Compounds according to the invention can be used alone or to achieve additive or synergistic effects in combination with others in tumor therapy applicable principles and substance classes are used.

Als Beispiele seien genannt die Kombination mit
Examples include the combination with

  • - Platinkomplexen wie z. B. Cisplatin, Carboplatin,- platinum complexes such as B. cisplatin, carboplatin,
  • - interkalierenden Substanzen z. B. aus der Klasse der Anthracycline wie z. B. Doxorubicin oder aus der Klasse der Antrapyrazole wie z. B. CI-941,- intercalating substances e.g. B. from the class of the anthracyclines such. B. Doxorubicin or from the class of the Antrapyrazole such. B. CI-941,
  • - mit Tubulin interagierenden Substanzen z. B. aus der Klasse der Vinka-Alkaloide wie z. B. Vincristin, Vinblastin oder aus der Klasse der Taxane wie z. B. Taxol, Taxotere oder aus der Klasse der Makrolide wie z. B. Rhizoxin oder andere Verbindungen wie z. B. Colchicin, Combretastatin A-4, Discodermolid und seine Analoga,- substances interacting with tubulin e.g. B. from the class of Vinka alkaloids such as z. B. vincristine, vinblastine or from the class of taxanes such. B. Taxol, Taxotere or from the class of the macrolides such. B. Rhizoxin or other compounds such as z. B. Colchicine, Combretastatin A-4, Discodermolide and its analogues,
  • - DNA Topoisomeraseinhibitoren wie z. B. Camptothecin, Etoposid, Topotecan, Teniposid,- DNA topoisomerase inhibitors such as e.g. B. camptothecin, etoposide, topotecan, Teniposide,
  • - Folat- oder Pyrimidin-Antimetaboliten wie z. B. Lometrexol, Gemcitubin,- Folate or pyrimidine antimetabolites such as B. Lometrexol, Gemcitubin,
  • - DNA alkylierenden Verbindungen wie z. B. Adozelesin, Dystamycin A,- DNA alkylating compounds such as. B. Adozelesin, Dystamycin A,
  • - Inhibitoren von Wachstumsfaktoren (z. B. von PDGF, EGF, TGFb, EGF) wie z. B. Somatostatin, Suramin, Bombesin-Antagonisten,- Inhibitors of growth factors (e.g. PDGF, EGF, TGFb, EGF) such as B. Somatostatin, suramin, bombesin antagonists,
  • - Inhibitoren der Protein Tyrosin Kinase oder der Protein Kinasen A oder C wie z. B. Erbstatin, Genistein, Staurosporin, Ilmofosin, 8-CI-cAMP, - Inhibitors of protein tyrosine kinase or protein kinases A or C such. B. Erbstatin, Genistein, Staurosporine, Ilmofosin, 8-CI-cAMP,
  • - Antihormonen aus der Klasse der Antigestagene wie z. B. Mifepriston, Onapriston oder aus der Klasse der Antiöstrogene wie z. B. Tamoxifen oder aus der Klasse der Antiandrogene wie z. B. Cyproteronacetat,- Antihormones from the class of the antigestagens such. B. mifepristone, onapristone or from the class of the antiestrogens such. B. Tamoxifen or from the class of Antiandrogens such as B. cyproterone acetate,
  • - Metastasen inhibierenden Verbindungen z. B. aus der Klasse der Eicosanoide wie z. B. PGI2, PGE1, 6-Oxo-PGE1 sowie deren stabiler Derivate (z. B. Iloprost, Cicaprost, Misoprostol),- Metastasis inhibiting compounds z. B. from the class of eicosanoids such. B. PGI 2 , PGE 1 , 6-Oxo-PGE 1 and their stable derivatives (e.g. iloprost, cicaprost, misoprostol),
  • - Inhibitoren onkogener RAS-Proteine, welche die mitotische Signaltransduktion beeinflussen wie beispielsweise Inhibitoren der Farnesyl-Protein-Transferase,- Inhibitors of oncogenic RAS proteins that inhibit mitotic signal transduction affect such as inhibitors of farnesyl protein transferase,
  • - natürlichen oder künstlich erzeugten Antikörpern, die gegen Faktoren bzw. deren Rezeptoren, die das Tumorwachstum fördern, gerichtet sind wie beispielsweise der erbB2-Antikörper.- natural or artificially generated antibodies against factors or their Receptors that promote tumor growth, such as the erbB2 antibodies.

Die Erfindung betrifft auch Arzneimittel auf Basis der pharmazeutisch verträglichen, d. h. in den verwendeten Dosen nicht toxischen Verbindungen der allgemeinen Formel I, gegebenenfalls zusammen mit den üblichen Hilfs- und Trägerstoffen.The invention also relates to medicaments based on the pharmaceutically acceptable, i. H. non-toxic compounds of the general formula I in the doses used, optionally together with the usual auxiliaries and carriers.

Die erfindungsgemäßen Verbindungen können mit Liposomen verkapselt oder in ein α-, β- oder γ-Cyclodextrinclathrat eingeschlossen sein.The compounds according to the invention can be encapsulated with liposomes or in an α-, β- or γ-cyclodextrin clathrate may be included.

Die erfindungsgemäßen Verbindungen können nach an sich bekannten Methoden der Galenik zu pharmazeutischen Präparaten für die enterale, percutane, parenterale oder lokale Applikation verarbeitet werden. Sie können in Form von Tabletten, Dragees, Gel­ kapseln, Granulaten, Suppositorien, Implantaten, injizierbaren sterilen wäßrigen oder öligen Lösungen, Suspensionen oder Emulsionen, Salben, Cremes und Gelen verabreicht werden.The compounds according to the invention can by methods known per se Galenics for pharmaceutical preparations for enteral, percutaneous, parenteral or local application can be processed. They can be in the form of tablets, coated tablets, gel capsules, granules, suppositories, implants, injectable sterile aqueous or oily solutions, suspensions or emulsions, ointments, creams and gels administered.

Der oder die Wirkstoffe können dabei mit den in der Galenik üblichen Hilfsstoffen wie z. B. Gummiarabikum, Talk, Stärke, Mannit, Methylcellulose, Laktose, Tensiden wie Tweens oder Myrj, Magnesiumstearat, wäßrigen oder nicht wäßrigen Trägern, Paraffin­ derivaten, Netz-, Dispergier-, Emulgier-, Konservierungsmitteln und Aromastoffen zur Geschmackskorrektur (z. B. etherischen Ölen) gemischt werden.The active ingredient (s) can be combined with the auxiliaries customary in galenicals such as z. B. gum arabic, talc, starch, mannitol, methyl cellulose, lactose, surfactants such as Tweens or Myrj, magnesium stearate, aqueous or non-aqueous vehicles, paraffin derivatives, wetting agents, dispersants, emulsifiers, preservatives and flavorings for Flavor correction (e.g. essential oils) can be mixed.

Die Erfindung betrifft somit auch pharmazeutische Zusammensetzungen, die als Wirk­ stoff zumindest eine erfindungsgemäße Verbindung enthalten. Eine Dosiseinheit enthält etwa 0,1-100 mg Wirkstoff(e). Die Dosierung der erfindungsgemäßen Verbindungen liegt beim Menschen bei etwa 0,1-1000 mg pro Tag.The invention thus also relates to pharmaceutical compositions which are used as active substance contain at least one compound according to the invention. Contains a dose unit about 0.1-100 mg of active ingredient (s). The dosage of the compounds according to the invention is around 0.1-1000 mg per day in humans.

Die nachfolgenden Beispiele dienen der näheren Erläuterung der Erfindung, ohne sie darauf einschränken zu wollen:The following examples serve to explain the invention in more detail, without it wanting to restrict:

Beispiel 1example 1 4S,7R,8S,9S,13Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion4S, 7R, 8S, 9S, 13Z, 16S (E)) - 4,8-dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione Herstellung von (4S(4R,5S,6S,10E/Z,13S,14E))-4-(13-Hydroxy-5-(tetrahydro-2H-pyran- 2-yloxy)-2,6,10,14-tetramethyl-3-oxo-15-(2-pyridyl)-4-(but-3-in-1-yl)-undec-6-in-2-yl)- 2,2-dimethyl-[1,3]dioxan; Variante IPreparation of (4S (4R, 5S, 6S, 10E / Z, 13S, 14E)) - 4- (13-hydroxy-5- (tetrahydro-2H-pyran- 2-yloxy) -2,6,10,14-tetramethyl-3-oxo-15- (2-pyridyl) -4- (but-3-yn-1-yl) -undec-6-yn-2-yl ) - 2,2-dimethyl- [1,3] dioxane; Variant I. Beispiel 1aExample 1a (3RS,4S)-4-(2-Methyl-3-hydroxy-8-(trimethylsily)-oct-7-in-2-yl)-2,2-dimethyl-[1,3]dioxan(3RS, 4S) -4- (2-methyl-3-hydroxy-8- (trimethylsily) -oct-7-yn-2-yl) -2,2-dimethyl- [1,3] dioxane

Die Lösung von 6,33 g (34 mmol) (4S)-4-(2-Methyl-1-oxo-prop-2-yl)-2,2-dimethyl- [1,3]dioxan, das man in Analogie zu den in DE 197 51 200.3 beschriebenen Verfahren hergestellt hat, in 10 ml wasserfreiem Tetrahydrofuran versetzt man portionsweise unter einer Atmosphäre aus trockenem Argon mit der Lösung von insgesamt 50 mmol 5- Trimethylsilyl-pent-4-in-1-yl-magnesiumbromid in Tetrahydrofuran, läßt auf 60°C erwärmen und rührt 1,5 Stunden. Man gießt auf Wasser und extrahiert mehrfach mit Ethylacetat. Die vereinigten organischen Extrakte wäscht man mit Wasser und gesättigter Natriumchloridlösung und trocknet über Natriumsulfat. Den nach Filtration und Lösungsmittelabzug erhaltenen Rückstand reinigt man durch Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylacetat. Isoliert werden 6,22 g (19 mmol, 56%) der chromatographisch trennbaren 3R- und 3S- Epimeren der Titelverbindung sowie 1,35 g (4S)-4-(2-Methyl-1-hydroxy-prop-2-yl)-2,2- dimethyl-[1,3]dioxan jeweils als farbloses Öl.
1H-NMR (CDCl3): δ = 0,14 (9H), 0,73 + 0,88 (3H), 0,91 (3H), 1,28-1,93 (12H), 2,21-2,33 (2H), 3,40-3,72 (2H), 3,80-4,03 (3H) ppm.The solution of 6.33 g (34 mmol) of (4S) -4- (2-methyl-1-oxo-prop-2-yl) -2,2-dimethyl- [1,3] dioxane, which can be obtained in analogy to the process described in DE 197 51 200.3, 10 ml of anhydrous tetrahydrofuran are added in portions under an atmosphere of dry argon with a solution of a total of 50 mmol of 5-trimethylsilyl-pent-4-yn-1-yl-magnesium bromide in tetrahydrofuran , allowed to warm to 60 ° C and stirred for 1.5 hours. It is poured into water and extracted several times with ethyl acetate. The combined organic extracts are washed with water and saturated sodium chloride solution and dried over sodium sulfate. The residue obtained after filtration and removal of the solvent is purified by chromatography on fine silica gel with a gradient system of n-hexane and ethyl acetate. 6.22 g (19 mmol, 56%) of the chromatographically separable 3R and 3S epimers of the title compound and 1.35 g of (4S) -4- (2-methyl-1-hydroxy-prop-2-yl) are isolated -2,2-dimethyl- [1,3] dioxane in each case as a colorless oil.
1 H NMR (CDCl 3 ): δ = 0.14 (9H), 0.73 + 0.88 (3H), 0.91 (3H), 1.28-1.93 (12H), 2.21 -2.33 (2H), 3.40-3.72 (2H), 3.80-4.03 (3H) ppm.

Beispiel 1bExample 1b (4S)-4-(2-Methyl-3-oxo-8-(trimethylsily)-oct-7-in-2-yl)-2,2-dimethyl-[1,3]dioxan(4S) -4- (2-Methyl-3-oxo-8- (trimethylsily) -oct-7-yn-2-yl) -2,2-dimethyl- [1,3] dioxane

Die Lösung von 6,22 g (19 mmol) eines Gemisches der nach Beispiel 1a dargestellten Verbindungen in 200 ml wasserfreiem Dichlormethan versetzt man mit Molekularsieb (4A, ca. 20 Kugeln), 4,01 g N-Methylmorpholino-N-oxid, 335 mg Tetrapropylammoniumperruthenat und rührt 16 Stunden bei 23°C unter einer Atmosphäre aus trockenem Argon. Man engt ein und reinigt das erhaltene Rohprodukt durch Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylacetat. Isoliert werden 5,17 g (15,9 mmol, 84%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,15 (9H), 1,07 (3H), 1,13 (3H), 1,28-1,36 (1H), 1,33 (3H), 1,41 (3H), 1,53-1,81 (3H), 2,22 (2H), 2,62 (2H), 3,85 (1H), 3,97 (1H), 4,06 (1H) ppm.Molecular sieve (4A, approx. 20 spheres), 4.01 g of N-methylmorpholino-N-oxide, 335 are added to the solution of 6.22 g (19 mmol) of a mixture of the compounds shown in Example 1a in 200 ml of anhydrous dichloromethane mg of tetrapropylammonium perruthenate and stirred for 16 hours at 23 ° C. under an atmosphere of dry argon. It is concentrated and the crude product obtained is purified by chromatography on fine silica gel with a gradient system that consists of n-hexane and ethyl acetate. 5.17 g (15.9 mmol, 84%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.15 (9H), 1.07 (3H), 1.13 (3H), 1.28-1.36 (1H), 1.33 (3H), 1.41 (3H), 1.53-1.81 (3H), 2.22 (2H), 2.62 (2H), 3.85 (1H), 3.97 (1H), 4.06 ( 1H) ppm.

Beispiel 1cExample 1c (4S(4R,5S,6S,10RS))-4-(5-Hydroxy-2,6-dimethyl-3-oxo-4-(4-(trimethylsily)-but-3-in-1- yl)-10-[[diphenyl(1,1-dimethylethyl)silyl]oxy]-undec-6-in-2-yl)-2,2-dimethyl-[1,3]dioxan (A) und (4S(4S,5R,6S,10RS))-4-(5-Hydroxy-2,6-dimethyl-3-oxo-4-(4-(trimethylsily)-but- 3-in-1-yl)-10-[[diphenyl(1,1-dimethylethyl)silyl]oxy]-undec-6-in-2-yl)-2,2-dimethyl- [1,3]dioxan (B)(4S (4R, 5S, 6S, 10RS)) - 4- (5-Hydroxy-2,6-dimethyl-3-oxo-4- (4- (trimethylsily) -but-3-yn-1- yl) -10 - [[diphenyl (1,1-dimethylethyl) silyl] oxy] -undec-6-yn-2-yl) -2,2-dimethyl- [1,3] dioxane (A) and (4S (4S, 5R, 6S, 10RS)) - 4- (5-Hydroxy-2,6-dimethyl-3-oxo-4- (4- (trimethylsily) -but- 3-yn-1-yl) -10 - [[diphenyl (1,1-dimethylethyl) silyl] oxy] -undec-6-yn-2-yl) -2,2-dimethyl- [1,3] dioxane (B)

Die Lösung von 1,33 ml Diisopropylamin in 35 ml wasserfreiem Tetrahydrofuran kühlt man unter einer Atmosphäre aus trockenem Argon auf -30°C, versetzt mit 4,28 ml einer 2,4 molaren Lösung von n-Butyllithium in n-Hexan und rührt noch 15 Minuten. Bei -78°C tropft man die Lösung von 2,87 g (8,84 mmol) der nach Beispiel 1c dargestellten Verbindung in 35 ml Tetrahydrofuran zu und läßt 1 Stunde reagieren. Anschließend versetzt man langsam mit der Lösung von 3,93 g (10,3 mmol) (2S,6RS)-2-Methyl-6- (tert.-butyl-diphenylsilyloxy)-heptanal, das man in Analogie zu den in DE 197 51 200.3 beschriebenen Verfahren hergestellt hat, in 35 ml Tetrahydrofuran und gießt nach 1 Stunde in gesättigte Ammoniumchloridlösung. Man verdünnt mit Wasser, extrahiert mehrfach mit Ethylacetat, wäscht die vereinigten organischen Extrakte mit gesättigter Natriumchloridlösung, trocknet über Natriumsulfat und engt im Vakuum ein. Nach Säulenchromatographie an Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylacetat werden neben Ausgangsmaterial 2,40 g (3,39 mmol, 38%) der Titelverbindung A sowie 1,52 g (2,15 mmol, 24%) des Diastereomeren B erhalten.
1H-NMR (CDCl3) von A: δ = 0,16 (9H), 0,83 (3H), 1,00 (3H), 1,02 (3H), 1,04 (9H), 1,10-­ 1,77 (10H), 1,28 (3H), 1,31 (3H), 1,37 (3H), 1,83-2,03 (2H), 2,19-2,38 (2H), 3,52 (1H), 3,62 (1H), 3,78-3,92 (2H), 3,98 (1H), 4,23 (1H), 7,30-7,46 (6H), 7,67 (4H) ppm.
1H-NMR (CDCl3) von B: δ = 0,13 (9H), 0,86 + 0,92 (3H), 0,95-1,77 (16H), 1,03 (9H), 1,21 + 1,25 (3H), 1,32 (3H), 1,40 (3H), 1,88-2,09 (2H), 2,26 (1H), 2,39 (1H), 3,29-3,54 (2H), 3,77-3,90 (2H), 3,96 (1H), 4,18 (1H), 7,31-7,46 (6H), 7,67 (4H) ppm.The solution of 1.33 ml of diisopropylamine in 35 ml of anhydrous tetrahydrofuran is cooled to -30 ° C. under an atmosphere of dry argon, treated with 4.28 ml of a 2.4 molar solution of n-butyllithium in n-hexane and stirred 15 minutes. The solution of 2.87 g (8.84 mmol) of the compound shown in Example 1c in 35 ml of tetrahydrofuran is added dropwise at -78 ° C. and the mixture is allowed to react for 1 hour. The solution of 3.93 g (10.3 mmol) (2S, 6RS) -2-methyl-6- (tert-butyl-diphenylsilyloxy) -heptanal, which is prepared in analogy to the in DE 197 51 200.3, in 35 ml of tetrahydrofuran and after 1 hour poured into saturated ammonium chloride solution. It is diluted with water, extracted several times with ethyl acetate, the combined organic extracts are washed with saturated sodium chloride solution, dried over sodium sulfate and concentrated in vacuo. After column chromatography on silica gel with a gradient system of n-hexane and ethyl acetate, 2.40 g (3.39 mmol, 38%) of the title compound A and 1.52 g (2.15 mmol, 24%) of the diastereomer B are obtained in addition to starting material .
1 H-NMR (CDCl 3 ) of A: δ = 0.16 (9H), 0.83 (3H), 1.00 (3H), 1.02 (3H), 1.04 (9H), 1, 10-1.77 (10H), 1.28 (3H), 1.31 (3H), 1.37 (3H), 1.83-2.03 (2H), 2.19-2.38 (2H ), 3.52 (1H), 3.62 (1H), 3.78-3.92 (2H), 3.98 (1H), 4.23 (1H), 7.30-7.46 (6H ), 7.67 (4H) ppm.
1 H-NMR (CDCl 3 ) of B: δ = 0.13 (9H), 0.86 + 0.92 (3H), 0.95-1.77 (16H), 1.03 (9H), 1 , 21 + 1.25 (3H), 1.32 (3H), 1.40 (3H), 1.88-2.09 (2H), 2.26 (1H), 2.39 (1H), 3 , 29-3.54 (2H), 3.77-3.90 (2H), 3.96 (1H), 4.18 (1H), 7.31-7.46 (6H), 7.67 ( 4H) ppm.

Beispiel 1dExample 1d (4S(4R,5S,6S,10RS))-4-(2,6-Dimethyl-3-oxo-4-(4-(trimethylsily)-5-(tetrahydro-2H- pyran-2-yloxy)-but-3-in-1-yl)-10-[[diphenyl(1,1-dimethylethyl)silyl]oxy]-undec-6-in-2-yl)- 2,2-dimethyl-[1,3]dioxan(4S (4R, 5S, 6S, 10RS)) - 4- (2,6-Dimethyl-3-oxo-4- (4- (trimethylsily) -5- (tetrahydro-2H- pyran-2-yloxy) -but-3-yn-1-yl) -10 - [[diphenyl (1,1-dimethylethyl) silyl] oxy] -undec-6-yn-2-yl) - 2,2-dimethyl- [1,3] dioxane

Die Lösung von 2,35 g (3,32 mmol) der nach Beispiel 1c dargestellten Verbindung A in 55 ml wasserfreiem Dichlormethan versetzt man unter einer Atmosphäre aus trockenem Argon mit 3,04 ml 3,4-Dihydro-2H-pyran, 0,67 g p-Toluolsulfonsäure und rührt 48 Stunden bei 23°C. Man gießt in eine gesättigte Natriumhydrogencarbonatlösung, trennt die organische Phase ab und trocknet über Natriumsulfat. Nach Filtration und Lösungsmittelabzug chromatographiert man den Rückstand an feinem Kieselgel mit einem Gemisch aus n-Hexan und Ethylacetat. Isoliert werden 2,29 g (2,89 mmol, 87%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,05 (9H), 0,88-2,15 (28H), 1,03 (9H), 1,41 (3H), 1,59 (3H), 2,21-­ 2,48 (1H), 3,31-4,53 (9H), 7,30-7,45 (6H), 7,69 (4H) ppm.The solution of 2.35 g (3.32 mmol) of the compound A shown in Example 1c in 55 ml of anhydrous dichloromethane is mixed with 3.04 ml of 3,4-dihydro-2H-pyran, 0, under an atmosphere of dry argon. 67 g of p-toluenesulfonic acid and stirred at 23 ° C. for 48 hours. It is poured into a saturated sodium hydrogen carbonate solution, the organic phase is separated off and dried over sodium sulfate. After filtration and removal of the solvent, the residue is chromatographed on fine silica gel with a mixture of n-hexane and ethyl acetate. 2.29 g (2.89 mmol, 87%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.05 (9H), 0.88-2.15 (28H), 1.03 (9H), 1.41 (3H), 1.59 (3H), 2.21-2.48 (1H), 3.31-4.53 (9H), 7.30-7.45 (6H), 7.69 (4H) ppm.

Beispiel 1eExample 1e (4S(4R,5S,6S,10RS))-4-(2,6-Dimethyl-10-hydroxy-3-oxo-5-(tetrahydro-2H-pyran-2- yloxy)-4-(but-3-in-1-yl)-undec-6-in-2-yl)-2,2-dimethyl-[1,3]dioxan(4S (4R, 5S, 6S, 10RS)) - 4- (2,6-Dimethyl-10-hydroxy-3-oxo-5- (tetrahydro-2H-pyran-2- yloxy) -4- (but-3-yn-1-yl) -undec-6-yn-2-yl) -2,2-dimethyl- [1,3] dioxane

Die Lösung von 2,48 g (3,13 mmol) der nach Beispiel 1d dargestellten Verbindung in 25 ml wasserfreiem Tetrahydrofuran versetzt man unter einer Atmosphäre aus trockenem Argon mit 12,5 ml einer 1 molaren Lösung von Tetrabutylammoniumfluorid in Tetrahydrofuran und rührt 4 Stunden bei 23°C. Man versetzt mit gesättigter Natriumhydrogencarbonatlösung, extrahiert mehrfach mit Ethylacetat, wäscht mit gesättigter Natriumchloridlösung und trocknet über Natriumsulfat. Den nach Filtration und Lösungsmittelabzug erhaltenen Rückstand reinigt man durch Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylacetat. Isoliert werden 1,41 g (2,93 mmol, 94%) der Titelverbindung als farbloses Öl.The solution of 2.48 g (3.13 mmol) of the compound shown in Example 1d in 25 ml anhydrous tetrahydrofuran is added under a dry atmosphere Argon with 12.5 ml of a 1 molar solution of tetrabutylammonium fluoride in Tetrahydrofuran and stir for 4 hours at 23 ° C. It is mixed with saturated Sodium hydrogen carbonate solution, extracted several times with ethyl acetate, washed with saturated sodium chloride solution and dried over sodium sulfate. After filtration The residue obtained and removal of the solvent is purified by chromatography fine silica gel with a gradient system of n-hexane and ethyl acetate. Isolated 1.41 g (2.93 mmol, 94%) of the title compound are obtained as a colorless oil.

Beispiel 1fExample 1f (4S(4R,5S,6S,10RS))-4-(2,6-Dimethyl-3,10-dioxo-5-(tetrahydro-2H-pyran-2-yloxy)-4- (but-3-in-1-yl)-undec-6-in-2-yl)-2,2-dimethyl-[1,3]dioxan(4S (4R, 5S, 6S, 10RS)) - 4- (2,6-Dimethyl-3,10-dioxo-5- (tetrahydro-2H-pyran-2-yloxy) -4- (but-3-yn-1-yl) -undec-6-yn-2-yl) -2,2-dimethyl- [1,3] dioxane

In Analogie zu Beispiel 1b setzt man 1,27 g (2,63 mmol) der nach Beispiel 1e dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 1,14 g (2,38 mmol, 91%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,95-2,48 (29H), 0,98 + 1,01 (3H), 1,42 (3H), 2,13 (3H), 3,29-3,47 (2H), 3,64-4,04 (4H), 4,20 + 4,32 (1H), 4,39 + 4,50 (1H) ppm.In analogy to Example 1b, 1.27 g (2.63 mmol) of the compound shown in Example 1e are reacted and, after work-up and purification, 1.14 g (2.38 mmol, 91%) of the title compound is isolated as a colorless oil.
1 H NMR (CDCl 3 ): δ = 0.95-2.48 (29H), 0.98 + 1.01 (3H), 1.42 (3H), 2.13 (3H), 3.29 -3.47 (2H), 3.64-4.04 (4H), 4.20 + 4.32 (1H), 4.39 + 4.50 (1H) ppm.

Beispiel 1gExample 1g (4S(4R,5S,6S,10E/Z,13S,14E))-4-(13-[[Diphenyl(1,1-dimethylethyl)silyl]oxy]-5- (tetrahydro-2H-pyran-2-yloxy)-2,6,10,14-tetramethyl-3-oxo-15-(2-pyridyl)-4-(but-3-in-1- yl)-undec-6-in-2-yl)-2,2-dimethyl-[1,3]dioxan(4S (4R, 5S, 6S, 10E / Z, 13S, 14E)) - 4- (13 - [[Diphenyl (1,1-dimethylethyl) silyl] oxy] -5- (tetrahydro-2H-pyran-2-yloxy) -2,6,10,14-tetramethyl-3-oxo-15- (2-pyridyl) -4- (but-3-yn-1- yl) -undec-6-yn-2-yl) -2,2-dimethyl- [1,3] dioxane

Die Suspension von 2,87 g (3,57 mmol) (5E,3S)-[3-[[(1,1- Dimethylethyl)diphenylsilyl]oxy]-4-methyl-5-(2-pyridyl)-pent-4-en-1-yl]-triphenyl­ phosphoniumiodid, das man in Analogie zu den in DE 197 51 200.3 beschriebenen Verfahren hergestellt hat, in 11 ml wasserfreiem Tetrahydrofuran versetzt man bei 0°C unter einer Atmosphäre aus trockenem Argon mit 2,72 ml einer 1,6 M Lösung von n- Butyllithium in n-Hexan und läßt auf 23°C erwärmen. Zu der roten Lösung tropft man langsam die Lösung von 1,14 g (2,38 mmol) der nach Beispiel 1f dargestellten Verbindung in 11 ml Tetrahydrofuran, läßt 2 Stunden rühren, gießt auf gesättigte Ammmoniumchloridlösung und extrahiert mehrfach mit Ethylacetat. Die vereinigten organischen Extrakte trocknet man über Natriumsulfat und engt im Vakuum ein. Nach Säulenchromatographie an Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylacetat werden neben 20% Ausgangsmaterial 860 mg (0,98 mmol, 41%) der Titelverbindung erhalten.
1H-NMR (CDCl3): δ = 0,82-2,41 (41H), 1,05 (9H), 2,00 (3H), 3,23-3,45 (2H), 3,60-4,02 (3H), 4,08-4,51 (3H), 4,92-5,24 (1H), 6,16-6,76 (1H), 6,92-7,08 (2H), 7,21-7,43 (6H), 7,49-7,72 (5H), 8,55 (1H) ppm.The suspension of 2.87 g (3.57 mmol) (5E, 3S) - [3 - [[(1,1-dimethylethyl) diphenylsilyl] oxy] -4-methyl-5- (2-pyridyl) -pent- 4-en-1-yl] triphenyl phosphonium iodide, which has been prepared in analogy to the process described in DE 197 51 200.3, in 11 ml of anhydrous tetrahydrofuran is mixed with 2.72 ml at 0 ° C. under an atmosphere of dry argon a 1.6 M solution of n-butyllithium in n-hexane and allowed to warm to 23 ° C. The solution of 1.14 g (2.38 mmol) of the compound shown in Example 1f in 11 ml of tetrahydrofuran is slowly added dropwise to the red solution, the mixture is stirred for 2 hours, poured into saturated ammonium chloride solution and extracted several times with ethyl acetate. The combined organic extracts are dried over sodium sulfate and concentrated in vacuo. After column chromatography on silica gel with a gradient system of n-hexane and ethyl acetate, in addition to 20% starting material, 860 mg (0.98 mmol, 41%) of the title compound are obtained.
1 H NMR (CDCl 3 ): δ = 0.82-2.41 (41H), 1.05 (9H), 2.00 (3H), 3.23-3.45 (2H), 3.60 -4.02 (3H), 4.08-4.51 (3H), 4.92-5.24 (1H), 6.16-6.76 (1H), 6.92-7.08 (2H ), 7.21-7.43 (6H), 7.49-7.72 (5H), 8.55 (1H) ppm.

Beispiel 1h; Variante I (4S(4R,5S,6S,10E/Z,13S,14E))-4-(13-Hydroxy-5-(tetrahydro-2H- pyran-2-yloxy)-2,6,10,14-tetramethyl-3-oxo-15-(2-pyridyl)-4-(but-3-in-1-yl)-undec-6-in-2- yl)-2,2-dimethyl-[1,3]dioxanExample 1h; Variant I (4S (4R, 5S, 6S, 10E / Z, 13S, 14E)) - 4- (13-Hydroxy-5- (tetrahydro-2H- pyran-2-yloxy) -2,6,10,14-tetramethyl-3-oxo-15- (2-pyridyl) -4- (but-3-yn-1-yl) -undec-6-yn-2 - yl) -2,2-dimethyl- [1,3] dioxane

In Analogie zu Beispiel 1b setzt man 482 mg (550 µmol) der nach Beispiel 1g dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 256 mg (401 µmol, 73%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,88-2,48 (35H), 1,42 (3H), 1,64 + 1,72 (3H), 2,08 (3H), 3,29-3,47 (2H), 3,64-4,04 (4H), 4,12-4,35 (2H), 4,41 + 4,51 (1H), 5,20 (1H), 6,59 (1H), 7,09 (1H), 7,23 (1H), 7,63 (1H), 8,60 (1H) ppm.In analogy to Example 1b, 482 mg (550 μmol) of the compound shown in Example 1g are reacted and, after work-up and purification, 256 mg (401 μmol, 73%) of the title compound are isolated as a colorless oil.
1 H NMR (CDCl 3 ): δ = 0.88-2.48 (35H), 1.42 (3H), 1.64 + 1.72 (3H), 2.08 (3H), 3.29 -3.47 (2H), 3.64-4.04 (4H), 4.12-4.35 (2H), 4.41 + 4.51 (1H), 5.20 (1H), 6, 59 (1H), 7.09 (1H), 7.23 (1H), 7.63 (1H), 8.60 (1H) ppm.

Herstellung von (4S(4R,5S,6S,10E/Z,13S,14E))-4-(13-Hydroxy-5-(tetrahydro-2H-pyran- 2-yloxy)-2,6,10,14-tetramethyl-3-oxo-15-(2-pyridyl)-4-(but-3-in-1-yl)-undec-6-in-2-yl)- 2,2-dimethyl-[1,3]dioxan; Variante IIPreparation of (4S (4R, 5S, 6S, 10E / Z, 13S, 14E)) - 4- (13-hydroxy-5- (tetrahydro-2H-pyran- 2-yloxy) -2,6,10,14-tetramethyl-3-oxo-15- (2-pyridyl) -4- (but-3-yn-1-yl) -undec-6-yn-2-yl ) - 2,2-dimethyl- [1,3] dioxane; Variation II Beispiel 1iExample 1i (4S(4R,5S,6S,10E/Z,13S,14E))-4-(13-[[Diphenyl(1,1-dimethylethyl)silyl]oxy]-5-hydroxy- 2,6,10,14-tetramethyl-3-oxo-15-(2-pyridyl)-4-(4-(trimethylsilyl)-but-3-in-1-yl)-undec-6-in- 2-yl)-2,2-dimethyl-[1,3]dioxan (A) und (4S(4S,5R,6S,10E/Z,13S,14E))-4-(13- [[Diphenyl(1,1-dimethylethyl)silyl]oxy]-5-hydroxy-2,6,10,14-tetramethyl-3-oxo-15-(2- pyridyl)-4-(4-(trimethylsilyl)-but-3-in-1-yl)-undec-6-in-2-yl)-2,2-dimethyl-[1,3]dioxan (B)(4S (4R, 5S, 6S, 10E / Z, 13S, 14E)) - 4- (13 - [[Diphenyl (1,1-dimethylethyl) silyl] oxy] -5-hydroxy- 2,6,10,14-tetramethyl-3-oxo-15- (2-pyridyl) -4- (4- (trimethylsilyl) -but-3-yn-1-yl) -undec-6-yne 2-yl) -2,2-dimethyl- [1,3] dioxane (A) and (4S (4S, 5R, 6S, 10E / Z, 13S, 14E)) - 4- (13- [[Diphenyl (1,1-dimethylethyl) silyl] oxy] -5-hydroxy-2,6,10,14-tetramethyl-3-oxo-15- (2- pyridyl) -4- (4- (trimethylsilyl) -but-3-yn-1-yl) -undec-6-yn-2-yl) -2,2-dimethyl- [1,3] dioxane (B)

In Analogie zu Beispiel 1c setzt man 2,85 g (8,78 mmol) der nach Beispiel 1b dargestellten Verbindung mit 3,62 g (6,71 mmol) (2S,6E/Z,9S,10E)-2,6,10-Trimethyl-9- [[diphenyl(1,1-dimethylethyl)silyl]oxy]-1-oxo-11-(2-pyridyl)-undeca-6,10-dien, das man in Analogie zu den in DE 197 51 200.3 beschriebenen Verfahren hergestellt hat, um und isoliert nach Aufarbeitung und Reinigung neben Ausgangsmaterial 1,28 g (1,48 mmol, 22%) der Titelverbindung A sowie 1,73 g (2,00 mmol, 30%) der Titelverbindung B jeweils als farbloses Öl.
1H-NMR (CDCl3) von A: δ = 0,13 (9H), 0,86-2,52 (36H), 1,08 (9H), 1,42 + 1,58 (3H), 2,01 (3H), 3,32-4,85 (9H), 5,00 (1H), 6,23 (1H), 6,97-7,09 (2H), 7,21-7,45 (6H), 7,57 (1H), 7,61-7,75 (4H), 8,56 (1H) ppm.
1H-NMR (CDCl3) von B: δ = 0,12 (9H), 0,77-2,53 (36H), 1,08 (9H), 1,38 + 1,62 (3H), 2,00 (3H), 3,23-4,86 (9H), 5,02 (1H), 6,23 (1H), 6,96-7,09 (2H), 7,19-7,47 (6H), 7,53-7,76 (5H), 8,57 (1H) ppm.In analogy to Example 1c, 2.85 g (8.78 mmol) of the compound shown according to Example 1b is added to 3.62 g (6.71 mmol) (2S, 6E / Z, 9S, 10E) -2.6, 10-Trimethyl-9- [[diphenyl (1,1-dimethylethyl) silyl] oxy] -1-oxo-11- (2-pyridyl) -undeca-6,10-diene, which can be obtained in analogy to that described in DE 197 51 200.3 has prepared and isolated after work-up and purification in addition to starting material 1.28 g (1.48 mmol, 22%) of the title compound A and 1.73 g (2.00 mmol, 30%) of the title compound B in each case as a colorless oil.
1 H-NMR (CDCl 3 ) of A: δ = 0.13 (9H), 0.86-2.52 (36H), 1.08 (9H), 1.42 + 1.58 (3H), 2 .01 (3H), 3.32-4.85 (9H), 5.00 (1H), 6.23 (1H), 6.97-7.09 (2H), 7.21-7.45 ( 6H), 7.57 (1H), 7.61-7.75 (4H), 8.56 (1H) ppm.
1 H-NMR (CDCl 3 ) of B: δ = 0.12 (9H), 0.77-2.53 (36H), 1.08 (9H), 1.38 + 1.62 (3H), 2 .00 (3H), 3.23-4.86 (9H), 5.02 (1H), 6.23 (1H), 6.96-7.09 (2H), 7.19-7.47 ( 6H), 7.53-7.76 (5H), 8.57 (1H) ppm.

Beispiel 1jExample 1j (4S(4R,5S,6S,10E/Z,13S,14E))-4-(13-[[Diphenyl(1,1-dimethylethyl)silyl]oxy]-5- (tetrahydro-2H-pyran-2-yloxy)-2,6,10,14-tetramethyl-3-oxo-15-(2-pyridyl)-4-(4- (trimethylsilyl)-but-3-in-1-yl)-undec-6-in-2-yl)-2,2-dimethyl-[1,3]dioxan(4S (4R, 5S, 6S, 10E / Z, 13S, 14E)) - 4- (13 - [[Diphenyl (1,1-dimethylethyl) silyl] oxy] -5- (tetrahydro-2H-pyran-2-yloxy) -2,6,10,14-tetramethyl-3-oxo-15- (2-pyridyl) -4- (4- (trimethylsilyl) -but-3-yn-1-yl) -undec-6-yn-2-yl) -2,2-dimethyl- [1,3] dioxane

In Analogie zu Beispiel 1d setzt man 1,16 g (1,34 mmol) der nach Beispiel 1i dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 1,12 g (1,18 mmol, 88%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,13 (9H), 0,86-2,52 (39H), 1,08 (9H), 2,01 (3H), 3,32-4,85 (9H), 5,00 (1H), 6,22 (1H), 6,96-7,09 (2H), 7,21-7,44 (6H), 7,56 (1H), 7,61-7,75 (4H), 8,56 (1H) ppm.In analogy to Example 1d, 1.16 g (1.34 mmol) of the compound shown in Example 1i is reacted and, after work-up and purification, 1.12 g (1.18 mmol, 88%) of the title compound is isolated as a colorless oil.
1 H NMR (CDCl 3 ): δ = 0.13 (9H), 0.86-2.52 (39H), 1.08 (9H), 2.01 (3H), 3.32-4.85 (9H), 5.00 (1H), 6.22 (1H), 6.96-7.09 (2H), 7.21-7.44 (6H), 7.56 (1H), 7.61 -7.75 (4H), 8.56 (1H) ppm.

Beispiel 1h; Variante II (4S(4R,5S,6S,10E/Z,13S,14E))-4-(13-Hydroxy-5-(tetrahydro-2H- pyran-2-yloxy)-2,6,10,14-tetramethyl-3-oxo-15-(2-pyridyl)-4-(but-3-in-1-yl)-undec-6-in-2- yl)-2,2-dimethyl-[1,3]dioxanExample 1h; Variant II (4S (4R, 5S, 6S, 10E / Z, 13S, 14E)) - 4- (13-Hydroxy-5- (tetrahydro-2H- pyran-2-yloxy) -2,6,10,14-tetramethyl-3-oxo-15- (2-pyridyl) -4- (but-3-yn-1-yl) -undec-6-yn-2 - yl) -2,2-dimethyl- [1,3] dioxane

In Analogie zu Beispiel 1e setzt man 1,12 g (1,18 mmol) der nach Beispiel 1j dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 654 mg (1,03 mmol, 87%) der Titelverbindung als farbloses Öl. Das 1H-NMR-Spektrum ist deckungsgleich mit dem unter Beispiel 1 h, Variante I beschriebenen.In analogy to Example 1e, 1.12 g (1.18 mmol) of the compound shown in Example 1j are reacted and, after work-up and purification, 654 mg (1.03 mmol, 87%) of the title compound are isolated as a colorless oil. The 1 H-NMR spectrum is congruent with that described under Example 1 h, variant I.

Beispiel 1kExample 1k (3S,6R,7S,8S,12E/Z,15S,16E)-1,3,7,15-Tetrahydroxy-4,4,8,12,16-pentamethyl-17-(2- pyridyl)-6-(but-3-in-1-yl)-heptadeca-12,16-dien-5-on(3S, 6R, 7S, 8S, 12E / Z, 15S, 16E) -1,3,7,15-tetrahydroxy-4,4,8,12,16-pentamethyl-17- (2- pyridyl) -6- (but-3-yn-1-yl) -heptadeca-12,16-dien-5-one

Die Lösung von 654 mg (1,03 mmol) der nach Beispiel 1h dargestellten Verbindung in 27 ml wasserfreiem Ethanol versetzt man unter einer Atmosphäre aus trockenem Argon mit 588 mg p-Toluolsulfonsäure-Monohydrat und rührt 3 Stunden bei 23°C. Nach Lösungsmittelabzug chromatographiert man den Rückstand an feinem Kieselgel mit einem Gemisch aus n-Hexan und Ethylacetat. Isoliert werden 484 mg (942 µmol, 91%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,90 + 0,92 (3H), 1,07 (3H), 1,11-2,16 (14H), 1,29 (3H), 1,63 + 1,42 (3H), 2,00 + 2,02 (3H), 2,20-2,60 (4H), 2,98 (1H), 3,48-3,67 (2H), 3,78-3,93 (2H), 4,06-­ 4,23 (3H), 5,16 + 5,24 (1H), 6,52 + 6,57 (1H), 7,11 (1H), 7,30 (1H), 7,66 (1H), 8,58 (1H) ppm.588 mg of p-toluenesulfonic acid monohydrate are added to the solution of 654 mg (1.03 mmol) of the compound shown in Example 1h in 27 ml of anhydrous ethanol under an atmosphere of dry argon and the mixture is stirred at 23 ° C. for 3 hours. After removal of the solvent, the residue is chromatographed on fine silica gel with a mixture of n-hexane and ethyl acetate. 484 mg (942 μmol, 91%) of the title compound are isolated as a colorless oil.
1 H NMR (CDCl 3 ): δ = 0.90 + 0.92 (3H), 1.07 (3H), 1.11-2.16 (14H), 1.29 (3H), 1.63 + 1.42 (3H), 2.00 + 2.02 (3H), 2.20-2.60 (4H), 2.98 (1H), 3.48-3.67 (2H), 3, 78-3.93 (2H), 4.06-4.23 (3H), 5.16 + 5.24 (1H), 6.52 + 6.57 (1H), 7.11 (1H), 7 , 30 (1H), 7.66 (1H), 8.58 (1H) ppm.

Beispiel 1lExample 1l (3S,6R,7S,8S,12E/Z,15S,16E)-1,3,7,15-Tetrakis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]- 4,4,8,12,16-pentamethyl-17-(2-pyridyl)-6-(but-3-in-1-yl)-heptadeca-12,16-dien-5-on(3S, 6R, 7S, 8S, 12E / Z, 15S, 16E) -1,3,7,15-tetrakis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] - 4,4,8,12,16-pentamethyl-17- (2-pyridyl) -6- (but-3-yn-1-yl) -heptadeca-12,16-dien-5-one

Die Lösung von 673 mg (1,31 mmol) der nach Beispiel 1k dargestellten Verbindung in 37 ml wasserfreiem Dichlormethan kühlt man unter einer Atmosphäre aus trockenem Argon auf -78°C, versetzt mit 2,14 ml 2,6-Lutidin, 2,41 ml Trifluormethansulfonsäure- tert.butyldimethylsilylester, läßt innerhalb von 2 Stunden auf 0°C erwärmen und rührt noch 2 Stunden. Man gießt in gesättigte Natriumhydrogencarbonatlösung und extrahiert mehrfach mit Dichlormethan. Die vereinigten organischen Extrakte trocknet man über Natriumsulfat und engt im Vakuum ein. Nach Säulenchromatographie an Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylacetat isoliert man 1,11 g (1,29 mmol, 99%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = -0,01-0,12 (24H), 0,82-2,33 (55H), 1,08 (3H), 1,22 (3H), 1,60 + 1,68 (3H), 2,05 (3H), 3,22 (1H), 3,51-3,73 (2H), 3,81 (1H), 3,92 (1H), 4,11 (1H), 5,18 (1H), 6,47 (1H), 7,08 (1H), 7,22 (1H), 7,61 (1H), 8,59 (1H) ppm.The solution of 673 mg (1.31 mmol) of the compound shown in Example 1k in 37 ml of anhydrous dichloromethane is cooled to -78 ° C. under an atmosphere of dry argon, mixed with 2.14 ml of 2,6-lutidine, 2, 41 ml of tert-butyldimethylsilyl trifluoromethanesulfonate, allowed to warm to 0 ° C. over the course of 2 hours and stir for a further 2 hours. It is poured into saturated sodium hydrogen carbonate solution and extracted several times with dichloromethane. The combined organic extracts are dried over sodium sulfate and concentrated in vacuo. After column chromatography on silica gel with a gradient system of n-hexane and ethyl acetate, 1.11 g (1.29 mmol, 99%) of the title compound is isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = -0.01-0.12 (24H), 0.82-2.33 (55H), 1.08 (3H), 1.22 (3H), 1, 60 + 1.68 (3H), 2.05 (3H), 3.22 (1H), 3.51-3.73 (2H), 3.81 (1H), 3.92 (1H), 4, 11 (1H), 5.18 (1H), 6.47 (1H), 7.08 (1H), 7.22 (1H), 7.61 (1H), 8.59 (1H) ppm.

Beispiel 1mExample 1m (3S,6R,7S,8S,12E/Z,15S,16E)-1-Hydroxy-3,7,15-tris-[[dimethyl(1,1- dimethylethyl)silyl]oxy]-4,4,8,12,16-pentamethyl-17-(2-pyridyl)-6-(but-3-in-1-yl)- heptadeca-12,16-dien-5-on(3S, 6R, 7S, 8S, 12E / Z, 15S, 16E) -1-hydroxy-3,7,15-tris - [[dimethyl (1,1- dimethylethyl) silyl] oxy] -4,4,8,12,16-pentamethyl-17- (2-pyridyl) -6- (but-3-yn-1-yl) - heptadeca-12,16-dien-5-one

Die Lösung von 1,10 mg (1,13 mmol) der nach Beispiel 1l dargestellten Verbindung in einem Gemisch aus 14 ml Dichlormethan und 14 ml Methanol versetzt man bei 23°C unter einer Atmosphäre aus trockenem Argon mit 312 mg Campher-10-sulfonsäure und rührt 2 Stunden. Man gießt in eine gesättigte Natriumhydrogencarbonatlösung und extrahiert mehrfach mit Dichlormethan. Die vereinigten organischen Extrakte trocknet man über Natriumsulfat und engt im Vakuum ein. Nach Säulenchromatographie an feinem Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylacetat isoliert man 814 mg (950 µmol, 84%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,01-0,13 (18H), 0,83-2,33 (47H), 1,12 (3H), 1,23 (3H), 1,61 + 1,68 (3H), 2,05 (3H), 3,28 (1H), 3,68 (2H), 3,84 (1H), 4,02-4,18 (2H), 5,18 (1H), 6,48 (1H), 7,08 (1H), 7,22 (1H), 7,61 (1H), 8,60 (1H) ppm.The solution of 1.10 mg (1.13 mmol) of the compound shown in Example 11 in a mixture of 14 ml of dichloromethane and 14 ml of methanol is mixed with 312 mg of camphor-10-sulfonic acid at 23 ° C. under an atmosphere of dry argon and stir for 2 hours. It is poured into a saturated sodium hydrogen carbonate solution and extracted several times with dichloromethane. The combined organic extracts are dried over sodium sulfate and concentrated in vacuo. After column chromatography on fine silica gel with a gradient system of n-hexane and ethyl acetate, 814 mg (950 μmol, 84%) of the title compound are isolated as a colorless oil.
1 H NMR (CDCl 3 ): δ = 0.01-0.13 (18H), 0.83-2.33 (47H), 1.12 (3H), 1.23 (3H), 1.61 + 1.68 (3H), 2.05 (3H), 3.28 (1H), 3.68 (2H), 3.84 (1H), 4.02-4.18 (2H), 5.18 (1H), 6.48 (1H), 7.08 (1H), 7.22 (1H), 7.61 (1H), 8.60 (1H) ppm.

Beispiel 1nExample 1n (3S,6R,7S,8S,12E/Z,15S,16E)-3,7,15-Tris-[[dimethyl(1,1-dimethylethyl)silyl]oxy]- 4,4,8,12,16-pentamethyl-5-oxo-17-(2-pyridyl)-6-(but-3-in-1-yl)-heptadeca-12,16-dienal(3S, 6R, 7S, 8S, 12E / Z, 15S, 16E) -3,7,15-Tris - [[dimethyl (1,1-dimethylethyl) silyl] oxy] - 4,4,8,12,16-pentamethyl-5-oxo-17- (2-pyridyl) -6- (but-3-yn-1-yl) -heptadeca-12,16-dienal

Die Lösung von 0,129 ml Oxalylchlorid in 6,3 ml wasserfreiem Dichlormethan kühlt man unter einer Atmosphäre aus trockenem Argon auf -70°C, versetzt mit 209 µl Dimethylsulfoxid, der Lösung von 814 mg (950 µmol) der nach Beispiel 1m dargestellten Verbindung in 6,3 ml wasserfreiem Dichlormethan und rührt 0,5 Stunden. Anschließend versetzt man mit 646 µl Triethylamin, läßt 1 Stunde bei -30°C reagieren und versetzt mit n-Hexan und gesättigter Natriumhydrogencarbonatlösung. Die organische Phase wird abgetrennt, die wässrige noch mehrfach mit n-Hexan extrahiert, die vereinigten organischen Extrakte mit Wasser gewaschen und über Magnesiumsulfat getrocknet. Den nach Filtration und Lösungsmittelabzug erhaltenen Rückstand setzt man ohne Reinigung weiter um.The solution of 0.129 ml of oxalyl chloride in 6.3 ml of anhydrous dichloromethane is cooled under an atmosphere of dry argon to -70 ° C, mixed with 209 µl Dimethyl sulfoxide, the solution of 814 mg (950 μmol) of that according to Example 1m compound shown in 6.3 ml of anhydrous dichloromethane and stirred for 0.5 hours. 646 μl of triethylamine are then added and the mixture is left to react at -30 ° C. for 1 hour and mixed with n-hexane and saturated sodium hydrogen carbonate solution. The organic phase is separated off, the aqueous phase is extracted several times with n-hexane, the combined organic extracts washed with water and washed over magnesium sulfate dried. The residue obtained after filtration and removal of the solvent sets you can continue around without cleaning.

Beispiel 1oExample 1o (3S,6R,7S,8S,12Z,15S,16E)-3,7,15-Tris-[[dimethyl(1,1-dimethylethyl)silyl]oxy]- 4,4,8,12,16-pentamethyl-5-oxo-17-(2-pyridyl)-6-(but-3-in-1-yl)-heptadeca-12,16- diensäure (A) und (3S,6R,7S,8S,12E,15S,16E)-3,7,15-Tris-[[dimethyl(1,1- dimethylethyl)silyl]oxy]-4,4,8,12,16-pentamethyl-5-oxo-17-(2-pyridyl)-6-(but-3-in-1-yl)- heptadeca-12,16-diensäure (B)(3S, 6R, 7S, 8S, 12Z, 15S, 16E) -3,7,15-Tris - [[dimethyl (1,1-dimethylethyl) silyl] oxy] - 4,4,8,12,16-pentamethyl-5-oxo-17- (2-pyridyl) -6- (but-3-yn-1-yl) -heptadeca-12,16- dienoic acid (A) and (3S, 6R, 7S, 8S, 12E, 15S, 16E) -3,7,15-tris - [[dimethyl (1,1- dimethylethyl) silyl] oxy] -4,4,8,12,16-pentamethyl-5-oxo-17- (2-pyridyl) -6- (but-3-yn-1-yl) - heptadeca-12,16-dienoic acid (B)

Die Lösung von 852 mg (max. 950 µmol) der nach Beispiel 1n dargestellten Verbindung in 23 ml Aceton kühlt man auf -30°C, versetzt mit 1,19 ml einer standardisierten, 8 N Chromschwefelsäurelösung und rührt 1 Stunde. Man gießt in ein Gemisch aus Wasser und Diethylether, wäscht die organische Phsse mit gesättigter Natriumchloridlösung und trocknet über Natriumsulfat. Nach Filtration und Lösungsmittelabzug reinigt man den Rückstand durch Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylacetat. Isoliert werden 298 mg (342 µmol, 36% bezogen auf Edukt in Beispiel 1l) der Titelverbindung A sowie 234 mg (269 µmol, 28% bezogen auf Edukt in Beispiel 1l) der Titelverbindung B jeweils als farbloses Öl.
1H-NMR (CDCl3) von A: δ = -0,02-0,15 (18H), 0,81-0,99 (30H), 1,05-2,3 (15H), 1,12 (3H), 1,24 (3H), 1,71 (3H), 1,92 (3H), 2,38 (1H), 2,51 (1H), 3,27 (1H), 3,80 (1H), 4,17 (1H), 4,43 (1H), 5,23 (1H), 6,67 (1H), 7,18 (1H), 7,36 (1H), 7,72 (1H), 8,62 (1H) ppm.
1H-NMR (CDCl3) von B: δ = -0,01-0,19 (18H), 0,80-0,96 (30H), 1,00-2,45 (16H), 1,13 (3H), 1,27 (3H), 1,57 (3H), 1,94 (3H), 2,54 (1H), 3,28 (1H), 3,88 (1H), 4,13 (1H), 4,40 (1H), 5,12 (1H), 6,49 (1H), 7,18 (1H), 7,38 (1H), 7,71 (1H), 8,62 (1H) ppm.The solution of 852 mg (max. 950 μmol) of the compound shown in Example 1n in 23 ml of acetone is cooled to -30 ° C., 1.19 ml of a standardized 8 N chromosulfuric acid solution are added and the mixture is stirred for 1 hour. It is poured into a mixture of water and diethyl ether, the organic phase is washed with saturated sodium chloride solution and dried over sodium sulfate. After filtration and removal of the solvent, the residue is purified by chromatography on fine silica gel with a gradient system that consists of n-hexane and ethyl acetate. 298 mg (342 μmol, 36% based on the starting material in Example 11) of the title compound A and 234 mg (269 μmol, 28% based on the starting material in Example 11) of the title compound B are isolated in each case as a colorless oil.
1 H NMR (CDCl 3 ) of A: δ = -0.02-0.15 (18H), 0.81-0.99 (30H), 1.05-2.3 (15H), 1.12 (3H), 1.24 (3H), 1.71 (3H), 1.92 (3H), 2.38 (1H), 2.51 (1H), 3.27 (1H), 3.80 ( 1H), 4.17 (1H), 4.43 (1H), 5.23 (1H), 6.67 (1H), 7.18 (1H), 7.36 (1H), 7.72 (1H ), 8.62 (1H) ppm.
1 H NMR (CDCl 3 ) of B: δ = -0.01-0.19 (18H), 0.80-0.96 (30H), 1.00-2.45 (16H), 1.13 (3H), 1.27 (3H), 1.57 (3H), 1.94 (3H), 2.54 (1H), 3.28 (1H), 3.88 (1H), 4.13 ( 1H), 4.40 (1H), 5.12 (1H), 6.49 (1H), 7.18 (1H), 7.38 (1H), 7.71 (1H), 8.62 (1H ) ppm.

Beispiel 1pExample 1p (3S,6R,7S,8S,12Z,15S,16E)-15-Hydroxy-3,7-bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]- 4,4,8,12,16-pentamethyl-5-oxo-17-(2-pyridyl)-6-(but-3-in-1-yl)-heptadeca-12,16- diensäure(3S, 6R, 7S, 8S, 12Z, 15S, 16E) -15-Hydroxy-3,7-bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] - 4,4,8,12,16-pentamethyl-5-oxo-17- (2-pyridyl) -6- (but-3-yn-1-yl) -heptadeca-12,16- dienoic acid

In Analogie zu Beispiel 1e setzt man 298 mg (342 µmol) der nach Beispiel 1o dargestellten Verbindung A um und isoliert nach Aufarbeitung 294 mg (max. 342 µmol) der Titelverbindung als Rohprodukt, das man ohne Reinigung weiter umsetzt.In analogy to Example 1e, 298 mg (342 μmol) of that according to Example 1o are used Compound A represented by and isolated after work-up 294 mg (max. 342 µmol) the title compound as a crude product, which is reacted further without purification.

Beispiel 1qExample 1q (4S,7R,8S,9S,13Z,16S(E))-4,8-Bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-16-(1-methyl- 2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en- 2,6-dion(4S, 7R, 8S, 9S, 13Z, 16S (E)) - 4,8-Bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -16- (1-methyl- 2- (2-pyridyl) ethenyl) -1-oxa-5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en- 2,6-dione

Die Lösung von 294 mg (max. 342 µmol) der nach Beispiel 1p dargestellten Verbindung in einem Gemisch aus 2,6 ml wasserfreiem Tetrahydrofuran und 30 ml Toluol versetzt man unter einer Atmosphäre aus trockenem Argon mit 284 µl Triethylamin, 268 µl 2,4,6-Trichlorbenzoylchlorid und rührt 20 Minuten. Man tropft diese Lösung innerhalb von 4,5 Stunden zu der Lösung von 434 mg 4-Dimethylaminopyridin in 132 ml Toluol und rührt 0,5 Stunden bei 23°C nach. Man engt ein, nimmt in wenig Dichlormethan auf und reinigt durch Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylacetat. Isoliert werden 136 mg (184 µmol, 54%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = -0,08 (3H), 0,13 (9H), 0,80-2,32 (12H), 0,85 (9H), 0,94 (9H), 0,99 (3H), 1,15 (3H), 1,24 (3H), 1,68 (3H), 2,13 (3H), 2,47 (1H), 2,59-2,89 (3H), 3,11 (1H), 4,00 (1H), 4,06 (1H), 5,00 (1H), 5,18 (1H), 6,57 (1H), 7,10 (1H), 7,26 (1H), 7,63 (1H), 8,60 (1H) ppm.The solution of 294 mg (max. 342 µmol) of the compound shown in Example 1p in a mixture of 2.6 ml of anhydrous tetrahydrofuran and 30 ml of toluene is mixed with 284 µl of triethylamine, 268 µl of 2.4, under an atmosphere of dry argon. 6-trichlorobenzoyl chloride and stir for 20 minutes. This solution is added dropwise to the solution of 434 mg of 4-dimethylaminopyridine in 132 ml of toluene over a period of 4.5 hours, and the mixture is stirred at 23 ° C. for 0.5 hours. It is concentrated, taken up in a little dichloromethane and purified by chromatography on fine silica gel with a gradient system of n-hexane and ethyl acetate. 136 mg (184 μmol, 54%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = -0.08 (3H), 0.13 (9H), 0.80-2.32 (12H), 0.85 (9H), 0.94 (9H) , 0.99 (3H), 1.15 (3H), 1.24 (3H), 1.68 (3H), 2.13 (3H), 2.47 (1H), 2.59-2.89 (3H), 3.11 (1H), 4.00 (1H), 4.06 (1H), 5.00 (1H), 5.18 (1H), 6.57 (1H), 7.10 ( 1H), 7.26 (1H), 7.63 (1H), 8.60 (1H) ppm.

Beispiel 1example 1 (4S,7R,8S,9S,13Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione

Die Lösung von 20 mg (27 µmol) der nach Beispiel 1p dargestellten Verbindung in 2 ml wasserfreiem Tetrahydrofuran versetzt man unter einer Atmosphäre aus trockenem Argon portionsweise mit insgesamt 0,57 ml HF-Pyridin-Komplex und rührt bei 23°C 24 Stunden. Man gießt in gesättigte Natriumhydrogencarbonatlösung, extrahiert mehrfach mit Dichlormethan und trocknet die vereinigten organischen Extrakte über Natriumsulfat. Nach Filtration und Lösungsmittelabzug reinigt man den erhaltenen Rückstand durch Chromatographie an feinem Kieselgel mit einem Gemisch aus n- Hexan und Ethylacetat. Isoliert werden 9,1 mg (17,9 µmol, 66%) der Titelverbindung als farbloses Öl sowie mg Monosilylether.
1H-NMR (CDCl3): δ = 1,09 (6H), 1,19-2,12 (11H), 1,38 (3H), 6,9 (3H), 2,06 (3H), 2,21-­ 2,41 (3H), 2,50 (1H), 2,63 (1H), 2,68 (1H), 3,53 (1H), 3,70 (1H), 4,42 (1H), 4,59 (1H), 5,12 (1H), 5,22 (1H), 6,61 (1H), 7,13 (1H), 7,29 (1H), 7,68 (1H), 8,53 (1H) ppm.A total of 0.57 ml of HF-pyridine complex is added in portions to a solution of 20 mg (27 μmol) of the compound shown in Example 1p in 2 ml of anhydrous tetrahydrofuran under an atmosphere of dry argon and the mixture is stirred at 23 ° C. for 24 hours. It is poured into saturated sodium hydrogen carbonate solution, extracted several times with dichloromethane and the combined organic extracts are dried over sodium sulfate. After filtration and removal of the solvent, the residue obtained is purified by chromatography on fine silica gel with a mixture of n-hexane and ethyl acetate. 9.1 mg (17.9 μmol, 66%) of the title compound are isolated as a colorless oil and also mg of monosilyl ether.
1 H-NMR (CDCl 3 ): δ = 1.09 (6H), 1.19-2.12 (11H), 1.38 (3H), 6.9 (3H), 2.06 (3H), 2.21-2.41 (3H), 2.50 (1H), 2.63 (1H), 2.68 (1H), 3.53 (1H), 3.70 (1H), 4.42 ( 1H), 4.59 (1H), 5.12 (1H), 5.22 (1H), 6.61 (1H), 7.13 (1H), 7.29 (1H), 7.68 (1H ), 8.53 (1H) ppm.

Beispiel 2Example 2 (4S,7R,8S,9S,13Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione Beispiel 2aExample 2a (4S,7R,8S,9S,13Z,16S(E))-4,8-Bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-16-(1-methyl- 2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en- 2,6-dion(4S, 7R, 8S, 9S, 13Z, 16S (E)) - 4,8-Bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -16- (1-methyl- 2- (2-pyridyl) ethenyl) -1-oxa-5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en- 2,6-dione

Die Lösung von 25 mg (34 µmol) der nach Beispiel 1q dargestellten Verbindung in 3 ml Ethanol versetzt man mit 25 µl Pyridin, einer katalytischen Menge von Palladium auf Bariumsulfat (10%ig) und hydriert unter 1 Atmosphäre Wasserstoff. Nach Filtration und Lösungsmittelabzug reinigt man den Rückstand durch Chromatographie an einer analytischen Dünnschichtplatte. Als Laumittel dient ein Gemisch aus n-Hexan und Ethylacetat. Isoliert werden 13 mg (18 µmol, 52%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = -0,10 (3H), 0,06 (3H), 0,11 (6H), 0,80-2,20 (11H), 0,83 (9H), 0,92 (9H), 0,98 (3H), 1,12 (3H), 1,19 (3H), 1,67 (3H), 2,12 (3H), 2,43 (1H), 2,55-2,82 (3H), 3,07 (1H), 4,00 (1H), 4,03 (1H), 4,90-5,03 (3H), 5,18 (1H), 5,72 (1H), 6,57 (1H), 7,09 (1H), 7,25 (1H), 7,62 (1H), 8,59 (1H) ppm.The solution of 25 mg (34 μmol) of the compound shown in Example 1q in 3 ml of ethanol is mixed with 25 μl of pyridine, a catalytic amount of palladium on barium sulfate (10%) and hydrogenated under 1 atmosphere of hydrogen. After filtration and removal of the solvent, the residue is purified by chromatography on an analytical thin-layer plate. A mixture of n-hexane and ethyl acetate is used as the detergent. 13 mg (18 μmol, 52%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = -0.10 (3H), 0.06 (3H), 0.11 (6H), 0.80-2.20 (11H), 0.83 (9H) , 0.92 (9H), 0.98 (3H), 1.12 (3H), 1.19 (3H), 1.67 (3H), 2.12 (3H), 2.43 (1H), 2.55-2.82 (3H), 3.07 (1H), 4.00 (1H), 4.03 (1H), 4.90-5.03 (3H), 5.18 (1H), 5.72 (1H), 6.57 (1H), 7.09 (1H), 7.25 (1H), 7.62 (1H), 8.59 (1H) ppm.

Beispiel 2Example 2 (4S,7R,8S,9S,13Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione

In Analogie zu Beispiel 1 setzt man 10,3 mg (14 µmol) der nach Beispiel 2a dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 5,7 mg (11 µmol, 80%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 1,04 (3H), 1,09 (3H), 0,25-2,38 (13H), 1,36 (3H), 1,70 (3H), 2,07 (3H), 2,48 (1H), 2,63 (1H), 2,74 (1H), 3,31 (1H), 3,69 (1H), 4,38 (1H), 4,61 (1H), 4,97 (1H), 5,02 (1H), 5,11 (1H), 5,19 (1H), 5,77 (1H), 6,60 (1H), 7,13 (1H), 7,29 (1H), 7,68 (1H), 8,54 (1H) ppm.In analogy to Example 1, 10.3 mg (14 μmol) of the compound shown in Example 2a are reacted and, after work-up and purification, 5.7 mg (11 μmol, 80%) of the title compound is isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 1.04 (3H), 1.09 (3H), 0.25-2.38 (13H), 1.36 (3H), 1.70 (3H), 2.07 (3H), 2.48 (1H), 2.63 (1H), 2.74 (1H), 3.31 (1H), 3.69 (1H), 4.38 (1H), 4 , 61 (1H), 4.97 (1H), 5.02 (1H), 5.11 (1H), 5.19 (1H), 5.77 (1H), 6.60 (1H), 7, 13 (1H), 7.29 (1H), 7.68 (1H), 8.54 (1H) ppm.

Beispiel 3Example 3 (4S,7R,8S,9S,13E,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13E, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione Beispiel 3aExample 3a (3S,6R,7S,8S,12E,15S,16E)-15-Hydroxy-3,7-bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]- 4,4,8,12,16-pentamethyl-5-oxo-17-(2-pyridyl)-6-(prop-2-in-1-yl)-heptadeca-12,16- diensäure(3S, 6R, 7S, 8S, 12E, 15S, 16E) -15-Hydroxy-3,7-bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] - 4,4,8,12,16-pentamethyl-5-oxo-17- (2-pyridyl) -6- (prop-2-yn-1-yl) -heptadeca-12,16- dienoic acid

In Analogie zu Beispiel 1e setzt man 234 mg (269 µmol) der nach Beispiel 1o dargestellten Verbindung B um und isoliert nach Aufarbeitung 229 mg (max. 269 µmol) der Titelverbindung als Rohprodukt, das man ohne Reinigung weiter umsetzt.In analogy to Example 1e, 234 mg (269 μmol) of that according to Example 1o are used Compound B represented by and isolated after work-up 229 mg (max. 269 µmol) the title compound as a crude product, which is reacted further without purification.

Beispiel 3bExample 3b (4S,7R,8S,9S,13E,16S(E))-4,8-Bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-16-(1-methyl- 2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en- 2,6-dion(4S, 7R, 8S, 9S, 13E, 16S (E)) - 4,8-bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -16- (1-methyl- 2- (2-pyridyl) ethenyl) -1-oxa-5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en- 2,6-dione

In Analogie zu Beispiel 1q setzt man 229 mg (max. 269 µmol) der nach Beispiel 3a dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 112 mg (152 µmol, 56%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,05 (3H), 0,11 (6H), 0,15 (3H), 0,80-2,30 (33H), 1,13 (3H), 1,21 (3H), 1,62 (3H), 2,16 (3H), 2,40-2,72 (4H), 3,10 (1H), 3,91 (1H), 4,46 (1H), 5,22 (1H), 5,30 (1H), 6,56 (1H), 7,09 (1H), 7,20 (1H), 7,62 (1H), 8,60 (1H) ppm.In analogy to Example 1q, 229 mg (max. 269 μmol) of the compound shown in Example 3a are reacted and, after working up and purification, 112 mg (152 μmol, 56%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.05 (3H), 0.11 (6H), 0.15 (3H), 0.80-2.30 (33H), 1.13 (3H), 1.21 (3H), 1.62 (3H), 2.16 (3H), 2.40-2.72 (4H), 3.10 (1H), 3.91 (1H), 4.46 ( 1H), 5.22 (1H), 5.30 (1H), 6.56 (1H), 7.09 (1H), 7.20 (1H), 7.62 (1H), 8.60 (1H ) ppm.

Beispiel 3Example 3 (4S,7R,8S,9S,13E,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13E, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione

In Analogie zu Beispiel 1 setzt man 72 mg (98 µmol) der nach Beispiel 3b dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 32 mg (63 µmol, 64%) der Titelverbindung als farblosen Schaum.
1H-NMR (CDCl3): δ = 1,00 (3H), 1,04 (3H), 1,30-2,71 (16H), 1,32 (3H), 1,61 (3H), 2,10 (3H), 3,63 (1H), 3,70 (1H), 3,86 (1H), 3,99 (1H), 4,48 (1H), 5,10 (1H), 5,41 (1H), 6,58 (1H), 7,13 (1H), 7,33 (1H), 7,68 (1H), 8,54 (1H) ppm.In analogy to Example 1, 72 mg (98 μmol) of the compound shown in Example 3b are reacted and, after working up and purification, 32 mg (63 μmol, 64%) of the title compound are isolated as a colorless foam.
1 H-NMR (CDCl 3 ): δ = 1.00 (3H), 1.04 (3H), 1.30-2.71 (16H), 1.32 (3H), 1.61 (3H), 2.10 (3H), 3.63 (1H), 3.70 (1H), 3.86 (1H), 3.99 (1H), 4.48 (1H), 5.10 (1H), 5 , 41 (1H), 6.58 (1H), 7.13 (1H), 7.33 (1H), 7.68 (1H), 8.54 (1H) ppm.

Beispiel 4Example 4 (1S,3S(E),7S,10R,11S,12S,16R)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9- dion (A) und (1R,3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3- (1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion (B)(1S, 3S (E), 7S, 10R, 11S, 12S, 16R) -7,11-dihydroxy-10- (prop-2-in-1-yl) -3- (1-methyl-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9- dione (A) and (1R, 3S (E), 7S, 10R, 11S, 12S, 16S) -7,11-dihydroxy-10- (prop-2-in-1-yl) -3- (1-methyl-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17- dioxabicyclo [14.1.0] heptadecane-5,9-dione (B)

Die Lösung von 5 mg (10 µmol) der nach Beispiel 1 dargestellten Verbindung in 1 ml Dichlormethan versetzt man unter einer Atmospäre aus trockenem Argon bei -20°C mit 11,3 µl einer 20%igen Lösung von Trifluoessigsäure in Dichlormethan und 5,6 mg m- Chlorperbenzoesäure (60%ig). Man rührt 18 Stunden bei -18°C, gießt auf gesättigte Natriumthiosulfatlösung, extrahiert mehrfach mit Dichlormethan, wäscht die vereinigten organischen Extrakte mit Natriumhydrogencarbonatlösung, gesättigter Natriumchlorid­ lösung und trocknet über Magnesiumsulfat. Den nach Filtration und Lösungsmittelabzug erhaltenen Rückstand reinigt man durch Chromatographie an einer analytischen Dünnschichtplatte. Als Lauf- und Elutionsmittel dient ein Gemisch aus Dichlormethan und Ethanol. Isoliert werden 1,3 mg (2,5 µmol, 25%) der Titelverbindung A (oder B) sowie 2,0 mg (3,8 µmol, 39%) der Titelverbindung B (oder A) jeweils als farbloses Öl.
1H-NMR (CDCl3) von A (oder B): δ = 1,01 (3H), 1,07 (3H), 1,23-2,20 (13H), 1,30 (3H), 1,46 (3H), 2,10 (3H), 2,26 (1H), 2,40 (1H), 2,58 (1H), 2,82 (1H), 2,97 (1H), 3,63 (2H), 4,39 (1H), 5,22 (1H), 5,47 (1H), 6,61 (1H), 7,15 (1H), 7,28 (1H), 7,69 (1H), 8,55 (1H) ppm.
1H-NMR (CDCl3) von B (oder A): δ = 0,98 (3H), 1,08 (3H), 1,27-2,19 (13H), 1,32 (3H), 1,43 (3H), 2,12 (3H), 2,30 (1H), 2,48 (1H), 2,70 (1H), 2,96 (1H), 3,15 (1H), 3,47 (1H), 3,57 (1H), 4,01 (1H), 4,49 (1H), 5,50 (1H), 6,67 (1H), 7,12 (1H), 7,27 (1H), 7,66 (1H), 8,58 (1H) ppm.The solution of 5 mg (10 μmol) of the compound shown in Example 1 in 1 ml of dichloromethane is mixed under an atmosphere of dry argon at -20 ° C. with 11.3 μl of a 20% solution of trifluoroacetic acid in dichloromethane and 5.6 mg m-chloroperbenzoic acid (60%). The mixture is stirred for 18 hours at -18 ° C., poured onto saturated sodium thiosulphate solution, extracted several times with dichloromethane, the combined organic extracts are washed with sodium hydrogen carbonate solution, saturated sodium chloride solution and dried over magnesium sulphate. The residue obtained after filtration and removal of the solvent is purified by chromatography on an analytical thin-layer plate. A mixture of dichloromethane and ethanol is used as the mobile phase and eluent. 1.3 mg (2.5 μmol, 25%) of the title compound A (or B) and 2.0 mg (3.8 μmol, 39%) of the title compound B (or A) are isolated in each case as a colorless oil.
1 H-NMR (CDCl 3 ) of A (or B): δ = 1.01 (3H), 1.07 (3H), 1.23-2.20 (13H), 1.30 (3H), 1 , 46 (3H), 2.10 (3H), 2.26 (1H), 2.40 (1H), 2.58 (1H), 2.82 (1H), 2.97 (1H), 3, 63 (2H), 4.39 (1H), 5.22 (1H), 5.47 (1H), 6.61 (1H), 7.15 (1H), 7.28 (1H), 7.69 (1H), 8.55 (1H) ppm.
1 H-NMR (CDCl 3 ) of B (or A): δ = 0.98 (3H), 1.08 (3H), 1.27-2.19 (13H), 1.32 (3H), 1 , 43 (3H), 2.12 (3H), 2.30 (1H), 2.48 (1H), 2.70 (1H), 2.96 (1H), 3.15 (1H), 3, 47 (1H), 3.57 (1H), 4.01 (1H), 4.49 (1H), 5.50 (1H), 6.67 (1H), 7.12 (1H), 7.27 (1H), 7.66 (1H), 8.58 (1H) ppm.

Beispiel 5Example 5 (1S,3S(E),7S,10R,11S,12S,16R)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9- dion (A) und (1R,3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3- (1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion (B)(1S, 3S (E), 7S, 10R, 11S, 12S, 16R) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9- dione (A) and (1R, 3S (E), 7S, 10R, 11S, 12S, 16S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17- dioxabicyclo [14.1.0] heptadecane-5,9-dione (B)

In Analogie zu Beispiel 4 setzt man 6,6 mg (13 µmol) der nach Beispiel 2 dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 1,4 mg (2,7 µmol, 20%) der Titelverbindung A (oder B) sowie 0,9 mg (1,7 µmol, 13%) der Titelverbindung B (oder A) jeweils als farblosen Schaum.
1H-NMR (CDCl3) von A (oder B): δ = 1,00 (3H), 1,07 (3H), 1,21-2,05 (12H), 1,30 (3H), 1,40 (3H), 2,10 (3H), 2,16 (1H), 2,38 (1H), 2,57 (1H), 2,81 (1H), 2,97 (1H), 3,44 (1H), 3,63 (1H), 4,38 (1H), 4,98 (1H), 5,02 (1H), 5,28 (1H), 5,45 (1H), 5,77 (1H), 6,62 (1H), 7,18 (1H), 7,31 (1H), 7,71 (1H), 8,56 (1H) ppm.
1H-NMR (CDCl3) von B (oder A): δ = 0,94 (3H), 1,05 (3H), 1,18-2,17 (13H), 1,30 (3H), 1,38 (3H), 2,12 (3H), 2,48 (1H), 2,62 (1H), 2,95 (1H), 3,28 (1H), 3,30 (1H), 3,50 (1H), 3,96 (1H), 4,41 (1H), 4,95 (1H), 5,00 (1H), 5,52 (1H), 5,25 (1H), 6,73 (1H), 7,18 (1H), 7,33 (1H), 7,71 (1H), 8,58 (1H) ppm.In analogy to Example 4, 6.6 mg (13 μmol) of the compound shown in Example 2 are reacted and, after working up and purification, 1.4 mg (2.7 μmol, 20%) of the title compound A (or B) and 0 are isolated , 9 mg (1.7 μmol, 13%) of the title compound B (or A) in each case as a colorless foam.
1 H-NMR (CDCl 3 ) of A (or B): δ = 1.00 (3H), 1.07 (3H), 1.21-2.05 (12H), 1.30 (3H), 1 , 40 (3H), 2.10 (3H), 2.16 (1H), 2.38 (1H), 2.57 (1H), 2.81 (1H), 2.97 (1H), 3, 44 (1H), 3.63 (1H), 4.38 (1H), 4.98 (1H), 5.02 (1H), 5.28 (1H), 5.45 (1H), 5.77 (1H), 6.62 (1H), 7.18 (1H), 7.31 (1H), 7.71 (1H), 8.56 (1H) ppm.
1 H-NMR (CDCl 3 ) of B (or A): δ = 0.94 (3H), 1.05 (3H), 1.18-2.17 (13H), 1.30 (3H), 1 , 38 (3H), 2.12 (3H), 2.48 (1H), 2.62 (1H), 2.95 (1H), 3.28 (1H), 3.30 (1H), 3, 50 (1H), 3.96 (1H), 4.41 (1H), 4.95 (1H), 5.00 (1H), 5.52 (1H), 5.25 (1H), 6.73 (1H), 7.18 (1H), 7.33 (1H), 7.71 (1H), 8.58 (1H) ppm.

Beispiel 6Example 6 (1S,3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9- dion (A) und (1R,3S(E),7S,10R,11S,12S,16R)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3- (1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion (B)(1S, 3S (E), 7S, 10R, 11S, 12S, 16S) -7,11-dihydroxy-10- (prop-2-in-1-yl) -3- (1-methyl-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9- dione (A) and (1R, 3S (E), 7S, 10R, 11S, 12S, 16R) -7,11-dihydroxy-10- (prop-2-in-1-yl) -3- (1-methyl-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17- dioxabicyclo [14.1.0] heptadecane-5,9-dione (B)

In Analogie zu Beispiel 4 setzt man 14 mg (27 µmol) der nach Beispiel 3 dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 7,8 mg (15 µmol, 55%) der Titelverbindung A (oder B) sowie 4,7 mg (9 µmol, 33%) der Titelverbindung B (oder A) jeweils als farblosen Schaum.
1H-NMR (CDCl3) von A (oder B): δ = 0,93 (3H), 1,04 (3H), 1,23-2,19 (13H), 1,29 (3H), 1,42 (3H), 2,13 (3H), 2,28 (1H), 2,48-2,65 (2H), 2,71 (1H), 2,89 (1H), 3,57 (1H), 3,83 (1H), 4,36 (1H), 4,47 (1H), 5,51 (1H), 6,63 (1H), 7,12 (1H), 7,28 (1H), 7,67 (1H), 8,57 (1H) ppm.
1H-NMR (CDCl3) von B (oder A): δ = 0,96 (3H), 1,10 (3H), 1,21-2,18 (13H), 1,26 (3H), 1,40 (3H), 2,10 (3H), 2,29 (1H), 2,61 (2H), 2,86 (1H), 2,99 (1H), 3,58 (1H), 3,79 (2H), 4,37 (1H), 5,46 (1H), 6,61 (1H), 7,12 (1H), 7,26 (1H), 7,66 (1H), 8,57 (1H) ppm.In analogy to Example 4, 14 mg (27 µmol) of the compound shown in Example 3 are reacted and, after work-up and purification, 7.8 mg (15 µmol, 55%) of the title compound A (or B) and 4.7 mg ( 9 μmol, 33%) of the title compound B (or A) in each case as a colorless foam.
1 H-NMR (CDCl 3 ) of A (or B): δ = 0.93 (3H), 1.04 (3H), 1.23-2.19 (13H), 1.29 (3H), 1 , 42 (3H), 2.13 (3H), 2.28 (1H), 2.48-2.65 (2H), 2.71 (1H), 2.89 (1H), 3.57 (1H ), 3.83 (1H), 4.36 (1H), 4.47 (1H), 5.51 (1H), 6.63 (1H), 7.12 (1H), 7.28 (1H) , 7.67 (1H), 8.57 (1H) ppm.
1 H-NMR (CDCl 3 ) of B (or A): δ = 0.96 (3H), 1.10 (3H), 1.21-2.18 (13H), 1.26 (3H), 1 , 40 (3H), 2.10 (3H), 2.29 (1H), 2.61 (2H), 2.86 (1H), 2.99 (1H), 3.58 (1H), 3, 79 (2H), 4.37 (1H), 5.46 (1H), 6.61 (1H), 7.12 (1H), 7.26 (1H), 7.66 (1H), 8.57 (1H) ppm.

Beispiel 7Example 7 (4S,7R,8S,9S,13E,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13E, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione

In Analogie zu Beispiel 2a setzt man 14 mg (27 µmol) der nach Beispiel 3 dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 4,1 mg (8 µmol, 29%) der Titelverbindung als farblosen Schaum.
1H-NMR (CDCl3): δ = 0,98 (3H), 1,02 (3H), 1,30 (3H), 1,36-2,68 (16H), 1,61 (3H), 2,09 (3H), 3,43 (1H), 3,70 (1H), 4,17 (1H), 4,45 (1H), 4,94 (1H), 5,00 (1H), 5,09 (1H), 5,39 (1H), 5,72 (1H), 6,58 (1H), 7,12 (1H), 7,35 (1H), 7,67 (1H), 8,52 (1H) ppm.In analogy to Example 2a, 14 mg (27 μmol) of the compound shown in Example 3 are reacted and, after work-up and purification, 4.1 mg (8 μmol, 29%) of the title compound is isolated as a colorless foam.
1 H-NMR (CDCl 3 ): δ = 0.98 (3H), 1.02 (3H), 1.30 (3H), 1.36-2.68 (16H), 1.61 (3H), 2.09 (3H), 3.43 (1H), 3.70 (1H), 4.17 (1H), 4.45 (1H), 4.94 (1H), 5.00 (1H), 5 , 09 (1H), 5.39 (1H), 5.72 (1H), 6.58 (1H), 7.12 (1H), 7.35 (1H), 7.67 (1H), 8, 52 (1H) ppm.

Beispiel 8Example 8 (1S,3S(E),7S,10R,11S,12S,16S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9- dion (A) und (1R,3S(E),7S,10R,11S,12S,16R)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3- (1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion (B)(1S, 3S (E), 7S, 10R, 11S, 12S, 16S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9- dione (A) and (1R, 3S (E), 7S, 10R, 11S, 12S, 16R) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17- dioxabicyclo [14.1.0] heptadecane-5,9-dione (B)

In Analogie zu Beispiel 4 setzt man 4,1 mg (8 µmol) der nach Beispiel 7 dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 1,7 mg (3,2 µmol, 40%) der Titelverbindung A (oder B) sowie 0,4 mg (0,8 µmol, 9%) der Titelverbindung B (oder A) jeweils als farblosen Schaum.
1H-NMR (CDCl3) von A (oder B): δ = 0,91 (3H), 1,02 (3H), 1,13-2,17 (15H), 1,28 (3H), 1,38 (3H), 2,11 (3H), 2,53 (2H), 2,87 (1H), 2,96 (1H), 3,38 (1H), 3,78 (1H), 4,35 (1H), 4,37 (1H), 4,95 (1H), 5,00 (1H), 5,50 (1H), 5,76 (1H), 6,64 (1H), 7,12 (1H), 7,30 (1H), 7,67 (1H), 8,57 (1H) ppm.
1H-NMR (CDCl3) von B (oder A): δ = 0,92 (3H), 1,09 (3H), 1,18-2,13 (15H), 1,26 (3H), 1,38 (3H), 2,08 (3H), 2,49-2,60 (2H), 2,85-2,99 (2H), 3,39 (1H), 3,72 (1H), 3,89 (1H), 4,28 (1H), 4,92-5,06 (2H), 5,45 (1H), 5,76 (1H), 6,60 (1H), 7,12 (1H), 7,26 (1H), 7,68 (1H), 8,57 (1H) ppm.In analogy to Example 4, 4.1 mg (8 μmol) of the compound shown in Example 7 are reacted and, after work-up and purification, 1.7 mg (3.2 μmol, 40%) of the title compound A (or B) and 0 are isolated , 4 mg (0.8 μmol, 9%) of the title compound B (or A) in each case as a colorless foam.
1 H-NMR (CDCl 3 ) of A (or B): δ = 0.91 (3H), 1.02 (3H), 1.13-2.17 (15H), 1.28 (3H), 1 , 38 (3H), 2.11 (3H), 2.53 (2H), 2.87 (1H), 2.96 (1H), 3.38 (1H), 3.78 (1H), 4, 35 (1H), 4.37 (1H), 4.95 (1H), 5.00 (1H), 5.50 (1H), 5.76 (1H), 6.64 (1H), 7.12 (1H), 7.30 (1H), 7.67 (1H), 8.57 (1H) ppm.
1 H-NMR (CDCl 3 ) of B (or A): δ = 0.92 (3H), 1.09 (3H), 1.18-2.13 (15H), 1.26 (3H), 1 , 38 (3H), 2.08 (3H), 2.49-2.60 (2H), 2.85-2.99 (2H), 3.39 (1H), 3.72 (1H), 3 , 89 (1H), 4.28 (1H), 4.92-5.06 (2H), 5.45 (1H), 5.76 (1H), 6.60 (1H), 7.12 (1H ), 7.26 (1H), 7.68 (1H), 8.57 (1H) ppm.

Beispiel 9Example 9 (4S,7R,8S,9S,13Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6- dion(4S, 7R, 8S, 9S, 13Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazole-4- yl) ethenyl) -1-oxa-5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6- dion Beispiel 9aExample 9a (3RS,4S)-4-(2-Methyl-3-hydroxy-hept-6-en-2-yl)-2,2-dimethyl-[1,3]dioxan(3RS, 4S) -4- (2-methyl-3-hydroxy-hept-6-en-2-yl) -2,2-dimethyl- [1,3] dioxane

In Analogie zu Beispiel 1a setzt man 5,5 g (30 mmol) (4S)-4-(2-Methyl-1-oxo-prop-2-yl)- 2,2-dimethyl-[1,3]dioxan, das man in Analogie zu den in DE 197 51 200.3 beschriebenen Verfahren hergestellt hat, mit Prop-2-en-1-yl-magnesiumbromid um und isoliert nach Aufarbeitung und Reinigung 3,84 g (15,8 mmol, 53%) der Titelverbindung als farbloses Öl.In analogy to Example 1a, 5.5 g (30 mmol) (4S) -4- (2-methyl-1-oxo-prop-2-yl) - 2,2-dimethyl- [1,3] dioxane, which is produced in analogy to the DE 197 51 200.3 has prepared the process described, with prop-2-en-1-yl-magnesium bromide and isolated after work-up and purification 3.84 g (15.8 mmol, 53%) of the title compound as a colorless oil.

Beispiel 9bExample 9b (4S)-4-(2-Methyl-3-oxo-hept-6-en-2-yl)-2,2-dimethyl-[1,3]dioxan(4S) -4- (2-Methyl-3-oxo-hept-6-en-2-yl) -2,2-dimethyl- [1,3] dioxane

In Analogie zu Beispiel 1b setzt man 3,84 g (15,8 mmol) der nach Beispiel 9a dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 3,0 g (12,5 mmol, 79%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 1,07 (3H), 1,14 (3H), 1,33 (4H), 1,41 (3H), 1,62 (1H), 2,29 (2H), 2,60 (2H), 3,86 (1H), 3,97 (1H), 4,05 (1H), 4,96 (1H), 5,02 (1H), 5,81 (1H) ppm.In analogy to Example 1b, 3.84 g (15.8 mmol) of the compound shown in Example 9a are reacted and, after working up and purification, 3.0 g (12.5 mmol, 79%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 1.07 (3H), 1.14 (3H), 1.33 (4H), 1.41 (3H), 1.62 (1H), 2.29 ( 2H), 2.60 (2H), 3.86 (1H), 3.97 (1H), 4.05 (1H), 4.96 (1H), 5.02 (1H), 5.81 (1H ) ppm.

Beispiel 9cExample 9c (4S(4R,5S,6S,10E/Z,13S,14E))-4-(13-[[Dimethyl(1,1-dimethylethyl)silyl]oxy]-5-hydroxy- 2,6,10,14-tetramethyl-3-oxo-15-(2-methylthiazol-4-yl)-4-(prop-2-en-1-yl)-pentadec-2-yl)- 2,2-dimethyl-[1,3]dioxan (A) und (4S(4S,5R,6S,10E/Z,13S,14E))-4-(13-[[Dimethyl(1,1- dimethylethyl)silyl]oxy]-5-hydroxy-2,6,10,14-tetramethyl-3-oxo-15-(2-methylthiazol-4-yl)- 4-(prop-2-en-1-yl)-pentadec-2-yl)-2,2-dimethyl-[1,3]dioxan (B)(4S (4R, 5S, 6S, 10E / Z, 13S, 14E)) - 4- (13 - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -5-hydroxy- 2,6,10,14-tetramethyl-3-oxo-15- (2-methylthiazol-4-yl) -4- (prop-2-en-1-yl) -pentadec-2-yl) - 2,2-dimethyl- [1,3] dioxane (A) and (4S (4S, 5R, 6S, 10E / Z, 13S, 14E)) - 4- (13 - [[dimethyl (1,1- dimethylethyl) silyl] oxy] -5-hydroxy-2,6,10,14-tetramethyl-3-oxo-15- (2-methylthiazol-4-yl) - 4- (prop-2-en-1-yl) -pentadec-2-yl) -2,2-dimethyl- [1,3] dioxane (B)

In Analogie zu Beispiel 1c setzt man 2,07 g (8,61 mmol) der nach Beispiel 9b dargestellten Verbindung mit 2,01 g (4,61 mmol) (2S,6E/Z,9S,10E)-2,6,10-Trimethyl-9- [[dimethyl(1,1-dimethylethyl)silyl]oxy]-1-oxo-11-(2-methylthiazol-4-yl)-undeca-6,10-dien, das man in Analogie zu den in DE 197 51 200.3 beschriebenen Verfahren hergestellt hat, um und isoliert nach Aufarbeitung und Reinigung neben Ausgangsmaterial 995 mg (1,47 mmol, 32%) der Titelverbindung A sowie 784 mg (1,16 mmol, 25%) der Titelverbindung B jeweils als farbloses Öl.
1H-NMR (CDCl3) von A: δ = 0,01 (3H), 0,07 (3H), 0,85 (3H), 0,90 (9H), 0,98 (3H), 1,00-­ 2,33 (12H), 1,23 (3H), 1,33 (3H), 1,39 (3H), 1,60 + 1,67 (3H), 2,00 (3H), 2,46 (1H), 2,72 (3H), 2,99 (1H), 3,34 (1H), 3,49 (1H), 3,87 (1H), 3,98 (1H), 4,09 (1H), 4,13 (1H), 4,98 (1H), 5,03 (1H), 5,13 (1H), 5,71 (1H), 6,44 (1H), 6,93 (1H) ppm.
1H-NMR (CDCl3) von B: δ = 0,00 (3H), 0,03 (3H), 0,88 (9H), 0,94 (3H), 1,03-1,72 (7H), 1,08 (3H), 1,17 (3H), 1,31 (3H), 1,39 (3H), 1,60 + 1,68 (3H), 1,89-2,08 (2H), 1,99 (3H), 2,17-2,51 (4H), 2,71 (3H), 2,74 + 2,87 (1H), 3,31 (1H), 3,57 (1H), 3,84 (1H), 3,95 (1H), 4,03417 (2H), 4,98 (1H), 5,03 (1H), 5,13 (1H), 5,73 (1H), 6,46 (1H), 6,92 (1H) ppm.In analogy to Example 1c, 2.07 g (8.61 mmol) of the compound shown according to Example 9b is added to 2.01 g (4.61 mmol) (2S, 6E / Z, 9S, 10E) -2.6, 10-Trimethyl-9- [[dimethyl (1,1-dimethylethyl) silyl] oxy] -1-oxo-11- (2-methylthiazol-4-yl) -undeca-6,10-diene, which can be obtained in analogy to has prepared the process described in DE 197 51 200.3, in order to isolate and after work-up and purification in addition to starting material 995 mg (1.47 mmol, 32%) of the title compound A and 784 mg (1.16 mmol, 25%) of the title compound B, respectively as a colorless oil.
1 H-NMR (CDCl 3 ) of A: δ = 0.01 (3H), 0.07 (3H), 0.85 (3H), 0.90 (9H), 0.98 (3H), 1, 00-2.33 (12H), 1.23 (3H), 1.33 (3H), 1.39 (3H), 1.60 + 1.67 (3H), 2.00 (3H), 2, 46 (1H), 2.72 (3H), 2.99 (1H), 3.34 (1H), 3.49 (1H), 3.87 (1H), 3.98 (1H), 4.09 (1H), 4.13 (1H), 4.98 (1H), 5.03 (1H), 5.13 (1H), 5.71 (1H), 6.44 (1H), 6.93 ( 1H) ppm.
1 H NMR (CDCl 3 ) of B: δ = 0.00 (3H), 0.03 (3H), 0.88 (9H), 0.94 (3H), 1.03-1.72 (7H ), 1.08 (3H), 1.17 (3H), 1.31 (3H), 1.39 (3H), 1.60 + 1.68 (3H), 1.89-2.08 (2H ), 1.99 (3H), 2.17-2.51 (4H), 2.71 (3H), 2.74 + 2.87 (1H), 3.31 (1H), 3.57 (1H ), 3.84 (1H), 3.95 (1H), 4.03417 (2H), 4.98 (1H), 5.03 (1H), 5.13 (1H), 5.73 (1H) , 6.46 (1H), 6.92 (1H) ppm.

Beispiel 9dExample 9d (3S,6R,7S,8S,12E/Z,15S,16E)-15-[[Dimethyl(1,1-dimethylethyl)silyl]oxy]-1,3,7- trihydroxy-4,4,8,12,16-pentamethyl-17-(2-methylthiazol-4-yl)-6-(prop-2-en-1-yl)- heptadeca-12,16-dien-5-on(3S, 6R, 7S, 8S, 12E / Z, 15S, 16E) -15 - [[Dimethyl (1,1-dimethylethyl) silyl] oxy] -1,3,7- trihydroxy-4,4,8,12,16-pentamethyl-17- (2-methylthiazol-4-yl) -6- (prop-2-en-1-yl) - heptadeca-12,16-dien-5-one

In Analogie zu Beispiel 1k setzt man 1,33 g (1,97 mmol) der nach Beispiel 9c dargestellten Verbindung A um und isoliert nach Aufarbeitung und Reinigung 1,02 g (1,60 mmol, 81%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,01 (3H), 0,07 (3H), 0,89 (12H), 1,00-2,38 (12H), 1,04 + 1,07 (3H), 1,23 + 1,25 (3H), 1,60 + 1,68 (3H), 1,97 + 1,99 (3H), 2,52 (1H), 2,67-2,89 (1H), 2,73 + 2,77 (3H), 3,01 (1H), 3,33 (1H), 3,40-3,53 (1H), 3,74-3,93 (3H), 4,03-4,19 (2H), 5,00 (1H), 5,06 (1H), 5,10 + 5,20 (1H), 5,71 (1H), 6,42 (1H), 6,93 (1H) ppm.In analogy to Example 1k, 1.33 g (1.97 mmol) of the compound A shown in Example 9c is reacted and, after work-up and purification, 1.02 g (1.60 mmol, 81%) of the title compound is isolated as a colorless oil.
1 H NMR (CDCl 3 ): δ = 0.01 (3H), 0.07 (3H), 0.89 (12H), 1.00-2.38 (12H), 1.04 + 1.07 (3H), 1.23 + 1.25 (3H), 1.60 + 1.68 (3H), 1.97 + 1.99 (3H), 2.52 (1H), 2.67-2, 89 (1H), 2.73 + 2.77 (3H), 3.01 (1H), 3.33 (1H), 3.40-3.53 (1H), 3.74-3.93 (3H ), 4.03-4.19 (2H), 5.00 (1H), 5.06 (1H), 5.10 + 5.20 (1H), 5.71 (1H), 6.42 (1H ), 6.93 (1H) ppm.

Beispiel 9eExample 9e (3S,6R,7S,8S,12E/Z,15S,16E)-1,3,7,15-Tetrakis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]- 4,4,8,12,16-pentamethyl-17-(2-methylthiazol-4-yl)-6-(prop-2-en-1-yl)-heptadeca-12,16- dien-5-on(3S, 6R, 7S, 8S, 12E / Z, 15S, 16E) -1,3,7,15-tetrakis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] - 4,4,8,12,16-pentamethyl-17- (2-methylthiazol-4-yl) -6- (prop-2-en-1-yl) -heptadeca-12,16- dien-5-on

In Analogie zu Beispiel 1l setzt man 1,02 g (1,60 mmol) der nach Beispiel 9d dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 1,46 g (1,49 mmol, 93%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,00-0,11 (24H), 0,83-0,98 (39H), 1,01-1,62 (8H), 1,07 (3H), 1,20 (3H), 1,59 + 1,67 (3H), 1,97 (1H), 2,00 (3H), 2,19-2,34 (3H), 2,48 (1H), 2,72 (3H), 3,13 (1H), 3,57 (1H), 3,67 (1H), 3,78 (1H), 3,87 (1H), 4,09 (1H), 4,93 (1H), 4,99 (1H), 5,15 (1H), 5,77 (1H), 6,46 (1H), 6,91 (1H) ppm.In analogy to Example 11, 1.02 g (1.60 mmol) of the compound shown in Example 9d is reacted and, after working up and purification, 1.46 g (1.49 mmol, 93%) of the title compound is isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.00-0.11 (24H), 0.83-0.98 (39H), 1.01-1.62 (8H), 1.07 (3H) , 1.20 (3H), 1.59 + 1.67 (3H), 1.97 (1H), 2.00 (3H), 2.19-2.34 (3H), 2.48 (1H) , 2.72 (3H), 3.13 (1H), 3.57 (1H), 3.67 (1H), 3.78 (1H), 3.87 (1H), 4.09 (1H), 4.93 (1H), 4.99 (1H), 5.15 (1H), 5.77 (1H), 6.46 (1H), 6.91 (1H) ppm.

Beispiel 9fExample 9f (3S,6R,7S,8S,12E/Z,15S,16E)-1-Hydroxy-3,7,15-tris-[[dimethyl(1,1- dimethylethyl)silyl]oxy]-4,4,8,12,16-pentamethyl-17-(2-methylthiazol-4-yl)-6-(prop-2-en- 1-yl)-heptadeca-12,16-dien-5-on(3S, 6R, 7S, 8S, 12E / Z, 15S, 16E) -1-hydroxy-3,7,15-tris - [[dimethyl (1,1- dimethylethyl) silyl] oxy] -4,4,8,12,16-pentamethyl-17- (2-methylthiazol-4-yl) -6- (prop-2-en- 1-yl) -heptadeca-12,16-dien-5-one

In Analogie zu Beispiel 1m setzt man 1,45 g (1,48 mmol) der nach Beispiel 9e dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 1,19 g (1,37 mmol, 93%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = -0,01-0,14 (18H), 0,82-0,97 (30H), 1,04-1,70 (7H), 1,09 (3H), 1,19 (3H), 1,59 + 1,68 (3H), 1,84-2,08 (3H), 2,00 (3H), 2,18-2,36 (3H), 2,47 (1H), 2,71 (3H), 3,13 (1H), 3,66 (2H), 3,80 (1H), 4,04 (1H), 4,10 (1H), 4,96 (1H), 5,01 (1H), 5,14 (1H), 5,77 (1H), 6,46 (1H), 6,92 (1H) ppm.In analogy to Example 1m, 1.45 g (1.48 mmol) of the compound shown in Example 9e are reacted and, after work-up and purification, 1.19 g (1.37 mmol, 93%) of the title compound is isolated as a colorless oil.
1 H NMR (CDCl 3 ): δ = -0.01-0.14 (18H), 0.82-0.97 (30H), 1.04-1.70 (7H), 1.09 (3H ), 1.19 (3H), 1.59 + 1.68 (3H), 1.84-2.08 (3H), 2.00 (3H), 2.18-2.36 (3H), 2 , 47 (1H), 2.71 (3H), 3.13 (1H), 3.66 (2H), 3.80 (1H), 4.04 (1H), 4.10 (1H), 4, 96 (1H), 5.01 (1H), 5.14 (1H), 5.77 (1H), 6.46 (1H), 6.92 (1H) ppm.

Beispiel 9gExample 9g (3S,6R,7S,8S,12E/Z,15S,16E)-3,7,15-Tris-[[dimethyl(1,1-dimethylethyl)silyl]oxy]- 4,4,8,12,16-pentamethyl-17-(2-methylthiazol-4-yl)-5-oxo-6-(prop-2-en-1-yl)-heptadeca- 12,16-dienal(3S, 6R, 7S, 8S, 12E / Z, 15S, 16E) -3,7,15-Tris - [[dimethyl (1,1-dimethylethyl) silyl] oxy] - 4,4,8,12,16-pentamethyl-17- (2-methylthiazol-4-yl) -5-oxo-6- (prop-2-en-1-yl) -heptadeca- 12,16-dienal

In Analogie zu Beispiel 1n setzt man 1,18 g (1,37 mmol) der nach Beispiel 9f dargestellten Verbindung um und isoliert nach Aufarbeitung 1,25 g (max. 1,37 mmol) der Titelverbindung als gelbes Öl, das man ohne Reinigung weiter umsetzt.In analogy to Example 1n, 1.18 g (1.37 mmol) of the according to Example 9f are used compound represented by and isolated after work-up 1.25 g (max. 1.37 mmol) the title compound as a yellow oil, which is reacted further without purification.

Beispiel 9hExample 9h (3S,6R,7S,8S,12Z,15S,16E)-3,7,15-Tris-[[dimethyl(1,1-dimethylethyl)silyl]oxy]- 4,4,8,12,16-pentamethyl-17-(2-methylthiazol-4-yl)-5-oxo-6-(prop-2-en-1-yl)-heptadeca- 12,16-diensäure (A) und (3S,6R,7S,8S,12E,15S,16E)-3,7,15-Tris-[[dimethyl(1,1- dimethylethyl)silyl]oxy]-4,4,8,12,16-pentamethyl-17-(2-methylthiazol-4-yl)-5-oxo-6-(prop- 2-en-1-yl)-heptadeca-12,16-diensäure (B)(3S, 6R, 7S, 8S, 12Z, 15S, 16E) -3,7,15-Tris - [[dimethyl (1,1-dimethylethyl) silyl] oxy] - 4,4,8,12,16-pentamethyl-17- (2-methylthiazol-4-yl) -5-oxo-6- (prop-2-en-1-yl) -heptadeca- 12,16-dienoic acid (A) and (3S, 6R, 7S, 8S, 12E, 15S, 16E) -3,7,15-tris - [[dimethyl (1,1- dimethylethyl) silyl] oxy] -4,4,8,12,16-pentamethyl-17- (2-methylthiazol-4-yl) -5-oxo-6- (prop- 2-en-1-yl) -heptadeca-12,16-dienoic acid (B)

In Analogie zu Beispiel 1o setzt man 1,25 g (max. 1,37 mmol) der nach Beispiel 9g dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 302 mg (0,34 mmol, 25%) der Titelverbindung A sowie 230 mg (0,26 mmol, 19%) der Titelverbindung B jeweils als farbloses Öl.
1H-NMR (CDCl3) von A: δ = -0,02-0,15 (18H), 0,82-0,97 (30H), 1,05-2,53 (14H), 1,12 (3H), 1,17 (3H), 1,70 (3H), 1,96 (3H), 2,71 (3H), 3,17 (1H), 3,72 (1H), 4,16 (1H), 4,37 (1H), 4,94 (1H), 4,99 (1H), 5,20 (1H), 5,73 (1H), 6,66 (1H), 6,93 (1H) ppm.
1H-NMR (CDCl3) von B: δ = -0,03-0,15 (18H), 0,81-0,95 (30H), 1,01-2,50 (13H), 1,12 (3H), 1,18 (3H), 1,57 (3H), 1,95 (3H), 2,60 (1H), 2,70 (3H), 3,22 (1H), 3,79 (1H), 4,08 (1H), 4,32 (1H), 4,94 (1H), 5,00 (1H), 5,11 (1H), 5,74 (1H), 6,46 (1H), 6,93 (1H) ppm.In analogy to Example 10, 1.25 g (max. 1.37 mmol) of the compound shown in Example 9g are reacted and, after work-up and purification, 302 mg (0.34 mmol, 25%) of the title compound A and 230 mg ( 0.26 mmol, 19%) of the title compound B in each case as a colorless oil.
1 H NMR (CDCl 3 ) of A: δ = -0.02-0.15 (18H), 0.82-0.97 (30H), 1.05-2.53 (14H), 1.12 (3H), 1.17 (3H), 1.70 (3H), 1.96 (3H), 2.71 (3H), 3.17 (1H), 3.72 (1H), 4.16 ( 1H), 4.37 (1H), 4.94 (1H), 4.99 (1H), 5.20 (1H), 5.73 (1H), 6.66 (1H), 6.93 (1H ) ppm.
1 H NMR (CDCl 3 ) of B: δ = -0.03-0.15 (18H), 0.81-0.95 (30H), 1.01-2.50 (13H), 1.12 (3H), 1.18 (3H), 1.57 (3H), 1.95 (3H), 2.60 (1H), 2.70 (3H), 3.22 (1H), 3.79 ( 1H), 4.08 (1H), 4.32 (1H), 4.94 (1H), 5.00 (1H), 5.11 (1H), 5.74 (1H), 6.46 (1H ), 6.93 (1H) ppm.

Beispiel 9iExample 9i (3S,6R,7S,8S,12Z,15S,16E)-3,7-Bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-15-hydroxy- 4,4,8,12,16-pentamethyl-17-(2-methylthiazol-4-yl)-5-oxo-6-(prop-2-en-1-yl)-heptadeca- 12,16-diensäure(3S, 6R, 7S, 8S, 12Z, 15S, 16E) -3,7-bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -15-hydroxy- 4,4,8,12,16-pentamethyl-17- (2-methylthiazol-4-yl) -5-oxo-6- (prop-2-en-1-yl) -heptadeca- 12,16-dienoic acid

In Analogie zu Beispiel 1e setzt man 302 mg (0,34 mmol) der nach Beispiel 9h dargestellten Verbindung A um und isoliert nach Aufarbeitung 296 mg (max. 0,34 mmol) der Titelverbindung als blass gelbes Öl, das man ohne Reinigung weiter umsetzt.In analogy to Example 1e, 302 mg (0.34 mmol) of that according to Example 9h are used Compound A represented by and isolated after work-up 296 mg (max. 0.34 mmol) the title compound as a pale yellow oil, which is reacted further without purification.

Beispiel 9jExample 9j (4S,7R,8S,9S,13Z,16S(E))-4,8-Bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-16-(1-methyl- 2-(2-methylthiazol-4-yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)- cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13Z, 16S (E)) - 4,8-Bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -16- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -1-oxa-5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) - cyclohexadec-13-en-2,6-dione

In Analogie zu Beispiel 1q setzt man 296 mg (max. 0,34 mmol) der nach Beispiel 9i dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 166 mg (0,22 mmol, 65%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = -0,10 (3H), 0,09 (3H), 0,11 (3H), 0,13 (3H), 0,86 (9H), 0,80-2,85 (13H), 0,94 (9H), 1,00 (3H), 1,10 (3H), 1,20 (3H), 1,68 (3H), 2,10 (3H), 2,71 (3H), 3,11 (1H), 4,01 (2H), 4,85-5,03 (3H) 5,16 (1H), 5,78 (1H), 6,57 (1H), 6,98 (1H) ppm.In analogy to Example 1q, 296 mg (max. 0.34 mmol) of the compound shown in Example 9i are reacted and, after work-up and purification, 166 mg (0.22 mmol, 65%) of the title compound are isolated as a colorless oil.
1 H NMR (CDCl 3 ): δ = -0.10 (3H), 0.09 (3H), 0.11 (3H), 0.13 (3H), 0.86 (9H), 0.80 -2.85 (13H), 0.94 (9H), 1.00 (3H), 1.10 (3H), 1.20 (3H), 1.68 (3H), 2.10 (3H), 2.71 (3H), 3.11 (1H), 4.01 (2H), 4.85-5.03 (3H) 5.16 (1H), 5.78 (1H), 6.57 (1H ), 6.98 (1H) ppm.

Beispiel 9Example 9 (4S,7R,8S,9S,13Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa-5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione

In Analogie zu Beispiel 1 setzt man 25 mg (34 µmol) der nach Beispiel 9j dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 10 mg (19 µmol, 57%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 1,03 (3H), 1,05 (3H), 1,20-2,74 (14H), 1,30 (3H), 1,69 (3H), 2,07 (3H), 2,69 (3H), 3,33 (1H), 3,69 (1H), 3,72 (1H), 4,23 (1H), 5,02 (1H), 5,07 (1H), 5,12 (1H), 5,21 (1H), 5,76 (1H), 6,57 (1H), 6,96 (1H) ppm.In analogy to Example 1, 25 mg (34 μmol) of the compound shown in Example 9j are reacted and, after work-up and purification, 10 mg (19 μmol, 57%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 1.03 (3H), 1.05 (3H), 1.20-2.74 (14H), 1.30 (3H), 1.69 (3H), 2.07 (3H), 2.69 (3H), 3.33 (1H), 3.69 (1H), 3.72 (1H), 4.23 (1H), 5.02 (1H), 5 .07 (1H), 5.12 (1H), 5.21 (1H), 5.76 (1H), 6.57 (1H), 6.96 (1H) ppm.

Beispiel 10Example 10 (1S,3S(E),7S,10R,11S,12S,12R)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion (A) und (1R,3S(E),7S,10R,11S,12S,16S)- 7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl-2-(2-methylthiazol-4-yl)ethenyl)- 8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion (B)(1S, 3S (E), 7S, 10R, 11S, 12S, 12R) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17- dioxabicyclo [14.1.0] heptadecane-5,9-dione (A) and (1R, 3S (E), 7S, 10R, 11S, 12S, 16S) - 7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) - 8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione (B)

Die Lösung von 8,0 mg (15,5 µmol) der nach Beispiel 9 dargestellten Verbindung in 1 ml Acetonitril versetzt man mit 89 µl einer 1 M Lösung von Natriumethylendiamin­ tetracetat, kühlt auf 0°C und versetzt mit 148 µl 1,1,1-Trifluoraceton sowie einem Gemisch aus 22 mg Oxon und 41 mg Natriumhydrogencarbonat. Man läßt 5 Stunden reagieren, gießt auf Natriumthiosulfatlösung und extrahiert mehrfach mit Ethylacetat. Die vereinigten organischen Extrakte wäscht man mit gesättigter Natriumchloridlösung und reinigt den nach Filtration und Lösungsmittelabzug erhaltenen Rückstand durch Chromatographie an einer analylischen Dünnschichtplatte. Als Laufmittel dient ein Gemisch aus n-Hexan und Ethylacetat. Isoliert werden 3,2 mg (6 µmol, 39%) der Titelverbindung A sowie 1,0 mg (2 µmol, 12%) der Titelverbindung B jeweils als farbloses Öl.
1H-NMR (CDCl3) von A: δ = 1,00 (3H), 1,02 (3H), 1,21-1,82 (7H), 1,29 (3H), 1,36 (3H), 1,95-2,06 (2H), 2,11 (3H), 2,30 (1H), 2,40 (1H), 2,48-2,62 (2H), 2,72 (3H), 2,81 (2H), 3,50 (1H), 3,69 (1H), 4,27 (1H), 4,52 (1H), 5,01 (1H), 5,06 (1H), 5,46 (1H), 5,72 (1H), 6,59 (1H), 6,99 (1H) ppm.
1H-NMR (CDCl3) von B: δ = 0,96 (3H), 1,00 (3H), 1,20-1,91 (8H), 1,29 (3H), 1,34 (3H), 2,04 (1H), 2,09 (3H), 2,33 (1H), 2,42-2,61 (3H), 2,76 (3H), 2,93 (1H), 2,96 (1H), 3,38 (1H), 3,68 (1H), 3,99 (1H), 4,29 (1H), 4,98 (1H), 5,01 (1H), 5,57 (1H), 5,74 (1H), 6,69 (1H), 7,01 (1H) ppm.The solution of 8.0 mg (15.5 μmol) of the compound shown in Example 9 in 1 ml of acetonitrile is mixed with 89 μl of a 1 M solution of sodium ethylenediamine tetracetate, cooled to 0 ° C. and mixed with 148 μl of 1.1, 1-trifluoroacetone and a mixture of 22 mg oxone and 41 mg sodium hydrogen carbonate. The mixture is left to react for 5 hours, poured onto sodium thiosulphate solution and extracted several times with ethyl acetate. The combined organic extracts are washed with saturated sodium chloride solution and the residue obtained after filtration and removal of the solvent is purified by chromatography on an analytical thin-layer plate. A mixture of n-hexane and ethyl acetate is used as the mobile phase. 3.2 mg (6 μmol, 39%) of the title compound A and 1.0 mg (2 μmol, 12%) of the title compound B are isolated in each case as a colorless oil.
1 H NMR (CDCl 3 ) of A: δ = 1.00 (3H), 1.02 (3H), 1.21-1.82 (7H), 1.29 (3H), 1.36 (3H ), 1.95-2.06 (2H), 2.11 (3H), 2.30 (1H), 2.40 (1H), 2.48-2.62 (2H), 2.72 (3H ), 2.81 (2H), 3.50 (1H), 3.69 (1H), 4.27 (1H), 4.52 (1H), 5.01 (1H), 5.06 (1H) , 5.46 (1H), 5.72 (1H), 6.59 (1H), 6.99 (1H) ppm.
1 H NMR (CDCl 3 ) of B: δ = 0.96 (3H), 1.00 (3H), 1.20-1.91 (8H), 1.29 (3H), 1.34 (3H ), 2.04 (1H), 2.09 (3H), 2.33 (1H), 2.42-2.61 (3H), 2.76 (3H), 2.93 (1H), 2, 96 (1H), 3.38 (1H), 3.68 (1H), 3.99 (1H), 4.29 (1H), 4.98 (1H), 5.01 (1H), 5.57 (1H), 5.74 (1H), 6.69 (1H), 7.01 (1H) ppm.

Beispiel 11Example 11 (4S,7R,8S,9S,13E,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6- dion(4S, 7R, 8S, 9S, 13E, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazole-4- yl) ethenyl) -1-oxa-5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6- dion Beispiel 11aExample 11a (3S,6R,7S,8S,12E,15S,16E)-3,7-Bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-15-hydroxy- 4,4,8,12,16-pentamethyl-17-(2-methylthiazol-4-yl)-5-oxo-6-(prop-2-en-1-yl)-heptadeca- 12,16-diensäure(3S, 6R, 7S, 8S, 12E, 15S, 16E) -3,7-bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -15-hydroxy- 4,4,8,12,16-pentamethyl-17- (2-methylthiazol-4-yl) -5-oxo-6- (prop-2-en-1-yl) -heptadeca- 12,16-dienoic acid

In Analogie zu Beispiel 1e setzt man 230 mg (0,26 mmol) der nach Beispiel 9h dargestellten Verbindung B um und isoliert nach Aufarbeitung 214 mg (max. 0,26 mmol) der Titelverbindung als blass gelbes Öl, das man ohne Reinigung weiter umsetzt.In analogy to Example 1e, 230 mg (0.26 mmol) of the according to Example 9h are used Compound B represented and isolated after work-up 214 mg (max. 0.26 mmol) the title compound as a pale yellow oil, which is reacted further without purification.

Beispiel 11bExample 11b (4S,7R,8S,9S,13E,16S(E))-4,8-Bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-16-(1-methyl- 2-(2-methylthiazol-4-yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)- cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13E, 16S (E)) - 4,8-bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -16- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -1-oxa-5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) - cyclohexadec-13-en-2,6-dione

In Analogie zu Beispiel 1q setzt man 214 mg (max. 0,26 mmol) der nach Beispiel 11a dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 114 mg (0,15 mmol, 59%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,05 (3H), 0,08 (3H), 0,10 (3H), 0,13 (3H), 0,82-0,94 (21H), 1,12 (3H), 1,15-2,62 (13H), 1,21 (3H), 1,59 (3H), 2,11 (3H), 2,71 (3H), 3,03 (1H), 3,87 (1H), 4,30 (1H), 4,99 (1H), 5,03 (1H), 5,21 (1H), 5,28 (1H), 5,79 (1H), 6,51 (1H), 6,91 (1H) ppm.In analogy to Example 1q, 214 mg (max. 0.26 mmol) of the compound shown in Example 11a are reacted and, after work-up and purification, 114 mg (0.15 mmol, 59%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.05 (3H), 0.08 (3H), 0.10 (3H), 0.13 (3H), 0.82-0.94 (21H), 1.12 (3H), 1.15-2.62 (13H), 1.21 (3H), 1.59 (3H), 2.11 (3H), 2.71 (3H), 3.03 ( 1H), 3.87 (1H), 4.30 (1H), 4.99 (1H), 5.03 (1H), 5.21 (1H), 5.28 (1H), 5.79 (1H ), 6.51 (1H), 6.91 (1H) ppm.

Beispiel 11Example 11 (4S,7R,8S,9S,13E,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13E, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa-5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione

In Analogie zu Beispiel 1 setzt man 15 mg (20 µmol) der nach Beispiel 11b dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 7,3 mg (14 µmol, 71%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,80-2,62 (13H), 0,99 (3H), 1,01 (3H), 1,26 (3H), 1,60 (3H), 2,04 (3H), 2,69 (3H), 3,49 (1H), 3,73 (1H), 4,01 (1H), 4,12 (1H), 4,42 (1H), 4,94-5,10 (3H), 5,37 (1H), 5,71 (1H), 6,56 (1H), 6,99 (1H) ppm.In analogy to Example 1, 15 mg (20 μmol) of the compound shown in Example 11b are reacted and, after work-up and purification, 7.3 mg (14 μmol, 71%) of the title compound is isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.80-2.62 (13H), 0.99 (3H), 1.01 (3H), 1.26 (3H), 1.60 (3H), 2.04 (3H), 2.69 (3H), 3.49 (1H), 3.73 (1H), 4.01 (1H), 4.12 (1H), 4.42 (1H), 4 , 94-5.10 (3H), 5.37 (1H), 5.71 (1H), 6.56 (1H), 6.99 (1H) ppm.

Beispiel 12Example 12 (1R,3S(E),7S,10R,11S,12S,16R,)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion (A) und (1S,3S(E),7S,10R,11S,12S,16S)- 7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl-2-(2-methylthiazol-4-yl)ethenyl)- 8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion (B)(1R, 3S (E), 7S, 10R, 11S, 12S, 16R,) - 7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17- dioxabicyclo [14.1.0] heptadecane-5,9-dione (A) and (1S, 3S (E), 7S, 10R, 11S, 12S, 16S) - 7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) - 8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione (B)

In Analogie zu Beispiel 10 setzt man 7,3 mg (14 µmol) der nach Beispiel 11 dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 2,3 mg (4,3 µmol, 31%) der Titelverbindung A (oder B) sowie 2,0 mg (3,7 µmol, 27%) der Titelverbindung B (oder A) jeweils als farbloses Öl.
1H-NMR (CDCl3) von A (oder B): δ = 0,90-2,34 (10H), 0,95 (3H), 1,01 (3H), 1,29 (3H), 1,38 (3H), 2,10 (3H), 2,47-2,62 (3H), 2,72 (3H), 2,88 (2H), 3,48 (1H), 3,80 (1H), 4,19 (1H), 4,32 (1H), 5,02 (1H), 5,07 (1H), 5,48 (1H), 5,77 (1H), 6,63 (1H), 7,00 (1H) ppm.
1H-NMR (CDCl3) von B (oder A): δ = 0,97 (3H), 1,06 (3H), 1,20-2,12 (9H), 1,25 (3H), 1,34 (3H), 2,08 (3H), 2,28 (1H), 2,46-2,62 (3H), 2,72 (3H), 2,92 (2H), 3,40 (1H), 3,68 (1H), 3,75 (1H), 4,28 (1H), 5,01 (1H), 5,06 (1H), 5,44 (1H), 5,72 (1H), 6,62 (1H), 6,99 (1H) ppm.In analogy to Example 10, 7.3 mg (14 μmol) of the compound shown in Example 11 are reacted and, after work-up and purification, 2.3 mg (4.3 μmol, 31%) of the title compound A (or B) and 2 are isolated , 0 mg (3.7 μmol, 27%) of the title compound B (or A) in each case as a colorless oil.
1 H-NMR (CDCl 3 ) of A (or B): δ = 0.90-2.34 (10H), 0.95 (3H), 1.01 (3H), 1.29 (3H), 1 , 38 (3H), 2.10 (3H), 2.47-2.62 (3H), 2.72 (3H), 2.88 (2H), 3.48 (1H), 3.80 (1H ), 4.19 (1H), 4.32 (1H), 5.02 (1H), 5.07 (1H), 5.48 (1H), 5.77 (1H), 6.63 (1H) , 7.00 (1H) ppm.
1 H-NMR (CDCl 3 ) of B (or A): δ = 0.97 (3H), 1.06 (3H), 1.20-2.12 (9H), 1.25 (3H), 1 , 34 (3H), 2.08 (3H), 2.28 (1H), 2.46-2.62 (3H), 2.72 (3H), 2.92 (2H), 3.40 (1H ), 3.68 (1H), 3.75 (1H), 4.28 (1H), 5.01 (1H), 5.06 (1H), 5.44 (1H), 5.72 (1H) , 6.62 (1H), 6.99 (1H) ppm.

Beispiel 13Example 13 (4S,7R,8S,9S,13Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione Beispiel 13aExample 13a (3RS,4S)-4-(2-Methyl-3-hydroxy-8-(trimethylsily)-hept-6-in-2-yl)-2,2-dimethyl-[1,3]dioxan(3RS, 4S) -4- (2-methyl-3-hydroxy-8- (trimethylsily) -hept-6-yn-2-yl) -2,2-dimethyl- [1,3] dioxane

In Analogie zu Beispiel 1a setzt man 7,0 g (37 mmol) (4S)-4-(2-Methyl-1-oxo-prop-2-yl)- 2,2-dimethyl-[1,3]dioxan, das man in Analogie zu den in DE 197 51 200.3 beschriebenen Verfahren hergestellt hat, mit 4-Trimethylsilyl-but-3-in-1-yl- magnesiumbromid um und isoliert nach Aufarbeitung und Reinigung 4,9 g (15,7 mmol, 42%) der Titelverbindung als farbloses Öl.In analogy to Example 1a, 7.0 g (37 mmol) (4S) -4- (2-methyl-1-oxo-prop-2-yl) - 2,2-dimethyl- [1,3] dioxane, which is produced in analogy to the DE 197 51 200.3 has prepared the method described, with 4-trimethylsilyl-but-3-yn-1-yl- magnesium bromide and isolated after work-up and purification 4.9 g (15.7 mmol, 42%) of the title compound as a colorless oil.

Beispiel 13bExample 13b (4S)-4-(2-Methyl-3-oxo-8-(trimethylsily)-hept-6-in-2-yl)-2,2-dimethyl-[1,3]dioxan(4S) -4- (2-Methyl-3-oxo-8- (trimethylsily) -hept-6-yn-2-yl) -2,2-dimethyl- [1,3] dioxane

In Analogie zu Beispiel 1b setzt man 4,87 g (15,6 mmol) der nach Beispiel 13a dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 4,10 g (13,2 mmol, 85%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,13 (9H), 1,08 (3H), 1,13 (3H), 1,32 (1H), 1,34 (3H), 1,41 (3H), 1,61 (1H), 2,45 (2H), 2,73 (2H), 3,84 (1H), 3,96 (1H), 4,02 (1H) ppm.In analogy to Example 1b, 4.87 g (15.6 mmol) of the compound shown in Example 13a are reacted and, after work-up and purification, 4.10 g (13.2 mmol, 85%) of the title compound is isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.13 (9H), 1.08 (3H), 1.13 (3H), 1.32 (1H), 1.34 (3H), 1.41 ( 3H), 1.61 (1H), 2.45 (2H), 2.73 (2H), 3.84 (1H), 3.96 (1H), 4.02 (1H) ppm.

Beispiel 13cExample 13c (4S(4R,5S,6S,10E/Z,13S,14E))-4-(13-[[Dimethyl(1,1-dimethylethyl)silyl]oxy]-5-hydroxy- 2,6,10,14-tetramethyl-3-oxo-15-(2-pyridyl)-4-(4-(trimethylsilyl)-prop-2-in-1-yl)-pentadec- 2-yl)-2,2-dimethyl-[1,3]dioxan (A) und (4S(4S,5R,6S,10E/Z,13S,14E)-4-(13- [[Dimethyl(1,1-dimethylethyl)silyl]oxy]-5-hydroxy-2,6,10,14-tetramethyl-3-oxo-15-(2- pyridyl)-4-(4-(trimethylsilyl)-prop-2-in-1-yl)-pentadec-2-yl)-2,2-dimethyl-[1,3]dioxan (B)(4S (4R, 5S, 6S, 10E / Z, 13S, 14E)) - 4- (13 - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -5-hydroxy- 2,6,10,14-tetramethyl-3-oxo-15- (2-pyridyl) -4- (4- (trimethylsilyl) -prop-2-yn-1-yl) -pentadec- 2-yl) -2,2-dimethyl- [1,3] dioxane (A) and (4S (4S, 5R, 6S, 10E / Z, 13S, 14E) -4- (13- [[Dimethyl (1,1-dimethylethyl) silyl] oxy] -5-hydroxy-2,6,10,14-tetramethyl-3-oxo-15- (2- pyridyl) -4- (4- (trimethylsilyl) -prop-2-yn-1-yl) -pentadec-2-yl) -2,2-dimethyl- [1,3] dioxane (B)

In Analogie zu Beispiel 1c setzt man 2,74 g (8,82 mmol) der nach Beispiel 13b dargestellten Verbindung mit 3,02 g (7,27 mmol) (2S,6E/Z,9S,10E)-2,6,10-Trimethyl-9- [[dimethyl(1,1-dimethylethyl)silyl]oxy]-1-oxo-11-(2-pyridyl)-undeca-6,10-dien, das man in Analogie zu den in DE 197 51 200.3 beschriebenen Verfahren hergestellt hat, um und isoliert nach Aufarbeitung und Reinigung neben 50% Ausgangsmaterial 1,63 g (2,2 mmol, 31%) der Titelverbindung A sowie 0,50 g (0,69 mmol, 9%) der Titelverbindung B jeweils als farbloses Öl.
1H-NMR (CDCl3) von A: δ = 0,00-0,20 (15H), 0,83-0,95 (12H), 1,00-1,80 (20H), 1,60 + 1,68 (3H), 1,90-2,10 (1H), 2,05 (3H), 2,28 (2H), 2,41 (1H), 2,55 (1H), 3,03 + 3,09 (1H), 3,46 (1H), 3,52 (1H), 3,78-4,20 (4H), 5,18 (1H), 6,49 (1H), 7,09 (1H), 7,23 (1H), 7,63 (1H), 8,60 (1H) ppm.
1H-NMR (CDCl3) von B: δ = 0,00-0,20 (15H), 0,86-1,00 (12H), 1,00-1,76 (19H), 1,61 + 1,70 (3H), 1,90-2,10 (2H), 2,06 (3H), 2,29 (2H), 2,53 (2H), 3,04 (1H), 3,43 (1H), 3,61 (1H), 3,80-4,18 (4H), 5,18 (1H), 6,48 (1H), 7,09 (1H), 7,23 (1H), 7,62 (1H), 8,59 (1H) ppm.In analogy to Example 1c, 2.74 g (8.82 mmol) of the compound shown according to Example 13b is added to 3.02 g (7.27 mmol) (2S, 6E / Z, 9S, 10E) -2.6, 10-Trimethyl-9- [[dimethyl (1,1-dimethylethyl) silyl] oxy] -1-oxo-11- (2-pyridyl) -undeca-6,10-diene, which can be obtained in analogy to that described in DE 197 51 200.3 has prepared and isolated after work-up and purification in addition to 50% starting material 1.63 g (2.2 mmol, 31%) of the title compound A and 0.50 g (0.69 mmol, 9%) of the title compound B in each case as a colorless oil.
1 H NMR (CDCl 3 ) of A: δ = 0.00-0.20 (15H), 0.83-0.95 (12H), 1.00-1.80 (20H), 1.60 + 1.68 (3H), 1.90-2.10 (1H), 2.05 (3H), 2.28 (2H), 2.41 (1H), 2.55 (1H), 3.03 + 3.09 (1H), 3.46 (1H), 3.52 (1H), 3.78-4.20 (4H), 5.18 (1H), 6.49 (1H), 7.09 ( 1H), 7.23 (1H), 7.63 (1H), 8.60 (1H) ppm.
1 H NMR (CDCl 3 ) of B: δ = 0.00-0.20 (15H), 0.86-1.00 (12H), 1.00-1.76 (19H), 1.61 + 1.70 (3H), 1.90-2.10 (2H), 2.06 (3H), 2.29 (2H), 2.53 (2H), 3.04 (1H), 3.43 ( 1H), 3.61 (1H), 3.80-4.18 (4H), 5.18 (1H), 6.48 (1H), 7.09 (1H), 7.23 (1H), 7 , 62 (1H), 8.59 (1H) ppm.

Beispiel 13dExample 13d (3S,6R,7S,8S,12E/Z,15S,16E)-15-[[Dimethyl(1,1-dimethylethyl)silyl]oxy]-1,3,7- trihydroxy-4,4,8,12,16-pentamethyl-17-(2-pyridyl)-6-(3-(trimethylsilyl)-prop-2-in-1-yl)- heptadeca-12,16-dien-5-on(3S, 6R, 7S, 8S, 12E / Z, 15S, 16E) -15 - [[Dimethyl (1,1-dimethylethyl) silyl] oxy] -1,3,7- trihydroxy-4,4,8,12,16-pentamethyl-17- (2-pyridyl) -6- (3- (trimethylsilyl) -prop-2-yn-1-yl) - heptadeca-12,16-dien-5-one

In Analogie zu Beispiel 1k setzt man 2,25 g (3,10 mmol) der nach Beispiel 13c dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung neben Ausgangsmaterial 1,31 g (1,91 mmol, 62%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,00-0,19 (9H), 0,85-0,98 (12H), 1,03-2,43 (25H), 1,60 + 1,69 (3H), 2,00 + 2,02 (3H), 2,69 (1H), 3,01 + 3,10 (1H), 3,31-3,60 (3H), 3,84 (2H), 4,02-4,26 (2H), 5,10 + 5,26 (1H), 6,41 (1H), 7,13 (1H), 7,32 (1H), 7,68 (1H), 8,61 (1H) ppm.In analogy to Example 1k, 2.25 g (3.10 mmol) of the compound shown in Example 13c are reacted and, after working up and purification, 1.31 g (1.91 mmol, 62%) of the title compound are isolated as a colorless oil in addition to starting material .
1 H-NMR (CDCl 3 ): δ = 0.00-0.19 (9H), 0.85-0.98 (12H), 1.03-2.43 (25H), 1.60 + 1, 69 (3H), 2.00 + 2.02 (3H), 2.69 (1H), 3.01 + 3.10 (1H), 3.31-3.60 (3H), 3.84 (2H ), 4.02-4.26 (2H), 5.10 + 5.26 (1H), 6.41 (1H), 7.13 (1H), 7.32 (1H), 7.68 (1H ), 8.61 (1H) ppm.

Beispiel 13eExample 13e (3S,6R,7S,8S,12E/Z,15S,16E)-1,3,7,15-Tetrakis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]- 4,4,8,12,16-pentamethyl-17-(2-pyridyl)-6-(3-(trimethylsilyl)-prop-2-in-1-yl)-heptadeca- 12,16-dien-5-on(3S, 6R, 7S, 8S, 12E / Z, 15S, 16E) -1,3,7,15-tetrakis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] - 4,4,8,12,16-pentamethyl-17- (2-pyridyl) -6- (3- (trimethylsilyl) -prop-2-yn-1-yl) -heptadeca- 12,16-diene-5-one

In Analogie zu Beispiel 1l setzt man 1,49 g (2,17 mmol) der nach Beispiel 13d dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 1,95 g (1,90 mmol, 87%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,00-0,18 (33H), 0,86-0,98 (39H), 1,01-1,73 (7H), 1,08 (3H), 1,26 (3H), 1,61 + 1,69 (3H), 1,90-2,09 (2H), 2,05 (3H), 2,29 (2H), 2,51 (2H), 3,29 (1H), 3,53-­ 3,71 (2H), 3,79 (1H), 3,89 (1H), 4,11 (1H), 5,17 (1H), 6,48 (1H), 7,09 (1H), 7,23 (1H), 7,61 (1H), 8,60 (1H) ppm.In analogy to Example 11, 1.49 g (2.17 mmol) of the compound shown in Example 13d are reacted and, after work-up and purification, 1.95 g (1.90 mmol, 87%) of the title compound is isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.00-0.18 (33H), 0.86-0.98 (39H), 1.01-1.73 (7H), 1.08 (3H) , 1.26 (3H), 1.61 + 1.69 (3H), 1.90-2.09 (2H), 2.05 (3H), 2.29 (2H), 2.51 (2H) , 3.29 (1H), 3.53-3.71 (2H), 3.79 (1H), 3.89 (1H), 4.11 (1H), 5.17 (1H), 6.48 (1H), 7.09 (1H), 7.23 (1H), 7.61 (1H), 8.60 (1H) ppm.

Beispiel 13fExample 13f (3S,6R,7S,8S,12E/Z,15S,16E)-1-Hydroxy-3,7,15-tris-[[dimethyl(1,1- dimethylethyl)silyl]oxy]-4,4,8,12,16-pentamethyl-17-(2-pyridyl)-6-(3-(trimethylsilyl)-prop- 2-in-1-yl)-heptadeca-12,16-dien-5-on(3S, 6R, 7S, 8S, 12E / Z, 15S, 16E) -1-hydroxy-3,7,15-tris - [[dimethyl (1,1- dimethylethyl) silyl] oxy] -4,4,8,12,16-pentamethyl-17- (2-pyridyl) -6- (3- (trimethylsilyl) -prop- 2-in-1-yl) -heptadeca-12,16-diene-5-one

In Analogie zu Beispiel 1m setzt man 1,95 g (1,89 mmol) der nach Beispiel 13e dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 1,56 g (1,71 mmol, 90%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,00-0,17 (27H), 0,86-0,99 (30H), 1,07-1,78 (8H), 1,11 (3H), 1,26 (3H), 1,60 + 1,69 (3H), 1,90-2,09 (2H), 2,04 (3H), 2,29 (2H), 2,48 (1H), 2,68 (1H), 3,27 (1H), 3,66 (2H), 3,80 (1H), 4,11 (2H), 5,18 (1H), 6,49 (1H), 7,09 (1H), 7,22 (1H), 7,62 (1H), 8,60 (1H) ppm.In analogy to Example 1m, 1.95 g (1.89 mmol) of the compound shown in Example 13e is reacted and, after work-up and purification, 1.56 g (1.71 mmol, 90%) of the title compound is isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.00-0.17 (27H), 0.86-0.99 (30H), 1.07-1.78 (8H), 1.11 (3H) , 1.26 (3H), 1.60 + 1.69 (3H), 1.90-2.09 (2H), 2.04 (3H), 2.29 (2H), 2.48 (1H) , 2.68 (1H), 3.27 (1H), 3.66 (2H), 3.80 (1H), 4.11 (2H), 5.18 (1H), 6.49 (1H), 7.09 (1H), 7.22 (1H), 7.62 (1H), 8.60 (1H) ppm.

Beispiel 13gExample 13g (3S,6R,7S,8S,12E/Z,15S,16E)-3,7,15-Tris-[[dimethyl(1,1-dimethylethyl)silyl]oxy]- 4,4,8,12,16-pentamethyl-5-oxo-17-(2-pyridyl)-6-(3-(trimethylsilyl)-prop-2-in-1-yl)- heptadeca-12,16-dienal(3S, 6R, 7S, 8S, 12E / Z, 15S, 16E) -3,7,15-Tris - [[dimethyl (1,1-dimethylethyl) silyl] oxy] - 4,4,8,12,16-pentamethyl-5-oxo-17- (2-pyridyl) -6- (3- (trimethylsilyl) -prop-2-yn-1-yl) - heptadeca-12,16-dienal

In Analogie zu Beispiel 1n setzt man 1,56 g (1,71 mmol) der nach Beispiel 13f dargestellten Verbindung um und isoliert nach Aufarbeitung 1,61 g (max. 1,71 mmol) der Titelverbindung als gelbes Öl, das man ohne Reinigung weiter umsetzt.In analogy to Example 1n, 1.56 g (1.71 mmol) of the according to Example 13f are used compound represented by and isolated after work-up 1.61 g (max. 1.71 mmol) the title compound as a yellow oil, which is reacted further without purification.

Beispiel 13hExample 13h (3S,6R,7S,8S,12Z,15S,16E)-3,7,15-Tris-[[dimethyl(1,1-dimethylethyl)silyl]oxy]- 4,4,8,12,16-pentamethyl-5-oxo-17-(2-pyridyl)-6-(3-(trimethylsilyl)-prop-2-in-1-yl)- heptadeca-12,16-diensäure (A) und (3S,6R,7S,8S,12E,15S,16E)-3,7,15-Tris- [[dimethyl(1,1-dimethylethyl)silyl]oxy]-4,4,8,12,16-pentamethyl-5-oxo-17-(2-pyridyl)-6-(3- (trimethylsilyl)-prop-2-in-1-yl)-heptadeca-12,16-diensäure (B)(3S, 6R, 7S, 8S, 12Z, 15S, 16E) -3,7,15-Tris - [[dimethyl (1,1-dimethylethyl) silyl] oxy] - 4,4,8,12,16-pentamethyl-5-oxo-17- (2-pyridyl) -6- (3- (trimethylsilyl) -prop-2-yn-1-yl) - heptadeca-12,16-dienoic acid (A) and (3S, 6R, 7S, 8S, 12E, 15S, 16E) -3,7,15-Tris- [[dimethyl (1,1-dimethylethyl) silyl] oxy] -4,4,8,12,16-pentamethyl-5-oxo-17- (2-pyridyl) -6- (3- (trimethylsilyl) -prop-2-yn-1-yl) -heptadeca-12,16-dienoic acid (B)

Die Lösung von 1,51 g (max. 1,60 mmol) der nach Beispiel 13g dargestellten Verbindung in 57 ml tert.-Butanol versetzt man mit 47 ml 2-Methyl-2-buten, kühlt auf 2°C, versetzt mit 12,9 ml Wasser, 685 mg Natriumdihydrogenphosphat, 1,16 g Natriumchlorit, läßt auf 23°C erwärmen und rührt 3 Stunden. Man gießt in gesättigte Natriumthiosulfatlösung, verdünnt mit Wasser und extrahiert mehrfach mit Ethylacetat. The solution of 1.51 g (max. 1.60 mmol) of that shown according to Example 13g 47 ml of 2-methyl-2-butene are added to the compound in 57 ml of tert-butanol, and the mixture is cooled 2 ° C, mixed with 12.9 ml of water, 685 mg of sodium dihydrogen phosphate, 1.16 g Sodium chlorite, allowed to warm to 23 ° C and stirred for 3 hours. One pours into saturated Sodium thiosulfate solution, diluted with water and extracted several times with ethyl acetate.

Die vereinigten organischen Extrakte trocknet man über Natriumsulfat und reinigt den nach Filtration und Lösungsmittelabzug erhaltenen Rückstand durch Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylacetat. Isoliert werden 749 mg (807 µmmol, 50%) der Titelverbindung A sowie 579 mg (623 µmol, 39%) der Titelverbindung B jeweils als farbloses Öl.
1H-NMR (CDCl3) von A: δ = -0,02-0,17 (27H), 0,76-1,72 (6H), 0,88 (27H), 0,94 (3H), 1,10 (3H), 1,29 (3H), 1,68 (3H), 1,91-2,60 (7H), 2,02 (3H), 2,91 (1H), 3,39 (1H), 3,81 (1H), 4,11 (1H), 4,31 (1H), 5,18 (1H), 6,51 (1H), 7,09 (1H), 7,23 (1H), 7,62 (1H), 8,60 (1H) ppm.
1H-NMR (CDCl3) von B: δ = 0,00-0,17 (27H), 0,80-0,98 (30H), 0,98-1,68 (6H), 1,08 (3H), 1,30 (3H), 1,60 (3H), 1,83-2,85 (8H), 2,05 (3H), 3,39 (1H), 3,79 (1H), 4,11 (1H), 4,30 (1H), 5,18 (1H), 6,48 (1H), 7,08 (1H), 8,22 (1H), 7,62 (1H), 8,60 (1H) ppm.The combined organic extracts are dried over sodium sulfate and the residue obtained after filtration and removal of the solvent is purified by chromatography on fine silica gel with a gradient system of n-hexane and ethyl acetate. 749 mg (807 μmol, 50%) of the title compound A and 579 mg (623 μmol, 39%) of the title compound B are isolated in each case as a colorless oil.
1 H-NMR (CDCl 3 ) of A: δ = -0.02-0.17 (27H), 0.76-1.72 (6H), 0.88 (27H), 0.94 (3H), 1.10 (3H), 1.29 (3H), 1.68 (3H), 1.91-2.60 (7H), 2.02 (3H), 2.91 (1H), 3.39 ( 1H), 3.81 (1H), 4.11 (1H), 4.31 (1H), 5.18 (1H), 6.51 (1H), 7.09 (1H), 7.23 (1H ), 7.62 (1H), 8.60 (1H) ppm.
1 H-NMR (CDCl 3 ) of B: δ = 0.00-0.17 (27H), 0.80-0.98 (30H), 0.98-1.68 (6H), 1.08 ( 3H), 1.30 (3H), 1.60 (3H), 1.83-2.85 (8H), 2.05 (3H), 3.39 (1H), 3.79 (1H), 4 , 11 (1H), 4.30 (1H), 5.18 (1H), 6.48 (1H), 7.08 (1H), 8.22 (1H), 7.62 (1H), 8, 60 (1H) ppm.

Beispiel 13iExample 13i (3S,6R,7S,8S,12Z,15S,16E)-15-Hydroxy-3,7-bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]- 4,4,8,12,16-pentamethyl-5-oxo-17-(2-pyridyl)-6-(prop-2-in-1-yl)-heptadeca-12,16- diensäure(3S, 6R, 7S, 8S, 12Z, 15S, 16E) -15-Hydroxy-3,7-bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] - 4,4,8,12,16-pentamethyl-5-oxo-17- (2-pyridyl) -6- (prop-2-yn-1-yl) -heptadeca-12,16- dienoic acid

In Analogie zu Beispiel 1e setzt man 726 mg (782 µmol) der nach Beispiel 13h dargestellten Verbindung A um und isoliert nach Aufarbeitung 657 mg (max. 782 µmol) der Titelverbindung, die man ohne Reinigung weiter umsetzt.In analogy to Example 1e, 726 mg (782 μmol) of that according to Example 13h are used Compound A represented by and isolated after work-up 657 mg (max. 782 µmol) the title compound, which is reacted further without purification.

Beispiel 13jExample 13j (4S,7R,8S,9S,13Z,16S(E))-4,8-Bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-16-(1-methyl- 2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en- 2,6-dion(4S, 7R, 8S, 9S, 13Z, 16S (E)) - 4,8-Bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -16- (1-methyl- 2- (2-pyridyl) ethenyl) -1-oxa-5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en- 2,6-dione

In Analogie zu Beispiel 1q setzt man 657 mg (max. 782 µmmol) der nach Beispiel 13i dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 300 mg (414 µmol, 53%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = -0,08 (3H), 0,10 (3H), 0,15 (3H), 0,19 (3H), 0,81-2,20 (8H), 0,86 (9H), 0,95 (9H), 1,02 (3H), 1,14 (3H), 1,23 (3H), 1,68 (3H), 2,14 (3H), 2,33-2,82 (6H), 3,12 (1H), 4,06 (1H), 4,11 (1H), 5,02 (1H), 5,19 (1H), 6,58 (1H), 7,11 (1H), 7,26 (1H), 7,63 (1H), 8,59 (1H) ppm.In analogy to Example 1q, 657 mg (max. 782 μmol) of the compound shown in Example 13i are reacted and, after work-up and purification, 300 mg (414 μmol, 53%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = -0.08 (3H), 0.10 (3H), 0.15 (3H), 0.19 (3H), 0.81-2.20 (8H) , 0.86 (9H), 0.95 (9H), 1.02 (3H), 1.14 (3H), 1.23 (3H), 1.68 (3H), 2.14 (3H), 2.33-2.82 (6H), 3.12 (1H), 4.06 (1H), 4.11 (1H), 5.02 (1H), 5.19 (1H), 6.58 ( 1H), 7.11 (1H), 7.26 (1H), 7.63 (1H), 8.59 (1H) ppm.

Beispiel 13Example 13 (4S,7R,8S,9S,13Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione

In Analogie zu Beispiel 1 setzt man 140 mg (193 µmol) der nach Beispiel 13j dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 52 mg (105 µmol, 54%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 1,08 (3H), 1,10 (3H), 1,20-1,92 (6H), 1,42 (3H), 1,68 (3H), 2,02 (1H), 2,08 (3H), 2,22-2,72 (7H), 2,86 (1H), 3,43 (1H), 3,78 (1H), 4,37 (1H), 4,54 (1H), 5,12 (1H), 5,20 (1H), 6,61 (1H), 7,13 (1H), 7,30 (1H), 7,69 (1H), 8,55 (1H) ppm.In analogy to Example 1, 140 mg (193 μmol) of the compound shown in Example 13j are reacted and, after work-up and purification, 52 mg (105 μmol, 54%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 1.08 (3H), 1.10 (3H), 1.20-1.92 (6H), 1.42 (3H), 1.68 (3H), 2.02 (1H), 2.08 (3H), 2.22-2.72 (7H), 2.86 (1H), 3.43 (1H), 3.78 (1H), 4.37 ( 1H), 4.54 (1H), 5.12 (1H), 5.20 (1H), 6.61 (1H), 7.13 (1H), 7.30 (1H), 7.69 (1H ), 8.55 (1H) ppm.

Beispiel 14Example 14 (4S,7R,8S,9S,13E,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13E, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione Beispiel 14aExample 14a (3S,6R,7S,8S,12E,15S,16E)-15-Hydroxy-3,7-bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]- 4,4,8,12,16-pentamethyl-5-oxo-17-(2-pyridyl)-6-(prop-2-in-1-yl)-heptadeca-12,16- diensäure(3S, 6R, 7S, 8S, 12E, 15S, 16E) -15-Hydroxy-3,7-bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] - 4,4,8,12,16-pentamethyl-5-oxo-17- (2-pyridyl) -6- (prop-2-yn-1-yl) -heptadeca-12,16- dienoic acid

In Analogie zu Beispiel 1e setzt man 534 mg (575 µmol) der nach Beispiel 13h dargestellten Verbindung B um und isoliert nach Aufarbeitung 434 mg (max. 585 µmol) der Titelverbindung, die man ohne Reinigung weiter umsetzt.In analogy to Example 1e, 534 mg (575 μmol) of that of Example 13h are used Compound B represented by and isolated after work-up 434 mg (max. 585 µmol) the title compound, which is reacted further without purification.

Beispiel 14bExample 14b (4S,7R,8S,9S,13E,16S(E))-4,8-Bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-16-(1-methyl- 2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en- 2,6-dion(4S, 7R, 8S, 9S, 13E, 16S (E)) - 4,8-bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -16- (1-methyl- 2- (2-pyridyl) ethenyl) -1-oxa-5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en- 2,6-dione

In Analogie zu Beispiel 1q setzt man 434 mg (max. 585 µmol) der nach Beispiel 14a dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 382 mg (527 µmol, 90%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,04 (3H), 0,07-0,12 (9H), 0,85 (9H), 0,88 (9H), 0,93 (3H), 1,00-­ 2,20 (8H), 1,14 (3H), 1,22 (3H), 1,58 (3H), 2,00 (1H), 2,12 (3H), 2,44-2,62 (5H), 3,19 (1H), 3,91 (1H), 4,41 (1H), 5,19 (1H), 5,29 (1H), 6,53 (1H), 7,09 (1H), 7,18 (1H), 7,62 (1H), 8,59 (1H) ppm.In analogy to Example 1q, 434 mg (max. 585 μmol) of the compound shown in Example 14a are reacted and, after work-up and purification, 382 mg (527 μmol, 90%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.04 (3H), 0.07-0.12 (9H), 0.85 (9H), 0.88 (9H), 0.93 (3H), 1.00-2.20 (8H), 1.14 (3H), 1.22 (3H), 1.58 (3H), 2.00 (1H), 2.12 (3H), 2.44- 2.62 (5H), 3.19 (1H), 3.91 (1H), 4.41 (1H), 5.19 (1H), 5.29 (1H), 6.53 (1H), 7 , 09 (1H), 7.18 (1H), 7.62 (1H), 8.59 (1H) ppm.

Beispiel 14Example 14 (4S,7R,8S,9S,13Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione

In Analogie zu Beispiel 1 setzt man 110 mg (152 µmol) der nach Beispiel 14b dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 48 mg (97 µmol, 64%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,89-1,80 (5H), 1,01 (3H), 1,06 (3H), 1,35 (3H), 1,61 (3H), 1,93 (1H), 2,00 (1H), 2,10 (3H), 2,17 (1H), 2,38-2,66 (6H), 3,58 (1H), 3,79 (2H), 3,88 (1H), 4,44 (1H), 5,10 (1H), 5,40 (1H), 6,59 (1H), 7,13 (1H), 7,33 (1H), 7,68 (1H), 8,56 (1H) ppm.In analogy to Example 1, 110 mg (152 μmol) of the compound shown in Example 14b are reacted and, after work-up and purification, 48 mg (97 μmol, 64%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.89-1.80 (5H), 1.01 (3H), 1.06 (3H), 1.35 (3H), 1.61 (3H), 1.93 (1H), 2.00 (1H), 2.10 (3H), 2.17 (1H), 2.38-2.66 (6H), 3.58 (1H), 3.79 ( 2H), 3.88 (1H), 4.44 (1H), 5.10 (1H), 5.40 (1H), 6.59 (1H), 7.13 (1H), 7.33 (1H ), 7.68 (1H), 8.56 (1H) ppm.

Beispiel 15Example 15 (4S,7R,8S,9S,13Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione Beispiel 15aExample 15a (4S,7R,8S,9S,13Z,16S(E))-4,8-Bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-16-(1-methyl- 2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en- 2,6-dion (A) und (4S,7R,8S,9S,13Z,16S(RS))-4,8-Bis-[[dimethyl(1,1- dimethylethyl)silyl]oxy]-16-(1-methyl-2-(2-pyridyl)ethyl)-1-oxa-5,5,9,13-tetramethyl-7- (prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion (B)(4S, 7R, 8S, 9S, 13Z, 16S (E)) - 4,8-Bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -16- (1-methyl- 2- (2-pyridyl) ethenyl) -1-oxa-5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en- 2,6-dione (A) and (4S, 7R, 8S, 9S, 13Z, 16S (RS)) - 4,8-bis - [[dimethyl (1,1- dimethylethyl) silyl] oxy] -16- (1-methyl-2- (2-pyridyl) ethyl) -1-oxa-5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione (B)

Die Lösung von 150 mg (207 µmmol) der nach Beispiel 13j dargestellten Verbindung in 16 ml Ethylacetat versetzt man mit einer katalylischen Menge Palladium auf Bariumsulfat, 153 µl Pyridin und hydriert bei 23°C unter einer Atmosphäre Wasserstoff. Nach Filtration und Lösungsmittelabzug reinigt man den Rückstand durch Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylacetat. Isoliert werden neben Ausgangsmaterial 66 mg (91 µmol, 44%) der Titelverbindung A sowie 64 mg (88 µmol, 42%) der Titelverbindungen B jeweils als farbloses Öl.
1H-NMR (CDCl3) von A: δ = -0,09 (3H), 0,07 (3H), 0,11 (6H), 0,78-1,82 (7H), 0,84 (9H), 0,92 (9H), 0,98 (3H), 1,09 (3H), 1,18 (3H), 1,67 (3H), 2,06-2,82 (7H), 2,13 (3H), 3,11 (1H), 4,02 (1H), 4,85-5,03 (3H), 5,18 (1H), 5,78 (1H), 6,57 (1H), 7,09 (1H), 7,25 (1H), 7,62 (1H), 8,59 (1H) ppm.The solution of 150 mg (207 μmol) of the compound shown in Example 13j in 16 ml of ethyl acetate is treated with a catalysis amount of palladium on barium sulfate, 153 μl of pyridine and hydrogenated at 23 ° C. under an atmosphere of hydrogen. After filtration and removal of the solvent, the residue is purified by chromatography on fine silica gel with a gradient system that consists of n-hexane and ethyl acetate. In addition to starting material, 66 mg (91 μmol, 44%) of the title compound A and 64 mg (88 μmol, 42%) of the title compound B are isolated in each case as a colorless oil.
1 H-NMR (CDCl 3 ) of A: δ = -0.09 (3H), 0.07 (3H), 0.11 (6H), 0.78-1.82 (7H), 0.84 ( 9H), 0.92 (9H), 0.98 (3H), 1.09 (3H), 1.18 (3H), 1.67 (3H), 2.06-2.82 (7H), 2 , 13 (3H), 3.11 (1H), 4.02 (1H), 4.85-5.03 (3H), 5.18 (1H), 5.78 (1H), 6.57 (1H ), 7.09 (1H), 7.25 (1H), 7.62 (1H), 8.59 (1H) ppm.

Beispiel 15Example 15 (4S,7R,8S,9S,13Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione

In Analogie zu Beispiel 1 setzt man 65,6 mg (90 mmol) der nach Beispiel 15a dargestellten Verbindung A um und isoliert nach Aufarbeitung und Reinigung 24,6 mg (49 µmol, 55%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 1,05 (6H), 1,19-1,89 (5H), 1,32 (3H), 1,69 (3H), 2,05 (3H), 2,13- 2,57 (6H), 2,64 (1H), 2,82 (1H), 3,33 (1H), 3,71 (2H), 4,34 (1H), 4,62 (1H), 5,01 (1H), 5,05 (1H), 5,12 (1H), 5,19 (1H), 5,75 (1H), 6,60 (1H), 7,12 (1H), 7,29 (1H), 7,68 (1H), 8,52 (1H) ppm.In analogy to Example 1, 65.6 mg (90 mmol) of the compound A shown in Example 15a are reacted and, after work-up and purification, 24.6 mg (49 μmol, 55%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 1.05 (6H), 1.19-1.89 (5H), 1.32 (3H), 1.69 (3H), 2.05 (3H), 2.13-2.57 (6H), 2.64 (1H), 2.82 (1H), 3.33 (1H), 3.71 (2H), 4.34 (1H), 4.62 ( 1H), 5.01 (1H), 5.05 (1H), 5.12 (1H), 5.19 (1H), 5.75 (1H), 6.60 (1H), 7.12 (1H ), 7.29 (1H), 7.68 (1H), 8.52 (1H) ppm.

Beispiel 16Example 16 (4S,7R,8S,9S,13E,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13E, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione Beispiel 16aExample 16a (4S,7R,8S,9S,13E,16S(E))-4,8-Bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-16-(1-methyl- 2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en- 2,6-dion(4S, 7R, 8S, 9S, 13E, 16S (E)) - 4,8-bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -16- (1-methyl- 2- (2-pyridyl) ethenyl) -1-oxa-5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en- 2,6-dione

In Analogie zu Beispiel 15a setzt man 114 g (157 µmol) der nach Beispiel 14b dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 68 mg (94 µmol, 60%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,04 (3H), 0,08 (3H), 0,10 (3H), 0,13 (3H), 0,83-0,98 (24H), 1,11 (3H), 1,15-1,96 (6H), 1,20 (3H), 2,08-2,65 (7H), 2,14 (3H), 3,03 (1H), 3,88 (1H), 4,31 (1H), 4,98 (1H), 5,02 (1H), 5,22 (1H), 5,29 (1H), 5,79 (1H), 6,54 (1H), 7,09 (1H), 7,20 (1H), 7,62 (1H), 8,60 (1H) ppm.In analogy to Example 15a, 114 g (157 μmol) of the compound shown in Example 14b are reacted and, after work-up and purification, 68 mg (94 μmol, 60%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.04 (3H), 0.08 (3H), 0.10 (3H), 0.13 (3H), 0.83-0.98 (24H), 1.11 (3H), 1.15-1.96 (6H), 1.20 (3H), 2.08-2.65 (7H), 2.14 (3H), 3.03 (1H), 3.88 (1H), 4.31 (1H), 4.98 (1H), 5.02 (1H), 5.22 (1H), 5.29 (1H), 5.79 (1H), 6 , 54 (1H), 7.09 (1H), 7.20 (1H), 7.62 (1H), 8.60 (1H) ppm.

Beispiel 16Example 16 (4S,7R,8S,9S,13E,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13E, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione

In Analogie zu Beispiel 1 setzt man 67,7 mg (93 µmol) der nach Beispiel 16a dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 36,8 mg (74 µmol, 80%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,96-2,66 (13H), 0,99 (6H), 1,28 (3H), 1,62 (3H), 2,10 (3H), 3,49 (1H), 3,72 (1H), 4,01 (2H), 4,43 (1H), 4,91-5,13 (3H), 5,39 (1H), 5,71 (1H), 6,58 (1H), 7,12 (1H), 7,34 (1H), 7,66 (1H), 8,53 (1H) ppm.In analogy to Example 1, 67.7 mg (93 μmol) of the compound shown in Example 16a are reacted and, after work-up and purification, 36.8 mg (74 μmol, 80%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.96-2.66 (13H), 0.99 (6H), 1.28 (3H), 1.62 (3H), 2.10 (3H), 3.49 (1H), 3.72 (1H), 4.01 (2H), 4.43 (1H), 4.91-5.13 (3H), 5.39 (1H), 5.71 ( 1H), 6.58 (1H), 7.12 (1H), 7.34 (1H), 7.66 (1H), 8.53 (1H) ppm.

Beispiel 17Example 17 (1S/1R,3S(E),7S,10R(RS),11S,12S,16R,/S)-7,11-Dihydroxy-10-(2,3-epoxyprop-1-yl)- 3-(1-methyl-2-(2-N-oxido-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion(1S / 1R, 3S (E), 7S, 10R (RS), 11S, 12S, 16R, / S) -7,11-dihydroxy-10- (2,3-epoxyprop-1-yl) - 3- (1-methyl-2- (2-N-oxido-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17- dioxabicyclo [14.1.0] heptadecane-5,9-dione

In Analogie zu Beispiel 10 setzt man 36 mg (74 µmol) der nach Beispiel 16 dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 12 mg (22 µmol, 30%) eines Gemisches zweier Diastereomeren A und B sowie 20 mg (37 µmol, 50%) eines Gemisches zweier Diastereomeren C und D der Titelverbindungen jeweils als farbloses Öl.
MS (FAB): m/e = 546 (M+ + 1)In analogy to Example 10, 36 mg (74 μmol) of the compound shown in Example 16 are reacted and, after working up and purification, 12 mg (22 μmol, 30%) of a mixture of two diastereomers A and B and 20 mg (37 μmol, 50%) are isolated %) of a mixture of two diastereomers C and D of the title compounds, each as a colorless oil.
MS (FAB): m / e = 546 (M + + 1)

Beispiel 18Example 18 (1S,3S(E),7S,10R(R oder S),11S,12S,16R,)-7,11-Dihydroxy-10-(2,3-epoxyprop-1-yl)- 3-(1-methyl-2-(2-N-oxido-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion (A) und (1R,3S(E),7S,10R(R oder S),11S,12S,16S)-7,11-Dihydroxy-10-(2,3-epoxyprop-1-yl)-3-(1-methyl-2-(2-N-oxido- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9- dion B(1S, 3S (E), 7S, 10R (R or S), 11S, 12S, 16R,) - 7,11-dihydroxy-10- (2,3-epoxyprop-1-yl) - 3- (1-methyl-2- (2-N-oxido-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17- dioxabicyclo [14.1.0] heptadecane-5,9-dione (A) and (1R, 3S (E), 7S, 10R (R or S), 11S, 12S, 16S) -7,11-dihydroxy-10- (2,3-epoxyprop-1-yl) -3- (1-methyl-2- (2-N-oxido- pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9- dion B

Die Lösung von 20 mg (37 µmol) eines Gemisches der nach Beispiel 17 dargestellten Verbindungen C und D in 3,1 ml wasserfreiem Trichlormethan versetzt man mit Molekularsieb (4A), 789 ml Isopropanol, 14,2 mg Tetrapropylammoniumperruthenat und rührt 5 Stunden bei 55°C unter einer Atmosphäre aus trockenem Argon. Man engt ein und reinigt das erhaltene Rohprodukt durch Chromatographie an analytischen Dünnschichtplatten. Als Laufmittel dient ein Gemisch aus Ethanol und Ethylacetat, als Elutionsmittel ein Gemisch aus Dichlormethan und Ethanol. Isoliert werden 4,6 mg (8,7 µmol, 23%) der Titelverbindung A oder B sowie 3,3 mg (6,2 µmol, 17%) der Titelverbindung B oder A jeweils als farbloses Öl.
1H-NMR (CDCl3) von A oder B: δ = 0,96 (3H), 1,06 (3H), 1,12-2,03 (11H), 1,22 (3H), 1,30 (3H), 2,11 (3H), 2,22 (1H), 2,58 (2H), 2,76 (1H), 3,44 (1H), 3,52 (1H), 3,73-3,91 (2H), 4,08-4,21 (2H), 4,47 (1H), 5,59 (1H), 6,59 (1H), 7,11 (1H), 7,23 (1H), 7,63 (1H), 8,59 (1H) ppm.
1H-NMR (CDCl3) von B oder A: δ = 0,96 (3H), 1,05 (3H), 1,11-1,96 (9H), 1,23 (3H), 1,31 (3H), 2,12 (3H), 2,19-2,35 (3H), 2,50-2,66 (2H), 2,78 (1H), 3,50-3,69 (3H), 3,93 (1H), 4,16 (1H), 4,25 (1H), 4,41 (1H), 5,59 (1H), 6,60 (1H), 7,12 (1H), 7,22 (1H), 7,64 (1H), 8,59 (1H) ppm. Molecular sieve (4A), 789 ml of isopropanol, 14.2 mg of tetrapropylammonium perruthenate are added to the solution of 20 mg (37 μmol) of a mixture of the compounds C and D shown in Example 17 in 3.1 ml of anhydrous trichloromethane, and the mixture is stirred at 55 for 5 hours ° C under an atmosphere of dry argon. It is concentrated and the crude product obtained is purified by chromatography on analytical thin-layer plates. A mixture of ethanol and ethyl acetate is used as the mobile phase, and a mixture of dichloromethane and ethanol is used as the eluent. 4.6 mg (8.7 μmol, 23%) of the title compound A or B and 3.3 mg (6.2 μmol, 17%) of the title compound B or A are isolated in each case as a colorless oil.
1 H NMR (CDCl 3 ) of A or B: δ = 0.96 (3H), 1.06 (3H), 1.12-2.03 (11H), 1.22 (3H), 1.30 (3H), 2.11 (3H), 2.22 (1H), 2.58 (2H), 2.76 (1H), 3.44 (1H), 3.52 (1H), 3.73- 3.91 (2H), 4.08-4.21 (2H), 4.47 (1H), 5.59 (1H), 6.59 (1H), 7.11 (1H), 7.23 ( 1H), 7.63 (1H), 8.59 (1H) ppm.
1 H NMR (CDCl 3 ) of B or A: δ = 0.96 (3H), 1.05 (3H), 1.11-1.96 (9H), 1.23 (3H), 1.31 (3H), 2.12 (3H), 2.19-2.35 (3H), 2.50-2.66 (2H), 2.78 (1H), 3.50-3.69 (3H) , 3.93 (1H), 4.16 (1H), 4.25 (1H), 4.41 (1H), 5.59 (1H), 6.60 (1H), 7.12 (1H), 7.22 (1H), 7.64 (1H), 8.59 (1H) ppm.

Beispiel 19Example 19 (1S/R,3S(E),7S,10R(S oder R),11S,12S,16R/S)-7,11-Dihydroxy-10-(2,3-epoxyprop- 1-yl)-3-(1-methyl-2-(2-N-oxido-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion(1S / R, 3S (E), 7S, 10R (S or R), 11S, 12S, 16R / S) -7,11-dihydroxy-10- (2,3-epoxyprop- 1-yl) -3- (1-methyl-2- (2-N-oxido-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17- dioxabicyclo [14.1.0] heptadecane-5,9-dione

1n Analogie zu Beispiel 18 setzt man 6,3 mg (12 µmol) der nach Beispiel 17 dargestellten Verbindungen A und B um und isoliert nach Aufarbeitung und Reinigung 2,4 mg (4,5 µmol, 38%) eines Gemisches Titelverbindungen als farbloses Öl.
1H-NMR (CDCl3): δ = 0,95-2,22 (11H), 1,01 (3H), 1,10 (3H), 1,27 (3H), 1,31 (3H), 2,11 (3H), 2,34 (1H), 2,45-2,57 (2H), 2,90 (1H), 3,39-3,87 (4H), 4,01-4,37 (3H), 5,49 (1H), 6,62 (1H), 7,13 (1H), 7,24 (1H), 7,66 (1H), 8,58 (1H) ppm.In analogy to Example 18, 6.3 mg (12 μmol) of the compounds A and B shown in Example 17 are reacted and, after work-up and purification, 2.4 mg (4.5 μmol, 38%) of a mixture of the title compounds is isolated as a colorless oil .
1 H-NMR (CDCl 3 ): δ = 0.95-2.22 (11H), 1.01 (3H), 1.10 (3H), 1.27 (3H), 1.31 (3H), 2.11 (3H), 2.34 (1H), 2.45-2.57 (2H), 2.90 (1H), 3.39-3.87 (4H), 4.01-4.37 (3H), 5.49 (1H), 6.62 (1H), 7.13 (1H), 7.24 (1H), 7.66 (1H), 8.58 (1H) ppm.

Beispiel 20Example 20 (4S,7R,8S,9S,13Z,16S(R oder S))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethyl)-1- oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion (A) und (4S,7R,8S,9S,13Z,16S(S oder R))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethyl)-1- oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion (B)(4S, 7R, 8S, 9S, 13Z, 16S (R or S)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethyl) -1- oxa-5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione (A) and (4S, 7R, 8S, 9S, 13Z, 16S (S or R)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethyl) -1- oxa-5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione (B)

In Analogie zu Beispiel 1 setzt man 7,0 mg (9,6 µmol) der nach Beispiel 15a dargestellten Verbindungen B um und isoliert nach Aufarbeitung und Reinigung 1,4 mg (2,8 µmol, 29%) der Titelverbindung A sowie 1,7 mg (3,4 µmol, 35%) der Titelverbindung B jeweils als farbloses Öl.
1H-NMR (CDCl3) von A: δ = 0,88 (1H), 0,92 (3H), 1,04 (3H), 1,07 (3H), 1,18-2,57 (14H), 1,30 (3H), 1,68 (3H), 2,91 (1H), 3,17 (1H), 3,28 (1H), 3,68 (1H), 4,47 (1H), 4,91-5,10 (4H), 5,70 (1H), 7,13-7,22 (2H), 7,68 (2H), 8,46 (1H) ppm.
1H-NMR (CDCl3) von B: δ = 1,00 (6H), 1,05 (3H), 1,10-2,59 (15H), 1,33 (3H), 1,63 (3H), 2,93 (1H), 3,11 (1H), 3,28 (1H), 3,63 (1H), 4,44 (1H), 4,91-5,12 (4H), 5,79 (1H), 6,39 (1H), 7,18 (2H), 7,67 (1H), 8,46 (1H) ppm.In analogy to Example 1, 7.0 mg (9.6 µmol) of the compounds B shown in Example 15a are reacted and, after work-up and purification, 1.4 mg (2.8 µmol, 29%) of the title compound A and 1, 7 mg (3.4 μmol, 35%) of the title compound B in each case as a colorless oil.
1 H NMR (CDCl 3 ) of A: δ = 0.88 (1H), 0.92 (3H), 1.04 (3H), 1.07 (3H), 1.18-2.57 (14H ), 1.30 (3H), 1.68 (3H), 2.91 (1H), 3.17 (1H), 3.28 (1H), 3.68 (1H), 4.47 (1H) , 4.91-5.10 (4H), 5.70 (1H), 7.13-7.22 (2H), 7.68 (2H), 8.46 (1H) ppm.
1 H NMR (CDCl 3 ) of B: δ = 1.00 (6H), 1.05 (3H), 1.10-2.59 (15H), 1.33 (3H), 1.63 (3H ), 2.93 (1H), 3.11 (1H), 3.28 (1H), 3.63 (1H), 4.44 (1H), 4.91-5.12 (4H), 5, 79 (1H), 6.39 (1H), 7.18 (2H), 7.67 (1H), 8.46 (1H) ppm.

Beispiel 21Example 21 (4S,7R,8S,9S,13Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13Z, 16S (E)) - 4,8-dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione Beispiel 21aExample 21a (2E/Z)-3-(2-Methyl-benzoxazol-5-yl)-2-propensäureethylester(2E / Z) -3- (2-methyl-benzoxazol-5-yl) -2-propenoic acid ethyl ester

Die Suspension aus 58 g (346 mmol) 5-Chlor-2-methylbenzoxazol, 200 ml Dimethylformamid, 57 g Natriumiodid und 16,2 g Nickel(II)bromid erhitzt man 4 Stunden auf 150°C. Nach dem Erkalten versetzt man mit 42 ml Acrylsäureethylester, 53 ml Triethylamin, 998 mg Tris-(dibenzylidenaceton)-dipalladium (0), 36,4 g Triphenylphosphin und erhitzt drei Tage auf 150°C. Man gießt das erkaltete Gemisch in Wasser, säuert an und extrahiert mehrfach mit Ethylacetat. Die vereinigten organischen Extrakte wäscht man mit gesättigter Natriumchloridlösung, trocknet über Natriumsulfat und reinigt den nach Filtration und Lösungsmittelabzug erhaltenen Rückstand durch Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylacetat. Isoliert werden 6,4 g (28 mmol, 8%) der Titelverbindung als kristalliner Feststoff.
1H-NMR (CDCl3): δ = 1,33 (3H), 2,64 (3H), 4,28 (2H), 6,42 (1H), 7,47 (2H), 7,78 (1H), 7,81 (1H) ppm.The suspension of 58 g (346 mmol) of 5-chloro-2-methylbenzoxazole, 200 ml of dimethylformamide, 57 g of sodium iodide and 16.2 g of nickel (II) bromide is heated to 150 ° C. for 4 hours. After cooling, 42 ml of ethyl acrylate, 53 ml of triethylamine, 998 mg of tris (dibenzylideneacetone) dipalladium (0), 36.4 g of triphenylphosphine are added and the mixture is heated to 150 ° C. for three days. The cooled mixture is poured into water, acidified and extracted several times with ethyl acetate. The combined organic extracts are washed with saturated sodium chloride solution, dried over sodium sulfate and the residue obtained after filtration and removal of the solvent is purified by chromatography on fine silica gel with a gradient system of n-hexane and ethyl acetate. 6.4 g (28 mmol, 8%) of the title compound are isolated as a crystalline solid.
1 H-NMR (CDCl 3 ): δ = 1.33 (3H), 2.64 (3H), 4.28 (2H), 6.42 (1H), 7.47 (2H), 7.78 ( 1H), 7.81 (1H) ppm.

Beispiel 21bExample 21b (2-Methyl-benzoxazol-5-yl)-carbaldehyd(2-methyl-benzoxazol-5-yl) -carbaldehyde

Die Lösung von 9,5 g (41 mmol) der nach Beispiel 21a dargestellten Verbindung in ml Tetrahydrofuran versetzt man mit ml Wasser, ml einer 2,5%igen Lösung von Osmiumtetroxid in tert.-Butanol, g Natriumperiodat und rührt 6 Stunden bei 23°C. Man gießt auf gesättigte Natriumthiosulfatlösung und extrahiert mehrfach mit Ethylacetat. Die vereinigten organischen Extrakte wäscht man mit gesättigter Natriumchloridlösung, trocknet über Natriumsulfat und reinigt den nach Filtration und Lösungsmittelabzug erhaltenen Rückstand durch Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylacetat. Isoliert werden 4,86 g (30 mmol, 74%) der Titelverbindung als kristalliner Feststoff.
1H-NMR (CDCl3): δ = 2,69 (3H), 7,60 (1H), 7,90 (1H), 8,16 (1H), 10,08 (1H) ppm.The solution of 9.5 g (41 mmol) of the compound shown in Example 21a in ml of tetrahydrofuran is mixed with ml of water, ml of a 2.5% solution of osmium tetroxide in tert-butanol, g of sodium periodate and stirred for 6 hours at 23 ° C. It is poured onto saturated sodium thiosulphate solution and extracted several times with ethyl acetate. The combined organic extracts are washed with saturated sodium chloride solution, dried over sodium sulfate and the residue obtained after filtration and removal of the solvent is purified by chromatography on fine silica gel with a gradient system of n-hexane and ethyl acetate. 4.86 g (30 mmol, 74%) of the title compound are isolated as a crystalline solid.
1 H-NMR (CDCl 3 ): δ = 2.69 (3H), 7.60 (1H), 7.90 (1H), 8.16 (1H), 10.08 (1H) ppm.

Beispiel 21cExample 21c (3RS)-3-(2-Methyl-benzoxazol-5-yl)-1-[(4S,5R)-4-methyl-5-phenyl-oxazolidin-2-on-3-yl]- 3-hydroxypropyl-1-on(3RS) -3- (2-methyl-benzoxazol-5-yl) -1 - [(4S, 5R) -4-methyl-5-phenyl-oxazolidin-2-on-3-yl] - 3-hydroxypropyl-1-one

Zu der Lösung von 14,1 ml Diisopropylamin in 670 ml wasserfreiem Tetrahydrofuran tropft man bei -30°C unter einer Atmosphäre aus trockenem Argon 50 ml einer 2,4 molaren Lösung von n-Buthyllithium in n-Hexan, rührt 20 Minuten, kühlt auf -70°C und versetzt innerhalb von 4,5 Stunden mit der Lösung von 19,8 g (4S,5R)-3-Acetyl-4- methyl-5-phenyloxazolidin-2-on in 670 ml Tetrahydrofuran. Nach 1 Stunde tropft man innerhalb von 1,5 Stunden die Lösung von 4,86 g (30,1 mmol) der nach Beispiel 21b dargestellten Verbindung in 175 ml Tetrahydrofuran zu und rührt 1 Stunde bei -70°C. Man gießt auf eine gesättigte Ammoniumchloridlösung, extrahiert mehrfach mit Ethylacetat, wäscht die vereinigten organischen Extrakte mit gesättigter Natriumchloidlösung und trocknet über Natriumsulfat. Den nach Filtration und Lösungsmittelabzug erhaltenen Rückstand reinigt man durch Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylaceta. Isoliert werden 11,3 g (29,7 mmol, 98%) der Titelverbindung als farbloses Öl.To the solution of 14.1 ml of diisopropylamine in 670 ml of anhydrous tetrahydrofuran 50 ml of a 2.4 are added dropwise at -30 ° C. under an atmosphere of dry argon molar solution of n-butyllithium in n-hexane, stirred for 20 minutes, cooled to -70 ° C and added within 4.5 hours with the solution of 19.8 g (4S, 5R) -3-acetyl-4- methyl-5-phenyloxazolidin-2-one in 670 ml of tetrahydrofuran. After 1 hour one drips within 1.5 hours the solution of 4.86 g (30.1 mmol) of the according to Example 21b compound shown in 175 ml of tetrahydrofuran and stirred at -70 ° C for 1 hour. It is poured into a saturated ammonium chloride solution and extracted several times Ethyl acetate, wash the combined organic extracts with saturated Sodium chloride solution and dry over sodium sulfate. After filtration and The residue obtained after removal of the solvent is purified by chromatography fine silica gel with a gradient system of n-hexane and ethylaceta. Isolated 11.3 g (29.7 mmol, 98%) of the title compound are obtained as a colorless oil.

Beispiel 21dExample 21d (3S)-3-(2-Methyl-benzoxazol-5-yl)-1-[(4S,5R)-4-methyl-5-phenyl-oxazolidin-2-on-3-yl]-3- [[dimethyl(1,1-dimethylethyl)silyl]oxy]-propyl-1-on (A) und (3R)-3-(2-Methyl-benzoxazol- 5-yl)-1-[(4S,5R)-4-methyl-5-phenyl-oxazolid in-2-on-3-yl]-3-[[dimethyl(1,1- dimethylethyl)silyl]oxy]-propyl-1-on (B)(3S) -3- (2-methyl-benzoxazol-5-yl) -1 - [(4S, 5R) -4-methyl-5-phenyl-oxazolidin-2-on-3-yl] -3- [[dimethyl (1,1-dimethylethyl) silyl] oxy] propyl-1-one (A) and (3R) -3- (2-methyl-benzoxazole- 5-yl) -1 - [(4S, 5R) -4-methyl-5-phenyl-oxazolidin-2-on-3-yl] -3 - [[dimethyl (1,1- dimethylethyl) silyl] oxy] propyl-1-one (B)

Die Lösung von 12,5 g (32,8 mmol) der nach Beispiel 21c dargestellten Verbindung in 110 ml wasserfreiem Dichlormethan kühlt man unter einer Atmosphäre aus trockenem Argon auf -70°C, versetzt mit 7,8 ml 2,6-Lutidin, 13,9 ml Trifluormethansulfonsäure- tert-butyldimethylsilylester und rührt 1 Stunde. Man gießt auf eine gesättigte Natriumhydrogencarbonatlösung, extrahiert mehrfach mit Dichlormethan, wäscht die vereinigten organischen Extrakte mit gesättigter Natriumchloidlösung und trocknet über Natriumsulfat. Den nach Filtration und Lösungsmittelabzug erhaltenen Rückstand trennt man durch Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n- Hexan, Ethylacetat und Ethanol. Isoliert werden 8,9 g (18,0 mmol, 55%) der Titelverbindung A als kristalliner Feststoff sowie 2,9 g (5,9 mmol, 18%) der Titelverbindung B als farbloses Öl.
1H-NMR (CDCl3) von A: δ = -0,19 (3H), 0,02 (3H), 0,82 (9H), 0,88 (3H), 2,61 (3H), 3,19 (1H), 3,51 (1H), 4,69 (1H), 5,36 (1H), 5,55 (1H), 7,21-7,44 (7H), 7,64 (1H) ppm.
1H-NMR (CDCl3) von B: δ = -0,19 (3H), 0,04 (3H), 0,85 (9H), 0,88 (3H), 2,63 (3H), 3,04 (1H), 3,67 (1H), 4,77 (1H), 5,39 (1H), 5,63 (1H), 7,21-7,46 (7H), 7,67 (1H) ppm.The solution of 12.5 g (32.8 mmol) of the compound shown in Example 21c in 110 ml of anhydrous dichloromethane is cooled to -70 ° C. under an atmosphere of dry argon, mixed with 7.8 ml of 2,6-lutidine, 13.9 ml of tert-butyldimethylsilyl trifluoromethanesulfonate and stirred for 1 hour. It is poured onto a saturated sodium hydrogen carbonate solution, extracted several times with dichloromethane, the combined organic extracts are washed with saturated sodium chloride solution and dried over sodium sulfate. The residue obtained after filtration and removal of the solvent is separated by chromatography on fine silica gel with a gradient system that consists of n-hexane, ethyl acetate and ethanol. 8.9 g (18.0 mmol, 55%) of the title compound A are isolated as a crystalline solid and 2.9 g (5.9 mmol, 18%) of the title compound B as a colorless oil.
1 H NMR (CDCl 3 ) of A: δ = -0.19 (3H), 0.02 (3H), 0.82 (9H), 0.88 (3H), 2.61 (3H), 3 , 19 (1H), 3.51 (1H), 4.69 (1H), 5.36 (1H), 5.55 (1H), 7.21-7.44 (7H), 7.64 (1H ) ppm.
1 H NMR (CDCl 3 ) of B: δ = -0.19 (3H), 0.04 (3H), 0.85 (9H), 0.88 (3H), 2.63 (3H), 3 .04 (1H), 3.67 (1H), 4.77 (1H), 5.39 (1H), 5.63 (1H), 7.21-7.46 (7H), 7.67 (1H ) ppm.

Beispiel 21eExample 21e (3S)-3-(2-Methyl-benzoxazol-5-yl)-3-[[dimethyl(1,1-dimethylethyl)silyl]oxy]- propionsäureethylester(3S) -3- (2-methyl-benzoxazol-5-yl) -3 - [[dimethyl (1,1-dimethylethyl) silyl] oxy] - ethyl propionate

Die Lösung von 13,9 g (28,2 mmol) der nach Beispiel 21d dargestellten Verbindung in 140 ml wasserfreiem Ethanol versetzt man bei 23°C unter einer Atmosphäre aus trockenem Argon mit 7,1 ml Titantetraethylat und erhitzt 3 Stunden auf 85°C. Man engt ein und reinigt den Rückstand durch Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylacetat. Isoliert werden 10,1 g (27,8 mmol, 99%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = -0,20 (3H), 0,02 (3H), 0,82 (9H), 1,26 (3H), 2,55 (1H), 2,62 (3H), 2,76 (1H), 4,12 (2H), 5,26 (1H), 7,29 (1H), 7,40 (1H), 7,62 (1H) ppm.7.1 ml of titanium tetraethylate are added to the solution of 13.9 g (28.2 mmol) of the compound shown in Example 21d in 140 ml of anhydrous ethanol at 23 ° C. under an atmosphere of dry argon and the mixture is heated to 85 ° C. for 3 hours . It is concentrated and the residue is purified by chromatography on fine silica gel with a gradient system that consists of n-hexane and ethyl acetate. 10.1 g (27.8 mmol, 99%) of the title compound are isolated as a colorless oil.
1 H NMR (CDCl 3 ): δ = -0.20 (3H), 0.02 (3H), 0.82 (9H), 1.26 (3H), 2.55 (1H), 2.62 (3H), 2.76 (1H), 4.12 (2H), 5.26 (1H), 7.29 (1H), 7.40 (1H), 7.62 (1H) ppm.

Beispiel 21fExample 21f (3S)-3-(2-Methyl-benzoxazol-5-yl)-3-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-propan-1-ol(3S) -3- (2-methyl-benzoxazol-5-yl) -3 - [[dimethyl (1,1-dimethylethyl) silyl] oxy] propan-1-ol

Die Lösung von 10,1 g (27,8 mmol) der nach Beispiel 21e dargestellten Verbindung in ml wasserfreiem Dichlormethan kühlt man unter einer Atmosphäre aus trockenem Argon auf -78°C, versetzt mit 58 ml einer 1,2 molaren Lösung von Diisobuthylaluminiumhydrid in Toluol und rührt noch 1 Stunde. Man versetzt mit 16 ml Isopropanol, 32 ml Wasser, läßt auf 23°C erwärmen und rührt noch so lange, bis sich ein feinkörniger Niederschlag gebildet hat. Nach Filtration und Lösungsmittelabzug isoliert man 7,2 g (22,4 mmol, 81%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = -0,18 (3H), 0,07 (3H), 0,89 (9H), 1,97 (2H), 2,35 (1H), 2,66 (3H), 3,73 (2H), 5,06 (1H), 7,28 (1H), 7,42 (1H), 7,60 (1H) ppm.The solution of 10.1 g (27.8 mmol) of the compound shown in Example 21e in ml of anhydrous dichloromethane is cooled to -78 ° C. under an atmosphere of dry argon, treated with 58 ml of a 1.2 molar solution of diisobutylaluminum hydride in Toluene and stir for 1 hour. 16 ml of isopropanol and 32 ml of water are added, the mixture is allowed to warm to 23 ° C. and stirred until a fine-grain precipitate has formed. After filtration and removal of the solvent, 7.2 g (22.4 mmol, 81%) of the title compound are isolated as a colorless oil.
1 H NMR (CDCl 3 ): δ = -0.18 (3H), 0.07 (3H), 0.89 (9H), 1.97 (2H), 2.35 (1H), 2.66 (3H), 3.73 (2H), 5.06 (1H), 7.28 (1H), 7.42 (1H), 7.60 (1H) ppm.

Beispiel 21gExample 21g (3S)-3-(2-Methyl-benzoxazol-5-yl)-3-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-1-iod-propan(3S) -3- (2-methyl-benzoxazol-5-yl) -3 - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -1-iodopropane

Die Lösung von 2,83 g Triphenylphosphin in 40 ml wasserfreiem Dichlormethan versetzt man bei 23°C unter einer Atmosphäre aus trockenem Argon mit 737 mg Imidazol, 2,71 g Iod und tropft unter Kühlung die Lösung von 2,65 g (8,2 mmol) der nach Beispiel 21f dargestellten Verbindung in 30 ml Dichlormethan zu. Man rührt 1 Stunde und reinigt direkt durch Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylacetat. Isoliert werden 2,3 g (5,3 mmol, 65%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = -0,20 (3H), 0,06 (3H), 0,85 (9H), 2,10 (1H), 2,21 (1H), 2,61 (3H), 3,11 (1H), 3,23 (1H), 4,82 (1H), 7,22 (1H), 7,39 (1H), 7,59 (1H) ppm.The solution of 2.83 g of triphenylphosphine in 40 ml of anhydrous dichloromethane is mixed with 737 mg of imidazole and 2.71 g of iodine at 23 ° C. under an atmosphere of dry argon and the solution of 2.65 g (8.2 mmol) of the compound shown in Example 21f in 30 ml of dichloromethane. The mixture is stirred for 1 hour and purified directly by chromatography on fine silica gel with a gradient system of n-hexane and ethyl acetate. 2.3 g (5.3 mmol, 65%) of the title compound are isolated as a colorless oil.
1 H NMR (CDCl 3 ): δ = -0.20 (3H), 0.06 (3H), 0.85 (9H), 2.10 (1H), 2.21 (1H), 2.61 (3H), 3.11 (1H), 3.23 (1H), 4.82 (1H), 7.22 (1H), 7.39 (1H), 7.59 (1H) ppm.

Beispiel 21hExample 21h (3S)-3-(2-Methyl-benzoxazol-5-yl)-3-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-propan-1- triphenylphosphoniumiodid(3S) -3- (2-methyl-benzoxazol-5-yl) -3 - [[dimethyl (1,1-dimethylethyl) silyl] oxy] propane-1- triphenylphosphonium iodide

2,3 g (5,3 mmol) der nach Beispiel 21g dargestellten Verbindung versetzt man mit 2,9 ml Ethyldiisopropylamin, 17,5 g Triphenylphosphin und erwärmt 4 Stunden auf 85°C. Den öligen Rückstand reinigt man durch Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylacetat. Isoliert werden 3,3 g (4,8 mmol, 89%) der Titelverbindung als kristalliner Feststoff.
1H-NMR (CDCl3): δ = -0,19 (3H), 0,12 (3H), 0,84 (9H), 1,89 (1H), 2,09 (1H), 2,60 (3H), 3,41 (1H), 4,06 (1H), 5,37 (1H), 7,38 (1H), 7,49 (1H), 7,59 (1H), 7,62-7,84 (15H) ppm.2.9 ml of ethyldiisopropylamine and 17.5 g of triphenylphosphine are added to 2.3 g (5.3 mmol) of the compound shown in Example 21g and the mixture is heated to 85 ° C. for 4 hours. The oily residue is purified by chromatography on fine silica gel with a gradient system that consists of n-hexane and ethyl acetate. 3.3 g (4.8 mmol, 89%) of the title compound are isolated as a crystalline solid.
1 H NMR (CDCl 3 ): δ = -0.19 (3H), 0.12 (3H), 0.84 (9H), 1.89 (1H), 2.09 (1H), 2.60 (3H), 3.41 (1H), 4.06 (1H), 5.37 (1H), 7.38 (1H), 7.49 (1H), 7.59 (1H), 7.62- 7.84 (15H) ppm.

Beispiel 21iExample 21i (2S,6E/Z,9S)-9-[[Dimethyl(1,1-dimethylethyl)silyl]oxy]-9-(2-methyl-benzoxazol-5-yl)-1- (tetrahydropyran-2-yloxy)-2,6-dimethyl-non-6-en(2S, 6E / Z, 9S) -9 - [[Dimethyl (1,1-dimethylethyl) silyl] oxy] -9- (2-methyl-benzoxazol-5-yl) -1- (tetrahydropyran-2-yloxy) -2,6-dimethyl-non-6-en

Die Lösung von 2,3 g (3,3 mmol) der nach Beispiel 21h dargestellten Verbindung in 15 ml wasserfreiem Tetrahydrofuran versetzt man unter einer Atmosphäre aus trockenem Argon bei 0°C mit 5 ml einer 1,0 molaren Lösung von Natriumhexamethyldisilazan in Tetrahydrofuran, tropft die Lösung von 513 mg (2,25 mmol) (2S)-2-Methyl-6-oxo­ heptan-1-(tetrahydropyran-2-yloxy), das man in Analogie zu den in DE 197 51 200.3 beschriebenen Verfahren hergestellt hat, in 15 ml Tetrahydrofuran zu, läßt auf 23°C erwärmen und noch 3 Stunden reagieren. Man gießt auf eine gesättigte Ammoniumchloridlösung, extrahiert mehrfach mit Ethylacetat, wäscht die vereinigten organischen Extrakte mit gesättigter Natriumchloidlösung und trocknet über Natriumsulfat. Den nach Filtration und Lösungsmittelabzug erhaltenen Rückstand trennt man durch Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n- Hexan und Ethylacetat. Isoliert werden 506 mg (1,0 mmol, 44%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = -0,15 (3H), 0,01 (3H), 0,80-0,92 (12H), 1,02 (1H), 1,19-1,97 (12H), 1,46 + 1,62 (3H), 2,21-2,48 (2H), 2,60 (3H), 3,10 + 3,19 (1H), 3,40-3,61 (2H), 3,82 (1H), 4,53 (1H), 4,69 (1H), 5,11 (1H), 7,22 (1H), 7,37 (1H), 7,57 (1H) ppm.The solution of 2.3 g (3.3 mmol) of the compound shown in Example 21h in 15 ml of anhydrous tetrahydrofuran is added under an atmosphere of dry argon at 0 ° C. with 5 ml of a 1.0 molar solution of sodium hexamethyldisilazane in tetrahydrofuran, the solution of 513 mg (2.25 mmol) of (2S) -2-methyl-6-oxo heptane-1- (tetrahydropyran-2-yloxy), which has been prepared in analogy to the process described in DE 197 51 200.3, is added dropwise , in 15 ml of tetrahydrofuran, allowed to warm to 23 ° C and react for another 3 hours. It is poured onto a saturated ammonium chloride solution, extracted several times with ethyl acetate, the combined organic extracts are washed with saturated sodium chloride solution and dried over sodium sulfate. The residue obtained after filtration and removal of the solvent is separated by chromatography on fine silica gel with a gradient system of n-hexane and ethyl acetate. 506 mg (1.0 mmol, 44%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = -0.15 (3H), 0.01 (3H), 0.80-0.92 (12H), 1.02 (1H), 1.19-1, 97 (12H), 1.46 + 1.62 (3H), 2.21-2.48 (2H), 2.60 (3H), 3.10 + 3.19 (1H), 3.40-3 , 61 (2H), 3.82 (1H), 4.53 (1H), 4.69 (1H), 5.11 (1H), 7.22 (1H), 7.37 (1H), 7, 57 (1H) ppm.

Beispiel 21jExample 21j (2S,6E/Z,9S)-9-[[Dimethyl(1,1-dimethylethyl)silyl]oxy]-9-(2-methyl-benzoxazol-5-yl)-1- hydroxy-2,6-dimethyl-non-6-en(2S, 6E / Z, 9S) -9 - [[Dimethyl (1,1-dimethylethyl) silyl] oxy] -9- (2-methyl-benzoxazol-5-yl) -1- hydroxy-2,6-dimethyl-non-6-en

In Analogie zu Beispiel 1k setzt man 447 mg (0,87 mmol) der nach Beispiel 21i dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 298 mg (0,69 mmol, 79%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = -0,12 (3H), 0,01 (3H), 0,82-0,92 (12H), 1,01 (1H), 1,16-1,67 (4H), 1,44 + 1,63 (3H), 1,83-1,98 (2H), 2,18 (1H), 2,33 (1H), 2,44 (1H), 2,62 (3H), 3,31-3,53 (2H), 4,71 (1H), 5,07 + 5,13 (1H), 7,24 + 7,29 (1H), 7,39 (1H), 7,53 + 7,58 (1H) ppm.In analogy to Example 1k, 447 mg (0.87 mmol) of the compound shown in Example 21i are reacted and, after work-up and purification, 298 mg (0.69 mmol, 79%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = -0.12 (3H), 0.01 (3H), 0.82-0.92 (12H), 1.01 (1H), 1.16-1, 67 (4H), 1.44 + 1.63 (3H), 1.83-1.98 (2H), 2.18 (1H), 2.33 (1H), 2.44 (1H), 2, 62 (3H), 3.31-3.53 (2H), 4.71 (1H), 5.07 + 5.13 (1H), 7.24 + 7.29 (1H), 7.39 (1H ), 7.53 + 7.58 (1H) ppm.

Beispiel 21kExample 21k (2S,6E/Z,9S)-9-[[Dimethyl(1,1-dimethylethyl)silyl]oxy]-9-(2-methyl-benzoxazol-5-yl)-1- oxo-2,6-dimethyl-non-6-en(2S, 6E / Z, 9S) -9 - [[Dimethyl (1,1-dimethylethyl) silyl] oxy] -9- (2-methyl-benzoxazol-5-yl) -1- oxo-2,6-dimethyl-non-6-ene

In Analogie zu Beispiel 1n setzt man 272 mg (0,63 mmol) der nach Beispiel 21j dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 236 mg (0,55 mmol, 87%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = -0,16 (3H), 0,01 (3H), 0,84 (9H), 1,02 + 1,05 (3H), 1,13-2,50 (9H), 1,44 + 1,61 (3H), 2,61 (3H), 4,71 (1H), 5,13 (1H), 7,21 (1H), 7,37 (1H), 7,55 (1H), 9,54 (1H) ppm.In analogy to Example 1n, 272 mg (0.63 mmol) of the compound shown in Example 21j are reacted and, after work-up and purification, 236 mg (0.55 mmol, 87%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = -0.16 (3H), 0.01 (3H), 0.84 (9H), 1.02 + 1.05 (3H), 1.13-2, 50 (9H), 1.44 + 1.61 (3H), 2.61 (3H), 4.71 (1H), 5.13 (1H), 7.21 (1H), 7.37 (1H) , 7.55 (1H), 9.54 (1H) ppm.

Beispiel 21lExample 21l (4S(4R,5S,6S,10E/Z,13S))-4-(13-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-4-(prop-2-en-1- yl)-13-(2-methyl-benzoxazol-5-yl)-3-oxo-5-hydroxy-2,6,10-trimethyl-tridec-10-en-2-yl)- 2,2-dimethyl-[1,3]dioxan (A) und (4S(4S,5R,6S,10E/Z,13S))-4-(13-[[(1,1- Dimethylethyl)dimethylsilyl]oxy]-4-(prop-2-en-1-yl)-13-(2-methyl-benzoxazol-5-yl)-3-oxo- 5-hydroxy-2,6,10-trimethyl-tridec-10-en-2-yl)-2,2-dimethyl-[1,3]dioxan (B)(4S (4R, 5S, 6S, 10E / Z, 13S)) - 4- (13 - [[(1,1-Dimethylethyl) dimethylsilyl] oxy] -4- (prop-2-en-1- yl) -13- (2-methyl-benzoxazol-5-yl) -3-oxo-5-hydroxy-2,6,10-trimethyl-tridec-10-en-2-yl) - 2,2-dimethyl- [1,3] dioxane (A) and (4S (4S, 5R, 6S, 10E / Z, 13S)) - 4- (13 - [[(1,1- Dimethylethyl) dimethylsilyl] oxy] -4- (prop-2-en-1-yl) -13- (2-methyl-benzoxazol-5-yl) -3-oxo- 5-hydroxy-2,6,10-trimethyl-tridec-10-en-2-yl) -2,2-dimethyl- [1,3] dioxane (B)

In Analogie zu Beispiel 1c setzt man 236 mg (0,55 mmol) der nach Beispiel 21k dargestellten Verbindung mit 433 mg (1,80 mmol) (4S)-4-(2-Methyl-3-oxo-hept-6-en-2- yl)-2,2-dimethyl-[1,3]dioxan, das man in Analogie zu den in DE 197 51 200.3 beschriebenen Verfahren hergestellt hat, um und isoliert nach Aufarbeitung und Reinigung neben Ausgangsmaterial 221 mg (0,33 mmol, 60%) der Titelverbindung A sowie 72 mg (0,11 mmol, 20%) der Titelverbindung B jeweils als farbloses Öl.
1H-NMR (CDCl3) von A: δ = -0,13 (3H), 0,01 (3H), 0,78-0,88 (12H), 0,96 (3H), 1,04 (1H), 1,11-2,52 (12H), 1,23 (3H), 1,31 (3H), 1,39 (3H), 1,47 + 1,64 (3H), 2,62 (3H), 2,90 + 2,98 (1H), 3,32 (1H), 3,47 (1H), 3,87 (1H), 3,97 (1H), 4,13 (1H), 4,70 (1H), 4,98 (1H), 5,03 (1H), 5,12 (1H), 5,71 (1H), 7,22 (1H), 7,38 (1H), 7,56 (1H) ppm.In analogy to Example 1c, 236 mg (0.55 mmol) of the compound shown according to Example 21k are added to 433 mg (1.80 mmol) (4S) -4- (2-methyl-3-oxo-hept-6-ene -2-yl) -2,2-dimethyl- [1,3] dioxane, which has been prepared in analogy to the process described in DE 197 51 200.3, in order to isolate and after work-up and purification in addition to starting material 221 mg (0.33 mmol, 60%) of the title compound A and 72 mg (0.11 mmol, 20%) of the title compound B in each case as a colorless oil.
1 H-NMR (CDCl 3 ) of A: δ = -0.13 (3H), 0.01 (3H), 0.78-0.88 (12H), 0.96 (3H), 1.04 ( 1H), 1.11-2.52 (12H), 1.23 (3H), 1.31 (3H), 1.39 (3H), 1.47 + 1.64 (3H), 2.62 ( 3H), 2.90 + 2.98 (1H), 3.32 (1H), 3.47 (1H), 3.87 (1H), 3.97 (1H), 4.13 (1H), 4 , 70 (1H), 4.98 (1H), 5.03 (1H), 5.12 (1H), 5.71 (1H), 7.22 (1H), 7.38 (1H), 7, 56 (1H) ppm.

Beispiel 21mExample 21m (3S,6R,7S,8S,12E/Z,15S)-15-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-6-(prop-2-en-1-yl)- 1,3,7-trihydroxy-4,4,8,12-tetramethyl-15-(2-methyl-benzoxazol-5-yl)-pentadec-12-en-5- on(3S, 6R, 7S, 8S, 12E / Z, 15S) -15 - [[(1,1-dimethylethyl) dimethylsilyl] oxy] -6- (prop-2-en-1-yl) - 1,3,7-trihydroxy-4,4,8,12-tetramethyl-15- (2-methyl-benzoxazol-5-yl) -pentadec-12-en-5- on

In Analogie zu Beispiel 1k setzt man 221 mg (0,33 mmol) der nach Beispiel 21l dargestellten Verbindung A um und isoliert nach Aufarbeitung und Reinigung 163 mg (0,26 mmol, 78%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = -0,15 (3H), 0,01 (3H), 0,79-0,90 (12H), 1,05 (3H), 1,17-2,59 (13H), 1,20 + 1,24 (3H), 1,43 + 1,62 (3H), 2,62 + 2,64 (3H), 2,81 + 3,07 (1H), 3,25-3,70 (3H), 3,86 (2H), 4,08 (2H), 4,68 (1H), 4,92-5,19 (3H), 5,69 (1H), 7,25 + 7,29 (1H), 7,39 (1H), 7,48 + 7,52 (1H) ppm.In analogy to Example 1k, 221 mg (0.33 mmol) of the compound A shown in Example 21l are reacted and, after work-up and purification, 163 mg (0.26 mmol, 78%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = -0.15 (3H), 0.01 (3H), 0.79-0.90 (12H), 1.05 (3H), 1.17-2, 59 (13H), 1.20 + 1.24 (3H), 1.43 + 1.62 (3H), 2.62 + 2.64 (3H), 2.81 + 3.07 (1H), 3 , 25-3.70 (3H), 3.86 (2H), 4.08 (2H), 4.68 (1H), 4.92-5.19 (3H), 5.69 (1H), 7 , 25 + 7.29 (1H), 7.39 (1H), 7.48 + 7.52 (1H) ppm.

Beispiel 21nExample 21n (3S,6R,7S,8S,12E/Z,15S)-6-(Prop-2-en-1-yl)-1,3,7,15-tetrakis-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-4,4,8,12-tetramethyl-15-(2-methyl-benzoxazol-5-yl)- pentadec-12-en-5-on(3S, 6R, 7S, 8S, 12E / Z, 15S) -6- (prop-2-en-1-yl) -1,3,7,15-tetrakis - [[(1,1- dimethylethyl) dimethylsilyl] oxy] -4,4,8,12-tetramethyl-15- (2-methyl-benzoxazol-5-yl) - pentadec-12-en-5-one

In Analogie zu Beispiel 1l setzt man 163 mg (0,26 mmol) der nach Beispiel 21m dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 236 mg (0,24 mmol, 93%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = -0,06 (3H), -0,04-0,08 (21H), 0,79-0,93 (39H), 0,96-1,66 (7H), 1,01 (3H), 1,17 (3H), 1,47 + 1,62 (3H), 1,88 (2H), 2,18-2,52 (4H), 2,61 (3H), 3,11 (1H), 3,53 (1H), 3,63 (1H), 3,73 (1H), 3,84 (1H), 4,68 (1H), 4,91 (1H), 4,97 (1H), 5,12 (1H), 5,72 (1H), 7,21 (1H), 7,36 (1H), 7,56 (1H) ppm.In analogy to Example 11, 163 mg (0.26 mmol) of the compound shown in Example 21m are reacted and, after work-up and purification, 236 mg (0.24 mmol, 93%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = -0.06 (3H), -0.04-0.08 (21H), 0.79-0.93 (39H), 0.96-1.66 ( 7H), 1.01 (3H), 1.17 (3H), 1.47 + 1.62 (3H), 1.88 (2H), 2.18-2.52 (4H), 2.61 ( 3H), 3.11 (1H), 3.53 (1H), 3.63 (1H), 3.73 (1H), 3.84 (1H), 4.68 (1H), 4.91 (1H ), 4.97 (1H), 5.12 (1H), 5.72 (1H), 7.21 (1H), 7.36 (1H), 7.56 (1H) ppm.

Beispiel 21oExample 21o (3S,6R,7S,8S,12E/Z,15S)-1-Hydroxy-6-(prop-2-en-1-yl)-3,7,15-tris-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-4,4,8,12-tetramethyl-15-(2-methyl-benzoxazol-5-yl)- pentadec-12-en-5-on(3S, 6R, 7S, 8S, 12E / Z, 15S) -1-hydroxy-6- (prop-2-en-1-yl) -3,7,15-tris - [[(1,1- dimethylethyl) dimethylsilyl] oxy] -4,4,8,12-tetramethyl-15- (2-methyl-benzoxazol-5-yl) - pentadec-12-en-5-one

In Analogie zu Beispiel 1m setzt man 236 mg (0,24 mmol) der nach Beispiel 21n dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 146 mg (0,17 mmol, 71%) der Titelverbindung als farbloses Öl.In analogy to Example 1m, 236 mg (0.24 mmol) of the according to Example 21n are used compound represented by and isolated after work-up and purification 146 mg (0.17 mmol, 71%) of the title compound as a colorless oil.

Beispiel 21pExample 21p (3S,6R,7S,8S,12E/Z,15S)-5-Oxo-6-(prop-2-en-1-yl)-3,7,15-tris-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-4,4,8,12-tetramethyl-15-(2-methyl-benzoxazol-5-yl)- pentadec-12-enal(3S, 6R, 7S, 8S, 12E / Z, 15S) -5-oxo-6- (prop-2-en-1-yl) -3,7,15-tris - [[(1,1- dimethylethyl) dimethylsilyl] oxy] -4,4,8,12-tetramethyl-15- (2-methyl-benzoxazol-5-yl) - pentadec-12-enal

In Analogie zu Beispiel 1n setzt man 146 mg (0,17 mmol) der nach Beispiel 21o dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 143 mg (0,17 mmol, 98%) der Titelverbindung als farbloses Öl.In analogy to Example 1n, 146 mg (0.17 mmol) of the according to Example 21o are used compound represented by and isolated after work-up and purification 143 mg (0.17 mmol, 98%) of the title compound as a colorless oil.

Beispiel 21qExample 21q (3S,6R,7S,8S,12Z,15S)-5-Oxo-6-(prop-2-en-1-yl)-3,7,15-tris-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-4,4,8,12-tetramethyl-15-(2-methyl-benzoxazol-5-yl)- pentadec-12-ensäure (A) und (3S,6R,7S,8S,12E,15S)-5-Oxo-6-(prop-2-en-1-yl)-3,7,15- tris-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4,4,8,12-tetramethyl-15-(2-methyl-benzoxazol- 5-yl)-pentadec-12-ensäure (B)(3S, 6R, 7S, 8S, 12Z, 15S) -5-oxo-6- (prop-2-en-1-yl) -3,7,15-tris - [[(1,1- dimethylethyl) dimethylsilyl] oxy] -4,4,8,12-tetramethyl-15- (2-methyl-benzoxazol-5-yl) - pentadec-12-enoic acid (A) and (3S, 6R, 7S, 8S, 12E, 15S) -5-oxo-6- (prop-2-en-1-yl) -3,7,15- tris - [[(1,1-dimethylethyl) dimethylsilyl] oxy] -4,4,8,12-tetramethyl-15- (2-methyl-benzoxazole- 5-yl) pentadec-12-enoic acid (B)

Die Lösung von 143 mg (0,17 mmol) der nach Beispiel 21p dargestellten Verbindung in 5 ml tert.-Butanol versetzt man bei 0°C mit der Lösung von 1,1 ml 2-Methyl-2-buten in 3,6 ml Tetrahydrofuran, 1,3 ml Wasser, 67 mg NatriumdihydrogenPhosphat, 117 mg Natriumchlorit und rührt 2 Stunden. Man gießt auf eine gesättigte Natriumthiosulfatlösung, extrahiert mehrfach mit Ethylacetat, wäscht die vereinigten organischen Extrakte mit gesättigter Natriumchloidlösung und trocknet über Natriumsulfat. Den nach Filtration und Lösungsmittelabzug erhaltenen Rückstand trennt man durch Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n- Hexan und Ethylacetat. Isoliert werden 58 mg (66 µmol, 39%) der Titelverbindung A sowie 52 mg (60 µmol, 35%) der Titelverbindung B jeweils als farbloses Öl.
1H-NMR (CDCl3) von A: δ = -0,13 (3H), -0,02 (6H), 0,04 (6H), 0,12 (3H), 0,80-0,92 (27H), 0,96 (3H), 1,06 (3H), 1,09-1,96 (7H), 1,15 (3H), 1,70 (3H), 2,13-2,60 (7H), 2,62 (3H), 3,20 (1H), 3,66 (1H), 4,43 (1H), 4,72 (1H), 4,92 (1H), 4,99 (1H), 5,26 (1H), 5,70 (1H), 7,34 (1H), 7,40 (1H), 7,89 (1H) ppm.
1H-NMR (CDCl3) von B: δ = -0,11 (3H), 0,02 (6H), 0,07 (3H), 0,10 (3H), 0,16 (3H), 0,86- 0,94 (30H), 0,90-2,05 (8H), 1,12 (3H), 1,19 (3H), 1,39 (3H), 2,23-2,60 (6H), 2,63 (3H), 3,21 (1H), 3,79 (1H), 4,36 (1H), 4,68 (1H), 4,98 (1H), 5,01 (1H), 5,10 (1H), 5,77 (1H), 7,36 (1H), 7,41 (1H), 7,54 (1H) ppm.The solution of 143 mg (0.17 mmol) of the compound shown in Example 21p in 5 ml of tert-butanol is mixed with a solution of 1.1 ml of 2-methyl-2-butene in 3.6 ml at 0 ° C Tetrahydrofuran, 1.3 ml of water, 67 mg of sodium dihydrogen phosphate, 117 mg of sodium chlorite and stir for 2 hours. It is poured onto a saturated sodium thiosulphate solution, extracted several times with ethyl acetate, the combined organic extracts are washed with saturated sodium chloride solution and dried over sodium sulphate. The residue obtained after filtration and removal of the solvent is separated by chromatography on fine silica gel with a gradient system of n-hexane and ethyl acetate. 58 mg (66 μmol, 39%) of the title compound A and 52 mg (60 μmol, 35%) of the title compound B are isolated in each case as a colorless oil.
1 H NMR (CDCl 3 ) of A: δ = -0.13 (3H), -0.02 (6H), 0.04 (6H), 0.12 (3H), 0.80-0.92 (27H), 0.96 (3H), 1.06 (3H), 1.09-1.96 (7H), 1.15 (3H), 1.70 (3H), 2.13-2.60 (7H), 2.62 (3H), 3.20 (1H), 3.66 (1H), 4.43 (1H), 4.72 (1H), 4.92 (1H), 4.99 ( 1H), 5.26 (1H), 5.70 (1H), 7.34 (1H), 7.40 (1H), 7.89 (1H) ppm.
1 H NMR (CDCl 3 ) of B: δ = -0.11 (3H), 0.02 (6H), 0.07 (3H), 0.10 (3H), 0.16 (3H), 0 , 86-0.94 (30H), 0.90-2.05 (8H), 1.12 (3H), 1.19 (3H), 1.39 (3H), 2.23-2.60 ( 6H), 2.63 (3H), 3.21 (1H), 3.79 (1H), 4.36 (1H), 4.68 (1H), 4.98 (1H), 5.01 (1H ), 5.10 (1H), 5.77 (1H), 7.36 (1H), 7.41 (1H), 7.54 (1H) ppm.

Beispiel 21rExample 21r (3S,6R,7S,8S,12Z,15S)-15-Hydroxy-5-oxo-6-(prop-2-en-1-yl)-3,7-bis-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-4,4,8,12-tetramethyl-15-(2-methyl-benzoxazol-5-yl)- pentadec-12-ensäure(3S, 6R, 7S, 8S, 12Z, 15S) -15-Hydroxy-5-oxo-6- (prop-2-en-1-yl) -3,7-bis - [[(1,1- dimethylethyl) dimethylsilyl] oxy] -4,4,8,12-tetramethyl-15- (2-methyl-benzoxazol-5-yl) - pentadec-12-enoic acid

In Analogie zu Beispiel 1p setzt man 58 mg (66 µmol) der nach Beispiel 21q dargestellten Verbindung A um und isoliert nach Aufarbeitung 52 mg (max. 66 µmol) der Titelverbindung, die man ohne Reinigung weiter umsetzt.In analogy to Example 1p, 58 mg (66 μmol) of the according to Example 21q are used Compound A represented by and isolated after work-up 52 mg (max. 66 µmol) the title compound, which is reacted further without purification.

Beispiel 21sExample 21s (4S,7R,8S,9S,13Z,16S)-4,8-Bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-16-(2-methyl- benzoxazol-5-yl)-7-(prop-2-en-1-yl)-1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6- dion(4S, 7R, 8S, 9S, 13Z, 16S) -4,8-bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -16- (2-methyl- benzoxazol-5-yl) -7- (prop-2-en-1-yl) -1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6- dion

In Analogie zu Beispiel 1q setzt man 52 mg (max. 66 µmol) der nach Beispiel 21r dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 42 mg (57 µmol, 86%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = -0,08 (3H), 0,09 (6H), 0,14 (3H), 0,77-1,88 (7H), 0,85 (9H), 0,93 (9H), 1,01 (3H), 1,09 (3H), 1,15 (3H), 1,71 (3H), 2,10-2,75 (6H), 2,62 (3H), 2,91 (1H), 3,11 (1H), 4,00 (1H), 4,92 (1H), 4,99 (1H), 5,19 (1H), 5,57 (1H), 5,79 (1H), 7,32 (1H), 7,44 (1H), 7,68 (1H) ppm.In analogy to Example 1q, 52 mg (max. 66 μmol) of the compound shown in Example 21r are reacted and, after work-up and purification, 42 mg (57 μmol, 86%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = -0.08 (3H), 0.09 (6H), 0.14 (3H), 0.77-1.88 (7H), 0.85 (9H) , 0.93 (9H), 1.01 (3H), 1.09 (3H), 1.15 (3H), 1.71 (3H), 2.10-2.75 (6H), 2.62 (3H), 2.91 (1H), 3.11 (1H), 4.00 (1H), 4.92 (1H), 4.99 (1H), 5.19 (1H), 5.57 ( 1H), 5.79 (1H), 7.32 (1H), 7.44 (1H), 7.68 (1H) ppm.

Beispiel 21Example 21 (4S,7R,8S,9S,13Z,16S)-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-7-(prop-2-en-1- yl)-1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13Z, 16S) -4,8-dihydroxy-16- (2-methyl-benzoxazol-5-yl) -7- (prop-2-en-1- yl) -1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dione

In Analogie zu Beispiel 1 setzt man 42 mg (57 µmol) der nach Beispiel 21s dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 19 mg (37 µmol, 65%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 1,02 (3H), 1,08 (3H), 1,14-1,97 (6H), 1,22 (3H), 1,70 (3H), 2,22-­ 2,60 (7H), 2,62 (3H), 2,78-2,95 (2H), 3,36 (1H), 3,78 (1H), 4,10 (1H), 5,03 (1H), 5,09 (1H), 5,19 (1H), 5,76 (1H), 5,85 (1H), 7,28 (1H), 7,43 (1H), 7,63 (1H) ppm.In analogy to Example 1, 42 mg (57 μmol) of the compound shown in Example 21s are reacted and, after work-up and purification, 19 mg (37 μmol, 65%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 1.02 (3H), 1.08 (3H), 1.14-1.97 (6H), 1.22 (3H), 1.70 (3H), 2.22-2.60 (7H), 2.62 (3H), 2.78-2.95 (2H), 3.36 (1H), 3.78 (1H), 4.10 (1H), 5.03 (1H), 5.09 (1H), 5.19 (1H), 5.76 (1H), 5.85 (1H), 7.28 (1H), 7.43 (1H), 7 , 63 (1H) ppm.

Beispiel 22Example 22 (4S,7R,8S,9S,13Z,16S)-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-7-(prop-2-en- 1-yl)-1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13Z, 16S) -4,8-dihydroxy-16- (2-methyl-benzoxazol-5-yl) -7- (prop-2-en- 1-yl) -1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dione Beispiel 22aExample 22a (3S,6R,7S,8S,12E,15S)-15-Hydroxy-5-oxo-6-(prop-2-en-1-yl)-3,7-bis-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-4,4,8,12-tetramethyl-15-(2-methyl-benzoxazol-5-yl)- pentadec-12-ensäure(3S, 6R, 7S, 8S, 12E, 15S) -15-Hydroxy-5-oxo-6- (prop-2-en-1-yl) -3,7-bis - [[(1,1- dimethylethyl) dimethylsilyl] oxy] -4,4,8,12-tetramethyl-15- (2-methyl-benzoxazol-5-yl) - pentadec-12-enoic acid

In Analogie zu Beispiel 1p setzt man 52 mg (60 µmol) der nach Beispiel 21q dargestellten Verbindung B um und isoliert nach Aufarbeitung 46 mg (max. 60 µmol) der Titelverbindung, die man ohne Reinigung weiter umsetzt.In analogy to Example 1p, 52 mg (60 μmol) of the according to Example 21q are used Compound B represented by and isolated after work-up 46 mg (max. 60 µmol) the title compound, which is reacted further without purification.

Beispiel 22bExample 22b (4S,7R,8S,9S,13E,16S)-4,8-Bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-16-(2-methyl- benzoxazol-5-yl)-7-(prop-2-en-1-yl)-1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6- dion(4S, 7R, 8S, 9S, 13E, 16S) -4,8-bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -16- (2-methyl- benzoxazol-5-yl) -7- (prop-2-en-1-yl) -1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6- dion

In Analogie zu Beispiel 1q setzt man 46 mg (max. 60 µmol) der nach Beispiel 22a dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 32 mg (43 µmol, 72%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,03-0,11 (12H), 0,89 (9H), 0,91 (9H), 0,94-1,96 (6H), 0,98 (3H), 1,12 (3H), 1,21 (3H), 1,59 (3H), 2,10-2,76 (7H), 2,63 (3H), 3,08 (1H), 3,91 (1H), 4,31 (1H), 5,02 (1H), 5,07 (1H), 5,29 (1H), 5,79 (1H), 5,89 (1H), 7,30 (1H), 7,42 (1H), 7,62 (1H) ppm.In analogy to Example 1q, 46 mg (max. 60 μmol) of the compound shown in Example 22a are reacted and, after working up and purification, 32 mg (43 μmol, 72%) of the title compound are isolated as a colorless oil.
1 H NMR (CDCl 3 ): δ = 0.03-0.11 (12H), 0.89 (9H), 0.91 (9H), 0.94-1.96 (6H), 0.98 (3H), 1.12 (3H), 1.21 (3H), 1.59 (3H), 2.10-2.76 (7H), 2.63 (3H), 3.08 (1H), 3.91 (1H), 4.31 (1H), 5.02 (1H), 5.07 (1H), 5.29 (1H), 5.79 (1H), 5.89 (1H), 7 , 30 (1H), 7.42 (1H), 7.62 (1H) ppm.

Beispiel 22Example 22 (4S,7R,8S,9S,13E,16S)-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-7-(prop-2-en-1- yl)-1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13E, 16S) -4,8-dihydroxy-16- (2-methyl-benzoxazol-5-yl) -7- (prop-2-en-1- yl) -1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dione

In Analogie zu Beispiel 1 setzt man 32 mg (43 µmol) der nach Beispiel 22b dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 15 mg (29 µmol, 68%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,99 (3H), 1,02 (3H), 1,27 (3H), 1,38-1,99 (6H), 1,64 (3H), 2,18 (1H), 2,23-2,76 (6H), 2,62 (3H), 3,34 (1H), 3,49 (2H), 3,75 (1H), 4,32 (1H), 4,96-5,08 (3H), 5,73 (1H), 5,98 (1H), 7,23 (1H), 7,42 (1H), 7,67 (1H) ppm.In analogy to Example 1, 32 mg (43 μmol) of the compound shown in Example 22b are reacted and, after working up and purification, 15 mg (29 μmol, 68%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.99 (3H), 1.02 (3H), 1.27 (3H), 1.38-1.99 (6H), 1.64 (3H), 2.18 (1H), 2.23-2.76 (6H), 2.62 (3H), 3.34 (1H), 3.49 (2H), 3.75 (1H), 4.32 ( 1H), 4.96-5.08 (3H), 5.73 (1H), 5.98 (1H), 7.23 (1H), 7.42 (1H), 7.67 (1H) ppm.

Beispiel 23Example 23 (4S,7R,8S,9S,13Z,16S(Z))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4- yl)ethenyl)-7-(prop-2-in-1-yl)-1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6- dion(4S, 7R, 8S, 9S, 13Z, 16S (Z)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazole-4- yl) ethenyl) -7- (prop-2-yn-1-yl) -1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6- dion Beispiel 23aExample 23a (4S(4R,5S,6S,10E/Z,13S,14Z))-4-(13-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-4-(prop-2- in-1-yl)-14-fluor-15-(2-methylthiazol-4-yl)-3-oxo-5-hydroxy-2,6,10-trimethyl-pentadeca- 10,14-dien-2-yl)-2,2-dimethyl-[1,3]dioxan (A) und (4S(4S,5R,6S,10E/Z,13S,14Z))-4-(13- [[(1,1-Dimethylethyl)dimethylsilyl]oxy]-4-(prop-2-in-1-yl)-14-fluor-15-(2-methylthiazol-4- yl)-3-oxo-5-hydroxy-2,6,10-trimethyl-pentadeca-10,14-dien-2-yl)-2,2-dimethyl- [1,3]dioxan (B)(4S (4R, 5S, 6S, 10E / Z, 13S, 14Z)) - 4- (13 - [[(1,1-dimethylethyl) dimethylsilyl] oxy] -4- (prop-2- in-1-yl) -14-fluoro-15- (2-methylthiazol-4-yl) -3-oxo-5-hydroxy-2,6,10-trimethyl-pentadeca- 10,14-dien-2-yl) -2,2-dimethyl- [1,3] dioxane (A) and (4S (4S, 5R, 6S, 10E / Z, 13S, 14Z)) - 4- (13 - [[(1,1-Dimethylethyl) dimethylsilyl] oxy] -4- (prop-2-yn-1-yl) -14-fluoro-15- (2-methylthiazole-4- yl) -3-oxo-5-hydroxy-2,6,10-trimethyl-pentadeca-10,14-dien-2-yl) -2,2-dimethyl- [1,3] dioxane (B)

In Analogie zu Beispiel 1c setzt man 2,89 g (6,57 mmol) (2S,6E/Z,9S,10Z)-9- [[Dimethyl(1,1-dimethylethyl)silyl]oxy]-10-fluor-11-(2-methyl-4-thiazolyl)-2,6- dimethylundeca-6,10-dienal, das man in Analogie zu dem in DE 199 07 480.1 beschriebenen Verfahren hergestellt hat, mit 5,09 g (16,4 mmol) (4S)-4-(2-Methyl-3- oxo-7-trimethylsily-hept-6-in-2-yl)-2,2-dimethyl-[1,3]dioxan, das man nach dem in DE 197 51 200.3 beschriebenen Verfahren hergestellt hat, um und isoliert nach Aufarbeitung und Reinigung neben Ausgangsmaterial 3,26 g (4,35 mmol, 66%) der Titelverbindung A sowie 602 mg (0,80 mmol, 12%) der Titelverbindung B jeweils als farbloses Öl.
1H-NMR (CDCl3) von A: δ = 0,03-0,13 (15H), 0,82-0,92 (12H), 0,97-2,08 (12H), 1,06 (3H), 1,30 (6H), 1,38 (3H), 1,58 + 1,65 (3H), 2,33-2,47 (3H), 2,55 (1H), 2,70 (3H), 3,44 (1H), 3,52 (1H), 3,804,28 (2H), 5,13 (1H), 6,03 (1H), 7,32 (1H) ppm.
1H-NMR (CDCl3) von B: δ = 0,05-0,65 (15H), 0,88-0,99 (12H), 1,02-1,73 (8H), 1,18 (6H), 1,32 (3H), 1,41 (3H), 1,60 + 1,69 (3H), 1,90-2,08 (2H), 2,33-2,58 (4H), 2,70 (3H), 3,43 (1H), 3,60 (1H), 3,79-4,26 (4H), 5,18 (1H), 6,05 (1H), 7,33 (1H) ppm.In analogy to Example 1c, 2.89 g (6.57 mmol) (2S, 6E / Z, 9S, 10Z) -9- [[dimethyl (1,1-dimethylethyl) silyl] oxy] -10-fluoro- 11- (2-methyl-4-thiazolyl) -2,6-dimethylundeca-6,10-dienal, which was prepared in analogy to the process described in DE 199 07 480.1, with 5.09 g (16.4 mmol ) (4S) -4- (2-methyl-3-oxo-7-trimethylsily-hept-6-yn-2-yl) -2,2-dimethyl- [1,3] dioxane, which is obtained after the in DE 197 51 200.3 has prepared and isolated after work-up and purification in addition to starting material 3.26 g (4.35 mmol, 66%) of the title compound A and 602 mg (0.80 mmol, 12%) of the title compound B in each case as colorless oil.
1 H-NMR (CDCl 3 ) of A: δ = 0.03-0.13 (15H), 0.82-0.92 (12H), 0.97-2.08 (12H), 1.06 ( 3H), 1.30 (6H), 1.38 (3H), 1.58 + 1.65 (3H), 2.33-2.47 (3H), 2.55 (1H), 2.70 ( 3H), 3.44 (1H), 3.52 (1H), 3.804.28 (2H), 5.13 (1H), 6.03 (1H), 7.32 (1H) ppm.
1 H-NMR (CDCl 3 ) of B: δ = 0.05-0.65 (15H), 0.88-0.99 (12H), 1.02-1.73 (8H), 1.18 ( 6H), 1.32 (3H), 1.41 (3H), 1.60 + 1.69 (3H), 1.90-2.08 (2H), 2.33-2.58 (4H), 2.70 (3H), 3.43 (1H), 3.60 (1H), 3.79-4.26 (4H), 5.18 (1H), 6.05 (1H), 7.33 ( 1H) ppm.

Beispiel 23bExample 23b (3S,6R,7S,8S,12E/Z,15S,16Z)-15-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-6-(3- (trimethylsilyl)-prop-2-in-1-yl)-16-fluor-1,3,7-trihydroxy-4,4,8,12-tetramethyl-17-(2- methylthiazol-4-yl)-heptadeca-12,16-dien-5-on(3S, 6R, 7S, 8S, 12E / Z, 15S, 16Z) -15 - [[(1,1-Dimethylethyl) dimethylsilyl] oxy] -6- (3- (trimethylsilyl) prop-2-yn-1-yl) -16-fluoro-1,3,7-trihydroxy-4,4,8,12-tetramethyl-17- (2- methylthiazol-4-yl) heptadeca-12,16-dien-5-one

In Analogie zu Beispiel 1k setzt man 3,26 g (4,35 mmol) der nach Beispiel 23a dargestellten Verbindung A um und isoliert nach Aufarbeitung und Reinigung neben Ausgangsmaterial 2,44 g (3,43 mmol, 79%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,03-0,15 (15H), 0,85-0,95 (12H), 0,98-2,08 (8H), 1,14 (3H), 1,26 (3H), 1,58 + 1,67 (3H), 2,31-2,49 (3H), 2,59-2,76 (2H), 2,72 (3H), 2,89 (1H), 3,06 (1H), 3,42 (1H), 3,47-3,58 (2H), 3,88 (2H), 4,08-4,22 (2H), 5,11 + 5,18 (1H), 5,98 (1H), 7,33 (1H) ppm.In analogy to Example 1k, 3.26 g (4.35 mmol) of the compound A shown in Example 23a are reacted and, after work-up and purification, 2.44 g (3.43 mmol, 79%) of the title compound are isolated as colorless in addition to starting material Oil.
1 H-NMR (CDCl 3 ): δ = 0.03-0.15 (15H), 0.85-0.95 (12H), 0.98-2.08 (8H), 1.14 (3H) , 1.26 (3H), 1.58 + 1.67 (3H), 2.31-2.49 (3H), 2.59-2.76 (2H), 2.72 (3H), 2, 89 (1H), 3.06 (1H), 3.42 (1H), 3.47-3.58 (2H), 3.88 (2H), 4.08-4.22 (2H), 5, 11 + 5.18 (1H), 5.98 (1H), 7.33 (1H) ppm.

Beispiel 23cExample 23c (3S,6R,7S,8S,12E/Z,15S,16Z)-16-Fluor-1,3,7,15-tetrakis-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-6-(3-(trimethylsilyl)-prop-2-in-1-yl)-4,4,8,12-tetramethyl- 17-(2-methylthiazol-4-yl)-heptadeca-12,16-dien-5-on(3S, 6R, 7S, 8S, 12E / Z, 15S, 16Z) -16-fluoro-1,3,7,15-tetrakis - [[(1,1- dimethylethyl) dimethylsilyl] oxy] -6- (3- (trimethylsilyl) -prop-2-yn-1-yl) -4,4,8,12-tetramethyl- 17- (2-methylthiazol-4-yl) -heptadeca-12,16-dien-5-one

In Analogie zu Beispiel 1l setzt man 2,77 g (3,90 mmol) der nach Beispiel 23b dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 3,48 g (3,31 mmol, 85%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,00-0,15 (33H), 0,83-0,97 (39H), 1,00-1,75 (7H), 1,07 (3H), 1,27 (3H), 1,60 + 1,68 (3H), 1,88-2,03 (2H), 2,31-2,48 (2H), 2,51 (2H), 2,70 (3H), 3,29 (1H), 3,52-3,71 (2H), 3,29 (1H), 3,89 (1H), 4,19 (1H), 5,15 (1H), 6,06 (1H), 7,33 (1H) ppm.In analogy to Example 11, 2.77 g (3.90 mmol) of the compound shown in Example 23b are reacted and, after work-up and purification, 3.48 g (3.31 mmol, 85%) of the title compound is isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.00-0.15 (33H), 0.83-0.97 (39H), 1.00-1.75 (7H), 1.07 (3H) , 1.27 (3H), 1.60 + 1.68 (3H), 1.88-2.03 (2H), 2.31-2.48 (2H), 2.51 (2H), 2, 70 (3H), 3.29 (1H), 3.52-3.71 (2H), 3.29 (1H), 3.89 (1H), 4.19 (1H), 5.15 (1H) , 6.06 (1H), 7.33 (1H) ppm.

Beispiel 23dExample 23d (3S,6R,7S,8S,12E/Z,15S,16Z)-16-Fluor-1-hydroxy-3,7,15-tris-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-6-(3-(trimethylsilyl)-prop-2-in-1-yl)-4,4,8,12-tetramethyl- 17-(2-methylthiazol-4-yl)-heptadeca-12,16-dien-5-on(3S, 6R, 7S, 8S, 12E / Z, 15S, 16Z) -16-fluoro-1-hydroxy-3,7,15-tris - [[(1,1- dimethylethyl) dimethylsilyl] oxy] -6- (3- (trimethylsilyl) -prop-2-yn-1-yl) -4,4,8,12-tetramethyl- 17- (2-methylthiazol-4-yl) -heptadeca-12,16-dien-5-one

In Analogie zu Beispiel 1m setzt man 3,48 g (3,31 mmol) der nach Beispiel 23c dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 2,36 g (2,51 mmol, 76%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,00-0,18 (27H), 0,83-0,99 (30H), 1,01-1,80 (7H), 1,12 (3H), 1,27 (3H), 1,60 + 1,68 (3H), 1,86-2,07 (3H), 2,83-2,52 (3H), 2,64 (1H), 2,70 (3H), 3,26 (1H), 3,66 (2H), 3,80 (1H), 4,10 (1H), 4,20 (1H), 5,16 (1H), 6,06 (1H), 7,32 (1H) ppm.In analogy to Example 1m, 3.48 g (3.31 mmol) of the compound shown in Example 23c are reacted and, after work-up and purification, 2.36 g (2.51 mmol, 76%) of the title compound is isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.00-0.18 (27H), 0.83-0.99 (30H), 1.01-1.80 (7H), 1.12 (3H) , 1.27 (3H), 1.60 + 1.68 (3H), 1.86-2.07 (3H), 2.83-2.52 (3H), 2.64 (1H), 2, 70 (3H), 3.26 (1H), 3.66 (2H), 3.80 (1H), 4.10 (1H), 4.20 (1H), 5.16 (1H), 6.06 (1H), 7.32 (1H) ppm.

Beispiel 23eExample 23e (3S,6R,7S,8S,12E/Z,15S,16Z)-16-Fluor-5-oxo-3,7,15-tris-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-6-(3-(trimethylsilyl)-prop-2-in-1-yl)-4,4,8,12-tetramethyl- 17-(2-methylthiazol-4-yl)-heptadeca-12,16-dienal(3S, 6R, 7S, 8S, 12E / Z, 15S, 16Z) -16-fluoro-5-oxo-3,7,15-tris - [[(1,1- dimethylethyl) dimethylsilyl] oxy] -6- (3- (trimethylsilyl) -prop-2-yn-1-yl) -4,4,8,12-tetramethyl- 17- (2-methylthiazol-4-yl) -heptadeca-12,16-dienal

In Analogie zu Beispiel 1n setzt man 2,36 g (2,51 mmol) der nach Beispiel 23d dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 2,25 g (2,40 mmol, 96%) der Titelverbindung als farbloses Öl.In analogy to Example 1n, 2.36 g (2.51 mmol) of the according to Example 23d are used compound represented by and isolated after work-up and purification 2.25 g (2.40 mmol, 96%) of the title compound as a colorless oil.

Beispiel 23fExample 23f (3S,6R,7S,8S,12Z,15S,16Z)-16-Fluor-5-oxo-3,7,15-tris-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-6-(3-(trimethylsilyl)-prop-2-in-1-yl)-4,4,8,12-tetramethyl- 17-(2-methylthiazol-4-yl)-heptadeca-12,16-diensäure (A) und (3S,6R,7S,8S,12E,15S,16Z)-16-Fluor-5-oxo-3,7,15-tris-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-6-(3-(trimethylsilyl)-prop-2-in-1-yl)-4,4,8,12-tetramethyl- 17-(2-methylthiazol-4-yl)-heptadeca-12,16-diensäure (B)(3S, 6R, 7S, 8S, 12Z, 15S, 16Z) -16-fluoro-5-oxo-3,7,15-tris - [[(1,1- dimethylethyl) dimethylsilyl] oxy] -6- (3- (trimethylsilyl) -prop-2-yn-1-yl) -4,4,8,12-tetramethyl- 17- (2-methylthiazol-4-yl) -heptadeca-12,16-dienoic acid (A) and (3S, 6R, 7S, 8S, 12E, 15S, 16Z) -16-fluoro-5-oxo-3,7,15-tris - [[(1,1- dimethylethyl) dimethylsilyl] oxy] -6- (3- (trimethylsilyl) -prop-2-yn-1-yl) -4,4,8,12-tetramethyl- 17- (2-methylthiazol-4-yl) -heptadeca-12,16-dienoic acid (B)

In Analogie zu Beispiel 22q setzt man 2,25 g (2,40 mmol) der nach Beispiel 23e dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 960 mg (1,01 mmol, 42%) der Titelverbindung A sowie 937 mg (0,98 mmol, 41%) der Titelverbindung B jeweils als farbloses Öl.
1H-NMR (CDCl3) von A: δ = -0,02-0,17 (27H), 0,89 (27H), 0,94 (3H), 1,08-1,67 (6H), 1,18 (3H), 1,22 (3H), 1,70 (3H), 1,89 (1H), 2,12 (1H), 2,28-2,53 (5H), 2,61 (1H), 2,69 (3H), 3,31 (1H), 3,71 (1H), 4,20 (1H), 4,38 (1H), 5,18 (1H), 6,40 (1H), 7,36 (1H) ppm.
1H-NMR (CDCl3) von B: δ = -0,01-0,18 (27H), 0,84-0,97 (30H), 1,00-1,55 (6H), 1,20 (3H), 1,23 (3H), 1,59 (3H), 1,82-2,05 (2H), 2,25-2,60 (4H), 2,65 (1H), 2,70 (3H), 3,33 (1H), 3,76 (1H), 4,16 (1H), 4,38 (1H), 5,13 (1H), 6,12 (1H), 7,38 (1H) ppm.In analogy to Example 22q, 2.25 g (2.40 mmol) of the compound shown in Example 23e are reacted and, after work-up and purification, 960 mg (1.01 mmol, 42%) of the title compound A and 937 mg (0, 98 mmol, 41%) of the title compound B in each case as a colorless oil.
1 H-NMR (CDCl 3 ) of A: δ = -0.02-0.17 (27H), 0.89 (27H), 0.94 (3H), 1.08-1.67 (6H), 1.18 (3H), 1.22 (3H), 1.70 (3H), 1.89 (1H), 2.12 (1H), 2.28-2.53 (5H), 2.61 ( 1H), 2.69 (3H), 3.31 (1H), 3.71 (1H), 4.20 (1H), 4.38 (1H), 5.18 (1H), 6.40 (1H ), 7.36 (1H) ppm.
1 H NMR (CDCl 3 ) of B: δ = -0.01-0.18 (27H), 0.84-0.97 (30H), 1.00-1.55 (6H), 1.20 (3H), 1.23 (3H), 1.59 (3H), 1.82-2.05 (2H), 2.25-2.60 (4H), 2.65 (1H), 2.70 (3H), 3.33 (1H), 3.76 (1H), 4.16 (1H), 4.38 (1H), 5.13 (1H), 6.12 (1H), 7.38 ( 1H) ppm.

Beispiel 23gExample 23g (3S,6R,7S,8S,12Z,15S,16Z)-16-Fluor-5-oxo-3,7-bis-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-15-hydroxy-6-(prop-2-in-1-yl)-4,4,8,12-tetramethyl-17- (2-methylthiazol-4-yl)-heptadeca-12,16-diensäure(3S, 6R, 7S, 8S, 12Z, 15S, 16Z) -16-fluoro-5-oxo-3,7-bis - [[(1,1- dimethylethyl) dimethylsilyl] oxy] -15-hydroxy-6- (prop-2-yn-1-yl) -4,4,8,12-tetramethyl-17- (2-methylthiazol-4-yl) -heptadeca-12,16-dienoic acid

In Analogie zu Beispiel 1e setzt man 960 mg (1,01 mmol) der nach Beispiel 23f dargestellten Verbindung A um und isoliert nach Aufarbeitung 898 mg (max. 1,01 mmol) der Titelverbindung, die man ohne Reinigung weiter umsetzt.In analogy to Example 1e, 960 mg (1.01 mmol) of the according to Example 23f are used Compound A represented by and isolated after work-up 898 mg (max. 1.01 mmol) the title compound, which is reacted further without purification.

Beispiel 23hExample 23h (4S,7R,8S,9S,13Z,16S(Z))-4,8-Bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-16-(1-fluor-2- (2-methylthiazol-4-yl)ethenyl)-7-(prop-2-in-1-yl)-1-oxa-5,5,9,13-tetramethyl- cyclohexadec-13-en-2,6-dion(4S, 7R, 8S, 9S, 13Z, 16S (Z)) - 4,8-Bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -7- (prop-2-yn-1-yl) -1-oxa-5,5,9,13-tetramethyl- cyclohexadec-13-en-2,6-dione

In Analogie zu Beispiel 1q setzt man in mehreren Portionen insgesamt 896 mg (max. 1,01 mmol) der nach Beispiel 23g dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 480 mg (0,64 mmol, 64%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = -0,10 (3H), 0,12 (3H), 0,15 (3H), 0,19 (3H), 0,80-1,83 (6H), 0,85 (9H), 0,94 (9H), 1,01 (3H), 1,18 (3H), 1,23 (3H), 1,68 (3H), 2,08 (1H), 2,22-2,89 (7H), 2,69 (3H), 3,09 (1H), 4,00-4,12 (2H), 5,07-5,21 (2H), 6,13 (1H), 7,36 (1H) ppm. Beispiel 23 (4S,7R,8S,9S,13Z,16S(Z))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-7- (prop-2-in-1-yl)-1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dion In Analogie zu Beispiel 1 setzt man 60 mg (80 µmol) der nach Beispiel 23h dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 28 mg (54 µmol, 67%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 1,05 (3H), 1,11 (3H), 1,18-1,42 (3H), 1,38 (3H), 1,56-1,97 (3H), 1,90 (3H), 2,05 (1H), 2,28 (1H), 2,33-2,66 (6H), 2,69 (3H), 2,79 (1H), 3,30 (1H), 3,38 (1H), 3,79 (1H), 4,21 (1H), 5,12 (1H), 5,46 (1H), 6,19 (1H), 7,36 (1H) ppm. Beispiel 24a (4S,7R,8S,9S,13E,16S(Z))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4- yl)ethenyl)-7-(prop-2-2-in-1-yl)-1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6- dion Beispiel 24a (3S,6R,7S,8S,12E,15S,16Z)-16-Fluor-5-oxo-3,7-bis-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-15-hydroxy-6-(prop-2-in-1-yl)-4,4,8,12-tetramethyl-17- (2-methylthiazol-4-yl)-heptadeca-12,16-diensäure In Analogie zu Beispiel 1e setzt man 937 mg (0,98 mmol) der nach Beispiel 23f dargestellten Verbindung B um und isoliert nach Aufarbeitung 914 mg (max. 0,98 mmol) der Titelverbindung, die man ohne Reinigung weiter umsetzt. Beispiel 24b (4S,7R,8S,9S,13E,16S(Z))-4,8-Bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-16-(1-fluor-2- (2-methylthiazol-4-yl)ethenyl)-7-(prop-2-in-1-yl)-1-oxa-5,5,9,13-tetramethyl- cyclohexadec-13-en-2,6-dion In Analogie zu Beispiel 1q setzt man 914 mg (max. 0,98 mmol) der nach Beispiel 24a dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 451 mg (603 µmol, 62%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,02-0,12 (12H), 0,79-1,73 (5H), 0,89 (18H), 0,96 (3H), 1,12 (3H), 1,22 (3H), 1,58 (3H), 1,91 (1H), 2,01 (1H), 2,11 (1H), 2,39-2,80 (6H), 2,69 (3H), 3,15 (1H), 3,91 (1H), 4,33 (1H), 5,17 (1H), 5,42 (1H), 6,12 (1H), 7,36 (1H) ppm. Beispiel 24 (4S,7R,8S,9S,13E,16S(Z))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-7- (prop-2-in-1-yl)-1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dion In Analogie zu Beispiel 1 setzt man 451 mg (603 µmol) der nach Beispiel 24b dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 170 mg (327 µmol, 54%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,86 (1H), 1,00 (3H), 1,03 (3H), 1,26-2,23 (7H), 1,33 (3H), 1,60 (3H), 2,41-2,62 (6H), 2,69 (3H), 3,59 (1H), 3,79 (1H), 4,02-4,19 (2H), 4,39 (1H), 5,11 (1H), 5,54 (1H), 6,17 (1H), 7,37 (1H) ppm. Beispiel 25 (1S,3S(Z),7S,10R,11S,12S,16R,)-7,11-Dihydroxy-3-(1-fluor-2-(2-methyl-4- thiazolyl)ethenyl)-10-(prop-2-in-1-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion (A) und (1R,3S(Z),7S,10R,11S,12S,16S)- 7,11-Dihydroxy-3-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-10-(prop-2-in-1-yl)- 8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion (B) Die Lösung von 50 mg (96 µmol) der nach Beispiel 23 dargestellten Verbindung in 4,5 ml Acetonitril versetzt man bei 0°C mit 554 µl einer 0,1 M wässrigen Lösung von Ethylendiamintetraacetat, 638 µl Trifluoraceton, 260 mg Natriumhydrogencarbonat, 150 mg Oxone und rührt 1,5 Stunden bei 23°C. Man versetzt mit Natriumthiosulfatlösung, extrahiert mehrfach mit Ethylacetat, wäscht die vereinigten organischen Extrakte mit gesättigter Natriumchloridlösung, trocknet über Natriumsulfat und reinigt den Rückstand durch Chromatographie an analytischen Dünnschichtplatten. Als Laufmittel dient ein Gemisch aus Dichlormethan und Isopropanol, als Elutionsmittel ein Gemisch aus Dichlormethan und Methanol. Isoliert werden 29 mg (54 µmol, 56%) der Titelverbindung A sowie 9 mg (17 µmmol, 18%) der Titelverbindung B jeweils als farbloses Öl.
1H-NMR (CDCl3) von A: δ = 1,01 (3H), 1,08 (3H), 1,22-1,81 (7H), 1,28 (3H), 1,39 (3H), 2,01 (1H), 2,04 (1H), 2,19 (1H), 2,40-2,76 (5H), 2,69 (3H), 2,91 (1H), 3,60 (1H), 3,80 (1H), 4,19 (1H), 4,31 (1H), 5,70 (1H), 6,23 (1H), 7,38 (1H) ppm.
1H-NMR (CDCl3) von B: δ = 0,97 (3H), 1,08 (3H), 1,19-1,96 (8H), 1,25 (3H), 1,42 (3H), 1,99 (1H), 2,28 (1H), 2,42-2,62 (4H), 2,70 (3H), 2,98 (1H), 3,04 (1H), 3,49 (1H), 3,62 (1H), 4,04 (1H), 4,23 (1H), 5,80 (1H), 6,21 (1H), 7,38 (1H) ppm. Beispiel 26 (1S,3S(Z),7S,10R,11S,12S,16S)-7,11-Dihydroxy-3-(1-fluor-2-(2-methyl-4- thiazolyl)ethenyl)-10-(prop-2-in-1-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]hetpadecan-5,9-dion (A) und (1R,3S(Z),7S,10R,11S,12S,16R,)- 7,11-Dihydroxy-3-(1-fluor-2-(2-methyl-4-thiazolyl)ethenyl)-10-(prop-2-in-1-yl)- 8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion (B) und (1SR,3S(Z),7S,10R,11S,12S,16SR)-7,11-Dihydroxy-3-(1-fluor-2-(2-methyl-4-(N- oxido)-thiazolyl)ethenyl)-10-(prop-2-in-1-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion (C) In Analogie zu Beispiel 25 setzt man 80 mg (154 µmol) der nach Beispiel 24 dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 21 mg (39 µmol, 25%) der Titelverbindung A, 31 mg (58 µmol, 38%) der Titelverbindung B sowie 3 mg (6 µmol, 4%) der Titelverbindungen C jeweils als farbloses Öl.
1H-NMR (CDCl3) von A oder B: δ = 0,96 (3H), 1,08 (3H), 1,18-1,85 (7H), 1,22 (3H), 1,38 (3H), 1,99 (1H), 2,09 (1H), 2,20 (1H), 2,40 (1H), 2,51-2,72 (3H), 2,68 (3H), 2,99 (1H), 3,13 (1H), 3,53 (1H), 3,75 (1H), 3,82 (1H), 4,30 (1H), 5,66 (1H), 6,21 (1H), 7,37 (1H) ppm.
1H-NMR (CDCl3) von B oder A: δ = 0,93 (3H), 1,04 (3H), 1,11-1,81 (7H), 1,28 (3H), 1,41 (3H), 1,99 (1H), 2,06-2,23 (2H), 2,43 (1H), 2,51-2,72 (4H), 2,69 (3H), 2,87 (1H), 3,55 (1H), 3,85 (1H), 4,19 (1H), 4,31 (1H), 5,66 (1H), 6,24 (1H), 7,39 (1H) ppm.
1H-NMR von C (CDCl3): δ = 0,95 + 0,99 (3H), 1,08 + 1,10 (3H), 1,13-2,77 (14H), 1,22 + 1,26 (3H), 1,45 + 1,51 (3H), 2,59 (3H), 2,95 (1H), 3,52-3,86 (2H), 4,13 + 5,41 (1H), 4,43-4,70 (2H), 5,63 + 5,72 (1H), 6,56 + 6,59 (1H), 7,41 + 7,46 (1H) ppm. Beispiel 27 (4S,7R,8S,9S,13Z,16S(Z))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4- yl)ethenyl)-7-(prop-2-in-1-yl)-1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6- dion Beispiel 27a 4-(2-Methyloxazolyl)-carbaldehyd Die Lösung von 36,6 g (236 mmol) 4-(2-Methyloxazolyl)-carbonsäureethylester in 795 ml wasserfreiem Dichlormethan kühlt man unter einer Atmosphäre aus trockenem Argon auf -78°C, versetzt mit 378 ml einer 1,0 molaren Lösung von Diisobuthylaluminiumhydrid in n-Hexan und rührt noch 1 Stunde. Man versetzt mit 96 ml Isopropanol, 160 ml Wasser, läßt auf 23°C erwärmen und rührt noch so lange, bis sich ein feinkörniger Niederschlag gebildet hat. Nach Filtration und Lösungsmittelabzug isoliert man 24,7 g (222 mmol, 94%) der Titelverbindung als blass gelbes Öl.
1H-NMR (CDCl3): δ = 2,53 (3H), 8,17 (1H), 9,90 (1H) ppm. Beispiel 27b (2Z)-3-(2-Methyloxazol-4-yl)-2-fluor-2-propensäureethylester (A) und (2E)-3-(2- Methyloxazol-4-yl)-2-fluor-2-propensäureethylester (B) Zu 19,1 g einer 55%igen Natriumhydrid-Dispersion in 224 ml wasserfreiem Ethylenglykoldimethylether tropft man unter einer Atmosphäre aus trockenem Argon bei 0°C die Lösung von 106 g 2-Fluor-2-phosphonoessigsäuretriethylester in 224 ml Ethylenglykoldimethylether und rührt 1 Stunde nach. Anschließend versetzt man mit der Lösung von 26,4 g (238 mmol) der nach Beispiel 27a dargestellten Verbindung in 224 ml Ethylenglykoldimethylether und läßt innerhalb 1 Stunde auf 23°C erwärmen. Man gießt auf eine gesättigte Ammoniumchloridlösung, extrahiert mehrfach mit Ethylacetat, wäscht die vereinigten organischen Extrakte mit gesättigter Natriumchloidlösung und trocknet über Natriumsulfat. Den nach Filtration und Lösungsmittelabzug erhaltenen Rückstand reinigt man durch Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylacetat. Isoliert werden 24,8 g (125 mmol, 52%) der Titelverbindung A als kristalliner Feststoff sowie 12,5 g (63 mmol, 26%) der Titelverbindung B als farbloses Öl.
1H-NMR (CDCl3) von A: δ = 1,37 (3H), 2,49 (3H), 4,32 (2H), 6,91 (1H), 7,94 (1H) ppm.
1H-NMR (CDCl3) von B: δ = 1,39 (3H), 2,47 (3H), 4,36 (2H), 6,75 (1H), 8,53 (1H) ppm. Beispiel 27c (2Z)-3-(2-Methyloxazol-4-yl)-2-fluor-2-propensäureethylester Die Lösung von 24,4 g (123 mmol) der nach Beispiel 27b dargestellten Verbindung B in 130 ml wasserfreiem Toluol versetzt man mit 5,3 ml Thiophenol und rührt 2 Tage unter einer Atmosphäre aus trockenem Argon bei 23°C. Man gießt in eine 5%ige Natronlauge, extrahiert mehrfach mit Ethylacetat, wäscht die vereinigten organischen Extrakte mit Wasser, gesättigter Natriumchloridlösung und trocknet über Magnesiumsulfat. Den nach Filtration und Lösungsmittelabzug erhaltenen Rückstand reinigt man durch Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n-Hexan und Ethylacetat. Isoliert werden 19,5 g (98 mmol, 80%) der Titelverbindung als kristalliner Feststoff. Beispiel 27d (2Z)-3-(2-Methyloxazol-4-yl)-2-fluor-2-propenal Die Lösung von 26,2 g (131 mmol) der nach Beispiel 27b bzw. 3c dargestellten Verbindung A in 380 ml wasserfreiem Toluol kühlt man unter einer Atmosphäre aus trockenem Argon auf -78°C, versetzt mit 180 ml einer 1,2 M Lösung von Diisobutylaluminiumhydrid in Toluol und rührt 8 Stunden. Man versetzt mit Wasser, extrahiert mehrfach mit Ethylacetat, wäscht die vereinigten organischen Extrakte mit gesättigter Natriumchloidlösung und trocknet über Natriumsulfat. Nach Filtration und Lösungsmittelabzug isoliert man 20,1 g (128 mmol, 98%) der Titelverbindung als farbloses Öl, das man ohne Reinigung weiter umsetzt.
1H-NMR (CDCl3): δ = 2,51 (3H), 6,69 (1H), 8,07 (1H), 9,32 (1H) ppm. Beispiel 27e (3S,4Z)-5-(2-Methyloxazol-4-yl)-1-[(4S,5R)-4-methyl-5-phenyl-oxazolidin-2-on-3-yl]-3- hydroxy-4-fluor-4-penten-1-on (A) und (3R,4Z)-5-(2-Methyloxazol-4-yl)-1-[(4S,5R)-4- methyl-5-phenyl-oxazolidin-2-on-3-yl]-3-hydroxy-4-fluor-4-penten-1-on (B) Zu der Lösung von 45,8 ml Diisopropylamin in 2 l wasserfreiem Tetrahydrofuran tropft man bei -30°C unter einer Atmosphäre aus trockenem Argon 136 ml einer 2,4 molaren Lösung von n-Buthyllithium in n-Hexan, rührt 20 Minuten, kühlt auf -70°C und versetzt innerhalb von 4 Stunden mit der Lösung von 64,2 g (4S,5R)-3-Acetyl-4-methyl-5- phenyloxazolidin-2-on in 1 l Tetrahydrofuran. Nach 1 Stunde tropft man innerhalb von 2 Stunden die Lösung von 15,1 g (97,6 mmol) der nach Beispiel 27d dargestellten Verbindung in 650 ml Tetrahydrofuran zu und rührt 16 Stunden bei -70°C. Man gießt auf eine gesättigte Ammoniumchloridlösung, extrahiert mehrfach mit Ethylacetat, wäscht die vereinigten organischen Extrakte mit gesättigter Natriumchloidlösung und trocknet über Natriumsulfat. Den nach Filtration und Lösungsmittelabzug erhaltenen Rückstand trennt man durch wiederholte Chromatographie an feinem Kieselgel mit einem Gradientensystem aus n-Hexan, Ethylacetat und Ethanol. Isoliert werden 19,9 g (53 mmol, 54%) der Titelverbindung A als kristallinen Feststoff sowie 8,2 g (22 mmol, 22%) der Titelverbindung B als farbloser Schaum.
1H-NMR (CDCl3) von A: δ = 0,92 (3H) 2,47 (3H), 3,33 (1H), 3,50 (1H), 3,70 (1H), 4,73-­ 4,88 (2H), 5,71 (1H), 5,97 (1H), 7,26-7,48 (5H), 7,75 (1H) ppm.
1H-NMR (CDCl3) von B: δ = 0,93 (3H), 2,48 (3H), 3,40 (2H), 4,73-4,90 (2H), 5,70 (1H), 5,98 (1H), 7,24-7,49 (5H), 7,76 (1H) ppm. Beispiel 27f (3S,4Z)-5-(2-Methyloxazol-4-yl)-1-[(4S,5R)-4-methyl-5-phenyl-oxazolidin-2-on-3-yl]-3- [[dimethyl(1,1-dimethylethyl)silyl]oxy]-4-fluor-4-penten-1-on In Analogie zu Beispiel 1l setzt man 16,2 g (43,5 mmol) der nach Beispiel 27e dargestellten Verbindung A um und isoliert nach Aufarbeitung und Reinigung 15,9 g (32,5 mmol, 75%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,11 (6H), 0,88 (9H), 0,90 (3H), 2,46 (3H), 3,24 (1H), 3,52 (1H), 4,77 (1H), 4,89 (1H), 5,66 (1H), 5,83 (1H), 7,23-7,48 (5H), 7,74 (1H) ppm. Beispiel 27g (3S,4Z)-5-(2-Methyloxazol-4-yl)-3-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-4-fluor-4- pentensäureethylester In Analogie zu Beispiel 22e setzt man 15,6 g (32,6 mmol) der nach Beispiel 27f dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 11,4 g (32 mmol, 98%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,08 (6H), 0,88 (9H), 1,26 (3H), 2,43 (3H), 2,67 (2H), 4,13 (2H), 4,71 (1H), 5,80 (1H), 7,72 (1H) ppm. Beispiel 27h (3S,4Z)-5-(2-Methyloxazol-4-yl)-3-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-4-fluor-4- penten-1-ol In Analogie zu Beispiel 22f setzt man 11,4 g (31,9 mmol) der nach Beispiel 27g dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 9,16 g (29 mmol, 91%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,07 (3H), 0,10 (3H), 0,90 (9H), 1,94 (2H), 2,08 (1H), 2,43 (3H), 3,73 (1H), 3,80 (1H), 4,49 (1H), 5,80 (1H), 7,71 (1H) ppm. Beispiel 27i (3S,4Z)-5-(2-Methyloxazol-4-yl)-3-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-1-iod-4-fluor-4- penten In Analogie zu Beispiel 22g setzt man 7,16 g (22,7 mmol) der nach Beispiel 27h dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 8,06 g (18,9 mmol, 83%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,09 (3H), 0,15 (3H), 0,91 (9H), 2,20 (2H), 2,46 (3H), 3,23 (2H), 4,33 (1H), 5,80 (1H), 7,73 (1H) ppm. Beispiel 27j (3S,4Z)-5-(2-Methyloxazol-4-yl)-3-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-4-fluor-4- penten-1-triphenylphosphoniumiodid In Analogie zu Beispiel 22h setzt man 8,06 g (18,9 mmol) der nach Beispiel 27i dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 10,7 g (15,6 mmol, 82%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,10 (3H), 0,18 (3H), 0,87 (9H), 1,97 (1H), 2,10 (1H), 2,42 (3H), 3,48 (1H), 3,97 (1H), 4,86 (1H), 5,93 (1H), 7,63-7,88 (16H) ppm. Beispiel 27k (2S,6E/Z,9S,10Z)-9-[[Dimethyl(1,1-dimethylethyl)silyl]oxy]-10-fluor-11-(2-methyloxazol- 4-yl)-1-(tetrahydropyran-2-yloxy)-2,6-dimethyl-undeca-6,10-dien In Analogie zu Beispiel 22i setzt man 3,20 g (14,0 mmol) der nach Beispiel 27j dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 3,53 g (6,9 mmol, 49%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,08 (6H), 0,84-0,97 (12H), 1,09 (1H), 1,22-2,04 (12H), 1,59 + 1,68 (3H), 2,30-2,49 (2H), 2,44 (3H), 3,06-3,27 (1H), 3,42-3,62 (2H), 3,86 (1H), 4,19 (1H), 4,55 (1H), 5,12 (1H), 5,73 (1H), 7,71 (1H) ppm. Beispiel 27l (2S,6E/Z,9S,10Z)-9-[[Dimethyl(1,1-dimethylethyl)silyl]oxy]-10-fluor-11-(2-methyloxazol- 4-yl)-1-hydroxy-2,6-dimethyl-undeca-6,10-dien In Analogie zu Beispiel 1k setzt man 3,48 g (6,83 mmol) der nach Beispiel 27k dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 2,28 g (5,36 mmol, 78%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,08 (6H), 0,83-0,94 (12H), 1,03 (1H), 1,21-1,70 (5H), 1,58 + 1,68 (3H), 1,91-2,05 (2H), 2,27-2,50 (2H), 2,44 (3H), 3,37-3,52 (2H), 4,19 (1H), 5,12 (1H), 5,72 (1H), 7,72 (1H) ppm. Beispiel 27m (2S,6E/Z,9S,10Z)-9-[[Dimethyl(1,1-dimethylethyl)silyl]oxy]-10-fluor-11-(2-methyloxazol- 4-yl)-2,6-dimethyl-undeca-6,10-dienal In Analogie zu Beispiel 1n setzt man 2,28 g (5,36 mmol) der nach Beispiel 27l dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 2,27g (5,36 mmol, 100%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,06 (6H), 0,90 (9H), 1,03 + 1,08 (3H), 1,21-1,46 (4H), 1,57 + 1,66 (3H), 2,00 (2H), 2,21-2,42 (3H), 2,45 (3H), 4,19 (1H), 5,14 (1H), 5,73 (1H), 7,71 (1H), 9,59 (1H) ppm. Beispiel 27n (4S(4R,5S,6S,10E/Z,13S,14Z))-4-(13-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-4-(prop-2- in-1-yl)-14-fluor-15-(2-methyloxazol-4-yl)-3-oxo-5-hydroxy-2,6,10-trimethyl-pentadeca- 10,14-dien-2-yl)-2,2-dimethyl-[1,3]dioxan (A) und (4S(4S,5R,6S,10E/Z,13S,14Z))-4-(13- [[(1,1-Dimethylethyl)dimethylsilyl]oxy]-4-(prop-2-in-1-yl)-14-fluor-15-(2-methyloxazol-4- yl)-3-oxo-5-hydroxy-2,6,10-trimethyl-pentadeca-10,14-dien-2-yl)-2,2-dimethyl- [1,3]dioxan (B) In Analogie zu Beispiel 1c setzt man 1,87 g (4,41 mmol) der nach Beispiel 27m dargestellten Verbindung mit (4S)-4-(2-Methyl-3-oxo-7-trimethylsilyl-hept-6-in-2-yl)-2,2- dimethyl-[1,3]dioxan, das man nach dem in DE 197 51 200.3 beschriebenen Verfahren hergestellt hat, um und isoliert nach Aufarbeitung und Reinigung neben Ausgangsmaterial 1,37 g (1,87 mmol, 42%) der Titelverbindung A sowie 190 mg (0,26 mmol, 6%) der Titelverbindung B jeweils als farbloses Öl.
1H-NMR (CDCl3) von A: δ = 0,02-0,16 (15H), 0,81-0,93 (12H), 0,97-1,78 (13H), 1,06 (3H), 1,39 (3H), 1,58 + 1,67 (3H), 1,91-2,08 (2H), 2,30-2,48 (3H), 2,44 (3H), 2,55 (1H), 3,03 (1H), 3,45 (1H), 3,52 (1H), 3,88 (1H), 3,99 (1H), 4,08-4,23 (2H), 5,12 (1H), 5,72 (1H), 7,72 (1H) ppm.
1H-NMR (CDCl3) von B: δ = 0,01-0,12 (15H), 0,82-1,73 (18H), 0,89 (9H), 1,17 (3H), 1,40 (3H), 1,58 + 1,67 (3H), 1,88-2,05 (2H), 2,28-2,57 (3H), 2,42 (3H), 3,41 (1H), 3,59 (1H), 3,79-4,05 (3H), 4,18 (1H), 5,11 (1H), 5,72 (1H), 7,70 (1H) ppm. Beispiel 27o (3S,6R,7S,8S,12E/Z,15S,16Z)-15-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-6-(3- (trimethylsilyl)-prop-2-in-1-yl)-16-fluor-1,3,7-trihydroxy-4,4,8,12-tetramethyl-17-(2- methyloxazol-4-yl)-heptadeca-12,16-dien-5-on In Analogie zu Beispiel 1k setzt man 2,16 g (2,94 mmol) der nach Beispiel 27n dargestellten Verbindung A um und isoliert nach Aufarbeitung und Reinigung 1,47 g (2,12 mmol, 72%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,03 (6H), 0,15 (9H), 0,85-0,95 (12H), 0,98-1,80 (7H), 1,15 (3H), 1,27 (3H), 1,57 + 1,66 (3H), 1,90-1,08 (2H), 2,30-2,45 (3H), 2,49 + 2,51 (3H), 2,58-2,72 (2H), 2,90 + 3,03 (1H), 3,37-3,72 (3H), 3,88 (2H), 4,07-4,22 (2H), 5,11 (1H), 5,63 + 5,70 (1H), 7,71 (1H) ppm. Beispiel 27p (3S,6R,7S,8S,12E/Z,15S,16Z)-16-Fluor-1,3,7,15-tetrakis-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-6-(3-(trimethylsilyl)-prop-2-in-1-yl)-4,4,8,12-tetramethyl- 17-(2-methyloxazol-4-yl)-heptadeca-12,16-dien-5-on In Analogie zu Beispiel 1l setzt man 1,47 g (2,12 mmol) der nach Beispiel 27o dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 2,13 g (2,05 mmol, 97%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,00-0,15 (33H), 0,83-0,98 (39H), 1,00-1,72 (7H), 1,07 (3H), 1,26 (3H), 1,59 + 1,67 (3H), 1,94 (2H), 2,27-2,43 (2H), 2,43 (3H), 2,51 (2H), 3,28 (1H), 3,52-­ 3,71 (2H), 3,78 (1H), 3,88 (1H), 4,18 (1H), 5,12 (1H), 5,73 (1H), 7,71 (1H) ppm. Beispiel 27q (3S,6R,7S,8S,12E/Z,15S,16Z)-16-Fluor-1-hydroxy-3,7,15-tris-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-6-(3-(trimethylsilyl)-prop-2-in-1-yl)-4,4,8,12-tetramethyl- 17-(2-methyloxazol-4-yl)-heptadeca-12,16-dien-5-on In Analogie zu Beispiel 1m setzt man 2,13 g (2,05 mmol) der nach Beispiel 27p dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 1,47 g (1,60 mmol, 78%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,00-0,15 (27H), 0,83-0,98 (30H), 1,02-1,77 (7H), 1,10 (3H), 1,27 (3H), 1,59 + 1,68 (3H), 1,89-2,07 (3H), 2,30-2,52 (3H), 2,45 (3H), 1,68 (1H), 3,27 (1H), 3,60-3,71 (2H), 3,79 (1H), 4,05-4,23 (2H), 5,13 (1H), 5,73 (1H), 7,70 (1H) ppm. Beispiel 27r (3S,6R,7S,8S,12E/Z,15S,16Z)-16-Fluor-5-oxo-3,7,15-tris-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-6-(3-(trimethylsilyl)-prop-2-in-1-yl)-4,4,8,12-tetramethyl- 17-(2-methyloxazol-4-yl)-heptadeca-12,16-dienal In Analogie zu Beispiel 1n setzt man 1,47 g (1,60 mmol) der nach Beispiel 27q dargestellten Verbindung um und isoliert nach Aufarbeitung 1,62 g (max. 1,60 mmol) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3) einer aufgereinigten Probe: δ = -0,01-0,11 (27H), 0,83-0,98 (30H), 1,00-1,56 (5H), 1,11 (3H), 1,28 (3H), 1,59 + 1,68 (3H), 1,88-2,02 (2H), 2,29-2,50 (4H), 2,43 (3H), 2,58-2,71 (2H), 3,26 (1H), 3,78 (1H), 4,18 (1H), 4,50 (1H), 5,12 (1H), 5,73 (1H), 7,71 (1H), 9,77 (1H) ppm. Beispiel 27s (3S,6R,7S,8S,12Z,15S,16Z)-16-Fluor-5-oxo-3,7,15-tris-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-6-(3-(trimethylsilyl)-prop-2-in-1-yl)-4,4,8,12-tetramethyl- 17-(2-methyloxazol-4-yl)-heptadeca-12,16-diensäure (A) und (3S,6R,7S,8S,12E,15S,16Z)-16-Fluor-5-oxo-3,7,15-tris-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-6-(3-(trimethylsilyl)-prop-2-in-1-yl)-4,4,8,12-tetramethyl- 17-(2-methyloxazol-4-yl)-heptadeca-12,16-diensäure (B) In Analogie zu Beispiel 22q setzt man 1,60 g (max. 1,60 mmol) der nach Beispiel 27r dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 601 mg (642 µmol, 40%) der Titelverbindung A sowie 500 mg (534 µmol, 33%) der Titelverbindung B jeweils als farbloses Öl.
1H-NMR (CDCl3) von A: δ = -0,04-0,19 (27H), 0,89 (27H), 0,96 (3H), 1,05-2,53 (13H), 1,19 (3H), 1,26 (3H), 1,69 (3H), 2,46 (3H), 2,63 (1H), 3,32 (1H), 3,71 (1H), 4,16 (1H), 4,39 (1H), 5,18 (1H), 6,08 (1H), 7,73 (1H) ppm.
1H-NMR (CDCl3) von B: δ = -0,02-0,18 (27H), 0,90 (30H), 0,99-2,67 (14H), 1,21 (6H), 1,58 (3H), 2,46 (3H), 3,32 (1H), 3,74 (1H), 4,13 (1H), 4,36 (1H), 5,10 (1H), 5,79 (1H), 7,72 (1H) ppm. Beispiel 27t (3S,6R,7S,8S,12Z,15S,16Z)-16-Fluor-5-oxo-3,7-bis-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-15-hydroxy-6-(prop-2-in-1-yl)-4,4,8,12-tetramethyl-17- (2-methyloxazol-4-yl)-heptadeca-12,16-diensäure In Analogie zu Beispiel 1e setzt man 601 mg (642 µmmol) der nach Beispiel 27s dargestellten Verbindung A um und isoliert nach Aufarbeitung 657 mg (max. 642 µmol) der Titelverbindung als als Rohprodukt, das man ohne Reinigung weiter umsetzt. Beispiel 27u (4S,7R,8S,9S,13Z,16S(Z))-4,8-Bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-16-(1-fluor-2- (2-methyloxazol-4-yl)ethenyl)-7-(prop-2-in-1-yl)-1-oxa-5,5,9,13-tetramethyl- cyclohexadec-13-en-2,6-dion In Analogie zu Beispiel 1q setzt man 657 mg (max. 642 µmol) der nach Beispiel 27u dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 91 mg (124 µmol, 19%) der Titelverbindung als farbloses Öl. Beispiel 27 (4S,7R,8S,9S,13Z,16S(Z))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)-7- (prop-2-in-1-yl)-1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dion In Analogie zu Beispiel 1 setzt man 91 mg (124 µmmol) der nach Beispiel 27u dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 45 mg (89 µmol, 73%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 1,05 (3H), 1,10 (3H), 1,20-1,42 (4H), 1,37 (3H), 1,58-1,94 (2H), 1,69 (3H), 2,04 (1H), 2,20-2,84 (8H), 2,45 (3H), 3,20 (1H), 3,38 (1H), 3,78 (1H), 4,20 (1H), 5,11 (1H), 5,43 (1H), 5,90 (1H), 7,73 (1H) ppm. Beispiel 28 (4S,7R,8S,9S,13E,16S(Z))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4- yl)ethenyl)-7-(prop-2-in-1-yl)-1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6- dion Beispiel 28a (3S,6R,7S,8S,12E,15S,16Z)-16-Fluor-5-oxo-3,7-bis-[[(1,1- dimethylethyl)dimethylsilyl]oxy]-15-hydroxy-6-(prop-2-in-1-yl)-4,4,8,12-tetramethyl-17- (2-methyloxazol-4-yl)-heptadeca-12,16-diensäure In Analogie zu Beispiel 1e setzt man 500 mg (534 µmmol) der nach Beispiel 27f dargestellten Verbindung B um und isoliert nach Aufarbeitung 517 mg (max. 534 µmol) der Titelverbindung als als Rohprodukt, das man ohne Reinigung weiter umsetzt. Beispiel 28b (4S,7R,8S,9S,13E,16S(Z))-4,8-Bis-[[dimethyl(1,1-dimethylethyl)silyl]oxy]-16-(1-fluor-2- (2-methyloxazol-4-yl)ethenyl)-7-(prop-2-in-1-yl)-1-oxa-5,5,9,13-tetramethyl- cyclohexadec-13-en-2,6-dion In Analogie zu Beispiel 1q setzt man 517 mg (534 µmmol) der nach Beispiel 28a dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 128 mg (175 µmol, 33%) der Titelverbindung als farbloses Öl. Beispiel 28 (4S,7R,8S,9S,13E,16S(Z))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4- yl)ethenyl)-7-(prop-2-in-1-yl)-1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6- dion In Analogie zu Beispiel 1 setzt man 128 mg (175 µmmol) der nach Beispiel 28b dargestellten Verbindung um und isoliert nach Aufarbeitung und Reinigung 54 mg (107 mmol, 61%) der Titelverbindung als farbloses Öl.
1H-NMR (CDCl3): δ = 0,89 (1H), 0,98 (3H), 1,02 (3H), 1,20-2,23 (7H), 1,33 (3H), 1,59 (3H), 2,40-2,61 (6H), 2,42 (3H), 3,57 (1H), 3,77 (1H), 3,82 (1H), 3,87 (1H), 4,33 (1H), 5,08 (1H), 5,53 (1H), 5,87 (1H), 7,72 (1H) ppm.In analogy to Example 1q, a total of 896 mg (max. 1.01 mmol) of the compound shown in Example 23g are reacted in several portions and, after work-up and purification, 480 mg (0.64 mmol, 64%) of the title compound are isolated as a colorless oil .
1 H-NMR (CDCl 3 ): δ = -0.10 (3H), 0.12 (3H), 0.15 (3H), 0.19 (3H), 0.80-1.83 (6H), 0.85 (9H), 0.94 (9H), 1.01 (3H), 1.18 (3H), 1.23 (3H), 1.68 (3H), 2.08 (1H), 2 , 22-2.89 (7H), 2.69 (3H), 3.09 (1H), 4.00-4.12 (2H), 5.07-5.21 (2H), 6.13 ( 1H), 7.36 (1H) ppm. Example 23 (4S, 7R, 8S, 9S, 13Z, 16S (Z)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -7- (prop -2-yn-1-yl) -1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dione. In analogy to Example 1, 60 mg (80 μmol) are added Compound prepared in Example 23h and isolated after work-up and purification 28 mg (54 μmol, 67%) of the title compound as a colorless oil.
1 H NMR (CDCl 3 ): δ = 1.05 (3H), 1.11 (3H), 1.18-1.42 (3H), 1.38 (3H), 1.56-1.97 (3H), 1.90 (3H), 2.05 (1H), 2.28 (1H), 2.33-2.66 (6H), 2.69 (3H), 2.79 (1H), 3.30 (1H), 3.38 (1H), 3.79 (1H), 4.21 (1H), 5.12 (1H), 5.46 (1H), 6.19 (1H), 7 , 36 (1H) ppm. Example 24a (4S, 7R, 8S, 9S, 13E, 16S (Z)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -7- (prop -2-2-yn-1-yl) -1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dione Example 24a (3S, 6R, 7S, 8S, 12E, 15S, 16Z) -16-fluoro-5-oxo-3,7-bis - [[(1,1-dimethylethyl) dimethylsilyl] oxy] -15-hydroxy-6- (prop-2-yn-1-yl) -4,4,8,12-tetramethyl-17- (2-methylthiazol-4-yl) -heptadeca-12,16-dienoic acid In analogy to Example 1e, 937 mg (0.98 mmol) of that shown in Example 23f are used Compound B and, after work-up, isolate 914 mg (max. 0.98 mmol) of the title compound, which is reacted further without purification. Example 24b (4S, 7R, 8S, 9S, 13E, 16S (Z)) - 4,8-Bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -16- (1-fluoro-2- ( 2-methylthiazol-4-yl) ethenyl) -7- (prop-2-yn-1-yl) -1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dione In analogy to Example 1q, 914 mg (max. 0.98 mmol) of the compound shown in Example 24a are reacted and, after working up and purification, 451 mg (603 μmol, 62%) of the title compound are isolated as a colorless oil.
1 H NMR (CDCl 3 ): δ = 0.02-0.12 (12H), 0.79-1.73 (5H), 0.89 (18H), 0.96 (3H), 1.12 (3H), 1.22 (3H), 1.58 (3H), 1.91 (1H), 2.01 (1H), 2.11 (1H), 2.39-2.80 (6H), 2.69 (3H), 3.15 (1H), 3.91 (1H), 4.33 (1H), 5.17 (1H), 5.42 (1H), 6.12 (1H), 7 , 36 (1H) ppm. Example 24 (4S, 7R, 8S, 9S, 13E, 16S (Z)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -7- (prop -2-yn-1-yl) -1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dione. In analogy to Example 1, 451 mg (603 μmol) are added Compound presented in Example 24b and isolated after work-up and purification 170 mg (327 μmol, 54%) of the title compound as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.86 (1H), 1.00 (3H), 1.03 (3H), 1.26-2.23 (7H), 1.33 (3H), 1.60 (3H), 2.41-2.62 (6H), 2.69 (3H), 3.59 (1H), 3.79 (1H), 4.02-4.19 (2H), 4.39 (1H), 5.11 (1H), 5.54 (1H), 6.17 (1H), 7.37 (1H) ppm. Example 25 (1S, 3S (Z), 7S, 10R, 11S, 12S, 16R,) - 7,11-Dihydroxy-3- (1-fluoro-2- (2-methyl-4-thiazolyl) ethenyl) -10 - (prop-2-yn-1-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione (A) and (1R, 3S (Z ), 7S, 10R, 11S, 12S, 16S) - 7,11-dihydroxy-3- (1-fluoro-2- (2-methyl-4-thiazolyl) ethenyl) -10- (prop-2-yn-1 -yl) - 8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione (B) The solution of 50 mg (96 μmol) of the compound shown in Example 23 in 554 μl of a 0.1 M aqueous solution of ethylenediaminetetraacetate, 638 μl of trifluoroacetone, 260 mg of sodium hydrogen carbonate, 150 mg of Oxone are added to 4.5 ml of acetonitrile at 0 ° C. and the mixture is stirred at 23 ° C. for 1.5 hours. Sodium thiosulphate solution is added, the mixture is extracted several times with ethyl acetate, the combined organic extracts are washed with saturated sodium chloride solution, dried over sodium sulphate and the residue is purified by chromatography on analytical thin-layer plates. A mixture of dichloromethane and isopropanol is used as the mobile phase, and a mixture of dichloromethane and methanol is used as the eluent. 29 mg (54 μmol, 56%) of the title compound A and 9 mg (17 μmol, 18%) of the title compound B are isolated in each case as a colorless oil.
1 H NMR (CDCl 3 ) of A: δ = 1.01 (3H), 1.08 (3H), 1.22-1.81 (7H), 1.28 (3H), 1.39 (3H ), 2.01 (1H), 2.04 (1H), 2.19 (1H), 2.40-2.76 (5H), 2.69 (3H), 2.91 (1H), 3, 60 (1H), 3.80 (1H), 4.19 (1H), 4.31 (1H), 5.70 (1H), 6.23 (1H), 7.38 (1H) ppm.
1 H NMR (CDCl 3 ) of B: δ = 0.97 (3H), 1.08 (3H), 1.19-1.96 (8H), 1.25 (3H), 1.42 (3H ), 1.99 (1H), 2.28 (1H), 2.42-2.62 (4H), 2.70 (3H), 2.98 (1H), 3.04 (1H), 3, 49 (1H), 3.62 (1H), 4.04 (1H), 4.23 (1H), 5.80 (1H), 6.21 (1H), 7.38 (1H) ppm. Example 26 (1S, 3S (Z), 7S, 10R, 11S, 12S, 16S) -7,11-Dihydroxy-3- (1-fluoro-2- (2-methyl-4-thiazolyl) ethenyl) -10- (prop-2-yn-1-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] hetpadecane-5,9-dione (A) and (1R, 3S (Z) , 7S, 10R, 11S, 12S, 16R,) - 7,11-dihydroxy-3- (1-fluoro-2- (2-methyl-4-thiazolyl) ethenyl) -10- (prop-2-yn-1 -yl) - 8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione (B) and (1SR, 3S (Z), 7S, 10R, 11S, 12S , 16SR) -7,11-dihydroxy-3- (1-fluoro-2- (2-methyl-4- (N-oxido) -thiazolyl) ethenyl) -10- (prop-2-yn-1-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione (C) In analogy to Example 25, 80 mg (154 μmol) of the compound shown in Example 24 are added around and isolated after work-up and purification 21 mg (39 μmol, 25%) of the title compound A, 31 mg (58 μmol, 38%) of the title compound B and 3 mg (6 μmol, 4%) of the title compound C in each case as a colorless oil.
1 H NMR (CDCl 3 ) of A or B: δ = 0.96 (3H), 1.08 (3H), 1.18-1.85 (7H), 1.22 (3H), 1.38 (3H), 1.99 (1H), 2.09 (1H), 2.20 (1H), 2.40 (1H), 2.51-2.72 (3H), 2.68 (3H), 2.99 (1H), 3.13 (1H), 3.53 (1H), 3.75 (1H), 3.82 (1H), 4.30 (1H), 5.66 (1H), 6 , 21 (1H), 7.37 (1H) ppm.
1 H NMR (CDCl 3 ) of B or A: δ = 0.93 (3H), 1.04 (3H), 1.11-1.81 (7H), 1.28 (3H), 1.41 (3H), 1.99 (1H), 2.06-2.23 (2H), 2.43 (1H), 2.51-2.72 (4H), 2.69 (3H), 2.87 (1H), 3.55 (1H), 3.85 (1H), 4.19 (1H), 4.31 (1H), 5.66 (1H), 6.24 (1H), 7.39 ( 1H) ppm.
1 H-NMR of C (CDCl 3 ): δ = 0.95 + 0.99 (3H), 1.08 + 1.10 (3H), 1.13-2.77 (14H), 1.22 + 1.26 (3H), 1.45 + 1.51 (3H), 2.59 (3H), 2.95 (1H), 3.52-3.86 (2H), 4.13 + 5.41 (1H), 4.43-4.70 (2H), 5.63 + 5.72 (1H), 6.56 + 6.59 (1H), 7.41 + 7.46 (1H) ppm. Example 27 (4S, 7R, 8S, 9S, 13Z, 16S (Z)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) -7- (prop -2-yn-1-yl) -1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dione Example 27a 4- (2-Methyloxazolyl) -carbaldehyde The solution of 36 , 6 g (236 mmol) of ethyl 4- (2-methyloxazolyl) carboxylate in 795 ml of anhydrous dichloromethane are cooled to -78 ° C. under an atmosphere of dry argon, 378 ml of a 1.0 molar solution of diisobutylaluminum hydride in n- Hexane and stir for 1 hour. 96 ml of isopropanol and 160 ml of water are added, the mixture is allowed to warm to 23 ° C. and stirred until a fine-grain precipitate has formed. After filtration and removal of the solvent, 24.7 g (222 mmol, 94%) of the title compound are isolated as a pale yellow oil.
1 H-NMR (CDCl 3 ): δ = 2.53 (3H), 8.17 (1H), 9.90 (1H) ppm. Example 27b (2Z) -3- (2-methyloxazol-4-yl) -2-fluoro-2-propenoic acid ethyl ester (A) and (2E) -3- (2-methyloxazol-4-yl) -2-fluoro-2 ethyl propenoate (B) The solution of 106 g of 2-fluoro-2-phosphonoacetic acid triethyl ester in 224 ml of ethylene glycol dimethyl ether is added dropwise under an atmosphere of dry argon at 0 ° C. to 19.1 g of a 55% strength sodium hydride dispersion in 224 ml of anhydrous ethylene glycol dimethyl ether and stirs for 1 hour. Then a solution of 26.4 g (238 mmol) of the compound shown in Example 27a in 224 ml of ethylene glycol dimethyl ether is added and the mixture is allowed to warm to 23 ° C. over the course of 1 hour. It is poured onto a saturated ammonium chloride solution, extracted several times with ethyl acetate, the combined organic extracts are washed with saturated sodium chloride solution and dried over sodium sulfate. The residue obtained after filtration and removal of the solvent is purified by chromatography on fine silica gel with a gradient system of n-hexane and ethyl acetate. 24.8 g (125 mmol, 52%) of the title compound A are isolated as a crystalline solid and 12.5 g (63 mmol, 26%) of the title compound B as a colorless oil.
1 H NMR (CDCl 3 ) of A: δ = 1.37 (3H), 2.49 (3H), 4.32 (2H), 6.91 (1H), 7.94 (1H) ppm.
1 H NMR (CDCl 3 ) of B: δ = 1.39 (3H), 2.47 (3H), 4.36 (2H), 6.75 (1H), 8.53 (1H) ppm. Example 27c (2Z) -3- (2-methyloxazol-4-yl) -2-fluoro-2-propenoic acid ethyl ester The solution of 24.4 g (123 mmol) of the compound B prepared according to Example 27b in 130 ml of anhydrous toluene is added with 5.3 ml of thiophenol and stirred for 2 days under an atmosphere of dry argon at 23 ° C. It is poured into a 5% sodium hydroxide solution, extracted several times with ethyl acetate, the combined organic extracts are washed with water, saturated sodium chloride solution and dried over magnesium sulfate. The residue obtained after filtration and removal of the solvent is purified by chromatography on fine silica gel with a gradient system of n-hexane and ethyl acetate. 19.5 g (98 mmol, 80%) of the title compound are isolated as a crystalline solid. Example 27d (2Z) -3- (2-methyloxazol-4-yl) -2-fluoro-2-propenal The solution of 26.2 g (131 mmol) of the compound A prepared according to Example 27b or 3c in 380 ml of anhydrous Toluene is cooled to -78 ° C. under an atmosphere of dry argon, mixed with 180 ml of a 1.2 M solution of diisobutylaluminum hydride in toluene and stirred for 8 hours. It is mixed with water, extracted several times with ethyl acetate, the combined organic extracts are washed with saturated sodium chloride solution and dried over sodium sulfate. After filtration and removal of the solvent, 20.1 g (128 mmol, 98%) of the title compound are isolated as a colorless oil, which is reacted further without purification.
1 H-NMR (CDCl 3 ): δ = 2.51 (3H), 6.69 (1H), 8.07 (1H), 9.32 (1H) ppm. Example 27e (3S, 4Z) -5- (2-methyloxazol-4-yl) -1 - [(4S, 5R) -4-methyl-5-phenyl-oxazolidin-2-on-3-yl] -3- hydroxy-4-fluoro-4-penten-1-one (A) and (3R, 4Z) -5- (2-methyloxazol-4-yl) -1 - [(4S, 5R) -4-methyl-5- phenyl-oxazolidin-2-on-3-yl] -3-hydroxy-4-fluoro-4-penten-1-one (B) is added dropwise at -30 to the solution of 45.8 ml of diisopropylamine in 2 l of anhydrous tetrahydrofuran ° C under an atmosphere of dry argon 136 ml of a 2.4 molar solution of n-butyllithium in n-hexane, stirred for 20 minutes, cooled to -70 ° C and added within 4 hours with the solution of 64.2 g ( 4S, 5R) -3-acetyl-4-methyl-5-phenyloxazolidin-2-one in 1 l of tetrahydrofuran. After 1 hour, the solution of 15.1 g (97.6 mmol) of the compound shown in Example 27d in 650 ml of tetrahydrofuran is added dropwise over the course of 2 hours, and the mixture is stirred at -70 ° C. for 16 hours. It is poured onto a saturated ammonium chloride solution, extracted several times with ethyl acetate, the combined organic extracts are washed with saturated sodium chloride solution and dried over sodium sulfate. The residue obtained after filtration and removal of the solvent is separated by repeated chromatography on fine silica gel with a gradient system of n-hexane, ethyl acetate and ethanol. 19.9 g (53 mmol, 54%) of the title compound A are isolated as a crystalline solid and 8.2 g (22 mmol, 22%) of the title compound B as a colorless foam.
1 H NMR (CDCl 3 ) of A: δ = 0.92 (3H) 2.47 (3H), 3.33 (1H), 3.50 (1H), 3.70 (1H), 4.73 - 4.88 (2H), 5.71 (1H), 5.97 (1H), 7.26-7.48 (5H), 7.75 (1H) ppm.
1 H NMR (CDCl 3 ) of B: δ = 0.93 (3H), 2.48 (3H), 3.40 (2H), 4.73-4.90 (2H), 5.70 (1H ), 5.98 (1H), 7.24-7.49 (5H), 7.76 (1H) ppm. Example 27f (3S, 4Z) -5- (2-methyloxazol-4-yl) -1 - [(4S, 5R) -4-methyl-5-phenyl-oxazolidin-2-one-3-yl] -3- [[dimethyl (1,1-dimethylethyl) silyl] oxy] -4-fluoro-4-penten-1-one In analogy to Example 11, 16.2 g (43.5 mmol) of the compound A shown in Example 27e are used around and isolated after work-up and purification 15.9 g (32.5 mmol, 75%) of the title compound as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.11 (6H), 0.88 (9H), 0.90 (3H), 2.46 (3H), 3.24 (1H), 3.52 ( 1H), 4.77 (1H), 4.89 (1H), 5.66 (1H), 5.83 (1H), 7.23-7.48 (5H), 7.74 (1H) ppm. Example 27g (3S, 4Z) -5- (2-methyloxazol-4-yl) -3 - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -4-fluoro-4-pentenoic acid ethyl ester In analogy to Example 22e, set 15.6 g (32.6 mmol) of the compound shown in Example 27f are converted and, after work-up and purification, 11.4 g (32 mmol, 98%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.08 (6H), 0.88 (9H), 1.26 (3H), 2.43 (3H), 2.67 (2H), 4.13 ( 2H), 4.71 (1H), 5.80 (1H), 7.72 (1H) ppm. Example 27h (3S, 4Z) -5- (2-methyloxazol-4-yl) -3 - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -4-fluoro-4-penten-1-ol By analogy to Example 22f, 11.4 g (31.9 mmol) of the compound shown in Example 27g are reacted and, after work-up and purification, 9.16 g (29 mmol, 91%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.07 (3H), 0.10 (3H), 0.90 (9H), 1.94 (2H), 2.08 (1H), 2.43 ( 3H), 3.73 (1H), 3.80 (1H), 4.49 (1H), 5.80 (1H), 7.71 (1H) ppm. Example 27i (3S, 4Z) -5- (2-methyloxazol-4-yl) -3 - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -1-iodo-4-fluoro-4-pentene By analogy to Example 22g, 7.16 g (22.7 mmol) of the compound shown in Example 27h are reacted and, after working up and purification, 8.06 g (18.9 mmol, 83%) of the title compound is isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.09 (3H), 0.15 (3H), 0.91 (9H), 2.20 (2H), 2.46 (3H), 3.23 ( 2H), 4.33 (1H), 5.80 (1H), 7.73 (1H) ppm. Example 27j (3S, 4Z) -5- (2-methyloxazol-4-yl) -3 - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -4-fluoro-4-pentene-1-triphenylphosphonium iodide By analogy for Example 22h, 8.06 g (18.9 mmol) of the compound shown in Example 27i are reacted and, after working up and purification, 10.7 g (15.6 mmol, 82%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.10 (3H), 0.18 (3H), 0.87 (9H), 1.97 (1H), 2.10 (1H), 2.42 ( 3H), 3.48 (1H), 3.97 (1H), 4.86 (1H), 5.93 (1H), 7.63-7.88 (16H) ppm. Example 27k (2S, 6E / Z, 9S, 10Z) -9 - [[Dimethyl (1,1-dimethylethyl) silyl] oxy] -10-fluoro-11- (2-methyloxazol-4-yl) -1- ( tetrahydropyran-2-yloxy) -2,6-dimethyl-undeca-6,10-diene In analogy to Example 22i, 3.20 g (14.0 mmol) of the compound shown in Example 27j are reacted and isolated after working up and purification 3.53 g (6.9 mmol, 49%) of the title compound as a colorless oil.
1 H NMR (CDCl 3 ): δ = 0.08 (6H), 0.84-0.97 (12H), 1.09 (1H), 1.22-2.04 (12H), 1.59 + 1.68 (3H), 2.30-2.49 (2H), 2.44 (3H), 3.06-3.27 (1H), 3.42-3.62 (2H), 3, 86 (1H), 4.19 (1H), 4.55 (1H), 5.12 (1H), 5.73 (1H), 7.71 (1H) ppm. Example 27l (2S, 6E / Z, 9S, 10Z) -9 - [[Dimethyl (1,1-dimethylethyl) silyl] oxy] -10-fluoro-11- (2-methyloxazol-4-yl) -1-hydroxy -2,6-dimethyl-undeca-6,10-diene In analogy to Example 1k, 3.48 g (6.83 mmol) of the compound shown in Example 27k are reacted and, after work-up and purification, 2.28 g (5th , 36 mmol, 78%) of the title compound as a colorless oil.
1 H NMR (CDCl 3 ): δ = 0.08 (6H), 0.83-0.94 (12H), 1.03 (1H), 1.21-1.70 (5H), 1.58 + 1.68 (3H), 1.91-2.05 (2H), 2.27-2.50 (2H), 2.44 (3H), 3.37-3.52 (2H), 4, 19 (1H), 5.12 (1H), 5.72 (1H), 7.72 (1H) ppm. Example 27m (2S, 6E / Z, 9S, 10Z) -9 - [[Dimethyl (1,1-dimethylethyl) silyl] oxy] -10-fluoro-11- (2-methyloxazol-4-yl) -2.6 -dimethyl-undeca-6,10-dienal In analogy to Example 1n, 2.28 g (5.36 mmol) of the compound shown in Example 27l are reacted and, after work-up and purification, 2.27 g (5.36 mmol, 100 %) of the title compound as a colorless oil.
1 H NMR (CDCl 3 ): δ = 0.06 (6H), 0.90 (9H), 1.03 + 1.08 (3H), 1.21-1.46 (4H), 1.57 + 1.66 (3H), 2.00 (2H), 2.21-2.42 (3H), 2.45 (3H), 4.19 (1H), 5.14 (1H), 5.73 (1H), 7.71 (1H), 9.59 (1H) ppm. Example 27n (4S (4R, 5S, 6S, 10E / Z, 13S, 14Z)) - 4- (13 - [[(1,1-Dimethylethyl) dimethylsilyl] oxy] -4- (prop-2-yn-1 -yl) -14-fluoro-15- (2-methyloxazol-4-yl) -3-oxo-5-hydroxy-2,6,10-trimethyl-pentadeca-10,14-dien-2-yl) -2 , 2-dimethyl- [1,3] dioxane (A) and (4S (4S, 5R, 6S, 10E / Z, 13S, 14Z)) - 4- (13- [[(1,1-dimethylethyl) dimethylsilyl] oxy] -4- (prop-2-yn-1-yl) -14-fluoro-15- (2-methyloxazol-4-yl) -3-oxo-5-hydroxy-2,6,10-trimethyl-pentadeca -10,14-dien-2-yl) -2,2-dimethyl- [1,3] dioxane (B) In analogy to Example 1c, 1.87 g (4.41 mmol) of the compound shown according to Example 27m are used with (4S) -4- (2-methyl-3-oxo-7-trimethylsilyl-hept-6-yn-2-yl) -2,2-dimethyl- [1,3] dioxane, which is obtained after the in DE 197 51 200.3 has prepared and isolated after work-up and purification in addition to starting material 1.37 g (1.87 mmol, 42%) of the title compound A and 190 mg (0.26 mmol, 6%) of the title compound B in each case as colorless oil.
1 H-NMR (CDCl 3 ) of A: δ = 0.02-0.16 (15H), 0.81-0.93 (12H), 0.97-1.78 (13H), 1.06 ( 3H), 1.39 (3H), 1.58 + 1.67 (3H), 1.91-2.08 (2H), 2.30-2.48 (3H), 2.44 (3H), 2.55 (1H), 3.03 (1H), 3.45 (1H), 3.52 (1H), 3.88 (1H), 3.99 (1H), 4.08-4.23 ( 2H), 5.12 (1H), 5.72 (1H), 7.72 (1H) ppm.
1 H NMR (CDCl 3 ) of B: δ = 0.01-0.12 (15H), 0.82-1.73 (18H), 0.89 (9H), 1.17 (3H), 1 .40 (3H), 1.58 + 1.67 (3H), 1.88-2.05 (2H), 2.28-2.57 (3H), 2.42 (3H), 3.41 ( 1H), 3.59 (1H), 3.79-4.05 (3H), 4.18 (1H), 5.11 (1H), 5.72 (1H), 7.70 (1H) ppm. Example 27o (3S, 6R, 7S, 8S, 12E / Z, 15S, 16Z) -15 - [[(1,1-Dimethylethyl) dimethylsilyl] oxy] -6- (3- (trimethylsilyl) -prop-2-yne -1-yl) -16-fluoro-1,3,7-trihydroxy-4,4,8,12-tetramethyl-17- (2-methyloxazol-4-yl) -heptadeca-12,16-diene-5- on In analogy to Example 1k, 2.16 g (2.94 mmol) of the compound A shown in Example 27n are reacted and, after work-up and purification, 1.47 g (2.12 mmol, 72%) of the title compound is isolated as a colorless oil .
1 H NMR (CDCl 3 ): δ = 0.03 (6H), 0.15 (9H), 0.85-0.95 (12H), 0.98-1.80 (7H), 1.15 (3H), 1.27 (3H), 1.57 + 1.66 (3H), 1.90-1.08 (2H), 2.30-2.45 (3H), 2.49 + 2, 51 (3H), 2.58-2.72 (2H), 2.90 + 3.03 (1H), 3.37-3.72 (3H), 3.88 (2H), 4.07-4 , 22 (2H), 5.11 (1H), 5.63 + 5.70 (1H), 7.71 (1H) ppm. Example 27p (3S, 6R, 7S, 8S, 12E / Z, 15S, 16Z) -16-Fluoro-1,3,7,15-tetrakis - [[(1,1-dimethylethyl) dimethylsilyl] oxy] -6- (3- (trimethylsilyl) -prop-2-yn-1-yl) -4,4,8,12-tetramethyl-17- (2-methyloxazol-4-yl) -heptadeca-12,16-diene-5- on In analogy to Example 11, 1.47 g (2.12 mmol) of the compound shown in Example 270 are reacted and, after work-up and purification, 2.13 g (2.05 mmol, 97%) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.00-0.15 (33H), 0.83-0.98 (39H), 1.00-1.72 (7H), 1.07 (3H) , 1.26 (3H), 1.59 + 1.67 (3H), 1.94 (2H), 2.27-2.43 (2H), 2.43 (3H), 2.51 (2H) , 3.28 (1H), 3.52-3.71 (2H), 3.78 (1H), 3.88 (1H), 4.18 (1H), 5.12 (1H), 5.73 (1H), 7.71 (1H) ppm. Example 27q (3S, 6R, 7S, 8S, 12E / Z, 15S, 16Z) -16-fluoro-1-hydroxy-3,7,15-tris - [[(1,1-dimethylethyl) dimethylsilyl] oxy] - 6- (3- (trimethylsilyl) -prop-2-yn-1-yl) -4,4,8,12-tetramethyl-17- (2-methyloxazol-4-yl) -heptadeca-12,16-diene- 5-one In analogy to Example 1m, 2.13 g (2.05 mmol) of the compound shown in Example 27p are reacted and, after working up and purification, 1.47 g (1.60 mmol, 78%) of the title compound is isolated as a colorless one Oil.
1 H-NMR (CDCl 3 ): δ = 0.00-0.15 (27H), 0.83-0.98 (30H), 1.02-1.77 (7H), 1.10 (3H) , 1.27 (3H), 1.59 + 1.68 (3H), 1.89-2.07 (3H), 2.30-2.52 (3H), 2.45 (3H), 1, 68 (1H), 3.27 (1H), 3.60-3.71 (2H), 3.79 (1H), 4.05-4.23 (2H), 5.13 (1H), 5, 73 (1H), 7.70 (1H) ppm. Example 27r (3S, 6R, 7S, 8S, 12E / Z, 15S, 16Z) -16-fluoro-5-oxo-3,7,15-tris - [[(1,1-dimethylethyl) dimethylsilyl] oxy] - 6- (3- (trimethylsilyl) -prop-2-yn-1-yl) -4,4,8,12-tetramethyl-17- (2-methyloxazol-4-yl) -heptadeca-12,16-dienal In Analogously to Example 1n, 1.47 g (1.60 mmol) of the compound shown in Example 27q are reacted and, after work-up, 1.62 g (max. 1.60 mmol) of the title compound are isolated as a colorless oil.
1 H-NMR (CDCl 3 ) of a purified sample: δ = -0.01-0.11 (27H), 0.83-0.98 (30H), 1.00-1.56 (5H), 1, 11 (3H), 1.28 (3H), 1.59 + 1.68 (3H), 1.88-2.02 (2H), 2.29-2.50 (4H), 2.43 (3H ), 2.58-2.71 (2H), 3.26 (1H), 3.78 (1H), 4.18 (1H), 4.50 (1H), 5.12 (1H), 5, 73 (1H), 7.71 (1H), 9.77 (1H) ppm. Example 27s (3S, 6R, 7S, 8S, 12Z, 15S, 16Z) -16-Fluoro-5-oxo-3,7,15-tris - [[(1,1-dimethylethyl) dimethylsilyl] oxy] -6- (3- (trimethylsilyl) -prop-2-yn-1-yl) -4,4,8,12-tetramethyl-17- (2-methyloxazol-4-yl) -heptadeca-12,16-dienoic acid (A) and (3S, 6R, 7S, 8S, 12E, 15S, 16Z) -16-fluoro-5-oxo-3,7,15-tris - [[(1,1-dimethylethyl) dimethylsilyl] oxy] -6- ( 3- (trimethylsilyl) -prop-2-yn-1-yl) -4,4,8,12-tetramethyl-17- (2-methyloxazol-4-yl) -heptadeca-12,16-dienoic acid (B) In Analogously to Example 22q, 1.60 g (max. 1.60 mmol) of the compound shown in Example 27r are reacted and, after work-up and purification, 601 mg (642 μmol, 40%) of the title compound A and 500 mg (534 μmol, 33%) of the title compound B in each case as a colorless oil.
1 H-NMR (CDCl 3 ) of A: δ = -0.04-0.19 (27H), 0.89 (27H), 0.96 (3H), 1.05-2.53 (13H), 1.19 (3H), 1.26 (3H), 1.69 (3H), 2.46 (3H), 2.63 (1H), 3.32 (1H), 3.71 (1H), 4 , 16 (1H), 4.39 (1H), 5.18 (1H), 6.08 (1H), 7.73 (1H) ppm.
1 H-NMR (CDCl 3 ) of B: δ = -0.02-0.18 (27H), 0.90 (30H), 0.99-2.67 (14H), 1.21 (6H), 1.58 (3H), 2.46 (3H), 3.32 (1H), 3.74 (1H), 4.13 (1H), 4.36 (1H), 5.10 (1H), 5 , 79 (1H), 7.72 (1H) ppm. Example 27t (3S, 6R, 7S, 8S, 12Z, 15S, 16Z) -16-fluoro-5-oxo-3,7-bis - [[(1,1-dimethylethyl) dimethylsilyl] oxy] -15-hydroxy- 6- (prop-2-yn-1-yl) -4,4,8,12-tetramethyl-17- (2-methyloxazol-4-yl) -heptadeca-12,16-dienoic acid 601 mg (642 μmol) of the compound A shown in Example 27s and, after work-up, 657 mg (max. 642 μmol) of the title compound is isolated as the crude product, which is reacted further without purification. Example 27u (4S, 7R, 8S, 9S, 13Z, 16S (Z)) - 4,8-Bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -16- (1-fluoro-2- ( 2-methyloxazol-4-yl) ethenyl) -7- (prop-2-yn-1-yl) -1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dione In analogy to Example 1q, 657 mg (max. 642 μmol) of the compound shown in Example 27u are reacted and, after work-up and purification, 91 mg (124 μmol, 19%) of the title compound are isolated as a colorless oil. Example 27 (4S, 7R, 8S, 9S, 13Z, 16S (Z)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) -7- (prop -2-in-1-yl) -1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dione In analogy to Example 1, 91 mg (124 μmol) of the Example 27u of the compound shown and isolated after work-up and purification 45 mg (89 μmol, 73%) of the title compound as a colorless oil.
1 H NMR (CDCl 3 ): δ = 1.05 (3H), 1.10 (3H), 1.20-1.42 (4H), 1.37 (3H), 1.58-1.94 (2H), 1.69 (3H), 2.04 (1H), 2.20-2.84 (8H), 2.45 (3H), 3.20 (1H), 3.38 (1H), 3.78 (1H), 4.20 (1H), 5.11 (1H), 5.43 (1H), 5.90 (1H), 7.73 (1H) ppm. Example 28 (4S, 7R, 8S, 9S, 13E, 16S (Z)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) -7- (prop -2-yn-1-yl) -1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dione Example 28a (3S, 6R, 7S, 8S, 12E, 15S, 16Z) -16-Fluoro-5-oxo-3,7-bis - [[(1,1-dimethylethyl) dimethylsilyl] oxy] -15-hydroxy-6- (prop-2-yn-1-yl) -4 , 4,8,12-tetramethyl-17- (2-methyloxazol-4-yl) -heptadeca-12,16-dienoic acid. In analogy to Example 1e, 500 mg (534 µmol) of compound B shown according to Example 27f are reacted and isolated after work-up 517 mg (max. 534 μmol) of the title compound as a crude product, which is reacted further without purification. Example 28b (4S, 7R, 8S, 9S, 13E, 16S (Z)) - 4,8-Bis - [[dimethyl (1,1-dimethylethyl) silyl] oxy] -16- (1-fluoro-2- ( 2-methyloxazol-4-yl) ethenyl) -7- (prop-2-yn-1-yl) -1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dione In analogy to Example 1q, 517 mg (534 μmol) of the compound shown in Example 28a are reacted and, after working up and purification, 128 mg (175 μmol, 33%) of the title compound are isolated as a colorless oil. Example 28 (4S, 7R, 8S, 9S, 13E, 16S (Z)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) -7- (prop -2-in-1-yl) -1-oxa-5,5,9,13-tetramethyl-cyclohexadec-13-en-2,6-dione In analogy to Example 1, 128 mg (175 μmol) are added Example 28b represented the compound and isolated after work-up and purification 54 mg (107 mmol, 61%) of the title compound as a colorless oil.
1 H-NMR (CDCl 3 ): δ = 0.89 (1H), 0.98 (3H), 1.02 (3H), 1.20-2.23 (7H), 1.33 (3H), 1.59 (3H), 2.40-2.61 (6H), 2.42 (3H), 3.57 (1H), 3.77 (1H), 3.82 (1H), 3.87 ( 1H), 4.33 (1H), 5.08 (1H), 5.53 (1H), 5.87 (1H), 7.72 (1H) ppm.

Claims (9)

1. Epothilon-Derivate der allgemeinen Formel I,
worin
R1a, R1b gleich oder verschieden sind und Wasserstoff, C1-C10-Alkyl, Aryl, C7- C20-Aralkyl, oder gemeinsam eine -(CH2)m-Gruppe mit m = 1, 2, 3, 4 oder 5, eine -(CH2)-O-(CH2)-Gruppe,
R2a Wasserstoff, C1-C10-Alkyl, Aryl, C7-C20-Aralkyl, -(CH2)ra-C∼C-(CH2)pa-R26a, -(CH2)ra-C=C-(CH2)pa-R26a,
R2b -(CH2)rbC∼C-(CH2)pb-R26b, -(CH2)rb-C=C-(CH2)pb-R26b,
n 0 bis 5,
ra, rb gleich oder verschieden sind und 0 bis 4,
pa, pb gleich oder verschieden sind und 0 bis 3,
R3a Wasserstoff, C1-C10-Alkyl, Aryl, C7-C20-Aralkyl,
R14 Wasserstoff, OR14a, Hal,
R3b OPG14,
R4 Wasserstoff, C1-C10-Alkyl, Aryl, C7-C20-Aralkyl, Hal, OR25, CN,
R25 Wasserstoff, eine Schutzgruppe PG5,
R26a, R26b gleich oder verschieden sind und Wasserstoff, C1-C10-Alkyl, Aryl, C7- C20-Aralkyl, C1-C10-Acyl, oder, falls pa bzw. pb < 0 sind, eine Gruppe OR27,
R27 Wasserstoff, eine Schutzgruppe PG6,
R5 Wasserstoff, C1-C10-Alkyl, Aryl, C7-C20-Aralkyl, (CH2)s-T, wobei s für 1, 2, 3 oder 4,
T für OR22 oder Hal,
R22 für Wasserstoff oder PG4 stehen,
R6, R7 je ein Wasserstoffatom, gemeinsam eine zusätzliche Bindung oder ein Sauerstoffatom,
G eine Gruppe X=CR8-, ein bi- oder tricyclischer Arylrest,
R8 Wasserstoff, Halogen, CN, C1-C20-Alkyl, Aryl, C7-C20-Aralkyl, die alle substituiert sein können,
X ein Sauerstoffatom, zwei Alkoxygruppen OR23, eine C2-C10-Alkylen-α,ω- dioxygruppe, die geradkettig oder verzweigt sein kann, H/OR9 oder eine Gruppierung CR10R11,
wobei
R23 für einen C1-C20-Alkylrest,
R9 für Wasserstoff oder eine Schutzgruppe PGx,
R10, R11 gleich oder verschieden sind und für Wasserstoff, einen C1-C20- Alkyl-, Aryl-, C7-C20-Aralkylrest oder R10 und R11 zusammen mit dem Methylenkohlenstoffatom gemeinsam für einen 5- bis 7-gliedrigen carbocyclischen Ring
stehen,
D-E eine Gruppe -CH2-CH2-, -O-CH2-,
A-Y eine Gruppe O-C(=O), O-CH2, CH2C(=O), NR29-C(=O), NR29-SO2,
R29 Wasserstoff, C1-C19-Alkyl,
Z ein Sauerstoffatom oder H/OR12,
wobei
R12 Wasserstoff oder eine Schutzgruppe PGz
ist,
Hal Halogen, vorzugsweise Fluor, Chlor, Brom oder Iod,
bedeuten. 1. Epothilone derivatives of the general formula I,
wherein
R 1a , R 1b are identical or different and are hydrogen, C 1 -C 10 -alkyl, aryl, C 7 -C 20 -aralkyl, or together a - (CH 2 ) m group with m = 1, 2, 3, 4 or 5, a - (CH 2 ) -O- (CH 2 ) group,
R 2a is hydrogen, C 1 -C 10 alkyl, aryl, C 7 -C 20 aralkyl, - (CH 2 ) ra -C∼C- (CH 2 ) pa -R 26a , - (CH 2 ) ra -C = C- (CH 2 ) pa -R 26a ,
R 2b - (CH 2 ) rb C∼C- (CH 2 ) pb -R 26b , - (CH 2 ) rb -C = C- (CH 2 ) pb -R 26b ,
n 0 to 5,
ra, rb are the same or different and 0 to 4,
pa, pb are the same or different and 0 to 3,
R 3a is hydrogen, C 1 -C 10 -alkyl, aryl, C 7 -C 20 -aralkyl,
R 14 hydrogen, OR 14a , Hal,
R 3b OPG 14 ,
R 4 hydrogen, C 1 -C 10 -alkyl, aryl, C 7 -C 20 -aralkyl, Hal, OR 25 , CN,
R 25 hydrogen, a protective group PG 5 ,
R 26a , R 26b are identical or different and are hydrogen, C 1 -C 10 -alkyl, aryl, C 7 -C 20 -aralkyl, C 1 -C 10 -acyl, or, if pa and pb are <0, a Group OR 27 ,
R 27 is hydrogen, a protective group PG 6 ,
R 5 is hydrogen, C 1 -C 10 -alkyl, aryl, C 7 -C 20 -aralkyl, (CH 2 ) s -T, where s is 1, 2, 3 or 4,
T for OR 22 or Hal,
R 22 represents hydrogen or PG 4 ,
R 6 , R 7 each represent a hydrogen atom, together an additional bond or an oxygen atom,
G is a group X = CR 8 -, a bi- or tricyclic aryl radical,
R 8 is hydrogen, halogen, CN, C 1 -C 20 -alkyl, aryl, C 7 -C 20 -aralkyl, all of which can be substituted,
X is an oxygen atom, two alkoxy groups OR 23 , a C 2 -C 10 -alkylene-α, ω-dioxy group, which can be straight-chain or branched, H / OR 9 or a grouping CR 10 R 11 ,
in which
R 23 is a C 1 -C 20 -alkyl radical,
R 9 for hydrogen or a protective group PG x ,
R 10, R 11 are identical or different and represent hydrogen, a C 1 -C 20 - alkyl, aryl, C 7 -C 20 aralkyl, or R 10 and R 11 together with the methylene carbon atom jointly represent a 5- to 7 -linked carbocyclic ring
stand,
DE is a group -CH 2 -CH 2 -, -O-CH 2 -,
AY is a group OC (= O), O-CH 2 , CH 2 C (= O), NR 29 -C (= O), NR 29 -SO 2 ,
R 29 hydrogen, C 1 -C 19 -alkyl,
Z is an oxygen atom or H / OR 12 ,
in which
R 12 is hydrogen or a protective group PG e.g.
is
Hal halogen, preferably fluorine, chlorine, bromine or iodine,
mean. 2. Verbindungen der allgemeinen Formel I nach Anspruch 1, dadurch gekennzeichnet, daß R2a für ein Wasserstoffatom steht.2. Compounds of general formula I according to claim 1, characterized in that R 2a represents a hydrogen atom. 3. Verbindungen der allgemeinen Formel I nach Anspruch 1, dadurch gekennzeichnet, daß R1a und R1b jeweils für eine Methylgruppe stehen oder gemeinsam eine Trimethylengruppe bilden.3. Compounds of general formula I according to claim 1, characterized in that R 1a and R 1b each represent a methyl group or together form a trimethylene group. 4. Verbindungen der allgemeinen Formel I nach Anspruch 1, dadurch gekennzeichnet, daß R8 ein Halogenatom oder eine Nitrilgruppe ist.4. Compounds of general formula I according to claim 1, characterized in that R 8 is a halogen atom or a nitrile group. 5. Verbindungen nach Anspruch 4, dadurch gekennzeichnet, daß R8 ein Fluoratom ist.5. Compounds according to claim 4, characterized in that R 8 is a fluorine atom. 6. Verbindungen der allgemeinen Formel I nach Anspruch 1, nämlich
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13- tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-fluor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-chlor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13- tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-fluor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-chlor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1- oxa-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-fluor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-chlor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13- tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-chlor-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl- 2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13- tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridy()ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-chlor-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1- oxa-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-chlor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-methyl-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-fluor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-chlor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-methyl-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-fluor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-chlor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-methyl-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1- oxa-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-chlor-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl- 2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-chlor-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-methyl-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1- oxa-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-chlor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-methyl-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-fluor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-chlor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-methyl-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-fluor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-chlor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-methyl-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1- oxa-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-chlor-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl- 2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-chlor-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-methyl-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1- oxa-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-chlor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5-trimethylen-9,13-dimethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa-5,5- trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- pyridyl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa-5,5- trimethylen-9,13-dimethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-pyridyl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5-trimethylen-9,13-dimethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-pyridyl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5-trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2- (2-methylthiazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5-trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- methylthiazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-oxa- 5,5-trimethylen-9,13-dimethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5-trimethylen-9,13-dimethyl-7-(oxacyclopropylmethyl)-cyclohexadec- 13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-oxa- 5,5-trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(p rop-2-in-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5-trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5-trimethylen-9,13-dimethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl- 2-(2-methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5-trimethylen-9,13-dimethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl-ethenyl)-1- oxa-5,5-trimethylen-9,13-dimethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6- dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (2-(2-methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5-trimethylen-9,13-dimethyl-7-(oxacyclopropylmethyl)-cyclohexadec- 13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-chlor-2-(2-methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1- methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1- methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1- methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1- methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1- yl)-3-(1-methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1- methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1- methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1- methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1- methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- oxa-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1- yl)-3-(1-methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-oxa-5,5,9,13- tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1- methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-oxa-5,5,9,13- tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1- methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-oxa-5,5,9,13- tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1- methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-oxa-5,5,9,13- tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1- methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-oxa-5,5,9,13- tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1- yl)-3-(1-methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1- methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1- methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1- methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1- methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzoxazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1- yl)-3-(1-methyl-2-(2-methyl-benzoxazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1- methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1- methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1- methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1- methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-methyl-benzothiazol-5-yl)-1- aza-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1- yl)-3-(1-methyl-2-(2-methyl-benzothiazol-5-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-aza-5,5,9,13- tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1- methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-aza-5,5,9,13- tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1- methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-aza-5,5,9,13- tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1- methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-aza-5,5,9,13- tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1- methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(chinolin-2-yl)-1-aza-5,5,9,13- tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1- yl)-3-(1-methyl-2-(chinolin-2-yl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-aza-5,5,9,13- tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-fluor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-chlor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-aza-5,5,9,13- tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-fluor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-chlor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1- aza-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-fluor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-chlor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-aza-5,5,9,13- tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-chlor-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl- 2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-aza-5,5,9,13- tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(2-(2- pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-chlor-2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1- aza-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-chlor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-methyl-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E)))-4,8-Dihydroxy-16-(2-(2-methylthylthiazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-fluor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-chlor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-methyl-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-fluor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-chlor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-methyl-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1- aza-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-chlor-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl- 2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-chlor-2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-methyl-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1- aza-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-chlor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-methyl-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-fluor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-chlor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-methyl-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-fluor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(but-3-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-en-1-yl)-3-(1-chlor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-methyl-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1- aza-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(2-oxacyclopropyl-1-ethyl)-cyclohexadec-13- en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(2-oxacyclopropyl-1- ethyl)-3-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-chlor-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl- 2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-chlor-2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-methyl-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1- aza-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-chlor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-aza- 5,5-trimethylen-9,13-dimethyl-7-(but-3-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(but-3-in-1-yl)-3-(1-methyl-2- (2-pyridyl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza-5,5- trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- pyridyl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza-5,5- trimethylen-9,13-dimethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-pyridyl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza- 5,5-trimethylen-9,13-dimethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-pyridyl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5-trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-methyl-2- (2-methylthiazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5-trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- methylthiazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-aza- 5,5-trimethylen-9,13-dimethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(2-(2- methylthiazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5-trimethylen-9,13-dimethyl-7-(oxacyclopropylmethyl)-cyclohexadec- 13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-fluor-2-(2-methylthiazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-aza- 5,5-trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(2-(2- methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5-trimethylen-9,13-dimethyl-7-(prop-2-in-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-in-1-yl)-3-(1-fluor-2-(2- methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5-trimethylen-9,13-dimethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-methyl- 2-(2-methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5-trimethylen-9,13-dimethyl-7-(prop-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(prop-2-en-1-yl)-3-(1-fluor-2- (2-methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1- aza-5,5-trimethylen-9,13-dimethyl-7-(oxacyclopropylmethyl)-cyclohexadec-13-en-2,6- dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (2-(2-methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R(RS),8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5-trimethylen-9,13-dimethyl-7-(oxacyclopropylmethyl)-cyclohexadec- 13-en-2,6-dion
(1S/R,3S(E),7S,10R(RS),11R,12S,16R/S)-7,11-Dihydroxy-10-(oxacyclopropylmethyl)-3- (1-chlor-2-(2-methyloxazol-4-yl)ethenyl)-8,8-trimethylen-12,16-dimethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-oxa-5,5,9,13- tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- fluor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- chlor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecan- 5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- methyl-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- fluor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- chlor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-oxa-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- methyl-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-oxa- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- fluor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-oxa-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- chlor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4,17- dioxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- methyl-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-pyridyl)ethenyl)-1-aza-5,5,9,13- tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(2- (2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17-oxabicyclo[14.1.0]heptadecan-5,9- dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- fluor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-pyridyl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- chlor-2-(2-pyridyl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methylthiazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- methyl-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methylthiazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(2- (2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- fluor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methylthiazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- chlor-2-(2-methylthiazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-methyl-2-(2-methyloxazol-4- yl)ethenyl)-1-aza-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en- 2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- methyl-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(2-(2-methyloxazol-4-yl)ethenyl)-1-aza- 5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(2- (2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-fluor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- fluor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion
(4S,7R,8S,9S,13E/Z,16S(E))-4,8-Dihydroxy-16-(1-chlor-2-(2-methyloxazol-4-yl)ethenyl)- 1-aza-5,5,9,13-tetramethyl-7-(3-methyl-but-2-en-1-yl)-cyclohexadec-13-en-2,6-dion
(1S/R,3S(E),7S,10R,11R,12S,16R/S)-7,11-Dihydroxy-10-(3-methyl-but-2-en-1-yl)-3-(1- chlor-2-(2-methyloxazol-4-yl)ethenyl)-8,8,12,16-tetramethyl-4-aza-17- oxabicyclo[14.1.0]heptadecan-5,9-dion 6. Compounds of general formula I according to claim 1, namely
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-oxa-5,5,9,13- tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- [2- (2 - pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-chloro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-oxa-5,5,9,13- tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- [2- (2 - pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-chloro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa-5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-methyl -2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9 , 13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl-cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (2- ( 2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa- 5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-fluoro -2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-oxa- 5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-chloro -2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-oxa-5,5,9,13- tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (2- (2 - pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-chloro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-oxa-5,5,9,13- tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- [2- (2 - pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridy () ethenyl) -1-oxa- 5.5 , 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-chloro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa-5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-methyl-2- (2- pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-oxa- 5,5,9 , 13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa- 5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-oxa- 5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-chloro-2- (2- pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4- yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- [2- (2 - methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-chloro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4- yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- [2- (2 - methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-chloro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-methyl -2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-oxa-5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (2- ( 2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-fluoro -2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-chloro -2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4- yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (2- (2 - methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-chloro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4- yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- [2- (2 - methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-chloro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-methyl-2- (2- methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-oxa-5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (2- (2-methylthiazole-4- yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-chloro-2- (2- methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- [2- (2 - methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-chloro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- [2- (2 - methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-chloro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-methyl -2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-oxa-5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (2- ( 2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-fluoro -2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-chloro -2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (2- (2 - methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-chloro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- [2- (2 - methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-chloro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-methyl-2- (2- methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-oxa-5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (2- (2-methyloxazole-4- yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) -1 -oxa-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-chloro-2- (2- methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5- trimethylene-9,13-dimethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa-5,5- trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa-5,5- trimethylene-9,13-dimethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa- 5 , 5-trimethylene-9,13-dimethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- pyridyl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4- yl) ethenyl) -1-oxa- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-oxa- 5,5- trimethylene-9,13-dimethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- [2- (2 - methylthiazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -1 -oxa-5,5-trimethylene-9,13-dimethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- methylthiazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5- trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-in-1-yl) -3- (2 - (2-methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methyloxazol-4-yl-ethenyl) -1-oxa-5 , 5-trimethylene-9,13-dimethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (2- (2-methyloxazole-4- yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) -1 -oxa-5,5-trimethylene-9,13-dimethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-chloro-2- (2- methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1- methyl- 2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1- methyl- 2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1- methyl- 2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1- methyl- 2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1- methyl- 2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1- methyl- 2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1- methyl- 2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1- methyl- 2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-oxa-5,5,9,13 -tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-oxa-5,5,9,13-tetramethyl-7 - (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1- methyl- 2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-oxa-5,5,9,13-tetramethyl-7 - (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1- methyl- 2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-oxa-5,5,9,13-tetramethyl-7 - (But-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1- methyl- 2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-oxa-5,5,9,13-tetramethyl-7 - (But-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1- methyl- 2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-oxa-5,5,9,13-tetramethyl-7 - (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1- methyl- 2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1- methyl- 2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1- methyl- 2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1- methyl- 2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzoxazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-methyl-benzoxazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1- methyl- 2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1- methyl- 2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1- methyl- 2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1- methyl- 2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (2-methyl-benzothiazol-5-yl) -1-aza-5,5,9,13 -tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-methyl-benzothiazol-5-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-aza-5,5,9,13-tetramethyl-7 - (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1- methyl- 2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-aza-5,5,9,13-tetramethyl-7 - (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1- methyl- 2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-aza-5,5,9,13-tetramethyl-7 - (But-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1- methyl- 2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-aza-5,5,9,13-tetramethyl-7 - (But-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1- methyl- 2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (quinolin-2-yl) -1-aza-5,5,9,13-tetramethyl-7 - (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (quinolin-2-yl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-aza-5,5,9,13- tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- [2- (2 - pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-chloro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-aza-5,5,9,13- tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- [2- (2 - pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-chloro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-methyl -2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-aza-5,5,9 , 13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (2- ( 2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-fluoro -2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-chloro -2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-aza-5,5,9,13- tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (2- (2 - pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-chloro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-aza-5,5,9,13- tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- [2- (2 - pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-chloro- 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-methyl-2- (2- pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-aza-5,5,9 , 13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-chloro-2- (2- pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E))) -4,8-Dihydroxy-16- (2- (2-methylthylthiazol-4-yl) ethenyl) -1-aza-5,5 , 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- [2- (2 - methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-chloro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- [2- (2 - methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-chloro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-methyl -2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (2- ( 2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-fluoro -2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-chloro -2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (2- (2 - methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-chloro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- [2- (2 - methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-chloro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-methyl-2- (2- methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (2- (2-methylthiazole-4- yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-chloro-2- (2- methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- [2- (2 - methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-chloro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- [2- (2 - methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (but-3-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-en-1-yl) -3- (1-chloro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-methyl -2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (2- ( 2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-fluoro -2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (2-oxacyclopropyl-1-ethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (2-oxacyclopropyl-1-ethyl) -3- (1-chloro -2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (2- (2 - methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-chloro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- [2- (2 - methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-chloro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-methyl-2- (2- methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-aza-5 , 5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (2- (2-methyloxazole-4- yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) -1 -aza-5,5,9,13-tetramethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-chloro-2- (2- methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-aza- 5,5- trimethylene-9,13-dimethyl-7- (but-3-yn-1-yl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (but-3-yn-1-yl) -3- (1-methyl- 2- (2-pyridyl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5,5- trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5,5- trimethylene-9,13-dimethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-pyridyl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5 , 5-trimethylene-9,13-dimethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- pyridyl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1-aza- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-methyl- 2- (2-methylthiazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-methylthiazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-aza- 5,5- trimethylene-9,13-dimethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- [2- (2 - methylthiazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -1 -aza-5,5-trimethylene-9,13-dimethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-fluoro-2- (2- methylthiazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-aza- 5,5- trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-ene-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (2- (2 - methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-yn-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-yn-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-aza- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-methyl- 2- (2-methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5-trimethylene-9,13-dimethyl-7- (prop-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (prop-2-en-1-yl) -3- (1-fluoro- 2- (2-methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) -4,8-dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-aza-5 , 5-trimethylene-9,13-dimethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (2- (2-methyloxazole-4- yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R (RS), 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) -1 -aza-5,5-trimethylene-9,13-dimethyl-7- (oxacyclopropylmethyl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R (RS), 11R, 12S, 16R / S) -7,11-dihydroxy-10- (oxacyclopropylmethyl) -3- (1-chloro-2- (2- methyloxazol-4-yl) ethenyl) -8,8-trimethylene-12,16-dimethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-oxa-5,5,9,13- tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-fluoro-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-chloro-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4- yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecan-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-chloro-2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-oxa- 5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-oxa- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-chloro-2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4,17-dioxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-pyridyl) ethenyl) -1-aza-5,5,9,13- tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-fluoro-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-pyridyl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-chloro-2- (2-pyridyl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methylthiazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-fluoro-2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methylthiazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-chloro-2- (2-methylthiazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -1-aza- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-methyl-2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (2- (2-methyloxazol-4-yl) ethenyl) -1-aza-5,5, 9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-fluoro-2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione
(4S, 7R, 8S, 9S, 13E / Z, 16S (E)) - 4,8-Dihydroxy-16- (1-chloro-2- (2-methyloxazol-4-yl) ethenyl) - 1-aza- 5,5,9,13-tetramethyl-7- (3-methyl-but-2-en-1-yl) -cyclohexadec-13-en-2,6-dione
(1S / R, 3S (E), 7S, 10R, 11R, 12S, 16R / S) -7,11-dihydroxy-10- (3-methyl-but-2-en-1-yl) -3- ( 1-chloro-2- (2-methyloxazol-4-yl) ethenyl) -8,8,12,16-tetramethyl-4-aza-17-oxabicyclo [14.1.0] heptadecane-5,9-dione 7. Pharmazeutische Präparate, enthaltend mindestens eine Verbindung der allgemeinen Formel I gemäß Anspruch 1 sowie einen pharmazeutisch verträglichen Träger.7. Pharmaceutical preparations containing at least one compound of the general formula I according to claim 1 and a pharmaceutical compatible carrier. 8. Verwendung der Verbindungen der allgemeinen Formel I gemäß Anspruch 1 zur Herstellung von Arzneimitteln.8. Use of the compounds of general formula I according to claim 1 for Manufacture of medicines. 9. Prodrugformulierungen der Verbindungen der allgemeinen Formel I gemäß Anspruch 1, dadurch gekennzeichnet, daß sie in vivo eine bioaktive Wirkstoffkomponente der allgemeinen Formel I freisetzen.9. Prodrug formulations of the compounds of the general formula I according to Claim 1, characterized in that it is bioactive in vivo Release active ingredient component of general formula I.
DE10015836A 1999-04-30 2000-03-27 New epothilone derivatives used for treating e.g. malignant melanoma, breast carcinoma, psoriasis, multiple sclerosis and arthritis Withdrawn DE10015836A1 (en)

Priority Applications (43)

Application Number Priority Date Filing Date Title
DE10015836A DE10015836A1 (en) 2000-03-27 2000-03-27 New epothilone derivatives used for treating e.g. malignant melanoma, breast carcinoma, psoriasis, multiple sclerosis and arthritis
ARP000102024A AR023792A1 (en) 1999-04-30 2000-04-28 DERIVATIVES 6-ALQUENILO- AND 6-ALQUINILO-EPOTILONA, THE PROCEDURES TO PREPARE THEM AND THEIR USE IN PHARMACEUTICAL PRODUCTS
PE2000000403A PE20010116A1 (en) 1999-04-30 2000-04-28 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTILONE DERIVATIVES, PROCEDURES FOR THEIR PREPARATION
PL351491A PL210762B1 (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
EP00922826A EP1173441B1 (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
MXPA01011039A MXPA01011039A (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations.
EA200101025A EA011502B1 (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production and their use in pharmaceutical preparations
HU0201010A HUP0201010A3 (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
AT00922826T ATE440847T1 (en) 1999-04-30 2000-05-01 6-ALKENYL, 6-ALKYNYL AND 6-EPOXY-EPOTHILONE DERIVATIVES. METHOD FOR THEIR PRODUCTION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS
PT00922826T PT1173441E (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
CA2371226A CA2371226C (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
CA2651653A CA2651653C (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
SI200031044T SI1173441T1 (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
PCT/IB2000/000657 WO2000066589A1 (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
NZ514989A NZ514989A (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkynyl- and 6-epoxy -epothilone derivatives
SK1551-2001A SK286858B6 (en) 1999-04-30 2000-05-01 6-Alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
CZ20013885A CZ299653B6 (en) 1999-04-30 2000-05-01 6-Alkenyl-, 6-alkynyl- and 6-epoxyepothilone derivatives, process of their preparation and pharmaceutical compositions in which the derivatives are comprised
IL14593800A IL145938A0 (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl-and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
ES00922826T ES2331506T3 (en) 1999-04-30 2000-05-01 DERIVATIVES OF 6-ALQUENIL-, 6-ALQUINIL-, 6-EPOXI-EPOTILONE, PROCEDURE FOR ITS PRODUCTION, AND ITS USE IN PHARMACEUTICAL PREPARATIONS.
JP2000615619A JP4024003B2 (en) 1999-04-30 2000-05-01 6-Alkenyl-, 6-alkynyl- and 6-epoxy-epothilone derivatives, methods for their production and their use in pharmaceutical formulations
MEP-139/08A MEP13908A (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
BR0010190-7A BR0010190A (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkynyl- and 6-epoxy-epothilone derivatives, process for their preparation, and their use in pharmaceutical preparations
DE60042821T DE60042821D1 (en) 1999-04-30 2000-05-01 6-ALKENYL, 6-ALKYNYL AND 6-EPOXY EPOTHILONE DERIVATIVES. PROCESS FOR THE PRODUCTION THEREOF AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS
DK00922826T DK1173441T3 (en) 1999-04-30 2000-05-01 6-alkenyl, 6-alkynyl and 6-epoxy-epothilone derivatives, processes for their preparation and their use in pharmaceutical compositions
AU43103/00A AU772750C (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
EEP200100568A EE05292B1 (en) 1999-04-30 2000-05-01 6-Alken-1, 6-alk n-1 and 6-epoxy epothilone derivatives, their preparation and their use in pharmaceutical preparations
YUP-776/01A RS51023B (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production,and their use in pharmaceutical preparations
KR1020017013840A KR100721488B1 (en) 1999-04-30 2000-05-01 6-Alkenyl-, 6-Alkinyl- and 6-Epoxy-Epothilone Derivatives, Process for Their Production and Their Use in Pharmaceutical Preparations
CNB008069786A CN100368415C (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl-and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
US09/979,939 US7125893B1 (en) 1999-04-30 2000-05-01 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
TW89108133A TWI280962B (en) 1999-04-30 2000-05-18 6-alkenyl-, 6-alkinyl-and 6-epoxy-epothilone derivatives process for their production and their use in pharmaceutical preparations
TW095145399A TWI294292B (en) 1999-04-30 2000-05-18 Combination of epothilone derivatives
IL145938A IL145938A (en) 1999-04-30 2001-10-15 6-alkenyl-, 6-alkinyl-and 6-epoxy-epothilone derivatives, process for their production, pharmaceutical compositions containing them and intermediates therefor
BG106053A BG65601B1 (en) 1999-04-30 2001-10-26 6-alkenyl-, 6-alkynyl- and 6-epoxy-epothilone derivatives, process for their production and their use in pharmaceutical preparations
NO20015278A NO328149B1 (en) 1999-04-30 2001-10-29 Epoxy-epothilone compounds, process for their preparation, their use for the preparation of pharmaceutical compositions and the pharmaceutical compositions.
ZA200109859A ZA200109859B (en) 1999-04-30 2001-11-29 6-Alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations.
HR20010892A HRP20010892A2 (en) 1999-04-30 2001-11-30 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
HK02108204.3A HK1046681B (en) 1999-04-30 2002-11-13 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use
US10/965,802 US7645891B2 (en) 1999-04-30 2004-10-18 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
US11/214,988 US7700621B2 (en) 1999-04-30 2005-08-31 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
JP2007104224A JP4886578B2 (en) 1999-04-30 2007-04-11 6-Alkenyl-, 6-alkynyl- and 6-epoxy-epothilone derivatives, methods for their production and their use in pharmaceutical formulations
CY20091101237T CY1109768T1 (en) 1999-04-30 2009-11-25 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-PRODUCED PRODUCTS, PROCEDURE FOR THEIR PREPARATION, AND THEIR USE IN PHARMACEUTICAL PARAMETERS
US12/721,614 US20100168179A1 (en) 1999-04-30 2010-03-11 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10015836A DE10015836A1 (en) 2000-03-27 2000-03-27 New epothilone derivatives used for treating e.g. malignant melanoma, breast carcinoma, psoriasis, multiple sclerosis and arthritis

Publications (1)

Publication Number Publication Date
DE10015836A1 true DE10015836A1 (en) 2001-10-11

Family

ID=7636982

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10015836A Withdrawn DE10015836A1 (en) 1999-04-30 2000-03-27 New epothilone derivatives used for treating e.g. malignant melanoma, breast carcinoma, psoriasis, multiple sclerosis and arthritis

Country Status (1)

Country Link
DE (1) DE10015836A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7750164B2 (en) 1996-12-03 2010-07-06 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7875638B2 (en) 2002-08-23 2011-01-25 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750164B2 (en) 1996-12-03 2010-07-06 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
USRE41990E1 (en) 1996-12-03 2010-12-07 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US8481575B2 (en) 1996-12-03 2013-07-09 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7759374B2 (en) 2002-08-23 2010-07-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7875638B2 (en) 2002-08-23 2011-01-25 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US8110590B2 (en) 2002-08-23 2012-02-07 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof

Similar Documents

Publication Publication Date Title
EP1150980B1 (en) 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
CA2651653C (en) 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
EP1005465B1 (en) New epothilone derivatives, method for producing same and their pharmaceutical use
WO2000000485A1 (en) Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
WO2001081342A2 (en) Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use
DE19908760A1 (en) New, chemically and metabolically stable epothilon derivatives having modified macrocyclic ring, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators
US20100168179A1 (en) 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
DE19908763A1 (en) New, chemically and metabolically stable benzo-fused epothilon derivatives, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators
WO2000047584A2 (en) Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
DE10020899A1 (en) New 9-oxa-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease
DE10015836A1 (en) New epothilone derivatives used for treating e.g. malignant melanoma, breast carcinoma, psoriasis, multiple sclerosis and arthritis
DE10041470A1 (en) New 6-substituted 12,13-(cyclopropyl or azacyclopropyl)-epothilone derivatives, useful as cell division regulators for treating e.g. malignant tumors, psoriasis or arthritis
DE19954228A1 (en) New epothilone derivatives used for treating e.g. malignant melanoma, breast carcinoma, psoriasis, multiple sclerosis and arthritis
DE19751200A1 (en) New epothilone derivatives
DE19908767A1 (en) New stable, modified epothilone derivatives, are cell division regulators useful for treating malignant tumors, angiogenesis or chronic inflammatory disease
DE19921086A1 (en) New stable 6-alkenyl- or 6-alkynyl-epothilone derivatives, are cell division regulators useful for treating malignant tumors, angiogenesis or chronic inflammatory disease
DE19830060A1 (en) New epothilone derivatives, used as mitosis regulators e.g. for treating malignant tumors, psoriasis or arthritis
DE19908765A1 (en) New, chemically and metabolically stable 16-halo or cyano-epothilone derivatives are cell division regulators useful e.g. for treating malignant tumors or chronic inflammatory disease
DE19923001A1 (en) New epothilone derivatives, used as mitosis regulators e.g. for treating malignant tumors, psoriasis or arthritis
DE19954230A1 (en) New, chemically and metabolically stable 16-halo or cyano-epothilone derivatives are cell division regulators useful e.g. for treating malignant tumors or chronic inflammatory disease
DE19954229A1 (en) New epothilone derivatives, useful for treating malignant tumors such as ovarian, stomach, colon, breast and lung carcinoma, acute lymphocytic and myelocytic leukemia and chronic inflammatory diseases such as psoriasis
DE19907480A1 (en) New epothilone derivatives, useful for treating malignant tumors such as ovarian, stomach, colon, breast and lung carcinoma, acute lymphocytic and myelocytic leukemia and chronic inflammatory diseases such as psoriasis

Legal Events

Date Code Title Description
8127 New person/name/address of the applicant

Owner name: BAYER SCHERING PHARMA AG, 13353 BERLIN, DE

8110 Request for examination paragraph 44
8127 New person/name/address of the applicant

Owner name: BAYER SCHERING PHARMA AKIENGESELLSCHAFT, 13353, DE

8139 Disposal/non-payment of the annual fee